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ABSTRACT 
 
RETHINKING ETHICS ASSESSMENT IN HEALTH TECHNOLOGY 
ASSESSMENT: A NONLINEAR APPROACH 
 
 
 
By 
Aimee D. Zellers 
May 2015 
 
Dissertation supervised by Henk ten Have, PhD, MD 
 The primary question this dissertation aims to answer is how ethics can be 
meaningfully integrated into health technology assessment (HTA).  The contribution of 
this dissertation is two-fold.  The first is to provide an honest and critical evaluation of 
current HTA practices, including those that involve ethics assessments and that do not.  
This evaluation will identify gaps and deficiencies in current HTA practices.  The second 
contribution of this dissertation is to propose an approach for meaningful ethics 
assessment.  The nonlinear approach contains five methodologically sound phases aimed 
to support both ethics assessment and scientific progress.  The approach will be applied 
to emerging genetic health technologies, with a specific hypothetical application to 
expanded genomes. 
 v 
These contributions will be systematically addressed in the following chapters.  
The first chapter will provide a general introduction to the connection and relationship 
between technology and values.  It will examine value statements and normative 
statements that are made about technology, including whether technology is value-
neutral, value-free, or value-laden.  This chapter will ultimately argue that technology is 
value-laden, and the relationship between society and technology is but two sides of the 
same coin.  Chapter two will address current HTA practices in both the USA and Europe. 
A distinction between technology assessment (TA) and HTA will be reviewed, as well as 
a number of basic procedural aspects in HTA.  Chapter three will critically assess the 
current methods of ethics assessment in HTA, including the role ethics plays, identify 
their shortcomings, and provide a justification for rethinking ethics in HTA.  In chapter 
four, the foundations, methodology, benefits and limitations of the nonlinear approach are 
delineated.  The nonlinear approach consists of five phases with methodologies grounded 
in multiple disciplines.  A detailed description of the function and projected benefits of 
the nonlinear approach will be given in Chapter five.  Chapter five will apply the 
nonlinear approach to an emerging genetic health technology.  Chapter six will consist of 
a brief summary of the arguments, address the strengths, weakness and feasibility of 
nonlinear approach, as well as concluding remarks regarding the future genetic health 
technologies and the role of ethics assessment.  
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Chapter 1: Society, Technology, and Values 
 
1.1 Introduction 
Over the past five decades, advances in technology yielded a plethora of 
significant and innovative devices and interventions in healthcare.  Breakthroughs in 
biotechnology, antivirals, surgical interventions, organ and tissue transplantation and 
generation, and diagnostics improved not only patient care but also efficiency, and 
effectively advanced healthcare delivery.  The term health technology applies not only to 
those devices and innovation used in the clinical setting, but also to a much wider range 
of fields including health promotion, preventative health, and rehabilitation, as well as all 
drugs, devices, substances and processes that may affect one’s health.  Assessing each 
new intervention, device, or process is an important and, at times, challenging task.  
However, it is not always guaranteed to happen.  Health technology assessment (HTA) 
generally uses an interdisciplinary process that includes researchers, investigators, 
stakeholders, and other relevant parties to assess the medical, social, economic, and 
ethical issues in new health technologies in an effort to guide policy development.  There 
is no standard approach; the scope and role of HTA is still hotly debated.  Most HTA 
approaches focus on two aspects, safety and economic issues, and often limit the 
assessment of ethical and social issues or ignore them altogether.  
There is consensus that systematic HTA is important; and there is a growing 
acknowledgement that ethics should play a larger role in assessment.  The question is 
how this can be effectively accomplished.  Many articles provide ideas on how to 
integrate ethics into existing HTA practices, as well as develop entirely new approaches.  
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While many of these suggestions and frameworks are useful, they are often incomplete or 
deficient in some way. It is imperative to address emerging technologies now, rather than 
later when the rapidly changing pace of technology may obscure important ethical 
considerations.  Ethics should be an integral part of HTA.  Many concerns that arise 
under the categories of benefit, risk and cost effectiveness are inextricably linked to 
moral concerns.  Nearly everyone values health and considers it a societal good.  
Emerging health technologies directly impact health; thus, a variety of perspectives must 
be taken into account in technology assessment because it is relevant to everyone.  
Technological advancements in healthcare influence much more than the medical field 
alone.  In many instances other aspects of society are affected as well, specifically our 
legal codes, economy, and societal norms. 
 Part of this inextricable tie between HTA and ethics is the very nature of 
technology itself.  Technology is value-laden.  If technology truly revolves around 
purposeful human action then it is never value-neutral.  Many agree that the integration 
of ethics into HTA is both necessary and beneficial; the question is how to go about 
developing an effective ethics assessment process.  This process is needed now more than 
ever given the exponential growth of technologies applicable to human health.  A sound 
HTA model is necessary to address emerging technologies.  
The next major technological watershed is the creation of a protocell or an 
artificial cell.  Protocell research is still in its infancy.  Craig Venter made a breakthrough 
with the creation of the synthetic cell in 2010.  However, a true bottom-up protocell—one 
created from spontaneous assembly in inorganic matter—has yet to be created.  The 
application of a protocell, more so than its development, presents the greatest risk the 
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environment, human health, and society.  Therefore, to responsibly and comprehensively 
consider risks, the potential applications of protocell research must be assessed.  The 
reason protocell creation is the next major watershed is because it will give researchers 
the capacity to synthesize life in a laboratory.  Also, the creation of protocells is the first 
step towards the next major development in intelligent machines.  Some scholars predict 
that protocells will help bridge the gap between the living and nonliving, the animate and 
inanimate.  This would allow scientists to dramatically increase the capacities of both 
living and inanimate systems.  If these technologies can be harnessed, there are an 
abundance of practical applications including, environmental, pharmacological, and 
medical diagnostic functions.  One specific benefit will likely be the advancement of 
human health. Better-quality or personalized drugs and vaccines and their delivery 
methods could be adapted to pharmacogenomics and improve through the use of 
protocells.  Protocells could be used as vehicles for drugs tailored to an individual’s 
genetic code to combat a specific disease or disorders such as immunodeficiency virus 
and cystic fibrosis.  This type of scientific breakthrough would greatly assist research 
efforts in gene therapy and other emerging genetic health technologies.  If HTA does not 
adequately take ethics into account for existing technologies, then it is not likely that 
current HTA approaches will be able to adequately address emerging technologies.  
Emerging technologies that are likely to be applied to human health devices and 
interventions need to be assessed much earlier in the design and development process. 
This dissertation has two primary aims:  first, to understand the nature of the 
relationship between emerging genetic technologies—specifically those technologies that 
impact protocells and gene therapy—and society, and second, to propose a reasonable 
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way to conduct ethics assessment in the research and development phases of these 
technologies.   In order to accomplish this one must first define “society” and 
“technology.”  Both terms are value-laden; and understanding these values enables one to 
make judgments about each. 
Chapter One lays the foundations for the thesis.  In order accomplish to this, there 
are several central concepts one must explore, including the complex relationship 
between technology and society.  When two concepts appear to have a natural association 
we tend to think of them as related.  However determining the nature of that relationship 
can be very challenging.  Society relies heavily upon technological advancements, most 
of which it values intrinsically without openly addressing the ethical considerations 
associated with adopting the advancements to everyday life.  Consciously addressing the 
relationship between society and technology exposes the ethical considerations, and 
forces society to acknowledge the impacts. 
 
1.2 Technology 
This section examines the nature of technological development in relation to 
norms and values.  In everyday language, it is common to speak as if technology is good 
or bad.  Individuals use normative terms to describe and assess it.  Norms are those social 
behaviors that individuals in a given society are expected to follow.  Values, while very 
similar to norms, are comprised of those value judgments individuals make surrounding 
personal preferences and beliefs about what is good or bad, right or wrong.  The 
important question is whether technology is value-free, value-neutral,1 or value-laden.2  
As William Petty wrote in Political Arithmetic that “Ships, and Guns do not fight 
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themselves, but Men who act and manage them do.”3  This perspective suggests that 
humans use technology for good and bad purposes, and perhaps ships and guns are not 
endowed with any particular values until they are put to use.  This represents the value-
neutral concept.4  Value-free refers to the idea that social, ethical, political and legal 
values have no influence on science.  Scientists should not pay attention to these 
additional considerations; rather, they should focus solely on progress and the 
advancement of scientific knowledge.5  Value-laden refers to the notion that technology 
is inextricably tied to society’s values and norms; the latter are inherent within the 
technology.6 
Technological developments are a hallmark of the twenty-first century.  
Significant debate ensues among scholars in the philosophy of science and technology as 
to whether technology is value-free, value-neutral, or value-laden.  Two other important 
debates also directly impact value considerations.  The first is the relationship between 
means and ends as it pertains to technology.  The second is the relationship between 
technology and society.  The following section provides a conceptual clarification of 
technology, as well as the arguments surrounding norms, values and technology. 
 
1.2.1 Description of technology 
Technology is a broad concept that describes the knowledge of tools or equipment 
and how their use affects “the ability to control and adapt to the social and political 
environment.”7  Technology is generally applied for a specific purpose.  It is often 
characterized as the application of science to practical needs. In the nineteenth century, 
individual physicians and scientists most often produced medical innovations.  This 
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paradigm has now expanded in the past generation to include physicians, engineers, 
industry leaders, national governments, and private entrepreneurs in the development of 
technology for medical advancements.8  Currently, the application of technology to 
medicine goes far beyond diagnostics.  Technology has the ability to “process 
information and present it in comprehensible forms; to treat disorders effectively when 
diagnosed; to monitor treatment and evaluate its efficacy; and to prevent disease.”9  
Michael Anbar, in Penetrating the Black Box: physical principles behind health 
care technology, notes that health care technology evolves in two primary ways.  First, it 
evolves in response to a particular medical problem; technology is developed or 
improved to resolve the specific medical problem. Second, a developed or existing 
technology can be applied to a specific medical problem for which its use was not 
originally intended, and thus provide new or better results.10  The adaptation of existing 
technology, as well as the development of new devices and techniques, assists medical 
practitioners in achieving two primary goals:  gaining an accurate assessment of the state 
of the patient; and, in turn, alleviating the patient of their physical or mental infirmity.  
There are many benefits of technology in its medical applications.  Anbar offers three 
examples that clearly demonstrate this including the refinement of prosthetics, surgery, 
and chemotherapy.11  Technology benefits the patient by providing services and 
therapies, and the ability to improve and refine both.  Anbar contends that if technology 
is going to be used appropriately, three criteria must be met: there must be an 
understanding of the physical aspects of the technology—that is, whether the technology 
works.  Second, the efficiency and usefulness of the technology must be assessed against 
alternatives.  Finally, the risks, including side-effects and financial costs, must also be 
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evaluated against alternatives.12  Technological advancements in health care are not 
strictly limited to influencing the medical field.  In many instances, other aspects of 
society are affected as well, particularly legal codes, economy and societal norms. 
 
1.2.2 Norms and technology 
 In the past, technology was thought to be a means to an end.  Some scholars argue 
that technology is now an end to itself.  As a result, technological advancements become 
so significant that individuals comprising entire societies adapt their lives to it without a 
second thought.13  
  Martin Heidegger, an influential twentieth century German philosopher, 
impacted many different areas of philosophy including phenomenology, political theory, 
existentialism, and postmodernism.  He also produced one of the most pivotal works in 
the philosophy of technology.  His essay, entitled The Question Concerning Technology, 
was not only foundational, but also highly controversial.  In this essay, he addressed three 
important aspects of technology:  the activity of technology; the ends of technology; and 
identifying the means used to achieve technological ends.  In asking these questions, 
Heidegger did not attempt to demonize technology in any way. Yet, he did caution that 
technology could present a danger of sorts.  However, he did not simply refer to the 
harms and benefits of specific technologies; rather, he referred to the danger technology 
posed to the understanding of individuals, their sense of being, and their understanding of 
their existence in the world—in a word, their ontology.  This technological lens through 
which one views the world dramatically impacts one’s perception and understanding of 
ontology, and tightly ties one to the constraints of efficiency.  The recognition of this way 
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of thinking leads one to understand how very much technology shades one’s 
understanding of existence and worldviews.  Heidegger called this “revealing;” 
technology was a way of revealing.  He argued that one begins to see their world, other 
humans, and nature simply as other resources.  This led Heidegger to conclude that 
technology is not neutral; rather it is a way that one understands themselves in the world.  
When individuals recognize this framework for what it is, the process of thinking outside 
of the framework can begin.  At this point, values existing outside of the technological 
framework—other than efficiency—can have meaning in the world and individual 
lives.14 
 
1.2.2.1 Technology as value-free or value-neutral 
The primary distinction between value-free and value-neutral is that the former 
rejects any association of values with science and technology.  The value-neutral 
position, while there are varying degrees, generally asserts that technology has no 
inherent value but might be utilized by humans for good or nefarious purposes.  The 
value-free position is most often applied to science exclusively, as it is often difficult to 
maintain that the use of technology has no moral or ethical bearing.15  This section will 
focus on the value-neutral arguments, as they are the stronger than value-free ones.  
There are a number of arguments supporting the value-neutral position, which has 
resulted in its growing acceptance among scientists.  First, a decision is made.  The 
individual chooses whether to develop or utilize technology.  Second, existing 
technologies can be adapted for new uses for different purposes.  Again, one makes that 
choice.  Third, and most controversial, is the argument that technology is based on 
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science; and science is value-neutral.  Thus technology is inherently value-neutral.16  To 
the second point, there are times in which one does not have a choice regarding the use of 
a particular technology.  For example, if an individual is dying, and a specific medical 
device is required to save the individual, then there is no choice whether to use the 
technology, or perhaps on a very limited range of options.  To the third point, if science is 
considered value-neutral, that fact that technology has its basis in science does not 
necessarily make technology value-neutral.  To the contrary, what makes technology 
value-laden is its function.  To ignore the function of technology is to ignore its inherent 
characteristics.17  
 When humans use and develop technologies, whether aware of it or not, they are 
making choices about values.  For example, when scientists developed dialysis machines, 
the resultant implication of being able to sustain life, despite kidney failure, is adjudged 
good or beneficial.  Likewise, the development of weapons of mass destruction implies 
that on some level it is beneficial to kill groups of people or subdue them with the threat.  
Depending upon one’s perspective, such goals are deemed worthwhile or valuable.  
Disregarding or completely ignoring the intersection of values and technology can lead to 
the development of unchecked values.  There is a very real danger in assuming 
technology exists in value-free or value-neutral space.  The following section will reject 
the arguments supporting technology is value-free or value-neutral and will offer instead 
that technology is inherently value-laden.  
  
1.2.2.2 Technology as value-laden 
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Current technologies are developed and produced with a particular function in 
mind.  Bjørn Hofmann, a prominent Norwegian bioethicist, gives the example of 
bacterial weapons and respirators to demonstrate this point in the article When means 
become ends: technology producing values.18  The purpose for creating bacterial weapons 
is to harm other human beings.  The purpose for creating a respirator is to sustain 
artificial respiration.  Not only do these two technologies have specific intended 
functions, but they also promote specific values.  In the case of bacterial weapons, 
Hofmann concludes that it is good to hurt people by making them sick or causing death.  
In the case of respirators, it is good to provide artificial respiration for those in need of 
it.19  There are obvious health benefits surrounding the use of respirators.  These 
technologies invoke specific ethical questions about their use.  When considering broader 
technologies, those with multiple and varying applications and capacities, such as 
genetics and emerging genetic health technologies, Hofmann notes that there are more 
general questions regarding good and bad, or appropriate and inappropriate, as opposed 
to those particular questions raised by technologies with a specific function.  For 
example, genetics can be very beneficial to advancements in human health.  However, it 
can also be used for controversial or, at worst, nefarious purposes.  For example, 
diagnostic ultrasounds can be used for screening fetus to determine any malady with the 
intent to abort a less-than-healthy fetus.  One must ask whether genomic screening, 
diagnosis, and in the near future modification or engineering, is good or bad, and 
ethically acceptable or impermissible.20  
Values and norms are important to recognize and evaluate because they reflect 
current social context.  Considering ethics at the macro level can illuminate ingrained, 
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pre-existing societal norms and values in relation to technology.  Therefore, depending 
upon which technologies are developed, promoted, and adopted, certain underlying 
values and norms will also be promoted.21  
Understanding underlying values and norms raises questions surrounding the term 
‘normative’ and what precisely it means.  Jonathan Dancy, a British philosopher, 
proposes an adequate characterization of ‘normative’ that will be used throughout this 
dissertation.  According to Dancy, what is normative has to do with the different facts 
about the world and how those facts impact actions, desires, and beliefs.  A normative 
fact or statement is what he terms a “second order fact.”  This means that facts about the 
world or facts about a particular technology have relevance to human action, belief, or 
wants.22  Dancy is not trying to establish a paradigm distinction between what is 
normative and what is purely non-normative.  Rather, he is trying to accurately capture 
facts that are commonly understood and have practical implications.  They necessarily 
have to include the facts pertaining to what particular individuals believe, want, and do.  
Desires and beliefs form a very important part of behavioral motives.  Individuals often 
speak of technological artifacts as having normative features.  One might hear a college 
undergraduate commenting “this is a good smartphone” or “this is a bad tablet.”  Whether 
it is a good smartphone cannot be analyzed as well as the statement that “it has certain 
features f, and these features make it the case that the person, or any person, has a reason 
to use” it.23  The latter is a fact-value characterization.  The connection of action with 
desire is an important philosophical tradition dating back to David Hume, as Maarten 
Franssen, notes. Desires can be evaluated morally but are indifferent to rational reasoning 
and grounds.24 
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Logically, the fact-value and is-ought distinctions are very similar; some might 
even say essentially the same.  However, Sven Ove Hansson, professor of philosophy and 
chair of the Department of Philosophy and History of Technology at the Royal Institute 
of Technology in Stockholm, Sweden, notes that normative concepts and value concepts 
are not the same.  He provides a very interesting example:  if someone says they believe 
one should do x, and then follow it up by recommending that they do not do x, then one 
would conclude that they are behaving erratically or at least inconsistently.  Yet, one 
might say that doing certain acts would be good; however, they might not recommend 
doing those certain acts.  There are many reasons why this could be the case, Hansson 
suggests actions that are of a supererogatory nature fall into this categorization, and one 
would not conclude that this person is acting inconsistently.25  The connection is that, 
logically, it is not sound to conclude that something ought to be a certain way because it 
is a certain way or exists in a certain way.  Likewise, it is not sound to conclude that 
something has a defined value based on its facts. 
Hansson makes another critical observation.  He suggests that presuming an 
artifact is good is not always easily reconcilable with the notion that technology should 
be treated as value-neutral.  He notes that the way one thinks and speaks about 
technology—in the patterns of thought that are clearly encoded in our linguistic 
practices—are more positive towards technology than negative.  This implies that 
categorizing technology as value-neutral is not an accurate categorization.  Rather, it is an 
inconsistency, or tension, between the characterization of technology as neutral and the 
way in which humans talk, think, and apply values to technological artifacts.  Hansson 
concludes that language is more easily compatible with a positive view of technology 
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than with a value-neutral view of technology.26  Furthermore, he goes on to argue that 
using technology as an extension of human capacities and capabilities is itself a positive 
value.  It is not considered, at least in Western society, as being value neutral.27  To 
accurately describe the way one thinks and talks about technology is not the same as to 
say “technology is neutral but it can be used for good or bad purposes;” rather, Hansson 
writes it would be more accurately categorized by saying “most technology is good but 
there is also bad technology and good technology can be used for bad purposes.”28  
 
1.2.2.3 Analysis 
Adopting a specific view of the nature of technology will directly impact any 
perspective on the relationship between technology and society.  The goal of this 
endeavor is not to generate a list of characteristics that categorize some technologies as 
“bad” and others as “good.”  Rather, the aim is to make an observation applicable to all 
technology.  The valuation of technology as a whole differs from the valuation of specific 
technical artifacts.  Technology raises questions of values that are general and not 
artifact-specific.  However, certain technologies raise value questions, which are specific 
to that technology and cannot be separated from it.  Hofmann makes the argument quite 
simple—these ethical issues are related to the function of the technology.  “Every 
technology has a function, and every function is related to a purpose and value.”29  The 
arguments surrounding the purposeful function of technology, linguistic patterns, and the 
valuation of technology make a stronger case that technology is value-laden than do the 
arguments against this position. The value-laden nature of technology, specifically health 
technology, will be further explored in chapter 3. 
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1.3 The relationship between technology and society 
As a result of this analysis it is clear that in order to address the question of 
technology in medicine in any meaningful way one must first examine the relationship 
between technology and society.  Five dominant perspectives on this relationship exist, 
including:  technological determinism, social construction of technology (SCOT), actor-
network theory, systems theory, and structuration theory.  The aim of this section is not to 
solve the puzzle of the relationship between technology and society; rather, it is to arrive 
at some well-founded observations and generalizations that can provide the basis for 
understanding the value nature of technology and its relation to society.  Provided and 
assessed below are high-level, broad overviews of these five theories.  Having an 
understanding and holding an position on this issue will shed light on the role of ethics in 
HTA, and how to better engage or conduct ethics assessment in HTA, if at all.     
 
1.3.1 Technological Determinism 
Technological determinism encompasses particular ideas about technology, 
determinism, and their combination.  Technology, as described in the previous section, 
consists of any tools, equipment, or artifacts, as well as the requisite knowledge to utilize 
these.  Determinism is a reductionist philosophy.  As such, it stands contrary to other 
doctrines such as free will and social constructivism.  Taken together, the term 
“technological determinism” is the idea that technology directly alters, shapes, and 
reshapes human behavior.  This impacts actions, thought patterns, values, and codes of 
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conduct, as well as society as a whole.  Under this principle, technology is the only, or at 
the very least the primary, driver of human behavior and society.30  
There are several different accounts and varying degrees of technological 
determinism that take on different meaning in different contexts.  Two dominant versions 
include those introduced by Jürgen Habermas and Van Inwagen.  The most common 
explanation of technological determinism attempts to explain technology’s influence on 
history and modern society.  Jürgen Habermas, in Toward a Rational Society, suggests 
that technological advancement occurs without the requisite human reflection and 
recognition of the impact on political and ethical structures and discourse.  As Heidegger 
noted, efficiency seems to take hold on the technical deterministic worldview.  Without 
being aware of this or understanding the implications, it may very well be argued that 
society is driven by technology, to no rational or coherent ends, only efficiency.31  When 
efficiency becomes the primary value one loses all sight of ends.  Habermas explains that 
society can utilize ethical considerations in the development of technical artifacts and 
thereby willfully control the norms associated with technological development.  Those 
individuals who develop new technologies, or adapt existing ones, have aims and specific 
judgments about both private and public goods.32  Furthermore, Habermas argues that the 
characterization of technology as autonomous is not correct due to several observable 
factors, one of the most influential being public investments.  He gives the example of the 
United States investing heavily in military defense and space programs.33  Habermas 
concludes that neither technological development nor society can exclude the other.  
However, he describes technology as a “project of the human species as a whole.”34  
Thus, technology takes on a non-social aspect.  For Habermas, it is not that there is too 
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much technology or too much dependence upon it; rather, it is the way humanity utilizes 
technology in society.  He concludes that technology is neutral; it is simply a means for 
completing human tasks.35 
Another interpretation of technological determinism comes from philosopher 
Peter Van Inwagen. In An Essay on Free Will, he argues that “given the past, and the 
laws of nature, there is only one possible future.”36  Bruce Bimber Karl Marx and the 
Three Faces of Technological Determinism, and G. A. Cohen in Karl Marx’s theory of 
history; a defense provide a useful discussion on Van Inwagen.  They suggest that 
technology itself has a causal influence on social practices. Taking the past as well as the 
laws of nature into account, they contend that there is only one possible future course for 
society and social change.37  Hence, technology determines societal development.  As 
with many theories, there are varying degrees and extremes in these interpretations.  
Some claim the absolute primacy of technology and its sole control over society.  Other 
scholars suggest that there are multiple drivers of society, yet technology is by far the 
dominant driver. 
 
1.3.2 Social Construction of Technology (SCOT) 
Social construction of technology is an approach that emerged in the 1980s.  
Social construction theories maintain that “the truth of scientific facts and the working of 
technical artifacts are studied as accomplishments—as being constructed rather than as 
intrinsic properties of those facts and machines.”38  There are two prongs to the social 
construction of the technology.  First, it studies technical change in society.  Second, it 
analyzes the relationship between the development of technology and society.  There are 
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mild and radical versions of social construction of technology.  Mild ones emphasize the 
inclusion of social contexts when assessing technology.  Radical versions claim that 
technology is entirely socially-constructed.  This means that technology development and 
all meaning and use prescribed to it, derives from the existing social structure and related 
processes.39  
Wiebe Bijker, Professor of Technology and Society at Maastricht University, 
argues that any techno-sociological framework ought to fulfill five requirements.  First, it 
must provide an account for technological change.  Second, it should explain constancy 
and lack of change throughout history.  Third, it must also evaluate failure and success 
with symmetrical modes.  Fourth, the actor’s approaches and constrains must be 
considered.  Finally, the framework must shun distinctions based on a priori 
assumptions.40  Bijker’s social constructivist framework is primarily a descriptive model 
that includes steps to analyze and understand society, technology, and their relation to 
each other.  In this schema, the initial focus is on an artifact.  An artifact is essentially an 
invention or technology.  It has an ever-changing character.  The artifact takes on a 
different meaning depending upon the perception of the relevant social group.  Each 
group changes the meaning of the artifact, thereby demonstrating a new set of problems 
and solutions that may or may not be addressed.41   
Social groups are very relevant for gaining a full grasp of the development of 
technology.  The first step in Bijker’s model is to identify the relevant social groups 
through the “snowball” and “follow the actor” rules.  The logic is that social groups are 
relevant for actors and thus relevant for analysis.42  The second step is to discern and 
describe the meaning of the artifact for all identified social groups.  Bijker suggests that 
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an effective method for this would be to focus on the problems and solutions that the 
relevant social groups identify.43  The third step is to use the descriptions for a 
“sociological deconstruction” of the artifact.  From this deconstruction the interpretative 
flexibility can be analyzed.  Identifying and understanding interpretative flexibility of an 
artifact guides the way to accurate social analysis of technology.44  This is truly the first 
stage that goes beyond identification and toward analysis.  After an artifact is 
deconstructed into different artifacts, their further development must be determined.  For 
example, one artifact as it is perceived by the relevant social groups may become 
dominant while others fade.  The key to understanding interpretative flexibility is to grasp 
that relevant social groups do not just perceive different aspects of the same artifact; 
rather, the meaning the group gives to the artifact is actually what constitutes the artifact. 
Therefore, Bijker notes that there are as many distinct artifacts as relevant social groups.  
An artifact does not exist unless it is given meaning by a social group.45  
This concept has its philosophical underpinnings in the principle of symmetry.  
One of the problems with traditional sociological approaches is the asymmetry of the 
analysis.46  Sociologists should use the same conceptual framework to evaluate truth and 
falsity of claims and beliefs, and in this case to evaluate the successful and failed 
artifacts.  This is a similar notion to the historical adage that the victors of war write the 
history, not the losers.  In this context, sociologists should avoid accepting a claim 
because it is the presently accepted belief.  False beliefs, and in this case unsuccessful 
inventions and technology, can be immensely useful to study.  They can provide a new 
perspective with regard to social implications as they can demonstrate social dynamics 
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that were previously overlooked.47  The concept of interpretative flexibility produces this 
radical social constructivist approach to the sociology of technology. 
The final step is then to establish the social construction of the artifact.  This is 
accomplished by evaluating the closure process.  This process ends interpretative 
flexibility due to the successful stabilization process in the relevant social groups.48  The 
concept of closure is closely connected to interpretative flexibility and is best reflected 
through inter-group analysis of artifact development.49  As mentioned above, the concept 
of interpretative flexibility is best evaluated in light of the meaning and problems relevant 
social groups attribute to an artifact.  Closure in technology begins to occur when a 
relevant social group perceives a problem with the artifact as being solved.  This process 
involves stabilizing the artifact.  To close a technologic controversy or problem is to 
solve the technical problem and glitches perceived by a relevant social group, thus 
inducing a stable set-up.50  
 Bijker introduces a wide interpretation of the “technological frame.”  This is 
important because the concept must include non-engineers and non-scientists.  It also 
must have a wide breadth in order to recognize different problems and available 
solutions.  Bijker claims that a technological frame is “a combination of current theories, 
tacit knowledge, engineering practice such as design methods and criteria, specialized 
testing procedures, goals, and also handling and using practice.”51  This concept describes 
the interaction between all the relevant actors.  The technological frame is not simply the 
individuals involved or system as a whole; rather, it is the interaction between the actors, 
not the actors themselves.52  Technological development is a two-sided coin:  one side is 
social impact and the other is social shaping.  Bijker uses the concept of technological 
  
 
20 
 
 
 
frame to demonstrate this.  The technological frame of a social group is shaped by an 
artifact’s development and stabilization within that social group.  This demonstrates 
social impact.  On the other hand, technological frames also influence and, to differing 
degrees, determine the design process within a specific group.  This demonstrates social 
shaping.  This holistic approach forms the concept of the technological frame.53 
The sociological study of technology is not simply a combination of different 
social and technical aspects shoved together, nor is it simply applying an existing social 
model to technology.  What Bijker has laid out is a mechanism for analysis that engages a 
“sociotechnical ensemble.”54  He argues that this approach allows one to find the 
socially-constructed character of an artifact while simultaneously being able to determine 
what constitutes a stable set-up.  Bijker concludes, “society is not determined by 
technology, nor is technology determined by society.  Both emerge as two sides of the 
sociotechnical coin, during the construction processes of artifacts, facts and relevant 
social groups.”55 
 
1.3.3 Actor Network Theory 
Actor network theory contends that all relevant entities and values linked to an 
invention or technology at its final stages of development have, in fact, been there from 
the start.  From the very inception of an invention the technical, scientific, social, 
economic, and political considerations and characteristics are indivisibly integrated in a 
single unit or network.  All actors are not sporadically introduced but, rather, present 
from the start; they are “interwoven in a seamless web.”56  Michel Callon, Professor of 
Sociology at the École des mines de Paris, argues that some engineers can actually act as 
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sociologists during the process of innovation and invention.  An actor network is not 
reducible to a single individual, entity or network.  It encompasses many heterogeneous 
components including individuals, organizations, and animate and inanimate objects, all 
connected for a particular reason at a specific time.  In short, “an actor network is 
simultaneously an actor whose activity is networking heterogeneous elements and a 
network that is able to redefine and transform what it is made of.”57  He explains this 
through the example of the introduction of the electric car (VEL) in France in the early 
1970s.  The project engineers designed the car with the characteristics of the vehicle they 
desired, as well as with the characteristics of the social context in which the car would 
exist.  Thus scientific, technical, economic, and social considerations were present from 
the start.  The actor networks give rise to the simultaneous evaluation of society and 
technology together.  This concept can also be used to explain the phases of invention 
and institutionalization.58  
The thrust of Callon’s theory is the “actor network.”  An actor network is not a 
reducible single individual, entity, or network.  It encompasses many heterogeneous 
components including individuals, organizations, and animate and inanimate objects all 
connected for a particular reason at a specific time.  Callon explains “an actor network is 
simultaneously an actor whose activity is networking heterogeneous elements and a 
network that is able to redefine and transform what it is made of.”59  This is beyond the 
current scope of sociological tools.  He utilized the actor network through the lens of the 
engineer-sociologist, which is the capacity of engineers to act as sociologists.  Callon 
argues that one must abandon traditional sociological paradigms and tools.  The actor 
networks give rise to the simultaneous evaluation of society and technology together.  
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This concept can be used to explain the phases of invention and institutionalization.  The 
actor network is essentially taking Hughes’ technological systems approach one step 
further.  It avoids certain methodology problems like distinguishing the system from the 
environment and recognizing patterns.60  
To organize these heterogeneous associations in actor networks, Callon identifies 
two necessary elements:  simplicity and juxtaposition.  Theoretically speaking, reality can 
be infinite; however when one addresses a specific case at a specific time, those actors 
have a limited number of possible associations.  These associations will have a finite 
number of discernible characteristics.  This element allows for a finite number of 
associates to be identified and evaluated.  The simplifications are only useful in an actor 
network if they are juxtaposed.  Juxtaposition, the second necessary element, places all 
the relevant entities in relation to one another thereby defining the conditions of operation 
of the actor network.  Moreover, this juxtaposition of associations supports “coherence, 
consistency, and structure of relationships that exists between the components that 
comprise it.”61   If a network did not exist, each component would individually fail.  
Callon’s actor network gives rise to the evaluation of society and technology 
simultaneously; society and technology impact and shape each other. 
Those opposing this approach maintain that during the process of innovation there 
are areas and processes that are uniquely technical and scientific which are distinct from 
other activities and stages that are economically- or commercially-minded.  Others argue 
that these heterogeneous components are interwoven by the end of the technological 
development, but are introduced and integrated throughout the development process.62  
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1.3.4 Systems Theory 
Systems theory posits that technological systems both shape society and are 
socially constructed.  Technological systems include artifacts, organizations, inventors, 
engineers, scientists, managers, economists, scientific processes, research programs, and 
other relevant groups.  Technological systems solve problems using everything at their 
disposal.  Many problems arise in artifacts; and the technological system must have the 
ability to reorder the physical world as a way to benefit those in the technological system.  
The development, expansion, and evolution of technological systems can be identified 
through a pattern involving several phases.  The pattern is flexible; and the different 
elements do not have to necessarily fall in a specific order.  Evolving technological 
systems go through the stages of invention, development, innovation, transfer, and 
growth, competition, and consolidation.  As systems stabilize they gain style and 
momentum.63  
Systems can be described as social, biological, technological, or material patterns; 
and these all operate for one common aim or purpose.  Systems theory developed 
primarily out of the discipline of biology, which harkens back to understanding the 
natural world primarily as ecosystems.  Most philosophers who study systems theory 
describe systems as very abstract.  These systems are independent and lack substance.  
They do not really exist in time and space as most understand it.  The aim of these 
philosophers and sociologists is twofold.  First they must describe the world in which 
they live and how it consists of different systems.  Second, they must view the interplay 
of elements in a holistic way so that they can truly understand their functions.64 
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System theory has evolved and been adapted to other disciplines in the course of 
the last century.  Herbert Spencer and Joseph Needham were pioneers in systems theory, 
as they developed and articulated key aspects of the theory. Herbert Spencer, in 1862, 
was one of the first to articulate the idea of increasing complexity among systems.65  
Following Spencer, Joseph Needham provided tremendous insights in fundamental 
aspects of the theory, specifically in the area of integrated levels.66  Combined, their work 
resulted in the articulation of nine characteristics of integrated levels.  These 
characteristics primarily described the organization and interaction of various levels.67  
Needham’s ideas surrounding integrated levels laid the groundwork for the current 
discourse surrounding adaptations of systems theory.  Systems theory has been adopted 
in the fields of comparative psychology, biology, biochemistry, and others.  
Subsequently, different articulations of system theory have developed, including but not 
limited to General Systems Theory (GTS), the Systems Approach, cybernetics, and 
operational analysis.  
The influence of systems theory can be tracked in other disciplines such as 
management science, mathematics, political science, psychology, sociology, and library 
and information science.68  However, such development is not without criticism.  One of 
the most damaging criticisms, by Robert Lilienfeld, is that systems theory is far too 
idealistic and that it, at times, escapes reality.69 
 
1.3.5 Structuration Theory 
Structuration theory is similar to, but distinct from, systems theory.  The study of 
structuration in social systems consists of examining the modes in which systems 
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“grounding in the knowledgeable activities of situation actors who draw upon rules and 
resources in the diversity of action contexts are produced and reproduced in 
interaction.”70  Structuration is, in essence, the arranging and structuring of social 
relationship through time and space, taking into account the dual nature of structure.  The 
duality of structure refers to the notion that agents and structure are not two separate or 
independent aspects of phenomena; rather, they are integrated components of a recursive 
organization process.71  As a result, this provides a unique perspective on human 
behavior.  Rather than human nature being constrained by vast societal structures, 
structuration theory acknowledges and embraces these relational aspects of society.72  
Many structuration theories posit that human behavior is a result of the 
individual’s socialization within a structure.  Anthony Giddens, a sociologist who 
focused his research on structuration theory, argues that structuration theory is a means 
by which one can understand social actions and behaviors.  This is accomplished by 
resolving competing views of “structure-agency” and “macro-micro” perspectives.73  In 
this process, the interface between the actor and the structure is analyzed.  The crux of the 
argument lies in that actor theories and system theories cannot alone explain these 
behaviors; rather, they must be examined simultaneously.  This could be conceived of as 
an integration of key elements from actor network theory and systems theory.  One of the 
interesting ramifications is that social rules and structures do not exist outside of human 
action because they are socially-constructed.  Giddens proposed a framework consisting 
of three kinds of structures in social systems.74  The first structure is signification, where 
meaning is derived from practice and language.  The second structure is legitimation, 
where meaning is derived from normative perspectives, which are embedded and 
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expressed as social and cultural norms.  Domination is the third structural element, 
whereby meaning is assessed by examining power structures and relations, specifically 
surrounding the control and allocation of resources.75  
Since the articulation of his theory in 1984, Giddens has faced harsh critiques, 
specifically from Jon Clark et al in the book Anthony Giddens: Consensus and 
Controversy.76  Despite criticism of this theory, other scholars have adapted Giddens’ 
work to examine the relationship between society and technology including publications 
from G. DeSanctis and M. S. Poole as well as Wanda Orlnkowski.  Specifically, 
DeSanctis and Poole have articulated an “adaptive structuration theory”.77  Orlinkowski 
also adapted this theory when she provided a very nuanced critique of Giddens’ duality of 
structure as applied to technology.  She argued, “The duality of technology identifies 
prior views of technology as either objective force or as socially constructed product–as a 
false dichotomy.”78  Much of her work surrounds issues at the corporate level.  However 
it is arguably applicable to wider ranges of technology and the structures in which 
technology exists.  In addition, as a result of her work, this theory can be adapted to 
account for issues that arise surrounding gender and technology.79  Michael Workman, 
Richard Ford and William Allen, professors at the Florida Institute of Technology, also 
utilized key elements of structuration theory in their adaptation, primarily agent theory 
aspects.  They adapted the revised theory and applied it to examine the socio-biological 
structuration in security software.  Specifically, they examined how humans behave in 
relation to information exchanged and communication.80 
In sum, structuration theory is a social constructivist theory aimed at 
understanding human behavior within social structures while recognizing the impact of 
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external forces.  It differs from other social constructivist theories in the way that it 
interprets duality.  It is a flexible framework, which resulted in multiple adaptations. 
 
1.3.6 Collective analysis of the relationship between society and technology 
All of these theories or perspectives have a common goal to provide a paradigm 
by which a realistic and accurate study of the relationship between society and 
technology can take place.  Traditional approaches to technological determinism leave 
much to be desired, as they are typically linear and treat technology as a value-neutral 
“black box,” of sorts.  If the development of technical artifacts can be more clearly 
understood, it would enhance comprehension of the social-technical relationship.  Then 
the assessment of new technologies might be possible as a fundamental understanding of 
this relationship.  Strong versions of technological determinism—those that eliminate the 
role of social influence—are very difficult to maintain.  Equally difficult to sustain are 
strong versions of social constructivism which maintain that technology has limited or no 
causal impact on society.81 
The social construction theories, including SCOT and structuration, provide some 
explanation for the development of technology.  However, if one takes a very strong 
constructivist position, it is extremely difficult to show that technological trajectories are 
solely influence by a myriad of social structures and forces.  In recent decades, research 
has enhanced the understanding of the nuances of technological change and the 
interrelatedness of science, technology, and society.  One of the most important concepts 
is the notion of technological trajectories, or how technology develops on a certain path.  
Clearly, the development, adaptation, and effects of a given technology depend to some 
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extent on social context.  For example, social context will determine whether or not a 
particular technology is adopted or whether it is repurposed for some other worthwhile 
use, thereby impacting the technologies impact on society.  This is consistent with 
Bijker’s work on the technical and social development of the bicycle.82 
The ultimate question is whether society is shaping technology or vice versa?  
Most of the scholars would agree, to some degree, that it is a two-sided coin; society is 
shaped by technology, and society impacts the design and evolution of technology.  Each 
author takes a unique approach to developing a new paradigm.  Hughes has the most 
limited approach, as he appeals to the use of flexible patterns.83  Whereas Bijker, while 
employing steps, identifies them all occurring very rapidly on the end of the analysis.  
There is not a step-by-step process for the development of technology; rather, the steps 
are for the analyst.  He does not describe patterns, but rather general observations 
regarding the development of each technology he examines in his dissertation:  bicycles, 
Bakelite, and florescent lighting.  In the example of the bicycle there was neither a single 
social group with an accompanying technological frame that was dominant, nor a clearly 
dominant technological frame guiding interactions.  In the second configuration, 
demonstrated in the Bakelite example, one technological frame was dominant and 
characterized by one social group.  In the third configuration, demonstrated in the 
florescent lighting example, two or more social groups with developed technological 
frames were vying for dominance; and several technological frames were simultaneously 
important for understanding interactions related to the artifact.  The difference between 
the first and third example have the largest disparity.  The first example did not, initially, 
have a dominant social group or technical framework, while the third example had 
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multiple developed social groups and technical frameworks.84  Bijker has a very robust 
approach; this is in part because he is able to support his theory with detailed evidence.  
While the evidence is a small sample, there are still insights he offers which are very 
beneficial to the sociology of the technology. 
 Callon’s version of the actor network theory is very appealing because of its 
initial simplicity.  The actor network contends that all relevant entities that are linked to 
an invention or technology at its final stages of development have in fact been there from 
the start.  This is a very difficult thesis to manage.  The course and trajectory of the 
technology or invention is unknowable in its entirety at its inception.  Therefore, when 
Callon claims that they are all present in the earliest stages, it does not appear that they 
exist in any real fashion.  This is, they may exist inherently or in some underlying 
fashion; but they are unknowable in the early stages.  If they are unknowable, then they 
cannot be made use of in the early stages.  Therefore, while it might be convincing that 
the network is integrated from the very beginning, it is of little consequence because it is 
only something that is beneficial in retrospect and reflection.  Some factors are simply 
unknowable at the onset. 
 Systems theory and structuration theory are both on the same end of the spectrum 
leaning toward social constructivism.  While systems theory was useful in providing a 
paradigm parallel to the actor network theory, it remains incomplete due to one-sidedness 
in its analysis of social structures.  Structuration provides a slightly more balanced 
approach by adopting the strengths of both actor network series and systems theory.  
However, as John Clark and others point out, there are massive challenges to overcome. 
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 The connection of these theories to ethics assessment in HTA is fairly 
straightforward.  The work completed thus far in Chapter One, provides the philosophical 
underpinning and theoretical understanding for the integration of ethics in HTA.  The 
argument will be more fully developed at the end of the following section. 
   
1.4 Technology as value laden and its relationship to society  
The final two sections of this chapter will introduce the concepts above in relation 
to health technologies.  The nature of values in health technologies, specifically emerging 
health technologies, will be discussed as well as the relationship between emerging 
genetic health technologies and society.85  When applied to technologies in health care 
one will see how the relevant social groups interact with the various technological frames 
in modern techno-medicine.  In evaluating the theories, two currents are immensely 
important for this dissertation. First, acknowledging that what drives technological 
innovation is not society or technology alone, it is both together.  These authors have 
persuasively made their point.  Technological development is not a determined, linear 
process.  The second important aspect to consider is that these studies are, academically 
speaking, relatively new concepts.  They must be further developed and refined; and then 
it will be possible to effectively introduce them into bioethics discourse to gain a greater 
understanding of the physician-patient-medical technology relationship. 
This dissertation will not adopt a specific perspective.  It is enough to observe that 
technology alone does not shape society and that society alone does not shape 
technology; rather, the relationship is symbiotic—society is shaped by technology; and 
society impacts the design and evolution of technology. The first portion of this chapter 
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introduced emerging genetic health technologies, HTA, and primary goal of this 
dissertation. Taking into consideration the position specified above, it is concluded that 
emerging genetic health technologies will influence society, and society will influence 
the nature and development of emerging genetic technologies. 
 Technology is value-laden which means that it inherently carries normative value.  
Society, made up of diverse human beings, is pluralistic, carrying with it a plethora of 
perspectives, opinions, values, and norms.  Technology shapes society and society shapes 
technology.  Both of these are laden with values.  Hence, ethics is useful and necessary to 
make meaningful progress in understanding and unpacking this relationship, as well as 
examining and impacting technological and social development.  However, this particular 
dissertation will not be taking on the former of these projects as it is outside the scope.  
Rather, this dissertation will examine and argue that ethics can contribute to 
technological development, specifically in the area of emerging genetic health 
technologies.  These arguments will be fully developed in Chapter 3. 
 
1.5 Conclusion 
This chapter has explained how the connection between values and technology is 
important; if there is a connection, a stronger case can be made for the role of the 
ethicists, philosophers, social scientist, and other disciplinary experts.  Moreover, when 
the complex nature of the relationship between technology and society is discussed, a 
very strong case will be made for the inclusion of ethics in Chapter 3. This was 
accomplished by reviewing some of the dominant theories surrounding the relationship 
between society and technology, including technological determinism, social construction 
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of technology, actor network theories, systems theory, and structuration theory. Both 
ends of the spectrum were addressed, ranging from technological determinism to pure 
social construction. The argument presented and basic assumption made in this 
dissertation, is that technology and society influence and shape one another, it is not a 
one-sided relationship.  
When emerging health technologies are examined, the argument for ethics 
assessment will be strong.  Health in itself is considered a “societal good” not just in the 
sense of a commodity, but also in a very positive or normative sense of the term.  Health 
is desirable.  So when talking about emerging health technologies, HTA is incredibly 
important because these technologies will be applied directly to humans and human 
health, which in itself is considered good. 
It is not difficult to argue for the inclusion of ethics in HTA, however; in fact, 
many scholars agree that ethics should play a role.  This will be explored fully in Chapter 
Three.  Yet, very few explicitly state the reasons.  Moreover, there is no consensus on 
how this is best accomplished within existing HTA processes.  Through the articulation 
of these philosophical and socio-biological foundations, a substantive starting point is 
provided.  From this juncture, Chapter Two will assess the current status of HTA 
practices at the local, national, and global levels.  This includes examining the 
organizations responsible for carrying out HTA, as well as the methods they use.  Chapter 
Three will provide an in-depth analysis of ethics methodologies currently paired with or 
integrated in HTA.  Chapter Four will present the nonlinear approach. The dissertation 
will close by applying the nonlinear approach to emerging genetic health technologies.  
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Chapter 2: Health Technology Assessment (HTA) 
 
2.1 Introduction 
Chapter Two builds on the philosophical and sociological foundation delineated 
in Chapter One, and specifically addresses health technology assessment (HTA).  The 
aim of this chapter is to explain the nature and origins of HTA and a number of current 
approaches and methods in HTA.  This will be accomplished by examining the current 
agencies and organizations responsible for HTA, as well as analyzing orientations, 
frameworks, established pillars, and basic practices. 
 
2.1.1 Connecting value and assessment 
 Chapter One presented several positions explaining the relationship of technology 
and society.  The position adopted in this dissertation is that society and technology 
impact each other; and furthermore that technology is value-laden.  
The Food and Drug Administration (FDA) provides a list of reasons why the U.S. 
government engages in HTA:  to promote advances in science; support intellectual 
property rights and patent protection; support aging populations; address the increased 
prevalence of chronic disease; address emerging pathogens and other health threats; 
insurance; incentives from technology and pharmaceutical companies; issues surrounding 
direct-to consumer advertising; off-label use of pharmaceuticals and devices; and 
increased costs of unnecessary tests, unexpected results, among others.1 
The items delineated by the FDA reflect the value placed upon them by the nation 
and the larger global community.  Even more so than emerging technologies, the 
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technologies created to improve human health hold a special place of importance.  Health 
is considered a human and societal “good.”  One of the primary goals of medicine is to 
improve and maintain health.  Health technologies are meant specifically to help people.  
This presents several interesting philosophical debates on one’s moral obligation to 
pursue technological development, which will be fully explored in Chapter Three. 
 
2.2 Health Technology Assessment (HTA) 
 This section will set the stage for the rest of the dissertation.  First, HTA will be 
described, and its origins outlined.  This will be further clarified by a discussion 
surrounding the scope for HTA, as well as some foundational topics including risk, 
uncertainty and the acceptability of risk.  The current status of HTA will also be 
addressed in subsequent sections. 
 
2.2.1 Defining and explaining HTA 
Health systems across the globe have developed at different rates with varying 
degrees of complexity.  Development often reflects the diverse cultural, political, and 
social structures and conditions in each country.  One of the very few generalizations that 
can be made about these diverse systems is that they are created in an effort to improve 
health.  Defining and describing HTA and its role can be a challenge since there are 
multiple perspectives and methods.  The Institute of Medicine, based out of Washington, 
D.C., defines HTA “to denote any process of examining and reporting properties of a 
medical technology used in health care, such as safety, efficacy, feasibility, and 
indications for use, cost, and cost-effectiveness, as well as social, economic, and ethical 
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consequences, whether intended or unintended.”2  Health Technology Assessment 
International (HTAI) expands the definition further, identifying HTA as “a field of 
scientific research to inform policy and clinical decision-making around the introduction 
and diffusion of health technologies [in a] multidisciplinary field that addresses the health 
impacts of technology, considering its specific healthcare context as well as available 
alternatives.”  HTAI further identifies several contextual factors in the definition of HTA, 
including “economic, organizational, social, and ethical impacts.”  Of equally important 
interest is the HTAI position that such assessment can be adapted due to the policy 
considerations of a particular health care system.3  Finally, the European Network for 
Health Technology Assessment defines HTA as “a multidisciplinary process that 
summarizes information about the medical, social, economic and ethical issues related to 
the use of a health technology in a systematic, transparent, unbiased, robust manner.”  
The goals of HTA, the network claims are to “inform the formulation of safe, effective, 
health policies that are patient focused and seek to achieve best value.”  Above all, the 
network concludes, HTA must maintain a foundation in rigorous research and the 
fundamental principles of the scientific method, more so than adapt to any particular 
policy considerations.4 
From these various definitions, one can conclude that HTA is a process to gather 
and disseminate information about new health technology to politicians, scientists, 
researchers, and the wider public in an effort to provide the necessary information so they 
can make informed policy decisions.  Concrete problems can arise from new technical 
developments; and HTA attempts to provide relevant information that can be used in 
addressing these challenges.  In many cases, the problems are not with the technologies 
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themselves, but rather in the greater context of real-life applications.  As a result, 
engaging multiple disciplines is necessary, which forces HTA to be an inter/trans/multi-
disciplinary process.  HTA must be, at the very least, multidisciplinary because it is 
impossible for a single discipline to have the capacity to adequately deal with the 
scientific, technical, economical, ecological, legal, ethical, political, and societal issues 
that must be taken into account when developing health care policies. 
Health technologies can be assessed at different times in development and trial 
phases; these are called stages of diffusion and maturity.5   HTA can be initiated by 
policy-makers, health professionals, health administrators, third-party payers, patient 
advocate organizations, or HTA institutions.6  The reasons for assessments are many, 
including, but not limited to, new technologies, adjustments in old technologies, 
adaptations of old technologies, organizational changes that affect technology, safety 
issues, social and ethical concerns, economic concerns, or the emergence of the new 
problem that requires action.7  The variation in orientations, frameworks, and practical 
functions in HTA will be addressed throughout this chapter. 
 
2.2.2 Origins of TA and HTA 
To provide a historical perspective, this section will address technology 
assessment juxtaposed with health technology assessment.  Technology assessment (TA) 
emerged in the 1960s as scholars and society as a whole began to critically reflect on 
developments in science and technology, and their relationship to policy-making.  In 
short, TA is a concerted effort to supply politicians, scientists, researchers, and the wider 
public with information regarding the social aspects of technology.  There are concrete 
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problems that arise from new technical developments; and TA attempts to provide advice 
on addressing these challenges.  A consensus emerged that the negative effects of 
scientific and technological developments ought to be curtailed as much as possible.  TA 
developed out of this discourse as a policy research tool aimed at identifying and 
anticipating problems as well as solving them.  The aim was to control the unintended 
consequences of emerging technologies.  It would be accurate to consider TA as a type of 
early warning system.8 
The United States Congress formed the Office of Technology Assessment (OTA) 
in 1972; and it operated until 1995.9  Technology assessment is a form of policy research. 
It attempts to address for short-term impacts and long-term effects.  While the primary 
concerns center on safety, efficacy and cost-effectiveness, there was some consideration 
given to ethical, legal and social issues. These additional considerations were deemed 
necessary in order to provide policy makers with the most accurate and helpful 
information.10  Technology assessment can be undertaken on any variety of technologies, 
ranging from health technologies to motor vehicles, and so on.  The focus of this 
dissertation is health technology assessment, which pertains to those technologies applied 
in a health care setting or more broadly to human health in general.11 
David Banta et al, in Toward Rational Technology in Medicine, note that there is 
confusion about technology and its relationship to society stemming from past “unbridled 
optimism” and a “new wave of negativism.”12  Arguably, over time, the function of 
technology has changed very little, yet its scale and power have dramatically increased.  
This has altered the function of technology insofar as it has increased the role it plays in 
daily life as well as in the biomedical field.13  Banta et al suggest that there is an 
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identifiable process of technological change.  It begins with general analysis and 
theoretical research, advancing to basic empirical research, which provides knowledge to 
properly assess where technological advancements can be made in a given system.  To 
demonstrate feasibility, applied research is carried out along with the development of 
implementation strategies, testing manufactured goods, marketing, and diffusion of the 
technology.14  This is a fairly limited, one-dimensional perspective.  Models such as these 
should be expanded to include social contexts and a broader understanding of the impact 
society and technology have on each other.  There is some recognition that assessment is 
needed.  By the early 1990’s, some scholars suggested that the rule should be “no 
evaluation—no technology.”15  The fundamental claim is that the inappropriate use of 
technology has led to inflating the price of health care and dehumanizing the practice of 
medicine.  Thus, it is important not only to assess the efficiency and cost of a particular 
technology but the social and ethical dimensions as well.16  The assessment of a specific 
technical intervention is not the only activity of the OTA.  There are also abstract 
considerations, such as examining the role of technology and society and understanding 
the rapid acceptance of new technology.  
Banta et al identify four primary concerns that arise as a result of advancements in 
medical technology including benefits, risks, financial costs, and social impact.  These in 
turn have a direct correlation to ethics, the economy, legal, and political systems.17  Many 
systems develop as a result of existing technology; medicine has not, according to Banta 
et al.  The medical infrastructure was not designed to provide cost-effective technology to 
patients; rather, technology entered an existing system and as a result evolved almost 
haphazardly with no rational plan for development or implementation.18 
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In 1976, the OTA provided a list of questions for consideration when introducing 
a new technology.  By the 1980’s there were only two agencies in the United States 
charged with examining the social implications of technology; the Office of Technology 
Assessment and the National Center for Health Care Technology.19  Past HTAs have 
focused on individual interventions such as diagnostic and therapeutic technologies and 
to a lesser degree organizational systems.  Typically evaluation is done of the singular 
intervention rather than the integral program in which it is embedded.20  
Robert Reuzel, a scholar at Nijmegen University Medical Centre, Department of 
Medical Technology Assessment, provides several reasons why HTA was, and in some 
cases continues to be, restricted in focus to emphasize on cost-effectiveness and efficacy.  
The first reason can be derived from history.  One of the primary reasons technology 
assessment started in health care was to determine whether certain expenditures could be 
justified by benefits.  Second, assessment requires input from highly specialized 
researchers and others who work in the development of health care technologies, which 
typically does not include ethicists and sociologists.  Finally, the political context of 
health care technologies must be considered.  Generally it is believed that determinations 
of cost and effect are scientific considerations and hence provide strong basis for 
decision-making.  Social and ethical considerations are considered debatable; and thus 
provide a weaker basis.  The effectiveness, safety, and market approval are often equated 
with acceptability of a technology.21  HTA as it currently stands can take one of two 
paths.  First, it can be a tool for estimating cost and effectiveness.  Second, it can be 
“recast as a formative evaluation framed in a constructivist scientific paradigm.”22  
Reuzel argues that HTA should aim at directing and managing health technology at the 
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political level.  This means that assessment must be grounded in a decision-making 
framework; otherwise it is not likely to affect decision-making at all.  Assessment 
research should result in the ability to provide the necessary information to manage 
technology in society.23  Surveys of recent HTAs show that there are two primary 
approaches.  The first emphasizes effectiveness, safety, and economic considerations of 
the new technology.  The second perspective is much broader, taking into consideration 
not only the items listed above but also social and ethical consequences.24 
 
2.2.2.1 Difference in scope 
There is a difference in scope between TA and HTA.  There are three central 
considerations in TA: (1) how to identify a problem (2) when should TA step in, and (3) 
what TA method should be employed.  The second consideration when TA should step in 
is an interesting one because it is very dependent up on the first step.  So how does one 
determine when a problem is relevant for political leaders, policy makers, researchers, 
and the general public?  There is no clear-cut or easy answer.  Whenever advice is 
solicited and there is evidence of desire for advice, then it is clear when to take up TA.  
Yet an organization that conducts TA or HTA can prioritize assessment needs as they see 
fit.  There is no structure for prioritization of TA and HTA needs. There is another reason 
why this particular consideration is important—TA institutions have limited resources 
(time, staff, and money).  Multiple problems that require solutions could arise 
simultaneously, which would necessitate the need for prioritization (most likely based on 
urgency) of projects.25  
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Comprehensive approaches to TA were originally intended; however, those 
practicing TA realized that partial approaches could serve as appropriate alternatives, and 
in fact might be preferable in situations where limited time and funds were available.26  
Thus, rather than having a full, robust holistic approach to TA, many only addressed 
specific concerns and issues.  While this is not ideal, when faced with time and fiscal 
restraints, the calls for both timely and affordable TA and HTA became consistent.27  
The following sections will address risk, specifically issues surrounding 
uncertainty and the acceptability of risk.  These are critical concepts because of the very 
nature of the health technology.  It is a human and social good; health technology is 
produced to make a positive impact on the lives of individuals and entire populations.  As 
such, a robust understanding of risk is crucial if one is to fulfill any moral obligations 
ingrained in HTA processes (these will be addressed in Chapter Three). 
 
2.2.2.2 Understanding risk 
Risk and uncertainty must be addressed in any discussion about emerging health 
technologies.  The mere fact that they are “emerging” complicates the situation because 
this increases the potential for risk of harm due to uncertainty.  Therefore, a brief 
explanation of risk and uncertainty is necessary in order to fully understand the task of 
HTA when it comes to evaluating the emerging genetic technologies which will be 
addressed in Chapter Five.  An understanding of risk is important for the broader concept 
of HTA because safety, especially from uncertain or unknown risks, is one of the primary 
evaluative aspects in HTA. This section will address how risk can be viewed and 
evaluated.28  
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A risk is a chance or probability of a bad or negative outcome.  One is concerned 
with negative outcomes that manifest as harm to an individual or multiple persons.  Risk 
analysis has several sub-disciplines including probabilistic risk analysis, health risk 
analysis, ecological risk assessment, risk-benefit analysis, risk perception, and risk 
communication.29  To begin, one should have a clear and distinct understanding of the 
terms.  Most people have general notions of how to characterize risk and harm; however, 
there are ambiguities.  When considering harm, it may be tempting to equate it to 
physical injury.  However, this leaves out other dimensions of harm.  Other types of harm 
include but are not limited to physiological, social, and economic harm.  So a more 
appropriate characterization of harm might be Joel Feinberg’s, an American political 
philosopher, definition which states: “someone is harmed when his or her interests have 
been thwarted, defeated, invaded or set back.”30  Identifying harm as any setback to the 
interests of an individual is attractive because it accounts for a multiplicity of harms, not 
just physical harm.  Many scholars begin the discussion of risk-benefit analysis without 
identifying what constitutes a risk.  For the purposes of this essay, risk is characterized as 
the probability and magnitude or severity of a potential, future, and undesired harm.31  
The nature of risk is two-fold; it describes the probability or chance of the harm 
happening, yet also accounts for the severity of the potential harm.  Thus, there are two 
levels of uncertainty:  first it is uncertain that the harm will occur—that is why the 
probability is estimated; and second, it is uncertain because the severity of the harm could 
vary per participant since no two participants are identical.  This means that the estimated 
probability of a risk will occur, as well as the severity or magnitude of the risk based on 
the average participant, is determined by the inclusion/exclusion criteria of the study.32 
  
 
48 
 
 
 
 Unfortunately, risk and harm are sometime conflated to share an identical 
meaning.  This is a mistake that should be avoided.  Risk is not harm; they are related but 
not identical or equivalent.  This is a convincing argument based on the distinctions 
outlined above, namely that risk and harm are not parallel constructions. Stephen Perry, a 
scholar in the field of jurisprudence and political theory from the University of 
Pennsylvania, makes a different type of argument when asserting that risk is not harm.  
When an individual has been subjected to a risk because of the actions of another, this 
exposure is not in itself a harm.33  However, the U.S. legal code does not embody this 
sentiment.  For example, in tort law an individual can be awarded damages by simply 
being exposed to a particular risk.  Perry notes that there has been an increase in the 
number of medical malpractice cases in which legal liability has been declared based on 
the exposure of a patient to risk.  For example, a case might unfold like this: the 
defendant is found to be negligent; and the plaintiff, as a result, of this negligence 
suffered exposure to risk which is then interpreted as “harm in the form of a lost or 
reduced chance of avoiding an adverse physical outcome.”34  Perry argues that this is a 
mistake in logic; risk cannot, logically, be conflated with harm and result in 
compensation.35  The basis for Perry’s assessment and argument—that risk is not harm—
is derived from the well-known “multiple reference classes” problem.36 
 
2.2.2.3 Understanding uncertainty 
Uncertainty, or a lack of information, is a characteristic of most decisions.  
Uncertainty exists when probabilities are either completely unknown, or are known only 
with insufficient precision.  Therefore, decision-making under uncertainty consists of 
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making decisions with no or insufficient information about risks and harm.  Most of the 
decisions made in human life are made under uncertainty.  Few circumstances exist in 
which the probabilities of possible outcomes are completely known; and many of these 
situations include closed contexts such as flipping a coin or rolling dice.  This section 
examines how humans with limited capabilities and knowledge cope with uncertainty in 
risk.37  
In HTA, all data represents certain thresholds and endpoints from which patients 
and populations are sampled.  While uncertainty is intentionally minimized there is 
always the possibility for errors in data collection, the measurement and benchmarking 
mechanisms, and the interpretation of data.  Later in this chapter a number of the 
methodologies and frameworks will be addressed.  Most of these rely on conceptual 
models; standardized best practices available at this point.  Some methods are assessed as 
better than others; but there are currently no concrete standards.  This very fact calls into 
question levels of uncertainty in HTA reports themselves.  For example, it is not unheard 
of to have two countries produce contradictory reports on the same device or 
pharmaceutical.38  Despite uncertainty, recommendations and decisions must still be 
made.  
 
2.2.2.4 The acceptability of risk 
Attempting to determine the acceptability of risk necessarily includes some form 
of moral reasoning, whether explicit or implicit.  When determining what is good or bad, 
beneficial or negative, the decision involves value-judgments that invoke ethical 
considerations.  This brief section will expose a very important connection between the 
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use of value-judgments and risk and uncertainty.  The connection involves ethics and 
other social considerations.  This connection strengthens the argument for an enhanced 
HTA approach with a substantial ethics component.39  
Why is philosophy, specifically ethics, needed in risk analysis?  Many approaches 
to risk assessment and evaluation are based on quantitative methodology, which in many 
cases focuses on utility maximization.40  Risk is measured based on the probability and 
severity of the outcome.  Probabilistic risk analysis is very useful; however it does not 
provide the decision maker with all the necessary contextual information to make an 
informed decision.  Risks are not created from nothingness; they are contextual.  Risks 
are either taken, run, or imposed.  Taking or imposing risks entails issues such as agency 
and relationships.41  These are very difficult to incorporate into an evaluation that looks at 
probability and severity of risk.  Therefore, to have any meaningful computation it should 
be determined who is doing what action and their reasons for doing it.  Hansson notes 
that, morally, it makes a substantial difference if one puts their life on the line and 
assumes that risk versus risking someone else’s life to further their own ends.42  Another 
moral aspect to consider is whether taking a risk is done so willingly or freely without 
coercion, manipulation, or exploitation.  Clearly, there are moral ramifications if one is 
not acting of their own free-will.  It is evident that while traditional risk calculations of a 
purely quantitative nature are necessary and provide a useful starting point, quantitative 
risk analysis must be accompanied with ethical considerations pertaining to risk.43 
Hansson argues that current moral theories are not equipped to deal with risk and 
uncertainty.  If one approaches risk from a utilitarian perspective, it suggests that pure 
interpersonal rectification of risks and benefits is acceptable.  Therefore, a risk for one 
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person could always be dominated or outweighed by a greater benefit for someone else.44  
If one examines risk from a deontological framework the converse problem exists.  It 
would be difficult for the deontologist to justify any action that would intentionally put 
another at risk.  Hansson notes that there appears to be a prima facie right at work:  
“everyone has a prima facie moral right not to be exposed to risk of negative impact to 
her health or her property, through the actions of others.”45  It is useful to view exposure 
to risk not as any type of moral maxim but rather as a prima facie rule or principle 
because a prima facie rule can be overridden.  It is self-evident that one should not 
intentionally be exposed to negative risks.  However, risk is involved in everyday life and 
social interaction.  One cannot live without subjecting others and themselves to risk.  For 
example, simply by driving a car to and from work one puts not only other drivers at risk 
but oneself as well.  Hansson explains that there is a way to maintain the prima facie rule 
despite unavoidable risks.  There must be an agreed upon normative account for 
overriding this rule and making some risk impositions acceptable.  Hansson suggests this 
can be done through an “appeal to reciprocal exchanges of risks and benefits.”46  Every 
individual takes risks in order to gain some benefit. For example, one risks driving to the 
grocery store—and all the potential risks that arise while driving a car and interacting 
with other humans—in order to benefit from buying food to sustain their family’s 
nutrition.  Therefore, it is reasonable for them to extend this practice to others.  As a 
result, everyone engages in mutual exchanges of risks and benefits.  Put another way, 
since other people are permitted to drive cars and expose others to certain car-related 
risks, then they are also allowed to drive their car and expose them to those similar risks.  
This reciprocal exchange of risk and benefits clearly benefits all of society.47 
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In subsequent sections, it will become evident how the understanding of risk and 
uncertainty impact HTA.  Also, in Chapter Three, it will be argued that ethics provides 
useful methods for determining socially acceptable thresholds and endpoints of risks. 
A recent article has taken up the issue of ethical acceptability of risk.  Patenaude 
et al, in the article titled Framework for the Analysis of Nanotechnologies’ Impacts and 
Ethical Acceptability: Basis of an Interdisciplinary Approach to Assessing Novel 
Technologies, argue that the acceptability of risk is an issue for ethics, and provide 
evidence that market interests and state regulations do not provide an ethical justification 
for certain technologies.48  Furthermore, the authors present a framework for the analysis 
of both impact and acceptability of emerging technologies.  In this particular article the 
authors are most specifically concerned nanotechnology.  Given the recent crisis and 
public rejection surrounding genetically manipulated organisms (GMOs), the authors 
suggest that researchers in nanotechnology stand to learn of few lessons. 
The authors address two important distinctions in risk assessment, they are the 
physical risk that is any aspect of the emerging technology that may be harmful to 
humans or the environment, and the other is comprised of the value judgments 
surrounding emerging technologies.  The authors argue that the very nature of risk 
assessment is value-laden.  This is because the risk assessment must not only weigh and 
balance the physical consequences of technology, but also must answer issues 
surrounding the weighing of social benefits versus regulation.49 
This article primarily focuses on nanotechnology however some of the basic 
arguments are the same as those used for the justification of ethics’ role in HTA.  The 
authors, a group of interdisciplinary researchers, suggest a model that complements 
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existing risk assessments in nanotechnology.  This seems to parallel the work that is 
being done in many other emerging technology venues, such as synthetic biology and 
emerging genetic health technologies.  Again, the aim is not to disrupt the process or 
move ethics to a special place outside of the process but rather to provide meaningful 
integration for a comprehensive impact on the acceptability analyses pertaining to risk.50 
 
2.2.3 A brief history of HTA 
The origins of HTA are fairly well delineated, as it is a recently developed 
practice.  The concept of technology assessment emerged in the 1960s as a recognition of 
the impact technology had on society as well as the unintended (or intended) and 
potentially harmful consequences. This occurred simultaneously with the recognition that 
some technologies raise important ethical and social concerns. The Office of Technology 
Assessment (OTA) was formed by the United States Congress and operated from 1972-
1995.  Technology assessment is a form of policy research.  Long-term and short-term 
consequences of the application of a given technology are assessed at the societal, 
economic, ethical, and legal levels.  The purpose is to provide policy makers with 
accurate information so they can develop new policies or alternatives to existing policies.  
In the US, issues such as the implications of supersonic transport, environment pollution 
and the ethics of genetic screening were a few of the first issues addressed by OTA.51 
Technology assessment can be undertaken on a wide variety of technologies. The focus 
here is health technology assessment, which applies to those technologies applied in a 
health care setting. The primary considerations in this field revolve around efficacy, 
safety and cost-effectiveness.52  
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2.2.4 Agencies responsible for HTA 
There are a variety of agencies and organizations that undertake HTA to varying 
degrees.  These agencies and organizations include regulatory agencies, government and 
private sector companies, government policy research agencies, managed care 
organizations, health professions organizations, standards-setting organizations, hospitals 
and health systems, group purchasing organizations, patient and consumer organizations, 
private sector assessment or policy research organizations, academic health centers, 
biomedical research agencies, health product companies, venture capital groups, and 
other investors.  Furthermore, these agencies often approach the process different 
depending upon the perspective.  There are four general perspectives on HTA including 
societal, hospital or health system, company, and consumer or user perspective.53  These 
will be addressed in the discussion of basic procedural aspects, in the subsequent 
sections.  To begin, the survey of HTA organizations and agencies specific countries and 
regions will be addressed as they carry the bulk of the workload in conducting HTA.  
 
2.2.4.1 USA and Canada 
There have been wide range of HTA efforts in the US.54  Many federal HTA 
efforts have failed.  B. Luce and R. S. Cohen argue that there are four politically-charged 
reasons for this.  First, scientists and investors perceived HTA as a threat to new medical 
technologies.  Second, some thought that HTA threatened the medical autonomy of 
organized medicine and practitioners.  Third, HTA was perceived by patient advocacy 
groups as a threat because it could restrict access to new innovations.  Fourth, with regard 
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to health care and economics, HTA was perceived by some as a mechanism to potentially 
ration care and contain costs.55  Due to these perceived threats, HTA met substantial 
political opposition in the US.  When OTA was disbanded in 1995, it received an annual 
budget of $21.9 million and employed 143 personnel.56  OTA came under fire in the 
1980s in a publication by Donald Lambro, a reporter in the 1980s and now chief political 
correspondent for The Washington Times, that regarded OTA as excessive and worthless 
because, he claimed, that the work it did overlapped and duplicated the work done by 
other government agencies.57  Despite these perceived threats and political opposition, 
many still recognized the necessity of HTA and the importance of the inclusion of ethics 
in the assessment. 
Since the 1960s many federal HTA initiatives have failed.  Currently, the US 
federal government plays a large role in HTA as a regulator.  Congress passed The Food, 
Drug, and Cosmetic Act in 1938; and as a result created the Food and Drug 
Administration (FDA).  One of the primary roles this agency fills is to determine whether 
new pharmaceutical products are safe and meet industry standards before they are made 
available to the public.  In 1976, this role was expanded to include the assessment of 
medical devices.58  However, the FDA only tests the safety of the proposed device or 
pharmaceutical.  Ethical and social considerations are not primary concerns if they are 
even addressed at all.  
 In 2005, the Veterans Health Administration (VHA) established the Technology 
Assessment Advisory Group (TAAG).  The purpose of this group is to provide evidence-
based policy recommendation to VHA leaders and policy makers.  TAAG is comprised 
of interdisciplinary experts primarily in the fields of clinical, research, and health 
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systems.  They select and prioritize topics for evaluation and have the power to call ad 
hoc panels of experts and physicians to disseminate information.59  Several other centers 
and committees exist in a similar fashion—that is, under the direct control of a larger 
agency.  In the past decade several other terms have been introduced that are related to 
HTA including “evidence-based medicine” (EBM) and “comparative effectiveness 
research” (CER).  They are all related terms, but not completely identical.  One way of 
conceptualizing this is that EBM and CER answer “does it work?” while HTA answers 
“is it worth it?”60  This distinction is important because some assessments focus only on 
evidence-based medicine and practices as opposed to comprehensive HTA.  Evidence-
based practice in medicine has been characterized as “the conscientious, explicit and 
judicious use of current best evidence in making decisions about the care of individual 
patients.”61  The origins of evidence-based practice of medicine focus primarily on the 
patient at the health care delivered application level.  However evidence-based decisions 
quickly expanded.  For example, making decisions for populations or the community 
should also be based on evidence; thus public health initiatives and interventions as well 
as health policy should be based on solid evidence.62 
One successful HTA-related initiative in the US was the establishment of the 
Agency for Health Care Policy and Research (AHCPR) in 1989.  The Center for Medical 
Effectiveness Research was located within this agency, which was responsible for 
improving the effectiveness and appropriateness of medical practice “by developing and 
disseminating scientific information regarding the effects of presently used healthcare 
services and procedures on patients’ survival, health status, functional capacity, and 
quality of life.”63  This agency subsequently transformed into the Agency for Healthcare 
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Research and Quality (AHRQ).  The primary aim is now to improve the health care 
system in the US by increasing safety and quality in health care.  The AHRQ tries to 
achieve this by increasing patient safety through reducing risk from health care 
interventions and services by conducting evidence-based research.  The AHRQ also tries 
to find ways to increase access to necessary services and contain costs.  The AHRQ 
makes their research available to the public in hopes that patients and providers will use 
the evidence-based information to make informed decisions.64 
It is unclear how AHRQ addresses HTA.  The majority of the information they 
publish deals directly with patient safety, quality of care, and evidence based practice.  
As recently as 2012, there were five assessment initiatives underway including one that 
focuses on creating a framework for “best evidence” approaches in systematic reviews.  
There is no mention of ethics.65  This leads to the obvious question—how are they doing 
comprehensive HTA?  Their methods are clear; and it appears that each topic has its own 
working group.  Furthermore, the topics selected are such that they do not always address 
a specific intervention or technology but rather a broad category such as cancer and blood 
disorders or musculoskeletal disorders.66  What can be gleaned from this lack of 
information is that ethics and HTA are not fully integrated; and there are no standards or 
specific guidelines for HTA. 
In the US, many federal HTA efforts have failed as well.  Some argue that this 
was due to politically charged accusations.  OTA was disbanded in 1995.67  Some strides 
at the national level have been made including initiatives by the VHA established the 
TAAG in 2005, as well as the creation of AHCPR in 1989.68  In the US, the FDA is one 
of the largest HTA regulators; however, they do not engage in a formal HTA process.  
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Their mission requires them to systematically assess all new pharmaceuticals as well as 
health devices for safety and efficacy.  Other aspects such as cost-effectiveness and 
ethical or social considerations are outside of their assessment scope.69  Although the 
agency’s charge was created under the Food, Drug, and Cosmetic Act in 1938, it was not 
until 1962, when federal criteria was established for evaluating the effectiveness of new 
drugs, that manufactures actually had to demonstrate both the safety and effectiveness of 
the drug. 
 In Canada, HTA started in the late 1980s.  The Conseil d’evaluation des 
technologies de la santé (CETS) was founded in 1988, and was later renamed the Agence 
d’evaluation des technologies et des modes d’intervention en santé in 2000.70  This 
organization operated primarily out of Quebec, and was ordered to focus their evaluation 
efforts on safety and efficiency of health technologies.  Canada formed a national agency, 
Canadian Coordinating Office for Health Technology Assessment (CCOHTA), in 1989.  
National guidelines for economic evaluation of HTA were put in place by 1994.  In 2006, 
CCOHTA was restructured and renamed the Canadian Agency for Drugs and 
Technologies in Health (CADTH).71  
 CADTH has been utilizing innovative methodologies to address HTA.  There has 
been an increased demand worldwide for faster and high quality HTA in order to make 
informed and urgent decisions.  CADTH developed and implemented a rapid review 
approach, which aims at providing an accurate and expedited mechanism to synthesize 
evidence.72  Rapid response reports are written specifically for Canadian health policy-
makers and decisions-makers.  As of 2014, CADTH has produced over 2,000 rapid 
reports.73 
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 Canada is not the only country utilizing rapid review processes; they are being 
used in various ways around the world.  However, there is no consensus surrounding a 
specific methodology or process for rapid reviews.  In fact, little is actually understood 
about the approach to evidence synthesis, specifically, what are the trade-offs when 
reducing the amount of time for a report.74 
 
2.2.4.2 Europe 
HTA methods vary considerably throughout Europe.75  HTA in Europe dates back 
to the 1970s as interest grew in examining the economic impact of emerging health 
technologies.76  It was not until the 1980s that countries started to engage in organized 
evaluations.  Most of these early efforts were at the local or regional level in France and 
Spain.77  In 1987, Sweden was the first European country to establish a national 
organization for HTA.78  In the following years, HTA practices started to become 
institutionalized by many countries.  At present, nearly all countries in the European 
Union engage in HTA whether it is through a private foundation or institute, an HTA 
program at a university, or through a government agency or organization.79  
This section will address the UK specifically, Central and Eastern European 
countries collectively, the European Union, as well as multinational and transnational 
HTA agencies and organizations. 
The UK began addressing health technology issues in the 1980s.  The first 
national action was in 1988, when the House of Lords released a report that set the 
priorities for medical research.80  The following year the Committee on Science and 
Technology was formed.  Throughout the 1990s, HTA efforts became more intentional 
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and more successful with the formation of the formal HTA program.  The National 
Institute for Health and Care Excellence (NICE) was created in 1999, and has grown 
substantially.  For example, the annual budget of the HTA program increased from £12 
million in 2005 to £70 million in 2012, and the projected budget for 2015 is £88 
million.81  
Currently, the NICE, like the FDA, must contend with the unwieldy task of 
licensing new pharmaceuticals and medical devices as well as performing holistic HTA.  
NICE is an independent institute charged with providing guidance on health technologies 
and clinical practice to the National Health Service (NHS).  In order to address the wide 
variety of pharmaceuticals, interventions, and medical devices, NICE has organized itself 
into four committees.  Each committee addresses one of the following responsibilities: 
technology appraisals, medical technologies, diagnostics, and public health.82  NICE 
attempts to have consistency across the four different committees; however, this is still a 
work in progress, as there appear to be significant differences in some of the 
methodologies according to W. Green and J. Hutton, of the University of York.83 Given 
NICE’s exclusive focus on the UK, international collaboration with other organizations 
and agencies has been rare.84  Also, the agency does not fund research programs outside 
of the UK. 
A recent article by A. Gulásci et al, a scholar from the Institute of Experimental 
Medicine, Hungarian Academy of Sciences, Hungary, conducted a survey of HTA in 
Central and Eastern European countries (CEE).  The study focused on Poland, the Czech 
Republic, Hungary, Romania and Bulgaria.  The vast majority of HTA developments 
have happened in the last decade.  In 2005, Poland established the Agency for Polish 
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Health Technology Assessments (AHTAPol), and corresponding guidelines in 2007.85  
Hungary established the office of health technology assessments in 2004.  Between the 
years 2004 and 2013 the Hungarian agency conducted an estimated 1,247 evaluations.86  
In both Romania and Bulgaria, HTA mechanisms and programs have just recently been 
established.  Romania, in consultation with the NICE, began integrating HTA into 
government functions in 2011, with the primary reason to use it as a cost-containment 
mechanism.87  In Bulgaria, the National Pricing and Reimbursement Council (NPRC) 
was charged with HTA responsibilities in 2013.  However, as of late 2014, they have not 
published HTA guidelines.  Their primary activities appear to focus around price setting 
and safety of pharmaceuticals.88  The Czech Republic does not have an independent or 
national HTA organization or agency.  They do have an institute responsible for pricing 
and reimbursement of pharmaceuticals and other health devices.  This indicates that some 
HTA practices might be occurring; however, they are not formally recognized as such.89  
Although HTA practices are occurring in all five of these countries, the emphasis, 
comprehensiveness, and competence vary widely.  Clearly, all the HTA activities 
primarily revolve around financial concerns; and nearly all these countries are conducting 
HTA on those technologies that will either be licensed or reimbursed by the government.  
There is still a lot to be accomplished when it comes to the institutionalization, 
standardization, adoption, and execution of guidelines and professionalization of HTA in 
CEE.90 
There have been multiple reviews of European HTA institutions and practices, 
each with a slightly different focus. As a result of these comprehensive reviews, it is 
difficult to get a true vision of HTA in Europe.  This is because of the number of 
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institutions performing HTA and the aim of their HTA practices. For example, some 
HTA institutions are aimed at focusing on the cost effectiveness of technology and the 
investment aspects as opposed to patient safety or other organizational impacts. 
There are multiple organizations that attempt to coordinate efforts between 
countries in Europe and the rest of the world.  These international efforts began in 1985 
with the formation of the International Society for Technology Assessment in Health 
Care (ISTAHC).  ISTAHC has since transitioned into Health Technology Assessment 
International (HTAi).91  In 1997, the report for the EUR-ASSESS project was published.  
This document provided the foundation for the initial steps towards standards and 
methods, specifically for priority setting, and HTA.92 
Currently, there are many international networks, agencies, and institutes that 
emphasize global collaboration, including the European Network for Health Technology 
Assessment (EUnetHTA), which is funded by the European Union; the International 
Network of Agencies for Health Technology Assessment (INAHTA); and Health 
Technology Assessment International (HTAi).93  Utilizing international organizations and 
collaborative partnerships provides several important opportunities.  It allows for the 
creation of new knowledge and information on global health priorities.  It also provides 
the opportunity to maximize the full potential of the new HTA tools.  Through 
collaboration, evidence-based research can more easily translated into practice.  Even as 
evidence is shared globally, it still allows for localized decision-making.94 
From this account of some of the HTA agencies and organizations in Europe, it 
becomes clear that the levels of intent, organization, and function vastly differ among 
countries.  The aim of many of these international organizations is to provide the 
  
 
63 
 
 
 
assistance to countries that have no HTA functions or primitive HTA bodies and 
processes, as well as to support those countries that have more advanced HTA 
mechanisms and organizations. 
 
2.2.4.3 The global HTA community 
This section will briefly address HTA outside of Europe and North America, 
which have some of the most developed HTA organizations and processes.  This includes  
Latin America and Africa.  In Latin America, HTA is significantly less developed.  A 
study conducted in 1998, by the Pan American Health Organization (PAHO), concluded 
that HTA was underdeveloped in Latin America for two primary reasons.  First, 
governments and other decision-makers did not understand the importance of HTA and 
healthcare systems.  Second, there was a general lack of specialized staff and experts.95  
Since 1998, HTA has made some progress in Latin America.  Red ESTA, created in 
2010, is an international organization commissioned as part of PAHO to address HTA.  
There were thirteen initial members including Argentina, Bolivia, Brazil, Canada, Chile, 
Costa Rica, Cuba, Ecuador, Mexico, Paraguay, Peru, and Uruguay.  That total has now 
risen to twenty-two.  Although some level of HTA may now be occurring in Latin 
America, Carolina Martin et al make a very important observation, in the article Ethical 
Health Technology Assessment in Latin America: Lessons from Canada and Argentina, 
regarding the quality of the practice. They argue that technical reports typically lack any 
form of direction or recommendation to policymakers and decision-makers about whether 
to include a specific technology in a given health care system.96  
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The story of HTA in sub-Saharan Africa resembles that of Latin America.  
However, there are additional challenges especially in resource-poor countries.  Arguably 
these resource-poor areas face more critical circumstances requiring even more accurate 
HTA.  With limited information, including availability of evidence-based choices, the 
threat of the inappropriate adoption or use of health technologies substantially increases. 
Sub-Saharan Africa also poses a unique question because the countries do not have the 
infrastructure or the educational resources to engage in traditional HTA.  The questions 
remain as to how appropriate HTA methods and tools will develop in resource-poor 
regions.  A recent analysis suggests that given all the HTA protocols, tools, and 
methodologies, there are six that are appropriate for the sub-Saharan Africa continent.  
These include the KNOW ESSENTIALS tool, Mini-HTA, Multi-Criteria Decision 
Analysis, and the WHO CHOICE method.97  Rather than focusing on building 
infrastructure, the current approach promotes the development of user-friendly, fiscally 
conservative, and timely HTA tools.  However, trade-offs due to the adoption of such 
approaches include a lack of depth, robustness, and holistic nature of the assessment. 
 
2.3 Methods in HTA 
This section will address current approaches to HTA.  There are several 
orientations to address the issues that new and existing health technologies pose.  These 
dominant orientations—technology oriented, problem oriented, and project oriented—are 
recognized primarily in those countries and organizations that have fairly advanced HTA 
practices.  Within each of these orientations, there are typically three pillars that comprise 
HTA assessments:  comparative effectiveness, economic evaluation, and organizational 
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impact.  The HTA methodologies utilized to assess these pillars or categories vary widely 
within counties and throughout the world; however, commonalities exist.  Given the vast 
array of methodologies available, only a few examples will be provided; and exhaustive 
assessments will not be provided here.  The last portion of this section will review three 
dominant frameworks approaches, the pillars of HTA, and how HTA is conducted, 
specifically with emerging innovations.  
 
2.3.1 Dominant frameworks/approaches 
There are three general or basic approaches to HTA:  a technology-oriented 
approach, a problem-oriented approach, and a project-oriented approach.  
 
2.3.1.1 Technology-oriented 
A technology-oriented approach is typically descriptive in nature and attempts to 
outline the characteristics and potential impacts of a given technology.  For example, a 
government agency like the FDA will want to determine the various impacts of adopting 
and utilizing electronic health record systems.  They want to determine the clinical, 
economic, social, and ethical impact of the technology.98 
 
2.3.1.2 Problem-oriented 
A problem-oriented approach is comparative in nature.  It focuses on identifying a 
problem and finding adequate solutions or management strategies.  Problem-oriented 
strategies attempt to find solutions for anything ranging from specific maladies to the use 
of alternative or emerging technologies in the treatment of patients.  For example, if 
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health professionals wanted to develop guidelines that involved the genetic sequencing of 
the patient's genome in order to identify hereditary and genetic abnormalities related to 
cancer, such as the BRCA 1/BRCA 2 mutations, they might call for an HTA to inform 
this process.99 
 
2.3.1.3 Project-oriented   
Project-oriented approaches, also referenced as program-oriented approaches at 
times, evaluate the use of technology, process, or program in a specific institution or 
designated project area.  For example, an HTA could be employed when a hospital 
system or even a specific hospital is attempting to determine whether to purchase a piece 
of new equipment or technology.  There are a number of key considerations including the 
facilities needed to operate the new equipment, or system readiness if it is a new piece of 
technology, personnel to operate it, financial resources, intended benefit; and etc.100  
 
2.3.1.4 Analysis  
These broad approaches—technology-oriented, problem-oriented and project-
oriented—may overlap and are not exclusive.  Yet, each may be an appropriate choice 
depending upon the case.101  All approaches draw on a similar body of knowledge, 
scientific evidence, and contextual aspects.  A technology-oriented approach would be 
immensely useful in determining how the new technology might be used and whether it is 
the most appropriate fit given the contextual circumstances (needs, personnel, finances, 
etc.).  Problem-oriented approaches are more comparative in nature because the primary 
objective is to solve an identified problem.  Thus, comparisons in efficacy, efficiency, 
  
 
67 
 
 
 
safety among possible technical solutions would be most appropriate.  Project-oriented 
approaches encompass aspects of both technology-oriented and problem-oriented 
approaches with one additional explicit layer—special attention to specific local contexts.  
Data analysis of local needs is required to determine which solution is appropriate for the 
hospital and hospital system.  HTA approaches are often a blend of these orientations.102 
Some scholars call for a more structured orientation, and prioritize some 
orientations over others.  Decker and Fleischer, two prominent TA scholars, argue that 
problem-oriented approaches should only be used from the very outset of an HTA 
project.103  Other scholars advocate for entirely different orientations of HTA 
frameworks.  For example, a decision-oriented framework, advocated for by Ritrovato et 
al, in the article Decision-Oriented Health Technology Assessment: One Step Forward in 
Supporting the Decision-Making Process in Hospitals, is built on integration of multiple 
frameworks and very specific HTA methodologies.  This will be explored in subsequent 
sections.104 
 
2.3.2 Pillars of HTA 
Within each of these orientations, there are three pillars of HTA assessment: 
comparative effectiveness, economic evaluation, and organizational impact of medical 
devices.  These pillars are essentially the three categories that must be addressed in order 
to have a holistic HTA.  Each of these will be described in detail in the sections below.  
This dissertation focuses on the specific methodologies of ethics assessment which, in the 
following descriptions and categorizations, fall in the organizational structure category.  
This will be explored in Chapter Three.  Therefore, only identification and high-level 
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overviews will be provided of any methodologies that might be using comparative 
analysis and economic evaluations. 
 
2.3.2.1 Comparative effectiveness 
There is a demand for evidence which demonstrates the effectiveness of the 
pharmaceutical or medical device in order to gain market access.  Most national licensing 
committees or reimbursement programs require this.  Comparative effectiveness 
addresses how the new technology compares to other similar technologies already in 
existence, as well as new technologies.  Comparative effectiveness aims to answer the 
questions surrounding whether the technology works, how well it works in relation to 
other options, and whether it can work in specific contexts.  Some technologies function 
properly only under greatly controlled conditions.  This assessment must consider how 
the technology will be deployed in reality, which requires understanding how the 
technology will be used and how it will function on a routine basis, not necessarily in 
ideal conditions.105  The technical aspects, including but not limited to reliability, user-
friendliness, required maintenance, overall design, composition and tolerances are taken 
into account.  Safety is a primary component of this assessment.  It is typically assessed 
in relation to the acceptable level of risk posed by the implementation and use of the new 
technology.106  For example, this HTA pillar may consider the probable outcome for a 
patient with health issue x, when operated by a health professional with training level z, 
in a given setting. 
One must draw a clear distinction between efficacy and effectiveness.  Efficacy 
answers the question of whether the technology can work.  Effectiveness answers the 
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question of whether it actually does work in a particular context.  These are important 
distinctions when it comes to understanding HTA’s impact on patient outcomes.  The aim 
is always to maintain or improve patient outcomes.107 
In the last decade, this is taken on a far more prominent role in HTA for a number 
of reasons.  Around the globe there has been increasing evidence of inappropriate and 
ineffective health technologies, such as over- or under-use.  In some cases, such as 
surgical procedures, there are at times insufficient rigor or lack of evidence because these 
technologies are often not subject to oversight.  National licensing organizations, such as 
the FDA, do not require full HTA.  As a result, they are only given the evidence required.  
This is often insufficient evidence upon which policymakers or health system decision-
makers can base their decisions because efficacy is often prized over effectiveness. 
The NIH articulates seven attributes of quality comparative effectiveness research 
which promotes direct comparisons of alternative interventions as opposed to 
comparisons with placebos or indirect comparisons.  Comparative effectiveness research 
should apply to all types of health technologies.  Effectiveness should be measured 
among populations and realistic healthcare contexts.  Healthcare outcomes should be the 
central focus.  Multiple research methods data sources and analytical tools should be 
utilized; and they should be applied and integrative or complementary way.   The ability 
to differentiate between patient types and populations should exist.  This research should 
take into account the emphasis on priority research, priority diseases, and priority 
populations.108 
 
2.3.2.2 Economic evaluation/cost-effectiveness 
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Economic evaluation addresses the cost-effectiveness of the new technology.  
Health care cost and expenditures have rapidly increased since the 1960s.  This is largely 
attributed to the introduction and unfettered diffusion of health technology.  US health 
care is generally thought of as technology driven.  That, taken together with the general 
sentiment that physicians should do all that is medically possible for patients (the 
technological imperative), adds to the pressure to adopt new and expensive 
technologies.109  
Economic evaluation is conducted at the micro-level and, when appropriate, at 
macro-levels as well.  At the micro-level, the assessment primarily revolves around cost 
(e.g. price, maintenance charges, utilities, expected revenues, upkeep and payment 
plans).110  The financial impact of the new technology is often compared to and balanced 
against current costs and expenditures and patient outcomes.  There are a number of 
different types of economic analyses including cost minimization analysis, cost 
effectiveness analysis, cost utility analysis, cost benefit analysis, and budget impact 
analysis.  Cost minimization analysis attempts to find the lowest costing product 
assuming the outcomes are equivalent.  Cost effectiveness analysis attempts to compare 
money with quantitative outcomes such as reduced mortality or morbidity.  Cost utility 
analysis compares monetary costs with outcomes defined by quality-adjusted life-years 
(QALY).  Cost benefit analysis compares the monetary cost with the benefits; however, 
the difference from cost effectiveness analysis is that both the costs and benefits are 
quantified in the same units, typically monetary units.  Budget impact analysis attempts 
to determine how the newly adopted technology will impact a given budget.111  These are 
just a few types of economic analysis that can occur in HTA.  These evaluations can 
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occur in conjunction, or overlap, with other processes.  Each organization adopts what is 
most practical for their purposes.  In addition, within each of these frameworks are 
additional tools and methodologies that vary from organization to organization. 
In some cases, it is beneficial to conduct an assessment of the technology’s 
macro-level impact.  This is especially relevant for agencies addressing HTA to inform 
national reimbursements, rates, and policies.  This can be as broad as the impact on a 
nation’s GDP, impact on national health costs, international relations and trade, and 
resources allocation in a given nation or throughout the world.112  Global markets are 
becoming increasingly attuned to the inner workings and potential financial benefits of 
healthcare, ranging from pharmaceuticals to biotechnology advances, health insurance, 
etc.  Recently, there have even been articles and reports published on the bioeconomy, 
which indicates that there are very specific market interests and patterns emerging in 
these areas that are driving research and production.113  The bioeconomy is a relatively 
new concept dating back to the mid-1990’s, and has emerged as a topic of significant 
interest in 2005.  The Organization for Economic Co-operation and Development 
(OECD) spurred this discourse.114  The OECD characterizes bioeconomy as “a world 
where biotechnology contributes to a significant share of economic output.”  The three 
primary elements of bioeconomy, according to the OECD, include “the use of advanced 
knowledge of genes and complex cell processes to develop new processes and products, 
the use of renewable biomass and efficient bioprocesses to support sustainable 
production, and the integration of biotechnology knowledge and applications across 
sectors.”115  
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The bioeconomy may become disruptive to existing business models.  This is 
because there is the possibility that the new technologies may not come to fruition.  There 
are a number of reasons for this, including overcoming economic challenges (e.g. the 
demand for capital upfront for development) and the additional challenge of overcoming 
social hurdles (e.g. public acceptance).116  Exaggeration and overpromising is often a 
problem among researchers driven by the need to secure funding for their projects.  They 
must convince investors that their approach and research is a good investment.117  This 
dramatically impacts how local, national, and multinational corporations invest and 
conduct business.  The emergence of the bioeconomy has demanded so much attention 
that, in 2012, it became a federal government priority in the US.  That year, the U.S. 
Office of Science and Technology Policy released the National Bioeconomy Blueprint.118  
This document details how certain agencies will take specific steps to “drive the 
bioeconomy” because this will allow “Americans to live longer and healthier lives, 
develop new sources of bioenergy, address key environmental challenges, transform 
manufacturing processes, and increase the productivity and scope of the agricultural 
sector while generating new industries and occupational opportunities.”119  Other macro- 
issues include regulation of technology, patent systems and intellectual property issues, 
and any policy changes at the state, national, or global level that impacts the 
development, integration and diffusion of technology.120 
 A recent international study conducted by Mathes et al, analyzed the methods of 
economic evaluations utilized by 127 HTA organizations and agencies.  The authors also 
requested information on methods used from these HTA agencies.  This resulted in the 
identification of thirteen methodological aspects for economic evaluations, including: 
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analysis of methods of economic evaluation, purpose of evaluation, evaluated 
technologies, types of evaluation outcomes, choice of alternatives, time horizon, 
perspective, costs, measurement of resource costs, valuation of resource use, 
measurement or evaluation of outcomes, sources for outcomes, discounting, modeling, 
analysis of uncertainty or sensitivity, equity aspects, and presentation of results.121  Of the 
127 agencies assessed, they found 63 relevant publications surrounding economic 
evaluations.  Of those 63 documents, only 25 manuals fulfilled all inclusion criteria.  A 
total of 14 HTA agencies representing 13 different countries were assessed.122  
The findings were rather stark, as the methods of economic evaluation varied 
greatly among the organizations.  The primary difference focused around the evaluation 
of efficacy and effectiveness.  The majority of HTA agencies carry out evaluations 
primarily to inform government-sponsored reimbursement decisions.  Given the plurality 
of approaches, this requires duplicate work in each of the countries.  The authors 
recommend generalizing the language to increase the transferability of studies.  This will 
eliminate much of the duplicative work being done by individual countries and increase 
collaboration.  Organizations such as EUnetHTA could play a prominent role in this.  The 
other, more disturbing, observation made by the authors was that there were conflicting 
recommendations between organizations.  Furthermore, the rationale supporting the 
recommendation was not always obvious.  The authors could not find a way to explain 
these considerable differences among methodological recommendations.123 
 
2.3.2.3 Organizational impact 
  
 
74 
 
 
 
The organizational impact of new technologies looks specifically at how the new 
technology would fit into the existing health system.  This is where considerations 
surrounding the ethical, legal, and social aspects of HTA arise.  Sensitivities surrounding 
normative concepts, such as the sanctity of human life and basic human rights, should 
inform the choices made regarding how and when to adopt a specific technology.  Also, 
the HTA processes themselves ought to be assessed for the highest levels of integrity.124  
Social, ethical, economic, and legal consequences should be considered and balanced in 
the adoption and integration of technology.  These considerations are taking on an 
important role in more recent national and multinational research.  For example, in the 
Human Genome Project, five per cent of the budget—roughly eighteen million dollars 
annually—was devoted to the exploration of social and ethical considerations.125  As a 
result, the US National Institute of Health also established the Ethical, Legal and Social 
Implications (ELSI) Research Program.126  Recently, there have been discussions about 
broadening ELSI to HELPCESS (humanitarian, ethical, legal, public relationships, 
economics, safety/security and social implications); although it is yet unclear how these 
broadened considerations might be adopted into existing frameworks.  The scope does 
appear to promote global health and brings personal dignity to the forefront of 
discussions.127 
There are many examples where technological innovation has challenged ethical, 
religious, or cultural norms.  For example, as technology advanced and medical experts 
were more capable of determining the time of death, the result had significant 
implications for organ transplantation but also required one to consider what it truly 
means for someone to be dead.  Hence, many ethical concerns around the practice of 
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organ donation through cardiac death arose.128  Whereas doctors in Western Europe and 
North America largely accept brain death criteria, other countries resist the notion and 
maintain that the individual, albeit brain-dead, is still alive.129  A non-health related 
example of technological impact was the influence of social media on the Arab Spring.130  
Currently, there are also concerns surrounding resource allocation of items that 
are scarce, yet lifesaving.  Issues such as organ shortages and limited access to quality 
care prompt researchers, scientists, health professionals and everyday people to 
collaborate on innovative solutions to these problems.131  Examples more specific to the 
endeavor at hand revolve around genetic testing, genetic engineering, stem cell 
cultivation and use and pharmacogenomics.  There are a host of political, economic, and 
ethical concerns surrounding the use, storage, and access to genetic information as well 
as the creation of genetically modified organisms.132  New technologies have the 
potential to negatively or positively impact patient autonomy as well as human integrity 
and dignity.  Innovations pertaining to genetic health are no different.  Stakeholder 
involvement and investments in decisions surrounding health technologies are critical.133  
The HTA processes in and of themselves should address the concerns between patients, 
practitioners, the general public, and technology.  
 
2.3.2.4 Analysis of the pillars 
Each of the three pillars brings important considerations to the forefront of HTA.  
It is immediately apparent why very accurate mechanisms for comparative effectiveness 
and economic evaluation are necessary.  It would be foolish to integrate a new or existing 
technology without engaging in any process to anticipate and calculate the anticipated 
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effect or impact.  It would also be unwise to adopt the technology without thoroughly 
investigating the cost.  These two pillars are aspects of every HTA; there are well-
founded methods by which one can accomplish a thorough investigation of each of these 
two pillars.  
The third pillar, organizational impact, is generally perceived as being an integral 
piece of the assessment process.  This is even a general consensus of its relevance and 
importance among the HTA community.134  However, the methods and processes by 
which ethics, legal, and social implications are assessed are woefully underdeveloped in 
comparison to the other two pillars.135  This assertion will be fully developed and 
articulated in Chapter Three.  In the last decade, there has been a fair amount of 
discourse; and many publications have developed frameworks that analyze ethical and 
social implications of health technologies. However, these are not integrated into every 
HTA process.136 
While it may seem that comparative effectiveness and economic evaluation are 
independent or at the very least distinct pillars of analysis, it is important to recognize 
that they have become very closely linked.  Y. Hoa and A. Thomas suggest, in a recent 
article on comparative effectiveness, that due to the ever-increasing healthcare 
expenditures and costs, there is increased pressure to include cost control as an aspect of 
comparative effectiveness.137  In the United States, there are two primary laws that push 
towards solid evidence-based practice of medicine as well as comparative analysis:  the 
American Recovery and Reimbursement Act (ARRA) and the Patient Protection and 
Affordable Care Act (PPACA), passed in 2009 and 2010 respectively.  The affordable 
care act also contained a provision that created the Patient-Centered Outcomes Research 
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Institute (PCORI).138  This institute is responsible for setting priorities in health research, 
funding studies, and, most relevant to this discussion, discerning methodological 
standards for comparative effectiveness research.  The PCORI, in conjunction with the 
NIH, are wading through the multiple definitions of comparative effectiveness research 
and resulting plurality of technologies.  There is a lot of tension, at least in the US, 
surrounding the role of economic evaluation within the context of comparative 
effectiveness.  The fear lies in the potential for health care rationing and barriers to access 
due to cost considerations.  This is also reflected in the current legislation, which prevents 
patient-centered outcomes research and comparative effectiveness findings from being 
used as “mandates for coverage appraisals, payment recommendations or even practice 
guidelines and federal health programs.”139 
It is evident from this overview of the pillars of HTA that their very conception or 
definition, scope, and related methodologies vary greatly among HTA agencies. Some 
aspects are even ignored altogether.  The following section will address some very basic 
procedural aspects based on the aforementioned orientations and pillars. 
 
2.3.3 Basic procedural aspects 
The previous two sections have established the general approaches and key pillars 
in HTA.  This section will explore a number of commonalities among procedural aspects.  
HTA is in no way a uniform practice or process; it varies from institution to institution 
and from country to country.  Yet, there are common currents and steps that can be 
identified, most notably ten that are found in virtually all HTA methodologies:  (1) 
identify technology for assessment, (2) identify and clarify the problem, (3) determine the 
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locus of assessment, (4) gather evidence, (5) retrieve new or additional data if necessary, 
(6) evaluate the evidence, (7) incorporate the evidence, (8) record findings and 
recommendations, (9) disseminate the findings and recommendations, and (10) monitor 
the impact.140  
While these commonalities exist, not all HTA processes and procedures include 
all ten; and likewise they are often not conducted in the exact order listed above.  Many 
HTA programs utilize integrated methods that combine steps, which often allows for 
easier data collection and analysis.  In some instance steps are even repeated multiple 
times until the data collection is considered comprehensive.  Also, depending upon the 
role of the body conducting the HTA, steps nine and ten may or may not be in their 
scope.  However, dissemination of findings and impact monitoring are very important 
steps in HTA.  
There are also significant implications on the utilization and execution of HTA 
depending upon the scope of the inquiry and the agency carrying it out.  For example, 
organizations that emphasize international collaboration will focus on overarching 
structures to guide all forms of HTA.  Those institutions that are much smaller focus on 
solving very specific problems or asking very specific questions of particular 
technologies.  Therefore, the focus is much more limited and questions of vision and 
overarching structure and collaboration are not on the table.  In the following paragraphs, 
two examples will be given on the distinction between HTA conducted at international 
levels versus how it is conducted at local levels. 
EUnetHTA has provided a robust international forum where discourse 
surrounding HTA's can be conducted.  One specific model for conducting HTA, 
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developed by EUnetHTA, is called the “core model.”  It was built to foster and enable 
international collaboration through results sharing.141  The core model consists of three 
distinct parts.  The first element is ontology.  This consists of a generic set of questions 
that help define the parameters and contents of an HTA.  The second component consists 
of the sets of methodological guidelines.  A set of questions is provided; and through 
answering these questions one begins to find the most appropriate methodology.  The aim 
of this methodological framework is to encourage and facilitate the sharing of HTA 
information and joint projects.142  The final aspect is a common reporting structure.  All 
reports and information have a standard reporting mechanism.143  Work is currently being 
done, through international collaboration, to enhance the usability of the core model.144 
At the national level, each country takes a slightly different approach to HTA.  In 
the US medical devices, interventions, and pharmaceuticals must obtain FDA approval.  
However this approval is primarily based on safety, and no formal HTA processes are 
undertaken by the FDA.145  The AHRQ engages in technology assessments, many of 
which surround health technologies, but not all.146  Private insurers have also started to 
engage in each day practices for employer-sponsored by self-insured health benefits 
programs.  However, little information is available regarding how HTA is conducted in 
the private sector and how each team reports impact decision-making.147  In sum, at the 
national level there are three general types of activities.  First, is the licensing of specific 
medical devices, interventions, and pharmaceuticals.  Second, are very specific in-depth 
systematic HTA processes (e.g. those undertaken by the AHRQ).  Finally, HTA is 
occurring with regard to specific questions inquiries posed by national health systems. 
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HTA looks quite different at the local or hospital-based level.148  A recent survey 
conducted by N. Martelli et al concluded that since 2008 the number of hospitals 
engaging HTA practices has increased.149  Yet, little is still known about the level of 
impact HTA reports and recommendations have at the local level.150  Marie-Pierre 
Gagnon et al recently conducted a systematic review of how local hospitals utilize HTA.  
This builds on the work started by a subgroup in HTAi, which was primarily interested in 
understanding how hospitals around the world utilize HTA.  The subgroup identified four 
primary approaches that individual hospitals use when conducting HTA:  the ambassador 
model, mini-HTA, internal committee, and HTA unit.151  In the ambassador model, 
clinicians take on the role of the disseminating specific HTA information and champion 
the adaptation use of this information.  Mini-HTA is a tool that provides support for 
decision-making.  The tool consists of contextual questions primarily surrounding the 
patient, the organization (hospital and system), and fiscal considerations in the 
technology itself.  A single person usually conducts this assessment.  The internal 
committee is typically an ad hoc committee of relevant stakeholders at the organization; 
ideally the members should reflect the various perspectives and stakeholders.  The 
committee is responsible for making recommendations.  The HTA unit is a structured 
component of the hospital, with a structured organization and charge.  Typically 
individuals who serve on this unit do so full-time and have specialized training.152 
Little is known about the impact of HTA on local decision-making cost 
effectiveness.  This is primarily due to the lack of research and reports generated by those 
who are engaging local HTA practices.  There is the added challenge that it often takes 
several years to realize the value accepting or rejecting an HTA recommendation.153  At 
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the local level, hospitals can commission HTA reports by private companies. Three 
popular companies in the USA include ECRI Institute, Hayes, Inc., and Blue Cross and 
Blue Shield Technology Evaluation Center.154 This is often a good option for hospitals 
that do not have the capacity to carry out their own HTA assessments. These companies 
provide context specific reports. However, the quality and comprehensiveness cannot be 
assessed here as access to these reports is limited. 
The impact of HTA is challenging to describe. Multiple reports have been 
published attempting to discern the impact of HTA.  These reports, many of which focus 
on NICE and other national HTA bodies, attempted to characterize the impact of HTA on 
health systems. By the late 2000s, approximately 17 of these studies had been 
conducted.155 Some of the reports concluded that health systems would act on the 
recommendations of the HTA reports, while other reports were not as conclusive. For 
example, one study concluded that health systems by and large reflected the 
recommendations of NICE appraisals; six appraisals were evaluated in the study.156 
While other studies suggest that these reports had very little impact on health systems.157 
Gerhardus et al suggest that while many recommendations are accepted at the policy 
making level, very few are actually implemented. It is only in those cases where there is 
significant risk or social issues that implementation of recommendations becomes 
evident.158 
It is clear from these descriptions of international, national, and local utilization of 
HTA that the focus, scope, and methodology differ.  In many cases international 
collaboration organizations rely on evidence-based practices to develop the tools they 
implement in order to maximize the effectiveness.  In the US, HTA practices and use 
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appear to be rather scattershot at the national level, based on the needs of the particular 
institution utilizing the HTA.  While the FDA has clearly outlined the strictest standards 
for evaluating effectiveness and safety, there are still strides to be made in addressing the 
organizational impact of technologies.  Currently, the onus is on specific health systems 
and hospitals to determine whether a medical device, intervention, or pharmaceutical is 
beneficial.  Some agencies do attempt in-depth HTA; however only a limited number of 
technologies are assessed; and there is no single repository where this information is 
collected and made available to the public.  Local hospitals are often utilizing what they 
have at hand, which could be anything from an ad hoc committee to a single professional 
or standing committee. There is some question as to whether the methodologies used at 
the local level are rigorous and reliable.159 
As a result of examining the function of HTA at various levels, several 
observations can be drawn.  One is the concept of developing HTA that is sensitive to the 
context of the health care system needs; a second is the development of another 
orientation, the decision-oriented HTA, to accompany the other dominant orientations 
(e.g. technology oriented, problem oriented, and project oriented). 
One way for HTA to become more inclusive is to be more specific about the 
precise technologies that are being assessed and why they are being assessed.  For 
example, the technologies that first come to mind are pharmaceuticals, medical devices, 
and interventions.  These are essentially technologies within the healthcare system.  
Garrido et al expands on these categories, in the article Develop Health Technology 
Assessment to address health care system needs, and suggests two additional categories 
that can assist in the selection of methodologies to provide clarity.  One of the categories 
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proposed is technologies and interventions applied to the healthcare system.160  This 
category would include the structural and organizational needs necessary to carry out the 
implementation of the new technology. This could include new policies or new physical 
space. They deal with the overall process and healthcare outcomes.  The second category 
identified includes those technologies and interventions that exist outside of the 
healthcare system.  These promote and protect how health technologies impact other 
sectors such as educational services, social services and the like.161  The authors suggest 
that clarity can be provided around what is expected from the HTA, and that by using 
these categories there will be greater focus on the goal and even a possible expansion of 
methodological approaches.  This is because a number of different methodologies can be 
applied in each of these categories as opposed to trying to apply a single methodology to 
all.  
The authors make the case that if HTA is truly going to develop and expand in 
order to meet the growing needs in healthcare more attention will need to be paid to other 
categories about technology assessments mainly increasing focus on regulatory policy 
measures organizations and health systems.162  They also contend that it will likely 
become important for individual hospitals and hospital systems to begin engaging in their 
own research in order to appropriately address all contexts of an issue, as opposed to 
relying upon data produced at the national or international level that is not context 
dependent.  The authors argue that while hospitals may need to engage in research, which 
does not mean that they should do so in a vacuum, or on an island.163  They should do so 
working collaboratively with national and international organizations. Across the globe, 
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countries at all different levels of HTA development and utilization; thus, the diversity of 
this collaborative opportunity should be fully utilized. 
 The proposal of a new orientation to HTA is the result of a thorough analysis and 
the combination of two specific methodologies into one coherent method.  Ritrovato et al 
have suggested a decision oriented HTA.  The aim is to bridge the gap that still exists 
between “the world of research” and “the world of decision-making.”  After extensive 
research, most of which focused on the core model proposed by EUnetHTA, these 
authors have suggested the combination of multi-criteria decision analysis (MCDA) and 
analytic hierarchy process (AHP).164  This new method consists of six steps.  The first is 
defining the problem.  The second is conducting a literature review.  The third is the 
creation of a hierarchy construction, which ought to be based on key performance 
indicators in alignment with the AHP method.  The fourth step is to conduct a priority 
analysis.  Step five includes the evaluation of alternative technologies.  The final step is a 
results presentation.165  This new orientation has already been utilized and tested.  This 
began in 2009 in the Bambino Gesú Children’s Hospital.  The results show that this 
Italian hospital was able to supply more precise and more structured output as well as 
contextualized evidence of specific technology, making it possible to obtain data that are 
more relevant and easier to interpret, and therefore more useful for the decision-makers to 
make investment choices with greater awareness.”166 
 
2.4 Conclusion 
This chapter reviewed current HTA practices as well as agencies, institutions, and 
governments that are charged or are voluntarily conducting HTA.  The predominant 
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orientations—technology oriented, problem oriented, and project oriented—were 
addressed along with the three pillars:  comparative effectiveness, economic evaluation, 
and organizational impact.  It is abundantly evident that HTA is not highly regulated or 
standardized.  The manner in which HTA is used, and when and how it is engaged, varies 
greatly across nations and agencies.  The information produced is utilized and interpreted 
in different ways.  The orientations differ depending upon the context.  The assessment of 
each pillar is not required.  In many cases, organizational impact is ignored altogether.  
The methodologies utilized vary greatly; and best practices are still being developed.  
HTA is unwieldy and it is very difficult to get a clear picture as the majority of aspects 
have very low levels of consensus developed around them.  Given that HTA started in the 
1970s, one must wonder whether these issues—the lack of standards, agreed upon 
methodologies, and dissemination of information—are ultimately reflective of the social 
and political contexts on which local, national, and international healthcare decisions rest. 
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Chapter 3: Ethics and Health Technology Assessment 
 
3.1 Introduction 
Chapter Three will examine ethics in HTA.  Particular emphasis will be placed on 
identifying how ethics is presently integrated into those processes, and on evaluating the 
role of ethics in HTA.  The value-laden nature of technology justifies the integration of 
ethics and social considerations, which is lacking in many current HTA models.  The 
chapter begins with a brief introduction to the task at hand and identifies a number of 
important aspects surrounding ethics and HTA, including: the role of ethics in HTA, 
appraisal of current HTA tools and methods, identification of gaps or deficiencies in 
ethics assessment, and finally the ramifications of these gaps. 
This chapter will show that, while most professionals involved in HTA believe 
that ethical assessments and considerations in HTA are critical and necessary, this largely 
appears to be lip-service, given the general lack of integration.  Many contend that ethics 
is neglected due to the practical limitations of implementing it.  
 
3.2 The role of ethics and HTA 
In this section, the role of ethics in HTA is reviewed from a theoretical 
perspective.  Arguments for the inclusion of ethics in HTA will be explored.  The 
implication surrounding the position of health technology as value-laden will also be 
explored in relationship to the inclusion of ethics in HTA.  Ethical perspectives and 
aspects of HTA are considered in direct reference to the values and norms of the health 
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care context; in a way this is prescriptive.  Ethics assessment offers guidance as to how to 
act or relate to the issue in question. 
Over a decade ago, a survey was conducted by the International Network of 
Agencies for Health Technology Assessment (INAHTA), and they reported that 80% of 
HTA organizations and agencies considered ethics to be an “integral part of the 
assessment”.1  As early as 2002, ethics assessments had already been included in a 
consensus statement about best practices in HTA.2  A more recent study by Arellano et 
al, from the Katholieke Universiteit Leuven, Belgium, in 2008, focused on attitudes 
towards ethics in HTA, from HTA experts themselves.  They found that there is a general 
consensus that ethics assessment is important.  For example, 90.1% of respondents in this 
survey disagreed with the statement that ethical implications should not be considered in 
HTA.  Furthermore, 58.4% of respondents agreed that ethical issues should be an integral 
part of HTA and be performed by HTA experts.  60.8% believed that at least one, if not 
more, of the HTA experts working on a given project should have formal ethics training 
or education.  In the absence of an ethics expert on the HTA team, 78.4% of respondents 
agreed that a professional ethicist should be hired in the role of a consultant.3 
In this study, the greatest consensus formed around the impact of technology on 
society.  Ninety-three per cent of respondents considered this impact to be important, and 
believed that ethical analysis should play a role in HTA.4  The consequentialist argument 
is really quite simple.  There are consequences for every action; this includes the 
implementation of new technologies.  It is often the aim of society to maximize utility; 
this includes balancing the need for technological advancement and improvement in 
conjunction with its usefulness.  Therefore, ethics assessment should not be minimized, 
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especially as it pertains to economic aspects of decision-making with regard to new 
technologies.5  
Armin Grunwald, a Dutch philosopher, argues that there are essentially two 
branches when it comes to how one acquires the knowledge necessary for decision-
making surrounding new technologies.  These two branches are the ethics of technology 
and technology assessment.  He argues that these two branches have developed largely 
independent of one another and are grounded on different assumptions about how to 
orient knowledge for the advancement of technology and policy.  The ethics of 
technology highlights philosophical ethics and analyzes the normative implications and 
potential moral conflicts.  Technology assessment, on the other hand, is primarily 
descriptive of sociological or economic research.6  Since the publication of Grunwald’s 
article in 1999, there has been much discourse over the role and methodologies of each, 
and how they overlap and intersect.  As a result of this discourse, suggestions of new 
orientations arose, including applying ethics through the lens of “technology as policy”.7 
 M. Giacomini et al, scholars from McMaster University, Canada, provide a 
theoretical contribution surrounding the notion of “technology as policy.”  The authors 
argue that there are three important shifts that need to occur in the current thinking about 
HTA perspectives and approaches.  First, there must be a shift from thinking of HTA as a 
research methodology and reframe it as a form of health technology policy analysis.  This 
would view technology essentially as a form of policy, that in itself forms, shapes, and 
produces policy.  Second, ethics must shift from a foundation in moral theory to focusing 
on only those values and norms most relevant to policymaking.  The final shift must be 
from the view of evidence as scientific research to viewing it as “intelligence sources” 
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that necessarily include experts, stakeholders, and public policy makers.8  The authors 
argue that understanding HTA as policy steers analysis away from philosophical 
questions, ethical principles, and theories. Rather, ethical analysis should be geared 
toward practical and pragmatic questions.  The authors contend that given a pluralistic 
global society, it is easier to generate consensus around “superficial and pragmatically 
express norms,” as opposed to “deep ideological commitments.”9 
One important question remains—can one justify technology development 
without the need for any ethical reflection.  Grunwald asks whether there are certain 
conditions that can be fulfilled that would constitute an “ethics-free” space in 
technological development.10  He proposes a principle and framework by which to 
determine these ethics-free spaces.  The principle states: “steps, decisions and processes 
in technological development are free from the demand or necessity for ethical reflection 
if, and only if, there is a comprehensive, clear, commonly accepted and factual 
acknowledged normative framework which has to be and factually is followed in 
technology development.”11 
From this section, one can discern three ways ethics can play a role in HTA.  
Ethics can be all-encompassing and integrated at the very core of HTA.  It can be rebuilt 
on procedure, which is what primarily exists now, as will become evident in subsequent 
sections.  Or, ethics can be ignored. Ethics can be neglected and remain unengaged; that 
is, of course, until a moral or ethical crisis hits.  
Within these three levels of integration, ethics can be usefully applied to HTA in 
two ways.  Ethics can operate within the existing framework of a given technology and 
also transcend a specific framework and address the technology itself.  When moral 
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issues, questions, or problems arise as the result of a particular technology they already 
exist within a framework of the given situation.  This framework accepts technology as 
value-neutral and attempts to identify what responsible and proper use should be.  A 
traditional or classical approach to this includes the four general principles put forth by 
Tom Beauchamp and James Childress:  autonomy, nonmaleficence, beneficence, and 
justice.  From these general principles, rules and guidelines are extrapolated to determine 
appropriate use of a given technology.  This includes both empirical and normative 
components.  Quantitative data is necessary to determine risk, benefit, and financial cost.  
The normative principles are needed to identify which facts, supplied by the quantitative 
data, require consideration from an ethical and social perspective.12  This is useful 
because the framework can determine which facts require further consideration and sets 
the stage for additional assessment. 
The second way ethics can contribute to health technology assessment, Henk ten 
Have, Director of the Center for Healthcare Ethics at Duquesne University, argues, is 
through an evaluation of the technology itself.  Technology in this case is not considered 
to be value-neutral but rather value-laden; that is, the technology incorporates value in 
itself.  This type of inquiry aims at uncovering the entrenched or pre-existing values in a 
given technology.  As a result, a diachronic and synchronic perspective is produced.  Ten 
Have writes: “values embodied in current technologies are explained in connection to 
similar values in history, but they are also clarified in connection to developments in 
other scientific disciplines, thus looking beyond the framework of present times and 
existing disciplines.”13  This type of ethics research attempts to demonstrate how humans 
understand their existence in the world, by evaluating what is acceptable and 
  
 
101 
 
unacceptable.  In addition to these macro-considerations, this type of research should also 
focus on the values of stakeholders who will be affected if the technology is adopted.14  
 
3.2.1 Justification for ethics in HTA 
This section provides a number arguments that justify the role of ethics in HTA, 
including arguments based on the value-laden nature of technology and the moral issues 
surrounding risk and uncertainty, theoretical arguments, and practical arguments. 
Ethics should be an integral part of health technology assessment.  Many concerns 
that arise under the categories of benefit, risk, and cost effectiveness are inextricably 
linked to moral concerns.  Health is valued by almost everyone.  Emerging health 
technologies directly impact health; so a variety of perspectives must be taken into 
account in technology assessment due to their relevance.  Furthermore, especially in 
health care, when new technologies are introduced they create new care or therapeutic 
options that will impact those already in existence.  
Social value impacts the development, evaluation, and use of health technologies.  
Health technologies reflect interactions between multiple social groups with various 
social values.  Social values impact which technologies will be developed as well as how 
the development will progress.  One example of the impact of technology on society and 
society shaping technology rests within the definition of death.  Margaret Lock argues 
that without the technological development and adoption of the artificial ventilator there 
would not have been a reason to create the brain death criteria for the determination of 
death.  Furthermore, it was judged by both the legal and medical communities in the 
United States that the determination of death is strictly a medical issue.  Lock ties this 
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technological development and results with the introduction of organ transplantation to 
demonstrate how death determination criteria are inextricably linked to technological 
developments in organ transplantation.15  A significant challenge to considering and 
assessing social impact and effects is that they may be directly correlated to, or the result 
of, other social effects, which are the result of still others and so forth.16  The questions 
that arise are inextricably linked with moral considerations, particularly when assessing 
the benefits and risks of technology.17 
Ten Have argues that the gap between ethics and HTA stems from the dominance 
of the physician-scientist perspective which emphasizes efficacy and cost-effectiveness.  
He also cites two other equally important reasons.  First, technology is often viewed as 
value-neutral; and thus it is established outside of, or away from, ethical issues.  The 
second reason pertains to the fact that bioethics is a technology in and of itself.  It is 
viewed as a tool to determine and, if possible, resolve the moral consequences of 
technology.18  Despite these dominant perspectives, he argues that ethics should play an 
integral role in health technology assessment. 
 
3.2.1.1 Value-laden nature of technology and moral issues in risk and uncertainty 
 Health is valuable because it is a social good.  This is why many scholars argue 
that ethics should be an integral part of health technology assessment.  Emerging health 
technologies directly impact health in a number of ways including access or allocation of 
resources, delivery, and so on.  Therefore, a variety of perspectives must be taken into 
account in technology assessment because it is relevant for everyone.  Furthermore, 
especially in healthcare, when new technologies are introduced they create new care or 
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therapeutic options that will impact those already in existence. Health technologies reflect 
interactions between multiple social groups with various social values.  Social values 
impact which technologies will be developed and adopted, as well as how the 
development progresses.19 
 One of the most persuasive arguments for integrating ethics in HTA is that health 
technology and its consequences or outcomes are morally relevant and have ethical 
ramifications.  The argument is as follows.  Society considers the promotion of health, 
the absence of pain, or improved health to be a moral good.  Technology is a means to 
that intended end.  Therefore, when assessing risks and benefits, and engaging in 
comparative effectiveness evaluations and economic analysis, the underlying 
presupposition is that this is being done to achieve a moral good.  These normative 
implications provide justification for including ethics and HTA.20  Given the focus and 
emphasis on the outcomes and consequences of the adoption of new technologies, this 
appears to encourage a strictly consequentialist utilitarian framework.  Consequentialist 
frameworks are also one of the primary theories central to economic evaluation.  This 
utilitarian framework, while relevant, is not necessarily the only or the most beneficial 
overarching framework for ethics assessments and HTA.  Recall the fear articulated by 
Heidegger surrounding the joining of human ontology and efficiency. 
Given the close connection between technology and society one might argue that 
it is just as important to consider the political aspects and applications of adopting new 
technology as it is the ethical consequences.  Some scholars, including Hofmann, argue 
that political, legal, and social applications should be included as well.  He even suggests 
that the political ramifications might appear to be “from more pressing for decision-
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makers than other normative issues.”21  These arguments, while closely related and 
similar in structure, are outside the scope of this dissertation.  Yet, it is important to be 
aware and recognize similar arguments in related fields as they may become relevant. 
Technology can also challenge society’s moral principles, practices and beliefs.  
For example, depending on the adaptation of the health technology, patient autonomy, 
integrity, or dignity might be impacted.  There are many examples of these types of 
technologies, including cochlear implants, genetic testing, in vitro fertilization (IVF), and 
prenatal genetic diagnosis (PGD).  Cochlear implants are controversial for a number of 
reasons one of which challenged the accepted understanding of the malady.  The deaf 
community does not necessarily see deafness as a malady; and therefore cochlear 
implants in young children will dramatically impact their community.22  The other 
genetic-based technologies mentioned challenge how humans understand themselves:  
the rights of embryos, handling predictive information, and considerations surrounding 
risks and outcomes, just to list a few.  Therefore, conducting an ethics assessment 
becomes critical in understanding the ethical challenges presented by a given technology 
to entire populations as well as specific communities, and ideally even those who are 
marginalized or vulnerable.23 
Every new technology does not pose a major moral challenge.  However, this 
does not mean that the ethics assessment should be overlooked or eliminated.  There 
could be implications for health policy regulations, which impact moral considerations as 
a result of adopting new technologies setting up those major ethical challenges.  One of 
the difficulties is determining whether or not a new technology will be controversial or 
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present as significant moral challenge.24  This could result from any number of reasons, 
including functional creep or repurposing. 
Health technology is value-laden, as there are normative underpinnings to health 
technology.  Hofmann argues that “technology is given its purposes (promoting health, 
preventing disease) and its systems (procedures and organizations), which are given by 
values, making ethics, or at least axiology, relevant for addressing evaluative issues 
related to technology.”25  Addressing the value-laden nature of a technology, while 
informative, may be inadequate.  This is largely due to function creep, which is the 
repurposing or adaptation of technology for unintended uses.  It can be borderline 
impossible to anticipate these unintended applications. 
Hofmann concludes that engaging in health care is not only a practical necessity 
but also a moral one.  Ethics is the vehicle for reflection of this moral obligation.  
Technology compounds and enhances moral issues in healthcare, thus, technology 
assessment that does not take this moral dimension into account is lacking as it misses a 
critical aspect.  Furthermore, Hofmann goes on to argue, that technology provides a direct 
improvement in human life.  As a result, this raises questions surrounding what a good 
life is, and therefore elicits ethical issues and concerns.  Eliminating ethics from 
assessment or neglecting it can lead to actions and adoptions of technology that directly 
conflict with the primary goal of healthcare, which is to help others.26  
Annette Braunack-Mayer, a professor at the University of Adelaide, provides an 
important distinction to help clarify this point—that is the distinction between ethics of 
HTA and ethics in HTA.  The ethics of HTA examines organizational structure, 
relationships, value systems, and “functions of HTA as a system of behavior.”  HTA is 
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regarded as its own normative discipline “subject to the same norms and values as the 
technologies it addresses.”27  When the considering the ethics of HTA, it becomes evident 
that there are ethical issues at the very center of HTA, particularly surrounding safety, 
efficacy, effectiveness, and efficiency.  Questions of how one defines safety and what 
acceptable amounts of risk are raise moral concerns.  Developing criteria to examine 
effectiveness or new models to address efficiency also raise moral concerns surrounding 
the threshold and limits of each.  Ethics assessment is critical in determining these 
thresholds and endpoints.28  
Theoretical critiques of technology appeal to the sweeping assessments of 
technology and society by philosophers such as Heidegger, Adorno, Foucault and many 
others.  These theories and concepts are vital to understanding the value-laden nature of 
technology.  Ethics in HTA focuses on the technology or intervention itself and assesses 
ethical problems and implication produced by the new technology.  The technology is 
often assessed for safety and efficacy while taking into consideration the wider social 
context and ethical implications.  This type of assessment typically extends from 
analytical philosophy, particularly a principlist approach.  Principles are applied to moral 
problems presented by a new technology with the aim of clarifying and potentially 
resolving the moral problem.29  Thus, on one level ethicists are working with HTA teams 
to comprehensively assess a new technology; and on another level, outside of HTA 
studies, ethicists are evaluating HTA as a whole to determine what is ethically legitimate 
in HTA.30 These two approaches complement one another and provide a more 
comprehensive assessment of and in HTA.  Both are important undertakings. 
There are several strong arguments that justify these applications of ethics in 
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HTA.  These arguments are tied directly to recognizing how technology is value-laden 
and a social good.  Ethics can provide two useful contributions.  It can identify and 
address moral issues that arise as a result of a particular technology in an existing 
framework.  Second, it can go beyond an existing framework and assess the value-laden 
nature of the technology as such.  It demonstrates that HTA is value-laden.  Moreover, it 
highlights the importance of, and gives a role to, community and public consultation. It is 
recognized that the inclusion of ethics in HTA is important; but it has not been fully 
integrated.31 
 
3.2.2 How ethics fits in HTA 
Ethics can be conceptually applied in HTA in two ways.  It can operate within the 
existing framework of a given technology and also transcend a specific framework and 
address the technology in itself.  When moral issues, questions, or problems arise as the 
result of a particular technology, they already exist within a framework of the given 
situation.  The second way ethics can contribute to health technology assessment is 
through an evaluation of the technology as such.  This type of inquiry aims at uncovering 
the entrenched or pre-existing values in a given technology.  As a result, a diachronic and 
synchronic perspective is produced. This type of ethics research attempts to demonstrate 
how we as humans understand our existence in the world, by evaluating what is 
acceptable and unacceptable.  
One argument made by Hofmann is that integrating ethics in HTA has the 
potential to make HTA more efficient.  This is largely due to the fact that traditional 
HTA's, in many cases, leave out important aspects of implementing new health 
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technologies.  Ethics provides a framework whereby one understands some of these other 
important aspects.  This speaks primarily to the dissemination of HCA reports.  Many 
organizations and agencies use these reports for different purposes and understand them 
in different ways, as seen in Chapter Two.  However, the outlooks assessments could 
provide the common linkage and rationale for either adopting or choosing not to adopt 
the new technology.  Hofmann makes an important caveat—ethics integration may not 
make HTA reports easier to implement; and in a practical sense it may not make HTA 
processes easier to execute.32 
 
3.3 Appraisal of current methods that include ethics 
This section will examine what the formal introduction of ethics into HTA 
processes actually accomplishes.  This will be done by exploring the integration of ethics 
into HTA conducted in the United States.  More importantly, this section examines 
current approaches, frameworks, and methodologies utilized in the application or 
integration of ethics, depending upon the organization. 
 
3.3.1 Brief history of ethics integration in the USA 
An ethics working group, in which sixteen agencies from across the globe were 
represented, was established in 2010 to address ethical issues in HTA.  They attempted to 
develop a framework to assist HTA teams in dealing with ethical issues.  The work of 
this group was published in an article, Tackling ethical issues in health technology 
assessment: A proposed framework, in 2011.  After considering many methodologies 
they decided that an “axiological” approach would be the most effective.  This approach 
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“aims to elicit ethical reflection by highlighting overt and covert value issues though a 
non-exhaustive selection of targeted questions.”33  Thirteen questions were proposed to 
flesh out the value issues of process, technology, its implementation and use, its 
assessment, and stakeholder consideration.  This type of assessment tool focuses only on 
ethics in HTA.  It is devised to stimulate debate and bring ethical concerns the fore.  
However, it provides no systematic way to handle ethical problems when they arise; it 
only identifies an ethical or moral problem.  The authors note that this is the first step 
towards developing a framework.  
It is interesting to note that this first step of suggesting discussion questions 
appears to have taken place in the 1970s with the OTA’s proposal of questions.34  To 
operationalize it, the OTA suggest the discussion of ethics issues “with the relevant 
decision makers at the topic refinement phase of each HTA, having first mapped out who 
the stakeholders are, including those who are not immediately apparent.”35  The proposed 
operational mechanism, to some extent, already exists. 
The AHRQ, which falls under the United States Department of Health and 
Human Services (USDHHS), conducts multiple in-depth technology assessments each 
year.  One, already completed earlier in 2015, focused on the topic of cardiovascular 
procedures and subsequent cognitive function.36  Such assessments provide a forum for 
public review and public participation, and provide recommendations on evidence-based 
practice.  Yet ethics is not integrated into the reports or procedures.  This is interesting as 
their mission states:  “AHRQ’s mission is to produce evidence to make healthcare safer, 
higher quality, more accessible, and affordable….”37  These aims, while admirable, carry 
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moral weight.  Yet, this work is being done with little to no explicit connection to ethics 
and social considerations. 
Outside of the AHRQ, the Presidential Commission for the Study of Bioethical 
Issues addresses number of high-level ethical assessments of emerging and existing 
technologies and processes.  However, they are not an HTA body, meaning they do not 
engage in any HTA processes.  Rather, they review ethical issues surrounding emerging 
technologies, which is valuable and similar to what should be occurring and HTA.38 
The FDA is a licensure agency focused on safety and cost effectiveness.  While 
they have an immense responsibility and do a fairly good job executing that 
responsibility they do not engage in holistic HTA, either.39 
The Center for Evidence-based Practice (CEP), much like the AHRQ, is charged 
with collecting research and conducting original research necessary for state and federal 
decision-makers to arrive at informed decisions surrounding drug effectiveness and 
Medicaid.  Two major initiatives in which they are engaged include the Drug 
Effectiveness Review Project (DERP) and Medicaid Evidence-based Decisions Project 
(MED).40  Again, it is interesting that a national organization that focuses on evidence-
based practice, safety, and decision-making at the national level does not make explicit 
reference to ethical considerations on their website or in their publications. 
There appeared to be no consistent standards or guidelines when it comes to the 
evaluation of technology, at the national level, in the US.  However, some organizations, 
private and abroad, utilize coherent and integrated ethics assessments; these will be 
explored in the following sections. 
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3.3.2 Current methods 
A recent study conducted by N. Assasi et al focuses on conducting systematic 
review of ethics methodologies and applications in HTA.  The authors identified 43 
conceptual frameworks comprising practical guidelines.  Each of these used a different 
philosophical approach and structure, and had varying degrees of robustness and 
comprehensiveness.  Furthermore they were designed to take place at very different 
points in the HTA process.41  The following are a number of ways the authors 
characterized the results of their finding.  Of the 1,474 potential citations only 128 met 
the initial criteria.  An additional 85 were removed from the list after further review, 
leaving the research team with twenty-one articles and twenty-two sets of guidelines 
included in the study.  Six of the twenty-two guidelines included in Assisi et al’s study 
were developed by international or multinational organizations and agencies including 
the World Health Organization (WHO) and EUnetHTA.  The rest, 16 in total, all had 
their origins in European countries.42  Interestingly, all ethics articles and guidelines were 
published in the English language. 
One common characteristic that the frameworks and models possessed was that 
they were based on multiple ethical theories.  It appears that—among ethics experts—
there is consensus that a holistic approach must be adopted if the framework is going to 
apply across emerging health technologies.43  The reviewed frameworks included a 
number of wide-ranging ethical considerations that might be relevant in HTA.  Primary 
ethical domains that the authors synthesized from their data collection include benefit and 
harm (safety), autonomy, equity (fairness or distributive justice), stake-holder values, 
utility, acceptability, psychological impact, impact on family and care givers, quality of 
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life, efficiency, opportunity cost, and ethical issues related to appropriateness of methods 
chosen for economic evaluations.44 
 With regard to practical and procedural guidelines the authors discerned roughly 
four general approaches.  These include what they termed as “classical methods” which 
rely on ethical reflection informed by well-founded ethical principles and theories.  The 
second category includes the integration methods with participatory and interactive 
approaches, including the wide-reflective equilibrium.  A third category centers about 
tools that enhance the synthesis of ethical data.  The final category includes those 
frameworks that discuss ethical data to inform HTA decision-making.45 
 The following sections will address the dominant ethics methodologies, including 
interactive and participatory approaches, social construction approaches, the wide-
reflective equilibrium, integrated approaches, principlism and casuistry, as well as 
practical approaches.  
 
3.3.2.1 Interactive, participatory HTA approaches 
Interactive or participatory approaches engage stakeholders in meaningful and 
honest discourse in an effort to limit bias in HTA.46  Participatory TA and HTA are 
qualitative methods. The aim is to determine the attitudes, concerns, interests, 
understanding, and patterns of thinking of laypersons.  Interactive approaches, in some 
cases, also assess the reasoning and arguments used by the public in relation to 
technology and policy.  This information is used to inform policy makers.  There are a 
number of different mechanisms proposed and utilized for participatory approaches, since 
the aim is to collect data on stakeholders.  In many cases, the stakeholders must be 
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educated through awareness initiatives, which is one technique available.  Other 
techniques include social experiments, discussions and focus groups, workshops, and 
consensus conferences.47 
One analysis model is the axiological-based value analysis model.  This is 
proposed by Burls et al.  Hofmann offers a similar participatory model.48  It centers on 
public attitudes, values, beliefs, including a wide range from economic to social.  It 
emphasizes the origins of the values, the relationship between them, and the resulting 
social dynamics. To map these values, Burls et al suggest a value analysis.49 
Another model that invites wide participation is the triangular model.  This model 
suggests that there are three data points:  facts, anthropology, and ethics.  Sacchini et al 
suggest that through data synthesis and reflection, informative data can be gleaned for the 
evaluation of health technologies.50 
Chantale Lessard, a Canadian scholar at the University of Montreal, developed a 
conceptual framework to specifically integrate ethical considerations into economic 
evaluation.  The framework is grounded in complexity theory.  The aim is to take into 
consideration a large number of technical, contextual, and environmental factors.  These 
should be viewed as interrelated and evaluated in light of each other, as one vision.  
Stakeholders are involved in the process, providing information on the environmental 
factors, including social and ethical considerations.  One emphasis is the sensitivity to 
uncertainty, namely the unanticipated interactions or reactions between health 
technologies and a given environment.51  
In the study conducted by Assisi et al, fourteen frameworks emphasized the 
necessity and importance of stakeholder perspectives and participation.  In many of the 
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participatory models reviewed, stakeholders were utilized to gain insights into personal 
and social values and norms pertaining to the technology.  The underlying assumption of 
these approaches is that the relationship between technology and society is not fixed or 
static.  They influence and shape one another.  Those scholars who champion 
participatory approaches often advocate for stakeholder engagement and involvement to 
occur early in the HTA process.52 
 
3.3.2.2 Social shaping of technology (SCOT) 
The social shaping of technology frameworks take up the same assumptions and 
arguments articulated in Chapter One.  Social shaping of technology (SCOT) approaches 
address the interaction between technology and society and assess ways to shape 
technology so that it benefits society.  Deliberation on the influence of technology on 
society and vice versa is central to the enterprise.  Social issues pertaining to societal 
norms and values as well as ethics are specifically addressed.53 
K. F. Douma et al propose a constructivist framework, in the article Methodology 
of constructive technology assessment in health care.  The proposed constructive 
technology assessment framework (CTA) emphasizes both the technological facts and 
questions at hand as well as the environment in which the technology will be situated.  
The continuous change and interaction of the technology and environment are monitored 
as the technology continues to develop and diffuse throughout the environment over time.  
The endpoint of the measurement is when the quality of the new technology is optimized 
or stable.  This means that it has stopped evolving and has a stable function, and 
application to society.54  
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There are many additional approaches and frameworks similarly structured and 
based on the same philosophical and sociological foundations.  Most notable are those 
forwarded by Grunwald and Clausen and Yoshinaka.55  Both of these frameworks contain 
elements of participation, and were mentioned in the previous section. 
 Bijker introduces a wide interpretation of the “technological frame.”  Recall from 
Chapter One that Bijker claims a technological frame is “a combination of current 
theories, tacit knowledge, engineering practice such as design methods and criteria, 
specialized testing procedures, goals, and also handling and using practice.”56  This is 
important because the concept must include laypersons and non-experts, such as non-
engineers and non-scientists.  A wide audience is necessary in order to recognize and 
connect different problems and available solutions.  This concept describes the 
interaction between all the relevant actors and stakeholder.  The technological frame is 
not simply a collection of the perspectives of relevant individuals or system as a whole; 
rather, the important aspect is interaction between the actors, not the actors themselves.57  
Technological development is a two-sided coin, one side is social impact and the other is 
social shaping.  Bijker uses the concept of technological frame to demonstrate this.  The 
technological frame of a social group is shaped by an artifact’s development and 
stabilization within that social group.  This demonstrates social impact, which is 
observable.  On the other hand, technological frames also influence and, to differing 
degrees, determine the design process within a specific group.  This demonstrates social 
shaping.  This holistic approach forms the concept of the technological frame.58  The 
identification of these shifts can provide useful information to HTA teams. 
SCOT is not just a combination of different social and technical aspects shoved 
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together; nor is it simply applying an existing sociology model to technology.  What 
Bijker has laid out is a mechanism for analysis that engages a “sociotechnical ensemble.”  
He argues that this approach allows one to find the socially-constructed character of an 
artifact while simultaneously being able to determine what constitutes a stable set-up.  
This approach amounts to three important theoretical activities.  First is the sociological 
deconstruction of the technology in an effort to understand its interpretive flexibility.  
Second is describing the technology’s social construction.  The final activity is to explain 
the social construction process in light of the technological frame, which is informed by 
relevant stakeholders.59 
Overall, the key difference between SCOT approaches and participatory 
approaches is the level to which participants are engaged, and the way the data gleaned 
from the participants is used.  In SCOT approaches, much more social surveillance and 
observation occurs, whereas in participatory approaches the majority of the data is 
informed by stakeholder and public responses. 
 
3.3.2.3 Wide reflective equilibrium and Integrated approaches 
Wide reflective equilibrium approaches attempt to arrive at consensus regarding 
ethical judgments of technology through a process of reflection.60  Through a thorough 
review of ethics methodologies it was found that the wide reflective equilibrium is not 
often used on its own, but rather in conjunction with other applications or methodologies.  
It usually functions as a decision-making mechanism.  The wide reflective equilibrium is 
a method that emphasizes stakeholder and layperson involvement in a reflection process.  
Deliberation occurs among a wide set of societal perspectives, beliefs, and values.  This 
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method seeks to balance normative claims and other judgments through reflection to 
arrive at a consensus on an issue.61 
One of the most robust frameworks utilizing the wide reflective equilibrium is an 
integrated approach.  Integrated approaches put forth a holistic assessment that actively 
integrates social and ethical considerations into health technology assessment by 
combining two or more approaches described above.  Interactive evaluation is one 
integrated approach that utilizes elements of social constructivism, stakeholder 
participation, and the wide reflective equilibrium.  It is designed to be a holistic approach 
and help avoid normative bias by considering multiple perspectives to yield an evaluation 
and decision-making process that is effective in assessing controversial issues.62  
Reuzel puts forth a holistic assessment that actively integrates social and ethical 
considerations into health technology assessment.63  Reuzel argues that a useful 
framework or paradigm can be constructed by combining social constructivism and 
Michael Scriven’s evaluation theory; he terms this approach “interactive evaluation.”64  
Scriven, known for his contributions to the theory of practice and evaluation, asserted 
that evaluation is the “science of valuing;” it is the determination of merit or worth.  
Generally there are four steps:  (1) establishing the criteria of merit; (2) constructing 
standards; (3) measuring performance and comparing with standards; and (4) 
synthesizing and integrating data into a judgment of merit or worth.65  The force of this 
evaluation strategy is strengthened when coupled with social constructivism. 
Constructivism asserts that the truth about something or its perceived merit is 
constructed.  This means that the technology in question resulted from directed choice 
(not haphazard chance) reflecting what is desirable and useful.  Therefore, when 
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constructivism is applied to health technology it asserts that—as the technology was 
being developed—decisions were constantly made regarding form, function, or use.  
Reuzel arrives at the conclusion that health technology can be, to some extent, directed.  
Thus, social scientists and ethicists have a role in evaluation research.66  They are charged 
with aiding in “constructing alternatives for a better society, which is based on insight 
into the social embedding of the things being evaluated.”67  Reuzel states that this 
paradigm aims at evaluating the interactions between relevant persons and parties 
involved with the interaction resulting in deliberation and harmonization.68  In the end 
questions must be answered and decisions must be reached. 
There are three essential axioms of this approach.  First, facts are contextual.  
They are given meaning through the norms and values of the individuals operating in a 
particular framework.  Second, it is impossible to circumvent this subjectivity, and 
arguably undesirable as well.  Therefore, what interactive evaluation attempts to 
accomplish is to explain the different frameworks, including norms and values, of the 
relevant social groups and stakeholders.  Problems and issues are identified and clarified 
as each framework is explored and considered alongside the others.  The most important 
tool in this process is interviewing.69 
It has been successfully argued that ethics should play a role in health technology 
assessment.  When one asks questions such as “what values are at stake?” or “what 
happens when different groups or individuals assign various or even conflicting values to 
the same technology?” moral considerations are already being made.  Reuzel recognizes 
this and places a substantial emphasis on the necessity for ethical consideration in 
interactive evaluation.  He lays out the role for ethics as it fits in his framework quite 
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clearly.  In controversial cases, ethics can provide precise clarification of the matter and 
issues at hand, as well as guide deliberation to avoid or escape the controversy.  He does 
not believe that traditional approaches, like the four principles approach of Beauchamp 
and Childress, will be useful because the goal of that framework is to assess moral right 
or wrong.  In the interactive evaluation framework the goal is to design alternative 
solutions and thus escape moral controversy, not solve moral issues or pass judgment.  
He employs the ethical tool of casuistic analysis as a mechanism for clarification, because 
it has the potential to find “a widely endorsed solution to aspects of a technology-in-
context that make up the controversy.”70  In addition to that, he utilizes a wide reflective 
equilibrium to promote legitimacy and fairness.  The equilibrium must be agreed to by all 
participants, eliminate power relationships, and should be a newly established 
equilibrium that reflects the current context.71  
Agreement or a temporary consensus is the goal.  While feasibility of agreement 
can be an issue, a more pertinent question is whether the agreement is justified.  Reuzel et 
al argue that yes, agreement can be justified if it is regarded as a wide reflective 
equilibrium.72  The wide reflective equilibrium is based on John Rawls initial conception 
of the reflective equilibrium; however, to be applicable here it must meet three criteria.  It 
must be inter-subjective; achieved by all individuals involved; and, finally, a new 
equilibrium must be produced as opposed to forcing individuals into an established 
ethical measure.73  Interactive evaluation can also reduce normative bias.  This is 
important because HTA is not always an objective enterprise.  For example, cochlear 
implants were being used in pre-lingual deaf children and this posed a threat to the deaf 
community.  Many physicians and proponents of the cochlear implant perceived deafness 
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as a handicap since having the capacity to hear is the norm.  However, many in the deaf 
community do not agree.  In this example, it was assumed that deafness should be 
eradicated and the considerations of the deaf community were not taken into account.74 
By taking into account three major axioms mentioned above it becomes possible to 
reduce normative bias.  For Reuzel, the role of ethics in health technology assessment is 
to address moral controversy.  By clarifying the issues, the goal of finding an escape from 
the controversy can begin.  The issues and values at stake, as well as moral beliefs, entail 
social constructions.  Therefore, by creating and designing acceptable alternatives 
participants have the ability to modify their values and perspectives.75 
Reuzel’s approach is both feasible and productive.  He succinctly demonstrates 
this in his assessment of cochlear implantation.  It is a comprehensive, labor intensive 
approach that merits serious consideration.  However, this framework only addresses 
ethics within the context of an existing technology that bring about some form of 
controversy.   Therefore, it only addresses one of the ways ethics can be employed in 
HTA.  Reuzel does not explicitly assess the ethics of HTA; it is only assessed in relation 
to the social impact and controversy.  The role he gives to ethics and social construction 
suggest that this could be a very useful paradigm.  
Several other frameworks utilize the same tools, similar logic and philosophical 
arguments, but arrive at different configurations of integrated approaches. One such 
example, from Johnson et al, originated in Canada.  It is a framework that uses multi-
criteria methodologies, with special attention to ethics.  The framework is based on four 
criteria for HTA assessments, including clinical benefit, consistency with ethical and 
social values, cost–effectiveness, and feasibility of implementation.76  The authors call 
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for systematic research including literature reviews, public participation, and stakeholder 
deliberation.  After this, policymakers may consider a recommendation or decision 
regarding the health technology.  Rather than utilizing the wide reflective equilibrium, 
this framework relies on a decision-making rubric developed by Goetghebeur et al, which 
is a structured decision-making process that takes all dimensions—ethical, social, 
technological, economic, safety, etc.—into consideration.  The information is transcribed 
into a matrix where it can be processed and scored by experts.  The goal is to provide a 
ranking for the best overall outcomes as well as the best overall alternatives among health 
technologies.77 
 
3.3.2.4 Principlism and Casuistry 
Principlism applies overarching ethical principles, which mirror a given society’s 
common morality, to ethical problems.  Casuistry is the practice of applying analogous 
logic; cases in question are compared to similar cases that have been undisputedly 
resolved.  These two are often practiced together.78  
Beauchamp and Childress identify and utilize four key principles which, when 
properly applied to the field of biomedical ethics, can provide a justified guide for action.  
It must be noted the Beauchamp and Childress are only addressing the field of biomedical 
ethics; they are not providing or attempting to explicate a general moral theory.  They do 
not start with abstract principles; rather, they begin with middle principles in conjunction 
with case specifics.  These four principles are considered to be prima facie principles, 
which mean that the principle must be fulfilled or adhered to, unless there is a conflict.  
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The first principle is autonomy, which is respect for the human person.  This 
means that each autonomous agent has the right, and others acknowledge that right, to 
have specific opinions, make choices, and act according to their own volition.  This 
principle demands not only a respectful attitude but also respectful action.  Respect for 
autonomy requires more than noninterference with others’ lives.  At times action is 
obligatory, such as helping others maintain their autonomy and help eliminate conditions 
that could disrupt autonomous action.79  The second principle is beneficence.  This 
principle is twofold; individuals must refrain from hurting one another, and furthermore 
must contribute to the welfare of others.  Beauchamp and Childress identify two key 
aspects of beneficence—positive beneficence and utility.  Positive beneficence stipulates 
that individuals provide benefits to others.  Utility requires that individuals “balance 
benefits, risks, and costs to produce the best overall results.”80  Third is the principle of 
nonmaleficence; this is the do no harm principle.  The principle of nonmaleficence 
imposes an obligation to not intentionally inflict harm on others.  In medical ethics it has 
been closely associated with the maxim Primum non nocere:  “Above all [or first] do no 
harm.”81  The fourth and final principle is justice.  Beauchamp and Childress do not 
endorse any specific theory of justice.  However, the concept of justice provides a 
foundation by which to analyze the other three principles.  For example, if one is an 
egalitarian the individual will appropriate these principles much differently than someone 
who is a libertarian.  However, which ever concept of justice is employed, it must be 
ethically justified.  
The relevance and roles these principles play depends upon which one is 
emphasized or given more weight.  This obviously effects the consequential conclusion 
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and decision.  This will be briefly demonstrated through the example organ donation after 
cardiac death (DCD).  It can be argued that DCD fulfills the principle of beneficence 
because this act benefits the donor, as their wishes are being carried out, and the 
recipient, who needs this organ to live.  On the other hand, the principle of 
nonmaleficence could be used to argue that just because there is a lack of evidence that 
the patient is being harmed does not mean that the patient is not being harmed by using a 
two to five minute interval for the determination of death.  The exact time of death is 
unknown, hence organ procurement could happen before death, which would harm the 
patient.82  Taking on a different perspective, if beneficence is championed, one could go 
as far as to argue that it is a moral duty to contribute organs to others.  Individuals have 
the moral obligation to allow their organs to be used in order to save the lives of others.  
On the other hand, if one emphasizes autonomy and nonmaleficence, it is arguable that 
organ donation is certainly not a duty and furthermore some methods of procurement 
directly violate or harm the patient.83  The goal of this example is not to show that one 
principle can trump another, because ordering is not the intention when it comes to these 
four principles.  Rather, the complexity rests in finding the proper balance of these four 
principles.  In the example above, it is not that one principle is perhaps more important or 
overarching than another; instead it is about finding the proper application. 
 From this, it is clear that several different arguments, with vastly different 
outcomes, can be justified through these principles.  It is the account of justice that needs 
explanation.  Justice does not seem like a middle principle at all.  In fact, in their theory it 
seems to be the guiding principle.  However justice, for Beauchamp and Childress, does 
not balance other principles; rather, it balances theories of justice that are applied to these 
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principles such as libertarianism, egalitarianism, utilitarianism, communitarianism, and so 
on.84   The methodology of ethical justification is the overarching aspect that allows for 
any sort of justification.  They maintain that “no single theory of justice or system of 
distributing health care is necessary, or sufficient, for constructive reflection on health 
policy.”85  While all of the general theories mentioned above provide a valuable 
perspective on morality they “only partially capture the rich diversity of that life.”86  Yet, 
Beauchamp and Childress tell us that although there are several viable and, at times, 
conflicting theories, this does not justify a piecemeal approach to health care.  They claim 
that this piecemeal approach, currently used in the United States, is simply a way to avoid 
the larger complex questions about justice.87  The exact role of justice in Beauchamp and 
Childress’s theory is that justice not only balances differently theories of justice but it is 
also “a group of moral norms for fairly distributing benefits, risks, and costs.”88  The 
purpose of this structured theory of biomedical ethics is to explicate principles that are 
derived from considered judgments that stem from common morality.  We will consider 
the problem of conflicting norms in the next section.  
 For Beauchamp and Childress, principles are the most general and comprehensive 
norms.  Although there is a loose distinction between rules and principles, both are 
general norms of obligation.  The key difference is that rules are more specific in content 
and more restricted in scope than principles.  Principles do not function as precise guides 
to action that direct society in each circumstance in the way that more detailed rules and 
judgments do.89  However, prima facie principles alone “do not contain sufficient content 
to address the nuances of moral problems.”90  This means that prima facie principles do 
not possess the specificity to deal with the complex issues of biomedical ethics.  
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Beauchamp and Childress employ the process of specification in order to reduce the 
indeterminacy of abstract moral norms.  That is, the specification adds content.91  Some 
specifications go as far as to prohibit certain actions, for example, prohibitions of cruelty.  
Weighing and balancing principles and rules is often a necessity.  Balancing is the 
process of finding reasons to support beliefs about which moral norms should be utilized; 
it also considers the relative weights, strengths, and weaknesses of different moral 
norms.92 
 Beauchamp and Childress’s analysis of conflicting moral norms relies heavily on 
W. D. Ross’s distinction between prima facie and actual obligations.  “A prima facie 
obligation is one that must be fulfilled unless it conflicts, on a particular occasion, with 
an equal or stronger obligation.”93  This means that the obligation is absolute or binding 
unless another moral obligation outweighs it.  The actual obligations result from 
examining the competing prima facie obligations and deciding what ought to be done.  
There is no moral theory or system that is free from conflicting norms and thus 
exceptions.  For Beauchamp and Childress there are six conditions that must be met in 
order to justify infringing one prima facie norm to another:  1) good reasons can be 
offered to act on the overriding norm rather than on the infringed norm; 2) the moral 
objective justifying the infringement has a realistic prospect of achievement; 3) no 
morally preferable alternative actions are available; 4) the lowest level of infringement, 
commensurate with achieving the primary goal of the action, has been selected; 5) and 
negative effects of the infringement have been minimized; and 6) all affected parities 
have been treated impartially.94 
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Beauchamp and Childress offer three methods for ethical justification:  top-down, 
bottom-up and an integrated approach.  Top-down models are similar to deductive logic.  
This is the model that Rawls employs; except he does not advocate for balancing 
principles.  Principlism begins with a set of principles or premises that collectively form 
normative precepts that result in justified moral judgments.  Simply put, a general 
principle is being applied to a specific case and that general principle informs individuals 
how to act or respond to that specific case.  The argument structure would like this:  1) 
Action X is morally obligatory, 2) Action Z is the same as action X, then 3) Action Z is 
morally obligatory.95  Many moral aspects of human life fit this model quite nicely.  
However, this model, while useful, can at times be insufficient.  This model requires that 
theories, principles, and rules take priority to traditional practices, institutional rules, and 
case judgments.96  The difficulty is that principles often are so abstract that it becomes 
incredibly difficult to determine an exact course of action for a specific case.  At times, 
when trying to achieve a stable balance, some principles must be specified and 
emphasized over others in order to make proper judgments.  In order to balance 
principles, the particulars from specific cases are taken into account to inform judgment.  
In difficult cases there is a complex interplay between principles and facts, rather than 
simply principles informing the actions of the individual involved.97  
The second type of ethical justification is the bottom-up model.  Casuistry is the 
most well-known bottom-up model.  Bottom-up models are similar to methods of 
inductive logic.  Essentially, the justification begins from a specific set of particular 
instances and progresses to generalities, rules, and norms.  Principles and rules are not 
prior, epistemologically speaking, but rather derivative.  The starting point for decision-
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making in particular cases includes preexisting social practices, precedent cases, the 
study of new cases, and comparative case analysis.98  Inductivists argue that this model is 
actually more allied with how human beings reason and problem solve on a daily basis.  
It reflects human experience and allows morality to evolve.  Simply put, a set of ethical 
rules are developed from a social consensus shaped directly by particular cases.99  There 
are some concerns that should be highlighted regarding this type of model.  First, there is 
no clear methodological resource; this means it is a highly subjective process.  As with 
any subjective process, it remains difficult to prevent destructive biases and is easy to 
ignore morally relevant aspects when they do not produce the desired end result.  Another 
concern is the issue of conflicting analogies.  The bottom-up model, for it to have any 
success, must result in cases being properly resolved.  If a case is improperly resolved 
and subsequently used as an analogy or precedent to address other cases, there will be a 
continuous chain of improperly resolved cases.  Hence, it will be incredibly difficult to 
break and correct that cycle.  Despite these challenges, this method is still a very useful 
tool.100  Casuistry is one form of bottom-up reasoning, it will be addressed later in this 
section. 
 There is a third method of justification put forth by Beauchamp and Childress.  As 
frequently happens, when faced with two opposing models a researcher inevitably 
combines the two in order to create a more palatable one.  This is exactly what 
Beauchamp and Childress have done; they suggest an integrated model that utilizes 
Rawls’s concept of the reflective equilibrium.  The key to Rawls’s notion of the reflective 
equilibrium is that when some aspect of moral theory, held by an individual, conflicts 
with their considered judgments, they are required to adjust one or the other to restore the 
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equilibrium.  This means that the process of revising and reevaluating our moral beliefs, 
in order to adhere with the moral principles we hold, will allow the individual to 
continually develop a consistent network of moral beliefs.  This is precisely what 
Beauchamp and Childress call for in the field of biomedical ethics.  Of course, it would 
be foolish to think that the achievement of a completely stable equilibrium is realistic.  
However, by continually waxing and waning through a network moral beliefs, in light of 
the goal of stability, the individual will move closer to that stable equilibrium.101  If 
accepted and properly applied, the reflective equilibrium is a sufficient methodology for 
justification.  
 According to Beauchamp and Childress, an individual’s initial norms are 
informed by common morality.  They explain that morality refers to a set of norms that 
dictate the right and wrong qualities of human action.  When these norms are widely 
accepted, a stable social agreement is formed.  Common morality applies to everyone in 
all places.  It provides the foundation to judge all humans and their conduct by the 
standards of common morality.  The point of emphasis is that common morality has 
normative force.  By establishing a set of standards by which all are judged, common 
morality creates a way to mediate human interaction by rendering some actions 
unethical.102  Common morality relies on shared moral belief as its starting point; 
however customary moral beliefs deriving from a specific culture do not qualify as part 
of common morality.  Common morality also maintains that when an ethical position is 
inconsistent with pre-theoretical moral values it is highly suspect and should come under 
scrutiny.103  Finally, common morality is pluralistic.  In sum, Beauchamp and Childress 
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are advocating for reflective equilibrium as a methodology working in tandem with a 
common morality approach to considered judgments.104 
Casuistry is a case-based reasoning method.  The basic logic is that similar cases 
ought to be treated similarly.  This assists in building coherence and consistency within 
systems.  Typically, this is done by describing the case in question and comparing the 
ethical considerations and or problems surrounding this case with examples of ethical 
considerations related to similar cases.  This helps to identify the paradigm that best fits 
the case.105  
There is an element of coherency that must be addressed when using principlism 
or casuistry.  Coherence analysis, as it is sometimes called, can be employed to ensure the 
consistency of an application and analysis of ethical reasoning and judgments.  
Beauchamp and Childress attempt to address this coherency through the reflective 
equilibrium.  This includes assessment of the use of theories, principles, and value 
judgments.  Assessment does not indicate whether some arguments are stronger than 
others, it simply attempts to ensure consistency and application.106 
 
3.3.2.5 Practical Applications  
Some frameworks go beyond the basic methodology and attempt to provide a 
practical skill set or toolbox for HTA processes.  This allows individuals or groups to 
conduct ethical assessments in a coherent, structured way.  Many of these tools include 
checklists and sets of questions.  Consensus is that ethical reflection on context-sensitive 
details that entertain different perspectives and apply multiple ethical theories or 
principles can be synthesized into usable information.  Three of these proposed tools will 
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be briefly described, including the frameworks proposed by Droste et al, Hofmann et al, 
and Culyer et al.107  
There are times when it is incredibly difficult to even locate relevant ethics 
materials, which can dash any desire to perform a thorough assessment.  There should be 
a systematic way to search for relevant ethics data.  Sigrid Droste et al, in the article 
Information on Ethical Issues in Health Technology Assessment: How and Where to Find 
Them, proposed a framework to make this more accessible, based on a similar tool used 
in the assessment of clinical benefits.108  Their framework specified key search terms and 
databases for ethics and HTA.  Along with this information, they introduced some 
relevant search strategies for ethics related content.  The framework also suggests the 
utilization of consultation from an expert ethicist.  Their eight-step process included:  (1) 
translation of the search question using the PICO scheme [Patient/Problem, Intervention, 
Comparator, Outcome] and additional components; (2) concept building by modeling and 
linking search components; (3) identification of synonyms in all relevant languages; (4) 
selection of relevant information sources; (5) design of search strategies for bibliographic 
databases; (6) execution of search strategies and information seeking, including hand-
searching; (7) saving of retrieval results and standardized reporting of the process and 
results; (8) final quality check and calculation of precision and recall.109 
Bjørn Hofmann published a series of thirty-three ethical, or morally relevant, 
questions, called the Socratic approach, related to the development and use of healthcare 
technologies in 2005.  The questions are broken into seven groups:  (1) the morally 
relevant issues related to the disease and patient group; (2) the ethical, social, cultural, 
legal, and religious challenges related to the health technology; (3) moral challenges with 
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structural changes related to the health technology; (4) issues related to the characteristics 
of the health technology; (5) the moral issues related stakeholders; (6) the moral issues 
related to the assessments of the health technology; and, (7) additional moral concerns.110  
Over the past decade this method has been implemented and incorporated into several 
methods.  It has been used in multiple HTA projects including human papilloma virus 
vaccination, neonatal screening for inborn metabolic disorders, stem cell transplantation, 
bariatric surgery, and many others.111  While the method has been useful, a number of 
working groups have come together to determine how to adapt the Socratic approach in 
HTA.  The goal is to increase the transferability of information. 
There are a number of limitations within this approach. One of the largest is the 
fact that it is a checklist of questions; and, as with most checklists, it is not exhaustive.  
This means that there is the possibility that some important ethical issues might be 
neglected.  An expert group assembled to assess the limitations of the Socratic approach 
identified fourteen limitations.112  They also made additional recommendations to 
increase the impact and value of the methodology.  The revised approach now only has 
six steps as opposed to the seven listed above.  They include:  (1) identify the intended 
purpose of the health technology and revealed the background for the assessment; (2) 
identify involved persons, groups, and stakeholders; (3) identify relevant moral questions 
from a list questions and justify the selection; (4) perform literature search in accordance 
with the identified moral questions; (5) analyze and discuss the moral questions identified 
in step three on the basis of  existing literature and hearings or statements have involved 
parties qualitative studies; and, (6) wrap up and summarize the process.113  It is important 
to articulate these six steps in order to draw an important comparison between the old and 
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the new versions.  There is a significant advantage to this new six-step approach as 
opposed to the previous set of thirty-three questions.  However one element that is 
missing from both of these is the final evaluative step, which is to evaluate the process 
and make recommendations on improving the process for further use. 
Another tool, in checklist format, was proposed by Anthony Culyer and Yvonne 
Bombard, both scholars at University of York.  These authors provide a comprehensive 
checklist for specifically addressing the issues of equity.  It can be adapted to different 
stages of the HTA process.  For example, it could be used to identify technology 
priorities; yet it could also be utilized to discuss equity considerations in the final 
recommendation and decision-making phases.114  The authors maintain that there are two 
issues that are hindering the development of a holistic HTA.  The first is the fact that 
there is no consensus on the significance or the scope of equity.  The second issue is that 
there is no consensus on a process or mechanism that allows for the systematic and 
comprehensive treatment of equity along with cost-effectiveness.  Based on these issues, 
the authors developed a framework to address equity issues in HTA.  A common 
understanding or consensus about equity in HTA is critical in moving the discourse 
forward.  This ensures that assessments treat similar cases similarly, and one can begin to 
resolve the discrepancies nationwide and globally of differing HTA results and adoptions, 
both appropriate and inappropriate, of technology.115 
 
3.3.3 Analysis 
 Some scholars argue that multiple ethics methodologies can be applied 
simultaneously; and this provides the benefit of multiple perspectives.  On the other hand, 
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however, there are the scholars who argue that there are underlying fundamental 
contradictions between some of these methodologies and this requires the use of one 
theory to ensure consistency.116  
 Several issues have been raised with the SCOT approaches.  Klein and Kleinman 
claim that the two problematic areas lie in method and explanation.  They call the 
“snowball method” into question.  The snowball method is how relevant social groups are 
identified.  They claim that this is inadequate because “identifying unrecognized and 
missing participants, while its emphasis on groups overlooks social structures that might 
account for such absences.”117  Social constructivism also struggles to explain success 
and failure in the creation of new technologies.  Bijker relies on the concepts of closure 
and consensus, but does not explain how consensus is reached.  
Klein and Kleinman argue that too little attention is paid to the power of the 
relevant groups.  Perhaps group power dynamics would explain why some groups’ 
meaning and interpretations carry more weight and ultimately become the consensus.118  
A final criticism of this theory rests on Bijker’s notion that “modern society must be 
analyzed as a seamless web.”119  Klein and Kleinman argue that this view of society 
makes the determination of cause and effect impossible; and thus, the proposed analysis 
also become impossible.120  This point may be off target.  Bijker’s notion is that 
technology and society are constantly shaping each other; it does not appear that proving 
cause and effect for one over the other is a primary concern in Bijker’s framework. 
In order to conduct ethics analysis there is a need for ethical knowledge and ethics 
expertise.  In Assasi et al’s appraisal of ethics methods, they noted that six frameworks 
specifically highlighted the need for ethics expertise. Specifically, ethics expertise is 
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necessary in preparing search strategies, making and assessing normative judgments, and 
providing the requisite ethical knowledge and education required for analysis, discourse, 
and decision-making.121  A recent study in Canada revealed that there was a general lack 
of available ethics experts.  However, they interestingly reported that it is “unlikely to be 
a barrier to conducting ethics analysis in HTA in the Canadian context.”122  Furthermore, 
Bond et al, in the article Ethics Expertise for Health Technology Assessment: A Canadian 
National Survey, cautioned against the employment or utilization of ethics experts, since 
there is not a currently reliable credential for ethics expertise. 
A very interesting distinction is made by Sandman and Heintz, two Swedish HTA 
scholars, in the article Assessment vs. appraisal of ethical aspects of health technology 
assessment: can the distinction be upheld?  They suggest that the distinction between 
assessment and appraisal is very tenuous and in many cases difficult to support.  This is 
relevant for ethics assessment and HTA because HTA are limited to the assessment 
aspect of it while other individuals or decision-makers are responsible for the appraisal 
and recommendation aspect of HTA.  Appraisals and recommendations carry the force of 
either accepting technology, possibly requiring mandatory adoption other technology, or 
eliminating the possibility of adoption of the technology due to ethical issues and or 
norms that we are expected to follow.  For example, if there is an incredibly positive 
appraisal within the ethics portion of an HTA, and it follows that the rest of the HTA is 
consistent with a positive appraisal, this could ultimately result in the recommendation 
that it is mandatory to implement this technology.  One can even go so far as to conclude 
there is a moral obligation to do so if the benefit is great enough.  The authors argue that 
as long as the ethics assessment portion is presented transparently it is an obligation of 
  
 
135 
 
ethics experts to disclose “well-founded conclusions are and or whether they're power 
alternative conclusions, the HTA agencies should not avoid taking the ethical analysis as 
close as possible to the definite conclusion.”123  What the authors conclude is that if 
experts engage ethics analysis honestly and as objectively as possible, they should not 
stop short of drawing conclusions and making recommendations.  They believe that these 
two elements—assessment and appraisal—can work hand-in-hand. 
 Some arguments posit that ethics is not necessary to address the question of 
whether a technology is “efficacious, effective and efficient, it is crucial to answer the 
question of whether it is right or not to implement and use the technology. Although this 
is relevant for health technology appraisal, it is not for assessment, where the issue of 
whether it is right or not to implement technology is declared to be beyond its scope. 
Accordingly, there would be no need for integrating ethics.”124  This position maintains 
that technology and HTA is value-free, or at the very least value-neutral. 
 
3.4 Deficiencies and Gaps  
This section addresses the deficiencies and gaps of current methods of HTA; they 
are noticeable in the theoretical and practical roles of ethics.  These include priority 
setting and completion rates, the narrowness of ethics in HTA, and the lack of oversight 
and general standards. 
 
3.4.1. Ethics is not a priority  
The word “priority” can have multiple meanings in different contexts.  Here the 
focus will be on two meanings of the word.  First, in the common use of the term, ethics 
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is not a priority in HTA.  Very few national HTA programs have a quality integration of 
ethics.  Ethical guidelines are often developed by multinational organizations with time 
and endowments to support operations, as well as a strong commitment to collaboration 
and inclusion.  When committed to these, ethical and social sensitivities are required. 
The second use of the term “priority,” deals with a specific function in HTA; that 
is priority setting.  Ethics, thus far, has had a limited role in priority setting in HTA’s.   
Few countries and organizations engage in meaningful and intentional priority setting 
processes.  Yet, the suggested benefits of ethics inclusion in priority setting have been 
articulated for the last fifteen years.125 
There is inconsistency regarding the types of technologies selected, as it is 
typically the purview of specific agencies which technologies they choose or are expected 
to review.  When a technology is assessed, there are also issues with completion rates.126  
Mitton and Donaldson, in the article Health Care Priority Setting: Principles, Practice 
and Challenges, conclude that applying an ethical framework to priority setting in HTA 
assists in the identification of organizational behavior.  This is important when 
developing a comprehensive priority-setting approach.127  A study of priority setting, 
conducted by Hussein Noorani et al. concludes that developing methods in priority-
setting is not necessarily a true priority.128  The authors identified fifty-nine unique 
priority-setting criteria in the eleven agencies examined.  There is immense variability 
among priority setting techniques; in addition, quantitative rating methods that include 
cost-benefit considerations were not often utilized.  Priority setting methods are really 
only being developed in those countries with well-established HTA bodies.  The impact 
of having a sound priority setting technique is that it will increase the timeliness and 
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relevance of topics, it will improve technology tracking, and will also allow for the 
identification of new criteria and the refining of existing criteria.129 
Here is a specific example of completion rates as they pertain to randomized 
controlled trials (RCTs).  Through March 2011, there were 98 RCTs published in the 
Health Technology Assessment journal.  These were the results surrounding the 
completeness of the reports:  
 
Components of the intervention description were missing in 68/98 (69.4%) 
reports. Baseline characteristics and descriptions of settings had the 
highest levels of completeness with over 90% of reports complete. Reports 
were less complete on patient information with 58.2% of the journals 
having an adequate description. When looking at individual intervention 
types, drug intervention descriptions were more complete than non-drug 
interventions with 33.3% and 30.6% levels of completeness, respectively, 
although this was not significant statistically. Only 27.3% of RCTs with 
psychological interventions were deemed to be complete, although again 
these differences were not significant statistically.130 
 
These results, complied by Douet et al, have some dramatic implications.  They call into 
question the replicability of the studies reviewed.  Douet et al were very careful to 
address the replicability of their study, and the authors conclude that their methods are 
transparent and easy to replicate.  They also raise questions as to whether the studies 
reviewed were transparent, complete, and ethical.131  They note that these are important 
aspects, however, ethics was only mentioned at one minor point in Douet et al’s entire 
article, and it was to note that this research did not require or solicit and ethics 
approval.132  
As ten Have points out, ethics can play a critical role in identifying those 
technologies that should be prioritized.133  This was demonstrated in the Dutch study 
conducted by Marc Berg et al, in the article Technology Assessment, Priority Setting, and 
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Appropriate Care in Dutch Health Care.134  The study commented on the appropriateness 
of HTA agendas, and the potential impact of calling into question the legitimacy of health 
professionals in determining prioritization, rationing, and resource allocation.  These are 
questions of ethics.  The authors note:  “in priority-setting debates and attempts, political 
and ethical considerations are discussed openly; any attempt to delete an intervention or 
service from the insurance package has always been met with an avalanche of moral, 
political, economical, and other reasons why it should or should not be included.”135 
 Through the assessment of emerging or new technologies recommendations can 
be made based on the observations and outcomes of current HTA's.  Given the priority of  
social impact and values, and considering the norms at stake, stakeholder involvement 
becomes crucial.  Stakeholder involvement puts ethics assessment in a prime position to 
make calculated and informed decisions about which technologies require immediate 
attention. In essence, this should play a role in priority setting. 
 Hofmann suggests that this could be due to the fact that practicing ethics or 
bioethics is significantly different from practicing HTA.  There are very few ethics 
experts who also have expertise in HTA.  Ethics does not usually fit in a nice tidy box or 
as a step in the process, which is counterintuitive to the way HTA processes are run.136 
 
3.4.2 Ethics in HTA is too narrow 
The second deficiency is that both theoretical and practical aspects of ethics in 
HTA are too narrow in multiple senses of the term.  They are too narrow because the 
questions asked and investigated are in some cases too specific.  Questions must be asked 
about the true goals of ethics integration with HTA.  Interdisciplinary approaches, while 
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recognized as vital, are often inadequate; and there are only a limited number of 
technologies addressed with HTA and even less so with ethics and HTA.  This relates 
directly back to the previous discussion about the role of ethics in HTA.  Since there is no 
defined role, and there are challenges to implementation, it becomes more convenient to 
neglect the endeavor altogether.137 
Ethical assessment often occurs late in technology development, which is 
problematic.  When reviewing HTA processes, if ethical assessment occurs at all it is 
often in one of the final phases.  Some examples will be explored where technology 
would have greatly benefited from early ethics assessment.  SCOT methodologies and 
participatory approaches call for this, but are not frequently adopted.138  The timing is 
problematic, because if ethics assessment is relegated to the end, there is potential for the 
assessment to be rushed or neglected altogether.  
 
3.4.3 There is a lack of oversight and consistency in standards 
The final deficiency to be addressed here is directly linked to and amplifies the 
first two; there are no standards, requirements, or oversights, outside of Institutional 
Review Boards, for research involving human participants.  There are only guidelines, 
proposed frameworks, and checklists.  This means that when ethics assessments is 
engaged in HTA process—if it is engaged at all-- it is done so with varying 
methodologies and scope.  Furthermore, HTA generally suffers from this problem.  The 
argument is not for regulation in the sense of government statutes or laws.  Regulation of 
HTA would be most helpful and beneficial if it came in the form of benchmarks and 
identification of best practices.  Evidence-based practices have been articulated for 
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economic evaluation and comparative analysis; however they are far from finalized.  
There are very limited evidence-based practices for measuring organizational impact and 
ethics assessment. 
There are a number of examples where lack of structure produced negative 
consequences.  One example of this is the drug mebeverine.139  Mebeverine is a drug 
used in the treatment of abdominal cramping and irritable bowel control.  Moret-
Hartman, Van der Wilt, and Grin conducted a case study around this drug.  The HTA 
conducted was not sufficient because the problem was not defined correctly.  Therefore 
the decision rendered and defended by clinicians and policymakers had the potential to be 
problematic.  Through a rigorous analysis using the theory of argumentative policy 
analysis, the authors concluded that the usage problem relating to this drug was not 
properly structured.  In reality, there was disagreement about norms at stake and the 
information needed to address problem.  For example, physicians were concerned with 
maintaining a positive relationship with the patient and patient satisfaction, while policy 
makers were concerned with the cost of the drug and reimbursement.140  This means that 
the experts conducting the HTA did not respond to the perceived problems of the target 
population.  The authors concluded that in the future, if HTA and participatory 
approaches are to be useful, they must accurately characterize all accounts and 
perspectives.141 
The lack of oversight, standards, and evidence-based practices is the direct result 
of having no consensus surrounding methodology.  Furthermore, many methodologies 
are deficient or flawed in some way.  There have been attempts to develop consensus 
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among multinational organizations such as workshops conducted by the INAHTA, HTAi, 
and EUnetHTA.  However, consensus has not been reached in the HTA community.142 
 
3.5 Challenges and why the deficiencies probably exist 
This section addresses the two largest categories of obstacles or challenges to the 
integration of ethics in HTA.  These challenges also likely account for existing 
deficiencies; although there are always difficulties in determining and proving causal 
relationships.  Two categories of issues will be addressed.  First are the practical issues of 
time, fiscal resources, and other factors.  The second major challenge, again, returns to 
the relationship between society and technology, medicine and values.  This is the issue 
of the technological imperative and how it is expressed in healthcare. 
 
3.5.1 Time, fiscal resources, and other factors 
The first obstacle is time and money.  Technological assessments are lengthy and 
expensive because they are interdisciplinary, requiring experts from an array of fields.  
Assessments are important because they can reveal information about intrinsic risk and 
therefore redirect research to mitigate such risks.  They can identify the need for new or 
additional controls and regulation, reveal the consequences of a particular technology, or 
even prevent potential abuses by evaluating potential risks.  Meeting these goals requires 
going beyond examining efficacy and cost-effectiveness.  There is no question about the 
value and necessity of health technology assessment or the inclusion of ethics in that 
assessment. 
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Timely execution of HTA is very important.  HTA is meant to inform key 
decision-makers and policymakers on the use of health technologies; this means that the 
information has to be available before a decision must be made.  For this to occur, those 
who engage in HTA must conduct their studies in a timely manner.  The decision to 
utilize HTA must include careful consideration of timing.  The goal is to find the balance 
between allowing reimbursement decisions to be made as quickly as possible while at the 
same time minimizing risks should the technology turn out to be of little or no value, or 
in the worst case scenario, dangerous.143 
HTA is not a one-and-done process.  For many agencies and organizations it 
might appear that way, because they carry it out in that fashion.  More advanced 
countries and organizations review decisions after a certain period of time; still they is 
few and far between.  For example, the DERP evaluates and updates its evidence-based 
medicine reviews once every two years.  Another example is NICE’s practice of 
reviewing recommendations every three years.  There are situations when review is 
required sooner; this occurs when new information becomes available or major 
adjustments have been made to the technology.144 
The importance of time is made clear by the recent flurry of publications 
surrounding the benefit and implementation of rapid reviews and mini-HTAs.145  
CADTH has established the Rapid Response Service in response to the high demand for 
timely HTA.  This new service allows them to conduct HTA in approximately five to six 
months.  The service includes providing reference lists, summaries of abstracts, 
summaries of critical appraisals, peer-reviewed summaries with critical appraisals, 
systematic reviews and meta-analysis, and the final review resulting in a Rapid HTA.146  
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However, expedited processes can also have severe ramifications.  To rush 
through the HTA process does not allow for the closing of the assessment loop; that is, 
reflection on the process as a whole and implementing action steps to improve the 
process.  This potentially impacts both priority setting and determining benefits.  
Furthermore, this can be linked to the general neglect of ethics and most HTA functions.  
If there is little time to conduct HTA that means little reflection on processes and 
procedures as well. 
Ethical assessment require time and money, both of which are often in short 
supply; experts generally do not work for free.  Until additional funding sources such as 
grants or expanded budgets become available and include provisions for ethical 
assessment, the participation of ethicists and other social scientists may be limited.  It is 
fiscally and temporally impossibly to do thorough technology assessments on every 
health technology.  Limitations in funding bring up additional ethical questions such as 
“should assessments only be carried out on selected projects, if so, which ones?”  Ethical 
and social examination of health technologies may be able to assist in answering these 
questions or developing creative solutions.147  Fiscal consideration and budgetary 
allocations are necessary for ethics assessments.  If such assessments do not appear as a 
line item on a budget, it will likely not happen.  Furthermore, physical limitations impact 
each of the three deficiencies already identified here. 
One final factor to consider is whether or not the integration of ethics is worth the 
efforts.  Hofmann summarizes this point by stating “it has taken so long to try to integrate 
ethics in HTA and so many resources has been spent; it obviously cannot be worth the 
effort.”148  He goes on to support this by acknowledging that there is no concrete 
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evidence of increased effectiveness or efficiency due to ethics integration.  Furthermore, 
it is difficult to demonstrate any concrete outcomes from the integration of ethics.  He 
suggests that including ethical considerations in HTA muddies the decision-making 
process, and ethicists tend to complicate issues rather than clarify them.  He says, 
anecdotally, “Letting one ethicist into the room is the same as letting in a pile of 
incoherent opinions.”149  Beyond, anecdotes, Hofmann argues that HTA professions 
believe they are capable of carrying out ethics assessments, and, thus, there is no need for 
the inclusion of ethics experts.150  
 From a strictly logistical and pragmatic position this may seem to be a very 
persuasive argument.  However, given the importance of moral considerations relating to 
human quality of life and health, ethical considerations must be assessed.  Hofmann 
succinctly articulates the three options for ethics:  no integration at all—in fact, remove 
the term ethics from HTA definitions; take current definitions seriously and integrate 
ethics to the same extent as economic evaluation and comparative effectiveness; finally, 
adjust the very nature of HTA so ethics assessments and be authentically carried out.151 
 
3.5.2 The technological imperative 
The second major obstacle is somewhat philosophical in nature, and that is the 
overuse of technology in medicine, which dramatically increases healthcare costs and can 
at times put the patient at unnecessary risk.  One driving factor of medical technology is 
the physician’s desire to provide good care of their patients; thus the most thorough tests 
are ordered.  Also fear of malpractice suits, because the US is a notoriously litigious 
society, causes many physicians to call for a litany of tests and be overly thorough as 
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opposed to discriminating in their selection of tests given to their patients.  This is an 
obstacle for technological assessment and, by extension, ethics.  Ethics, in this case, may 
have the capacity to help contend with this issue.  If ethics is able to explore the value-
laden nature of technology as such, the results may shed light on this overreliance and 
overuse of technology in medicine.152  
Hofmann notes that there are many different conceptions and characterizations of 
the technological imperative, especially as it is applied to health.  It was a significant 
topic of discussion in the 1980s when observations were being made that there seemed to 
be a reliance on technology to the extent that “medical technology has grown from being 
a tool to becoming a companion and, in some cases, the master of physicians.”153  Those 
scholars who were part of the discussion then apparently held a positive outlook and 
thought that in the coming decades there would be a more rational integration of medical 
technologies.  Hofmann observes, however, that there does not seem to be any reason to 
believe that the application of technology in healthcare is any more rational today then it 
was in 1980s.  In fact, he writes that there seems to be a “pathological reliance on 
technology” and that “technology has become the bias of our culture.”154  He asks the 
appropriate questions about our understanding of technological imperative. “How is it 
possible that although we develop and apply technology in healthcare ourselves, we can 
still feel that we are controlled by it?”155  
There are a number of reasons why society adapts and integrates existing 
technologies and new technologies in healthcare.  When addressing patient concerns, 
running additional tests that may be outside of the necessary scope can relieve anxiety.  
From the physician’s perspective, running additional tests can assist in the avoidance of 
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malpractice suits.  Outside of relieving anxiety and avoiding malpractice, sometimes 
patients demand to have certain procedures; and they are obliged by physicians who do 
not wish to argue the finer points of necessity.  This partially harkens back to respecting 
patient autonomy.  Some may argue that there is a moral imperative to the use of 
technology, and that it helps in some way to advance patient autonomy.  An observation 
that takes a slightly more cynical turn is that new technology is integrated to retain some 
level of paternalism.  By rendering the technology so difficult to understand, it becomes 
nearly impossible for patients not familiar with medicine to fully comprehend the 
technologies themselves and the implications of treatment.  That puts the onus of 
understanding and application on the physician. 
It is very difficult to determine whether a technological imperative truly exists in 
healthcare.  This relies completely on the characterization of the technological 
imperative.  An important observation is that regardless of the characterization, the 
technological imperative somehow impacts human responsibility in healthcare.  It can 
reduce responsibility or increase responsibility.  For example, the application of 
technology in healthcare has been very powerful and allowing experts to more precisely 
diagnose and respond to health maladies.  If it is argued that society ought to do 
everything possible to help the patient, then it might be conceivable to view the 
technological imperative as both an imperative and a moral obligation.  Conversely, the 
adaptation of technology can be seen to reduce the human responsibility in medicine.  
This is because the human element is to some degree taken out of it and the responsibility 
is placed on technology's ability to function properly.156 
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3.6 Conclusion 
 This chapter covered landscape of ethics and HTA.  First, the role of HTA was 
considered in light of the value laden nature of technology and the relationship between 
technology and society.  Arguments were presented that supported health as a social 
good, and confirmed the conclusion that ethics should be an integral part of HTA 
processes.  This was followed by a brief survey of how ethics assessments can 
theoretically and practically fit in, or not fit in, current HTA processes.   
 Several existing methodologies and theoretical approaches were reviewed. These 
ranged from highly theoretical methodologies, such as the SCOT approach, to very 
practical approaches such as the Socratic approach. Each methodology reflected the 
underlying vision and understanding of the role of ethics in HTA.    
The remainder of the chapter surveyed current frameworks and approaches to 
deliver HTA.  It was concluded that while these efforts are portable, there are some 
remaining gaps and deficiencies.  They are: (1) ethics as a priority; (2) the timing and 
narrowness of ethics assessment; and (3) the lack of standards, guidelines, and consensus 
surrounding methodology.  In addition to these deficiencies and gaps there are a number 
of obstacles that must be overcome as well.  The obstacles include limitations and 
restrictions around time limitations and fiscal resources. Furthermore, questions 
surrounding the philosophical positions posed in response to the technological imperative 
must be addressed. 
 When considering the integration of ethics in HTA there are three definitions that 
become incredibly important:  integration, ethics, and HTA.  It is clear from the global 
overview provided that the HTA community and experts have no consensus on any of 
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these. Hence, the level of ethics in HTA is dependent upon the answers to what HTA is 
and what HTA should strive to become. Thus HTA experts may see ethics as a threat or 
burden to the current assessment nature of HTA or possibly as a mechanism for further 
development and enhancement of current processes. 
 It is unreasonable and naïve to think that a single dissertation can solve, or even 
adequately address, any one of these deficiencies or gaps in HTA.  What this dissertation 
does attempt to accomplish is to solidify the role of ethics in HTA, specifically in 
emerging genetics health technologies, and alleviate some of the practical problems 
identified in this chapter.  This is accomplished by recognizing the reality of the 
landscape for what it is, and embrace the inconsistencies, flux, and chaotic nature of 
implementation.   
The nonlinear approach will be fully outlined in the following chapter, and 
attempts to take the strengths of ethics methodology and combine them with sound 
methodologies from other disciplines to increase the validity of this approach.  The goal 
is to find a way to have meaningful ethics assessment occur throughout the process of 
new technological development.
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Chapter 4: Rethinking ethics in HTA: A nonlinear approach 
 
4.1 Rethinking ethics in HTA 
Chapter Three identified a number of deficiencies and gaps in current ethics 
methodologies and approaches applied to HTA.  This chapter will address these 
deficiencies by proposing an approach that rethinks and broadens the integration of ethics 
in HTA.  In addition to addressing the deficiencies, this chapter will also provide a 
response to the obstacles in HTA, and how this new approach can have a positive impact.  
The approach specifically addresses time on task, fiscal concerns, and the technological 
imperative.  Additional benefits and limitations outside of those addressed in Chapter 
Three will be discussed at the end of this chapter.  Many of these observations are not 
new; however, the argument to incorporate them into a nonlinear approach is unique and 
original.  The contribution of this dissertation is to provide a methodologically sound and 
valid ethics approach with the appropriate corresponding tools.   
To accomplish all of this, the first section of this chapter will provide a brief 
overview of the deficiencies, outlined in Chapter Three, to frame the introduction of the 
non-linear approach.  The following sections will introduce and fully detail the nonlinear 
approach.  Throughout the delineation of the nonlinear approach, methodological 
justification and evidence of validity will be presented and discussed.  A description of 
how the nonlinear approach addresses the deficiencies, gaps, and obstacles, as well as an 
articulation of expected benefits and limitations, will be provided.  The chapter will close 
with some remarks on how the nonlinear approach does and does not fit with current 
HTA practices and processes.  
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4.1.1 Priority and priority setting  
 From the analysis provided in Chapter Three, it is clear that, for most HTA 
processes, ethics is not a priority.  This is despite the general consensus around its 
integral role in HTA.1  The United States, one of the most developed countries in the 
world, does not have a coherent ethics framework by which to address HTA.  Most of the 
existing and more well developed ethics methodologies and frameworks have originated 
in Europe or in multinational organizations such as the WHO, INAHTA, and 
EUnetHTA.2 
 Priority setting is currently becoming a major concern in the HTA community.   
This is due to the seemingly exponential increase of emerging health technologies, which 
increases the demand for HTA.  There must be a way to prioritize these technologies to 
ensure that those posing the greatest risks, both normative and practical, are being 
immediately addressed.  However, there are no evidence-based practices or best practices 
available as this is still a newly emerging issue.  Ethics assessments, which have the 
capacity to identify those important norms and values of greatest concern to stakeholders 
and society at large, is currently not part of the priority setting discourse in any 
meaningful way.  Some scholars maintain ethics has insights and valid methods to 
contribute to priority setting; but these have yet to be systematically explored.3 
  
4.1.2 Ethics assessment occurs late in the process and is too narrowly focused 
If ethics is employed in HTA, it is typically relegated to a specific point in the 
process.  Many of the models articulated in the previous section do not function properly 
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as a cog in machine, or in this case a step in a process.  Ethics methodologies and 
approaches that take broader ethical considerations seriously include SCOT methods, 
participatory approaches, and integrated approaches.4  These are very challenging to 
integrate into existing HTA frameworks.  Many of the practical approaches have been 
built to function as a step in a process.  For example, Hofmann’s 33-question framework, 
known as the Socratic approach, fulfills this role.  This is meant as a systematic 
framework that can be executed within a known timeframe.  That is a great benefit to 
HTA planning and execution.  In fact, Hofmann’s approach has been successfully 
integrated into many HTA processes and reports.5  This indicates the willingness to 
integrate methodologies that are low-maintenance and flexible.  There is nothing 
inherently wrong with this, as it makes sense from a logistical perspective.  However, the 
trade-off of depth, breadth, and inclusion are not to be taken lightly.  This has been noted 
in recent assessments of the Socratic approach. 
 
4.1.3 Limited oversight and guidelines 
Limited oversight, lack of standards, and lack of regulations have a profound 
impact on the integration of ethics in HTA.6  Since there is no professional consensus 
around guidelines, and limited consensus about the role of ethics, including appropriate 
integration of methodologies, it is challenging for HTA agencies and organizations to 
make coherent progress.  Furthermore, there does not appear to be an overwhelming 
demand from national or global bodies for the integration of ethics.  There is, however, a 
call for greater transparency.7  Simply because there is a lack of oversight does not mean 
that everything should be regulated or subject to external review.  Rather, a good first 
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step would be to formulate best practices based on evidence.  This falls more in line with 
the ethics of HTA as opposed to the ethics in HTA, which is not the focus here.  It is 
legitimate to question the benefit of conducting ethics assessment at all.  Currently, there 
is no clear data on return on investment, cost-savings, or life-saving interventions on the 
part of ethical recommendations.  Despite the lack of concrete evidence, though, there are 
still arguments to be made.  The answer is part philosophical and part practical.  The 
philosophical arguments have been addressed in Chapter Three.  The practical argument 
for the integration of a nonlinear approach will be fully delineated in Chapter Five. The 
following section details the phases of the nonlinear approach. The analysis will return to 
these deficiencies and gaps after the approach has been explained. 
 
4.2 A nonlinear approach 
4.2.1 Explanation of the approach 
This section details the components of the nonlinear approach; it is based on 
foundations laid in Chapters One through Three, and shapes a model of ethics integration 
in HTA.  The model provides a way to make ethics relevant and meaningful in HTA.8  
The theoretical foundation is grounded in the conclusions drawn in Chapter One 
surrounding the relationship of society and technology9 and the value-laden nature of 
technology.10  It is nonlinear in the sense that it does not function as a point in a process, 
and is cyclical in nature.  Also, it emphasizes finding an optimal solution among multiple 
alternatives, because that is the best possible answer when addressing emerging 
technologies.  This is grounded in methods of nonlinear programming. 
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This approach has a number of primary aims: (1) begin ethics assessments earlier, 
(2) provide a flexible framework whereby ethics experts and non-experts can coherently 
work together; (3) support, not stymie, scientific progress; (4) provide meaningful 
discourse and recommendations; and, (5) continually improve by assessing the ethics 
assessment mechanism itself.  All of these elements are embodied in this approach. These 
overarching aims assist the approach in addressing a number of the deficiencies and gaps 
introduced in Chapter Three. 
 
4.2.2 Scope 
The nonlinear approach is developed specifically for emerging genetic health 
technologies.  Emerging genetic technologies are of a unique variety, as the very nature 
of the technology calls into question some of our most foundational normative principles.  
As such, at this point in time, a practical methodology is needed to address emerging 
genetic technologies specifically.  The reasoning and justification for selecting genetic 
technologies will be provided in Chapter Five.  Initial arguments will be provided in the 
analysis of the nonlinear approach in this chapter. 
The aim of the approach is to be flexible, accessible, and inclusive.  This means 
that it is flexible based on the context of technology.  It can be adapted to meet the needs 
and scope of the project, as it is based on specific research questions.  It is an accessible 
methodology in that it is easily understood.  However, experts are needed to undertake 
some of the data analysis and project design aspects.  Scientists, researchers, and for that 
matter any person involved in the development of a given emerging genetic technology, 
can use this approach.  
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This assessment tool should be employed while the technology is still in the 
research and design phase.  This takes the nonlinear approach out of the restrictive HTA 
timelines and processes.  It is more akin to a TA process, in this respect.  It can be 
engaged from the very start of a new research project or shortly after a study is 
undertaken.  As the project reaches certain benchmarks for major breakthroughs the 
process will continually be reengaged.  The ethics assessment will continue to grow with 
the emerging technology. 
 
4.2.3 Overview of the nonlinear approach 
 There are five overarching phases in the nonlinear approach.  They include:  (1) 
identification and inquiry; (2) research and data analysis; (3) concept mapping; (4) 
evaluation; and, (5) closing the loop.  The visual below represents the intention of this 
approach to be continually utilized, engaged, and reengaged at critical points in the 
development of emerging genetic health technologies. 
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Figure 1: Visual representing the Nonlinear Approach 
The nonlinear approach is nonlinear in two overarching ways.  First, it is 
nonlinear in the sense that it moves through multiple cycles and it does not function as 
one point in an HTA process.  Second, within the approach itself there are elements of 
nonlinearity, including the flexibility to transition back and forth between phases, reflect 
on the entirety of the approach at any point, and the inclusion of elements that are 
unknown or unconstrained (this will be addressed in Phase 3). The nonlinear approach 
retains a structure, and this structure at points requires certain things to happens.  
However, this must be done for purposes of coherence. 
The rest of this chapter will fully detail the intended activities in each phase of the 
nonlinear approach.  The methodological strength of each phase will be presented and 
discussed.  Finally, a coherent picture of how each phase fits in the larger context on the 
nonlinear approach, as well as in broader HTA processes, will be presented and discussed 
along with the projected benefits and limitations of this approach.  
Identification 
and Inquiry
Research and 
Data Analysis
Concept 
Mapping
Evaluation
Closing the 
Loop
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4.2.3.1 Phase one: Identification and inquiry 
The first phase identifies the scope of the technology and all intended and 
potential uses.  There are two activities in this phase that must be completed.  First one 
must identify research benchmarks and construct a rough timeline.  Second, the 
facilitators or research team must identify the values associated with these intended uses, 
and construct a research question. 
As previously stated, this methodology is developed for emerging genetic health 
technology.  Ideally, this approach would be adopted at the onset of new research or 
integrated into research soon after scientific results are available.  There are a number of 
ways to identify technology in need of assessment; one such methodology is horizon 
scanning.  The technique of horizon scanning is a process that systematically examines 
emerging technologies for early signs of potential threats or opportunities.  The emphasis 
on new technologies surrounds the uncertainties in risk prediction.  It takes seriously the 
trends in technological developments, explores unexpected issues that arise in existing 
technology, and evaluates persistent problems.  This is all done in an effort to predict 
what technologies will present opportunities or threats in the future.11  A recent horizon 
scanning study surrounding health-related genetic tests conducted by Gwinn et al, in the 
article Evidence on Genomic Tests at the Crossroads of Translation, reported that: 
After the pilot phase, our scan detected approximately two to three new 
genomic tests per week. Nearly two thirds of all tests (122/188, 65%) were 
related to cancer; only 6% were related to hereditary disorders. Although 
88 (47%) of the tests, including 2 marketed directly to consumers, were 
commercially available, only 12 (6%) claimed United States Food and 
Drug Administration licensure.12 
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The contribution of engaging in horizon scanning is the positive impact it has on priority 
setting for other emerging genetic health technologies.  Utilizing the work that has been 
conducted is central to anticipating future developments.  It will also help to identify 
whether there are similar technologies being developed that could be included or benefit 
from being included in this research.  A recommended activity, although not required, is 
that researchers consult recent horizon scans to determine similar technologies or 
research being conducted or developed. 
This approach will likely not work well if utilized by an outside agency or body 
assessing a research firm or team’s work.  This approach is meant to adapt and grow as a 
technology is developed.  Therefore the perspective of an outsider observing the research 
is not as useful as this approach being integrated with the work of the scientific research 
team.  For meaningful ethics assessment the approach must be integrated with the 
research.  Thus, to attain meaningful results, the inclusion of the research team is 
paramount.  The important point is that this is not an appropriate methodology for 
oversight or regulatory bodies.  This is an internal mechanism by which a research team 
or research firm can conduct ethics assessment in a meaningful way.  The benefit of this 
is twofold.  The data can be directly transferred to any formal HTA processes.  Second, it 
will alleviate some of the societal skepticism that usually accompanies emerging genetic 
technologies.  Further explanation and arguments surrounding the reasons why emerging 
genetic technologies hold a special place, at this point in human history, will be 
articulated in Chapter Five. 
If a research team is curious whether or not this approach is appropriate to 
engage, they need to consider several points.  First, will this technology at any point 
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perceivably impact human health in any way, whether it be as a direct medical device, 
treatment or intervention or something that will address human health in other ways such 
as environmental improvements?  Second, is the foundation of this research dealing with 
genomics or genetics?  If the research will impact human health or quality of life and is 
based in genomics or genetics, then this approach is appropriate for that technology. 
After a research team engages this approach, phase one can officially commence 
by formulating a research question for assessment.  Basic inquiry and question-framing is 
critical to this process.  The formulation of the question will impact how it is answered.  
Each cycle starts with a research question that relations directly to ethical considerations.  
That question can be massaged and reframed throughout the process.  Questions will be 
different depending upon the stage of development of the technology.  For example, 
technology in the very early stages of development may ask questions of general 
population perceptions of values or morality towards the potential uses and benefits of 
the technology.  Questions can also be as open-ended as asking what the potential ethical 
or social problems, issues, or controversies in this technology might include.  
Technologies in more advanced stages of development may ask more specific questions 
to elicit results that guide education or advocacy plans.  For example, questions might 
surround whether a given population will utilize this technology, or how adoption of this 
technology might impact current health system structure or other existing policies. 
 
4.2.3.2 Phase two: Research and data synthesis 
 There are two actions that need to be completed in this phase:  the literature 
review and analysis; and outcomes setting.  It is important to gather as much information 
  
 
167 
 
as possible about the scholarship already completed pertaining to the new technology or 
any similar technologies.  To accomplish this, a literature review should be conducted 
that directly engages both the technology and the research question.  This research should 
be compiled and a brief analysis developed.  All participating researchers should 
familiarize themselves with this material.  There are three recommended methods to go 
about conducting a successful literature review, these include the methodology proposed 
by Droste et al, outsourcing the work, and conducting a literature review based on sound 
research practices.  It is also important that after the literature is collected that it be 
synthesized and disseminated to the research team.  
First, is to utilize Sigrid Droste et al’s research methodology, which is specifically 
developed for locating ethics information for HTA.  The benefit of utilizing this approach 
is that it allows research teams that do not have a strong foundation in research 
methodology conduct a literature review on their own. The authors provide a robust 
eight-step framework. The steps include:  
Step 1: Translation of the search question using the PICO scheme and 
additional components.  Step 2: Concept building by modeling and linking 
search components.  Step 3: Identification of synonyms in all relevant 
languages.  Step 4: Selection of relevant information sources.  Step 5: 
Design of search strategies for bibliographic databases.  Step 6: Execution 
of search strategies and information seeking, including hand-searching. 
Step 7: Saving of retrieval results and standardized reporting of the 
process and results.  Step 8: Final quality check and calculation of 
precision and recall.13 
 
This useful and user-friendly methodology was discussed in Chapter Three.  The second 
option is to outsource the research.  This can be accomplished in a number of ways, 
including partnering with a research university or college, or other organization such as a 
rapid report service or private HTA firm.  For example, Canada has developed a rapid 
  
 
168 
 
report service that provides concise and semi-synthesized data on HTA related topics and 
technologies.  Furthermore, they allow clients to specify research parameters.  Given the 
need for expedited HTA, it is likely other organizations will soon offer similar options.  
The Canadian rapid report system can provide reliable research in a little as five to six 
months.14  Depending on the timeline of the research, this may or may not be an 
appropriate selection.  If the two options recommended above are not practicable, the 
third option includes conducting the research and literature review internally using other 
reliable research methods.   
From this research, the information collected must be synthetized and 
disseminated.  The synthetics should provide a summary of information collected, this 
can take the form of an annotated bibliography or a white paper.  These materials should 
be circulated to the research team, and they should familiarize themselves with it.  
In some cases, information may be limited or non-existent given the newness of 
the technology.  This is acceptable, as this process will be repeated; therefore, literature 
reviews may yield more results after the technology has existed for some time.  The final 
action in this phase is to set research objectives or intended outcomes.  Based on the 
research question and the information gathered the following questions should be 
answered:  (1) what is the knowledge to be gained?; (2) in what way is this knowledge 
going to be useful?; and, (3) who can help to gain it? 
 
4.2.3.3 Phase three: Concept mapping 
Concept mapping is a means by which to visualize the connections between, ideas 
and concepts from a wide range of perspectives.  Concept mapping has sound 
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mythological foundations in the social sciences since its inception more than two decades 
ago.  There is an impressive body of technical literature supporting the process.15  This 
methodology is a pattern-oriented.16  Concept mapping has also been applied to a broad 
range of disciplines and projects, including some in health care.  The methodology 
continues to be developed, refined, and adapted. HTA literature surrounding the 
application of ethics methodologies contain multiple frameworks that mention mapping 
or finding a coherent way to link concepts, ideas, facts, and perspectives.  In effect, this is 
seeking social patterns of values and coherency in them.  Concept mapping is a tool that 
can accomplish this in a comprehensive way with a very high level of validity. 
Groups utilizing concept mapping draw on both qualitative and quantitative 
research.  This information is then translated into a visual, which helps simplify the 
complex task of balancing and connecting multiple stakeholder perspectives.  A concept 
is an element or component of a larger theory—in this application, the nonlinear 
approach.  Kane and Trochim state that, “fundamentally, concept mapping facilitates the 
identification of common themes to enable theory development, decision-making, action, 
or assessment.”17  Groups that participate in any sort of public planning must address the 
challenge of finding a way to coherently work together.  Not only is the challenge of 
communication and collaboration daunting, but it can also be difficult to find a common 
framework that can guide the group work.  The use of concept maps provides a flexible, 
inclusive framework that can be fit to any group, because concept mapping is 
contextually specific and naturally inclusive. 
Concept mapping has been used in healthcare as an education tool, specifically in 
nursing.18  It has been shown to improve organizational skills, critical thinking, and has a 
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tremendous impact on how students understand and create care plans.19  Concept 
mapping has also been used in very practical ways, including as a mechanism to improve 
decision-making in health care.20  Concept mapping has been used to collect data and 
evaluate diverse stakeholder opinions on primary health care services.21  It has been 
utilized to explore how patients cope with disease or illness in a given health system.22  
The challenges faced by individuals with traumatic brain injury have been assessed using 
concept mapping.  Concept mapping has also been used in public health and many other 
areas.23  The application of concept mapping to healthcare is not new.  There are well-
established examples; and it has been integrated in many university curricula. 
This method has even been suggested as a possible methodology in HTA.  Donna 
Southern et al, an Australian scholar at Monash University, suggested concept mapping 
as an alternative to discussion or focus groups.  The suggestion was made as a way to 
remedy issues in face-to-face meetings and audit group dynamics.  The concept map 
would allow all to express their views in a safe, stress-free environment period.24  The 
authors also found the use of both qualitative and quantitative data very appealing.  They 
suggested the creation of multiple maps to establish cross cutting links and issues.  They 
expressed the desire for participant engagement via feedback in an effort to solidify the 
validity of participant responses.25   
William Trochim and Rhoda Linton also provide some very useful observations.  
One is the relevance this method has for priority setting.26  Additionally, it is a useful 
decision-making tool, and can collect group opinions in a methodologically sound 
manner.  Trochim and Linton also note other methodological benefits.  These include the 
fact that researchers have little control over the outcomes of the data sets and results.  
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Thus, there is less room for tampering or manipulation of data, and other unethical 
conduct in the ethics assessment.  Like Southern et al, they praise the ability to validate 
participant responses, which lends an increased validity to the entire method. 27  
However, Trochim and Linton state that this process can be both time-consuming and 
expensive.  It should be noted that this comment was taken from an article written in the 
mid-1980s.  Given the technological advances in both communication and the computing 
of large data sets, the cost can likely be significantly reduced with the application of 
appropriate technologies and software.  
Outside of these very limited instances—using it as a mechanism to collect and 
evaluate public opinions—concept mapping, as it is being described and used in the 
nonlinear approach, has not been applied in HTA.  However, many HTA methodologies 
do have some elements of mapping in them.  For example, SCOT approaches map 
development over time; and participatory approaches attempt to map stakeholder 
perspectives and attitudes. 
Concept mapping is theoretically grounded in structured conceptualization.28  
This means that the resulting model represents part of the theory.  The model allows for 
the comprehension and description of relationships between concepts within the theory.  
There are three major components in structured conceptualization.  First are the process 
steps.  Stakeholders and relevant parties must generate ideas and set the parameters of the 
domain.  The structure emerges by connecting all the ideas and facts that are related.  
This can be done in words, through pictures or mathematical symbols.  The second 
component is perspective.  There are three broad perspectives desired, including that of 
individuals, groups, and the assessment mechanism or algorithm.  The third major 
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component is the representational forms.  Any conceptualization with multiple 
perspectives can be represented in multiple ways.  For example, it can be represented as a 
list with descriptions, as a pictorial representation such as a map or chart, or even as a 
symbolic representation such as a mathematic equation.29 
Concept mapping has a number of concrete principles that ground it as a sound 
methodology.  The first is that it values individual knowledge.  An expert with the 
requisite knowledge can provide individual contributions.  So, while multiple experts are 
engaged, this means that the concept mapping aggregates individual knowledge of all the 
experts.  It takes it in conjunction across disciplines and sources.  The key to properly 
utilizing this principle is that the appropriate areas of expertise must be included.  The 
second principle of concept mapping is that it provides the rules for building and 
recognizing emergent relationships of meaning among concepts.  The activity that is 
occurring in this process is that participants link ideas, concepts, facts, and observations 
to discern relationships between them.  The third principle is that concept mapping 
produces a conceptual model.  The accuracy of the model is based on the inputs from 
those involved in the process.  Again, it is crucial that the relevant experts be available to 
provide additional input.  The inclusion of both experts and laypeople increases the 
diversity of perspectives.  The emerging visual framework provides a unique 
representation of the issue.  Concept mapping explicitly includes disparate units of 
existing knowledge in a unified conceptual framework.  Finally, concept mapping should 
be applied within a specific context.  This means that when applying concept mapping to 
the issues of emerging genetic health technologies the content of the concepts map should 
be highly reflective of the realistic or real-world context.30  
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There is a wide number of concept mapping approaches including idea maps, 
mind maps, mental maps, cognitive maps and so on.31  As discussed by Kane and 
Trochim, these correspond to different traditions within the social sciences.  For this 
endeavor, the most appropriate mapping approach is collaborative group concept 
mapping.  Group concept mapping is a recognized as an applied research methodology, 
and has its foundations in a number of social science traditions.  For example, discussion 
and facilitation methods are linked to the Delphi methodology; and the computation of 
results, depending up on the system used, may be grounded in multivariate statistics or 
multidimensional scaling.32 
The creation of a concept map in the research and development phase of a 
technology may appear to be simply another bolt-on ethics approach to HTA.  If 
implemented cynically or inauthentically, that could be an accurate description.  
However, the very nature of concept mapping lends itself to a high level of authenticity, 
because it is not a checklist or one-and-done approach.  Furthermore, it illuminates those 
ethical and social considerations that may not be obvious, and draws connections 
between existing ethical issues and concerns so a more complete picture and 
understanding of the landscape can be gathered. 
The following section addresses the practical steps for creating a concept map for 
planning and evaluation of ethics.  Before launching into the concept mapping, 
consideration of the results from step one and two must be addressed.  First, one must 
gather the information collected for step one and step two, and then reevaluate step one in 
light of the information collected in step two.  Step three begins with conceptualization of 
the project.  This should be based on the information from steps one and two, and 
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broadened to include thoughts, ideas, or even hunches.  If there are no adjustments that 
need to be made to the research question, proceed to step three.  If adjustments need to be 
made, make them before proceeding to step three.  Any adjustments should directly 
reflect the research gathered in the literature review and the intended outcomes. 
 
4.2.3.3.1 Practical Concept Mapping Steps 
The process of group concept mapping, including basic rules and practical steps, 
follows the method established by Kane and Trochim in the SAGE Handbook of Applied 
Social Research Methods.  Again, it is important to note the recognized validity of this 
methodology.  This is a highly relevant methodology for ethical assessment for a number 
of reasons.  Concept mapping identifies ethical and social issues, connects these concepts 
and issues, and identifies particular issues among specific populations or sub-groups.  In 
addition, concept mapping fits well in the overall structure of the nonlinear approach in 
that step six of the concept map lends itself quite well to the development of action steps 
in phase five of the nonlinear approach.  Concept mapping alone will not resolve ethical 
problems, but it will provide valid data for the justification of future action steps.  It is in 
phases four and five of the nonlinear approach where there is an opportunity to address 
ethical issues themselves in more depth.  There are six steps: (1) preparing for concept 
mapping; (2) generating ideas; (3) structuring statements; (4) concept mapping analysis; 
(5) interpreting the maps; and, (6) utilization.33 
 Step one, preparing for concept mappings, revolves around identifying two key 
knowledge sources.  The first is the facts of the problem or issue at hand; and the second 
is the participants or stakeholders.  To identify the knowledge contained in the 
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participants and stakeholders oftentimes requires a wider discussion takes place or a more 
structured set of questions and answers can be applied.  For example, a prompt or open-
ended question that will focus participants and elicit the appropriate knowledge sources 
might look like “we know that this new technology is successful when…” or “a specific 
issue that affects patients receive predictive information as a result of genetic testing 
is….”  Intentional and careful consideration must be given to construction of questions, 
prompts, or open-ended statements.  They must elicit the appropriate breadth and depth 
of responses.  Also, the answer is often determined by the way the question is asked; 
careful attention to existing biases must be given.  Additional considerations in this step 
that must be made include the selection of participants and stakeholders as well as the 
appropriate number. 34 
Step two, generating ideas, involves generating responses to the prompt and 
collecting those responses.  Kane and Trochim suggest using a form of structured 
brainstorming articulated by A. P. M. Coxon, a professor of social sciences from the 
UK.35  This builds on the intentional structuring of the prompts and open-ended 
statements in step one.  To generate these brainstormed responses there are number of 
mechanisms by which to engage participants.  These can include face-to-face meetings, 
web-based meetings (e.g. webinars, Skype, Adobe Connect and so on), and emailed 
surveys or traditional mail-based surveys.  Either during or immediately after the 
generation of the responses, there are a number of other options by which researchers can 
gain additional ideas and information.  These include but are not limited to excerpts or 
conclusions from documents resulting from a literature review or interviews with experts 
in the field.36 
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This step concludes with a synthesis of information.  The researchers review all 
ideas generated and collected and organize them into rational sets.  The goal is to reduce 
or eliminate any redundancies as well as determine if any ideas fall outside the scope of 
the current project or are simply not relevant to this research.  There are methods by 
which a formal content analysis can be used to synthesize the collection of statements, 
one of which is proposed by Klaus Krippendorf, who is the Gregory Bateson professor 
for Cybernetics, Language, and Culture at the Annenberg School for Communication, 
University of Pennsylvania.37  For example, if more than 600 statements are collected, 
there will be overlapping and irrelevant statements.  Kane and Trochim suggest that 
ideally, after engaging idea synthesis, this number would be reduced to approximately 
100 - 120.38 
Step three centers around the structuring of statements.  In this step there are three 
tasks that must be performed by the participants and stakeholders.  The first task consists 
of participants sorting the statements.  Then, in the second task, they must rank the 
statements, and, finally, in the third task, provide some basic demographic and 
characterization information.  The former consists of an unstructured sorting of the 
statements resulting from step two.  Each individual is responsible for sorting the 
statements into groups in any way that makes sense for them.  Kane and Trochim 
articulate a number of guidelines to assist in this sorting.  First, there cannot be the same 
number of ideas as groups, this means that participants actually have to engage in the 
sorting process. They cannot establish every idea as separate from another, thereby 
having the same number of groups as ideas.  All the statements cannot be put in the same 
group, because this provides no distinctions.  There should be no miscellaneous group.  If 
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the statement is wholly unique it should be separated out.  The benefits of using this type 
of sorting are that it can accommodate large number of statements or ideas.  The most 
important benefit is analyzing the connections individual participants have made between 
the different statements.  For example how participant sorts and connects ideas will be 
different from other participants; and this will reveal the nature of relationships and 
connections on multiple levels.39 
The second task participants and stakeholders must complete is rating the 
statements.  The statements can be rated by a number of measures; these will be specific 
to the context of the project.  The statements could be rated on level of importance or 
priority, feasibility, or any other relevant characteristic.  A Likert scale is a useful 
mechanism for rating.  This will reveal the most relevant concerns to specific 
participants.  This allows for a very rich data analysis.  In the final task, participants must 
provide some basic personal and demographic information.  Demographics or 
characteristics of participants can be viewed in relation to the information gleaned from 
statement ratings.  This allows correspondence to be grouped into subgroups or focus 
groups if need be or for detailed analysis.40   
Collecting responses, organizing and ranking those responses, and collecting 
participant information are all fairly standard and routine practices in qualitative group 
research.  Step four is what separates concept mapping from other similar qualitative 
group research methods.  Kane and Trochim advocate for a combination of analysis 
methods that integrate two key components, qualitative input and quantitative analysis.  
The aggregation of this information allows for the creation of a concept map.  The image 
below is an example of a pictorial concept map. 
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Figure 2: A concept map on concept maps. Developed by Novak and Cañas.41 
 
Pictorial concept maps, like the example above, are very useful in visualizing 
connections and maintaining a coherent vision of the entire project.  It is recommended 
that in the first cycle of the nonlinear approach, that a pictorial concept map is developed 
to coherently demonstrate crosscutting concerns and themes.  These connections are not 
always as explicit in other visual representations.  In the example above, there is 
coherence both in the organization of the concepts as well as the connections between 
them. 
Depending upon the size of the focus group, it may or may not be appropriate to 
move beyond a pictorial representation.  In the initial cycles of the nonlinear approach, 
when focus groups may only include the research team and relevant experts, the pictorial 
concept map is likely the most appropriate.  As broader participation becomes necessary, 
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the more likely the need becomes to transition to representative models outside of the 
pictorial representation.  These other concept representations have great capacity to 
aggregate and display data.  When moving through the multiple cycles of the nonlinear 
approach, options exist to build upon the concept map originally created in prior cycles.  
Or create a new concept map more appropriate and reflective of the participants may be 
created.  Then, integrate the prior work with the new. 
The other types of concept mapping that are more adept at handling large 
numbers of participants are also more systematic in nature due to the fact that the input is 
identical to the information gathered.  Computers are required to complete this analysis.  
Specifically they identify the basic analysis as the combination of three methodologies 
including sort aggregation, multi-dimensional scaling (MDS), and hierarchical cluster 
analysis.42  Concept maps can be represented in many different ways.  This involves 
placing the rankings, in their numeric form, into a matrix that is then represented in a 
plot-chart or point map to display, visually, the proximity of related issues.  The result of 
this input reveals clusters of ideas and statements on a highly conceptual level.43  This 
requires the use of computer software.  
Depending upon the depth of analysis in the given cycle there are a variety of 
software options.  For pictorial concept mapping available software includes, 
MindMaple, Cmap, Freemind, VUE (visual understanding environment), iMindMap, 
MindMangager, NovaMind, and several more.  Many of these are free and include both a 
web-based version and an application. For more advanced mapping and data collection 
software, options include Microsoft Excel (although this is typically not the most user 
friendly), NCSS10 Data Analysis, SigmaPlot, and Thinkmap.  This type of software can 
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range from anywhere from free to $1,500.44  Flexibility exists based on the needs and 
skillsets of the research team.  Selection of software should be appropriate to the scope of 
the current cycle.  A brief example of how to utilize these more complex statistical tools 
will be provided in Chapter Five. 
In step five the maps are interpreted.  Since this is based in stakeholder and expert 
participation, it is useful to include both in the analysis.  A simple rule to follow is that all 
participants who provided responses should be presented with the visual product and be 
given the opportunity for further feedback.  Inclusion increases transparency and lends 
itself to additional participant buy-in and joint authorship.  Kane and Trochim also note 
that it yields “richness” to the results, as well as increases the value for both the 
participants and the researchers.45  
Evaluating and interpreting the maps—whether a point map, cluster map, or 
pictorial map—can occur in several different ways.  Pictorial maps, point maps, and 
cluster maps (the more basic configurations of concept maps) can be read in a way that 
informs further analysis.  This means that based on the finding there is now a more clear 
direction and indication for additional research necessary to address the research 
question.  The data can also be formulated in different ways to reveal crosscutting issues 
between different sub-groups identified in the participant sample.  This information can 
be used to identify areas where problems exist.  For example, in the case of evaluating a 
large number of participant responses, if there is a huge difference or gap between the 
ranking of importance of a given social value between the subgroup included in the 
research and a non-expert subgroup, that indicates that this is an issues that should be 
given particular attention.  If a certain group is ignoring a specific aspect, while another 
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group finds it very important, further examination is essential.  This divergence can yield 
some very insightful information and guide future action steps. 
The question becomes, what actions are appropriate to take based on data?   
Obviously, to some extent that depends on the data.  Step six involves using the 
evaluation of information in step five to inform action.  Collecting data lacks purpose if it 
is not going to be utilized.  The information yielded in the research should provide the 
foundation for future action.  This also means that the action should be consistent with 
the findings.  Connections have been identified, crosscutting links have been established,  
and this can inform a wide range of actions surrounding emerging technologies. 
Actions can range from pursing further, more focused, research.  Education 
initiatives can be initiated or those in existence can benefit from being properly informed.  
Social change programs can also be initiated or better-informed, such as advocacy 
groups.  One example of concept mapping informing social change is the evaluation of 
the Centers for Disease Control and Prevention Research Centers Program, conducted by 
L. A. Anderson et al.  Concept mapping was used to take a very large and diverse set of 
participant and stakeholder perspectives into account.  A logic model was developed and 
used to evaluate the centers.46  Valuable information surrounding the perception of the 
center and understanding of the center’s function and outcomes was gathered and 
analyzed from stakeholders and program partners.  As a result of this research, important 
program expectations were established.47 
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4.2.3.3.2 Linear vs Non-linear HTA 
HTA practices have not been traditionally thought of as nonlinear.  HTA 
processes typically occur in a step-by-step process, where the former step triggers the 
next.  This is linear.  This process is acceptable for safety and cost-effectiveness 
evaluations, but not for ethics.  This is because ethical issues, questions, and problems are 
not structured the same way, and thus do not lend themselves to fitting nicely in an rigid 
framework or process. 
Linear and nonlinear programming are problem solving processes in the subfield 
of mathematical optimization.  Optimization problems can be either linear or nonlinear.  
An optimization problem is one in which a single solution is not sought, but rather the 
best solution among many solutions is discerned.  Optimization problems have existed 
since ancient times.  Optimization is easily observed in nature; and as a result, “many 
laws of physics are formulated as principles of minimum or maximum of some scalar 
characteristics of observed objects or systems, like energy or entropy.”48  The most 
important application of linear and nonlinear programming is to solve optimization 
problems surrounding human activities.  For example, it might be beneficial to figure out 
what the most cost-effective means are to reach a certain goal.  Likewise in cases where 
resources are scarce or limited, it is important to consider how to maximize those 
resources. 
Linear programming is a mathematical technique that attempts to find the best 
possible solutions.  This can be applied to real-world situations such as allocating limited 
resources, including output surrounding energy, machines, human power, time, and 
cost.49  Linear programming can only be used when all constraints and all functions are 
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themselves linear—having one dimension and, when graphed, resembling a straight line.  
Essentially, a linear equation is an equation, which forms a straight line when it is plotted 
on a two-dimensional graph.  Another characteristic is that linear equations and their 
variables only appear to the first power.  This differs from nonlinear equation in which 
dependent variables can exist to different powers or even in other mathematical forms.50  
Linear programming allows one to take multiple independent variables into consideration 
simultaneously.  These are called linear relationships. 
Nonlinear programming is primarily used for those problems that have unknown 
variables, equalities and inequalities, and undefined constraints.  The focus remains on 
optimization, a concept well rooted in many decision-making mechanisms.51   This is 
typically addressed in mathematics, where the object or solution is portrayed as an 
integer, graph, or equation.  Nonlinear programming has taken on a vital role in many 
disciplines including management science, engineering, systems analysis, economics, and 
computer science.52  It is a mechanism, which one can use for decision-making.  
There are three general stages when utilizing nonlinear programming.  The first 
stage surrounds the development of a mathematical model that identifies and accurately 
represents the problem.  This includes identification of all the variables, retrieving data 
relevant to those variables, determining which function is to be optimized (minimized or 
maximized), and organizing these variables and the corresponding data into mathematical 
relationships.  These mathematical relationships are called restraints and are represented 
as equations or any qualities.53  The second stage entails the analysis of the mathematical 
model produced by the first stage.  It must be determined what the appropriate numerical 
technique is for finding the optimal solution.  It is at this stage where one can determine 
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whether or not the problem is in fact linear or nonlinear.  For example, if one or more of 
the constraints is nonlinear the model becomes nonlinear; also if the objective function is 
nonlinear than the entire optimization problem can be said to be nonlinear.54  The third 
stage aims at finding the optimal solution.  In the vast majority of cases computers are 
used to do the mathematical computations.  In some cases, a new code must even be 
written to address the multiple variables.  The numerical solutions provided by the 
computation must be reinterpreted and analyzed; these are then evaluated and utilized to 
make decisions.55  Mordecai Avriel, in his book Nonlinear Programming states, “analysis 
of a nonlinear program provides valuable insights into the structure of the problem and 
answers questions about the existence and characterization of feasible and optimal 
decisions.”56  This sums up what ethical and social research, in many cases, is attempting 
to do; that is, make optimal decisions or arrive at a justified conclusion among unknown 
and unconstrained variables.  However, this is not to say that the sole focus of ethics 
assessment is arriving at a justified conclusion.  Rather, the focus is on the whole process, 
which includes identifying the problem or ethical issue, analyzing the substance of the 
issues in order to understand the potential social impact, and then arriving at the 
conclusion or decision.  There is no justified conclusion without careful attention to and 
analysis of the specific ethical issues. 
Nonlinear programming has been applied to many specific real-world phenomena 
and problems including sports, chemistry, weather prediction, war, and disease, just to 
name a few.  In sports, nonlinear programming is critical in understanding the 
aerodynamics of sports balls.  For example, it would be incredibly beneficial to 
understand how to bend the soccer ball like David Beckham or Wayne Rooney, throw a 
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major league curveball, understand the ball trajectory, or even the implications of using a 
traditional bow as opposed to a compound bow.57  
In the book, Political Complexity: nonlinear models of politics, each chapter 
focuses on utilizing a nonlinear model to understand politics.  One of the chapters was 
written by Walter Mebane, and focused on campaign funds.  The primary question was 
how incumbent congressmen/congresswoman are able to amass substantial campaign 
funds.58  Through nonlinear programming and analysis, Mebane determined that there 
was a nonlinear relationship between campaign contributions, district service, quality of 
the challenger, and election outcomes.  He concluded, as a result of this analysis, that 
“voter preferences only partially determine election outcomes.”59 
A final example of how nonlinear programming is applied is in the understanding 
of disease transmission, including both the spread and growth of diseases.  The analysis 
provided by Richard Enns, in his book It’s a Nonlinear World, focuses primarily on 
infectious diseases such as influenza.  Each year in the United States and across the world 
there are fears of an influenza epidemic whether it is the strain of the horrific Spanish 
influenza (H1N1) of 1918, bird flu (H5N1), or any of the other dangerous strains.  Is 
estimated that as many as 22 - 40 million people died in a ten month period as a result of 
the Spanish flu.60  Based on the danger posed by influenza, it is imperative to understand 
disease spread and transmission.  In an effort to understand disease transmission, Enns 
considered a number of models including the SIR model with and without the dynamics, 
as well as different constraints such as herd immunity and vaccination and geographic 
location.  Furthermore, he has applied these models to various infectious diseases 
including mad cow disease and the Black Death.  The result of these models indicates the 
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minimum speed of transmission for the spread of Black Death and other contagious 
diseases.61 
There have been some attempts to utilize nonlinear programming in TA and HTA.  
An early example of nonlinear programming being applied to emerging technologies 
dates back to 1976.  An article by Alan Manne, ETA: a Model for Energy Technology 
Assessment, argues that nonlinear modeling could predict own- and cross-price elasticity 
of demand and energy conservation of different fuel sources (e.g. coal, synthetic fuels, 
nuclear energy, water, hydrogen and solar).62  One of the possible outcomes, based on the 
interpretation of data is characterized by the following: 
 
As of 1970, virtually the entire U.S. electricity supply was provided by 
fossil-fired and hydroelectric units. During subsequent years, it appears 
optimal to install nuclear facilities at a rapid rate. According to Figure 3, 
the energy output of LWR's will overtake that of hydroelectric by the late 
1970's and will overtake fossil plants during the J990's. LWR capacity 
reaches a maximum of 1200 GW in 2015, and then begins to drop as old 
units are retired at the end of their 30-year service life. The LWR is in turn 
replaced-first by the FBR and later by the ADV technology. By 2030, only 
a small proportion of the electrical energy is generated by fossil or 
hydroelectric plants. Adaptations of both linear and nonlinear programing 
have been employed throughout the decades.63  
 
According to the U.S. energy information administration about 67% of the electricity 
used in the United States was from fossil fuels in 2013.64  19% is derived from nuclear 
energy, 7% from hydropower, and 6% from other renewable sources.65  While these 
predictions might have been pragmatic considering the data, social and political 
constraints were likely not successfully taken into accounts.  A few modern examples 
include photochemical air pollution control and proposed modeling for 
pharmacoeconomics.66 
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 It should be noted that the utilization of linear and nonlinear programming in 
emerging technologies and health technologies can provide valuable information in the 
HTA process but it does not substitute for the HTA process.  The benefit of using this 
line of reasoning is that the aim of nonlinear programing is to fully represent complexities 
of interactions that have many variables, including unknowns, defined and undefined 
constraints, and appropriate objectives when aiming to arrive at a decision in a complex 
problem.67  Applying the general philosophy of nonlinear programing, here termed 
nonlinear thinking, is a qualitative not an empirical analysis.  Therefore, nonlinear 
programming is not strictly applied; only the overarching conceptual framework is 
applied to ethics in HTA. 
The application of key concepts from nonlinear programing, such as optimization 
and the inclusion of unanticipated or unconstrained problems, have informed aspects of 
the nonlinear approach presented in this section.  First is the notion of optimization—that  
finding a singular solution to a problem is not only unlikely but impossible given the 
polarity of society.  Rather the focus is to find the best solution among many possible 
solutions.  It is similar reasoning when choosing which technologies to fund, develop, 
and so on.  Similarly, with ethical considerations, there are often many possible 
justifications and reasoning to support a conclusion; the aim is to find the strongest 
solution among many. 
The second connection is in the language and the way nonlinear programing deals 
with uncertainties and unconstrained variables.  In emerging technologies, there are, at 
times, immense uncertainties and well as unknowns.  Having a meaningful way to 
incorporate these concepts in the nonlinear programming suggests that it can be 
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analogous to the nonlinear approach.  All the ethical questions will not be answered. 
There are unknowns.  By recognizing the uncertainties exist and unknown consequences 
are possible, they can be accounted for through placeholders.  It is critical not to dismiss 
uncertainty or to deny the potential for unanticipated or unknown consequences.  The 
mathematical model of nonlinear programing provides insights for including these into a 
coherent decision-making model.  The adaptation of the nonlinear approach as applied to 
ethics requires that these uncertainties and unknowns be coherently accounted for and 
discussed without stymieing scientific progress.  Part of this was addressed in Chapter 
Two, surrounding the discussion of risk, uncertainties, and the ethical acceptability of 
risks.  That is the contribution of nonlinear programing to the nonlinear approach.  It 
allows for the frank conversations surrounding these very issues concerning the ethical 
acceptability of risk. 
 
4.2.3.4 Phase four: Evaluation 
In the fourth phase, the results of the concept map are taken into context with the 
larger research project.  There is one central activity in this phase and that is answering 
the question: “were the outcomes, set in phase two, met?”  Three additional follow-up 
questions should also be answered: (1) “How was the outcome(s) met?”; (2) “What do 
these finding indicate about the research?”; and, (3) “What does this mean moving 
forward?”  Recall that the outcomes from phase two articulate the expected gains from 
the concept mapping exercise.  This brief evaluation phase is setting the foundation for 
phase five, which calls for action based on the results of the concept mapping exercise. 
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4.2.3.5 Phase five: Closing the loop 
This phase is the most crucial and distinctive in this approach.  First, reflection 
must occur on the process as a whole; and an honest appraisal of the results must be 
given.  The nonlinear approach stems from the collision of four areas:  mathematics, 
bioethics, emerging health technologies, and higher education assessment.  The 
inspiration for phase five, however, can be credited to assessment in higher education 
Assessment in higher education occurs at two levels, institutional effectiveness 
and student learning.  Here the emphasis will be on those processes utilized in student 
learning assessment.  The same logic applies; but rather than asking questions of 
emerging technologies, questions are being asked of student learning.  Outcomes are 
created, often labeled student learning outcomes (SLO) or simply learning outcomes 
(LOs).  Assessment takes the form of measures by which one can determine whether the 
outcome have been met, evaluate the results, and then make adjustments that impact 
student learning so they are better prepared to meet the outcome.  The final phase, closing 
the loop, is the most critical.  This methodology has been demonstrated, and is supported 
by national agencies such as the American Association of Colleges and Universities.68  It 
is a step phase that is, at times, overlooked because it is difficult.  Yet, it is absolutely 
critical when it comes to analyzing and attempting to create positive change.  Without 
reflecting and determining what needs to be improved or adjusted—teaching, advising, 
student services, or learning—in order to continually improve student learning, students 
will not improve and the assessments have been completely devalued as the information 
was not appropriately utilized.69  
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Overall, the goal of student learning assessment in higher education is to produce 
credible evidence of student learning.  Then, use the data to continuously improve 
programs and services.  This allows institutions to demonstrate and maintain 
accountability.  Furthermore, it creates a culture where outcomes assessment is a 
continuous process and not cobbled together by a small portion of the faculty.  Finally, 
the evaluation aspect of assessments allows for reflection and improvement upon the 
assessment mechanism and process itself.70  Having a mechanism for continual 
improvement is important, but equally, if not more so, is having the capacity to assess the 
assessment mechanism.  This is a key step toward increasing the effectiveness of any 
assessment program, mechanism, and protocol.  One of the most important questions 
does not involve the quality of the assessment measures themselves but rather, whether 
the data or information that has been gathered is the right information.  The right 
information consists of information that can lead to action steps toward meaningful and 
positive change.71  The most appealing aspect of learning assessments is that they 
represent an internally driven, formative process.  This means they can be undertaken and 
adapted to each institution’s specific needs.  It is this element that is most beneficial when 
reflecting on and attempting to improve ethics assessment in HTA. 
The connection between student learning assessments and ethics assessment, 
outside of the word “assessment,” is the fact that both processes are aimed at gaining new 
knowledge and insight, and then utilizing that information to affect positive change for 
the future.  The only way to determine whether or not positive change has occurred is to 
continue the assessment process by closing the loop and re-engaging the assessment 
cycle.  It is evident from the literature and analysis provided in Chapter Three that many 
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scholars and institutions are reflecting on the use of ethics in HTA, and critiquing the 
various models and frameworks; but the question becomes how those reflections move 
the discourse forward. 
The final phase of the nonlinear approach requires reflection and action.  
Reflection should occur on two levels.  First, reflections surrounding the methodological 
aspects of the process should be conducted.  Questions to be asked include: What 
worked?  What it did not work?  What helped progress?  What hindered process?  Did the 
implementation tools work correctly (e.g. meetings, technology, data analysis)?  What 
can be done to improve the process?  
The second level of reflection occurs when the approach needs to be reengaged.  
This approach is not meant to run through a single cycle.  It is meant to have as many 
cycles as needed to shed light on the relevant issues, frame the question properly, and 
provide insights for decision-makers and policymakers.  It is unlikely this will be 
completely attained in one cycle.  Since this approach is engaging emerging technologies 
very early in the research and development phases, they are likely to be substantial 
breakthroughs benchmarks that are met throughout the research process.  As these 
benchmarks are met and major breakthroughs occur, the approach should be reengaged. 
This is a cyclical approach; and the process should begin again, building on the work of 
prior cycles. 
 
4.3 Discussion and analysis of benefits and limitations 
This section will provide an assessment of the non-linear approach.  This will be 
accomplished by addressing the overarching benefits and limitations.  The gaps and 
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deficiencies identified in Chapter Three will also be specifically addressed, along with 
the practical obstacles also presented in Chapter Three. 
 
4.3.1 Benefits 
 By adhering to the overarching aims—(1) begin ethics assessments earlier then 
formal HTA assessments; (2) provide a flexible framework whereby ethics experts and 
non-experts can coherently work together; (3) support, not stymie, scientific progress; (4) 
provide meaningful discourse and recommendations; and, (5) continually improve by 
assessing the ethics assessment mechanism itself—the nonlinear approach produces some 
benefits.  The benefits include increased time, sound methodologies, increased inter- and 
multi-disciplinary collaboration, the inclusion of wider ethical and social issues including 
socioeconomic issues, improved transferability of information, and finally as a step closer 
toward creating consistency in ethics assessment while not stymieing scientific progress. 
This approach is cyclical in nature, meaning that it is not a one-and-done process nor is it 
a single point in general HTA process.  It is ongoing and happens concurrently with 
technical development.  This approach is accessible to scientists and non-ethics experts 
due to its interdisciplinary methodology.  However, ethics expertise is still needed in the 
research and evaluation portions of the approach. 
 
4.3.1.1 Increased time 
Increased time for reflection and evaluation is one of the most distinct and 
important advantages.  Time is gained by moving the ethics assessment outside of the 
traditional HTA process.  That elevates ethics to a more integral position for 
  
 
193 
 
technological development as a whole, as it is now embedded from the very onset of 
scientific research.  This rejects the notion that scientific development and technical 
innovation occur in a value-free or value-neutral space.  When concerning emerging 
genetic health technologies, those positions are simply not tenable.  With the benefit of 
added time, thoughtful reflection can occur.   
In addition, the cyclical nature of the approach means that one does not have to 
“get it all right the first time.”  That allows for researchers to continually build on and add 
to the robust understanding of ethical issues.  It also increases checks and balances, 
because results can be compared between the cycles.  It was evident from Chapter Three 
that ethics assessment in HTA is, at times, a nearly static function in the overall HTA 
process.  Thus, if the assessment is not accurate the first time, researchers are not moving 
forward with inconsistent or invalid data and recommendations.  Multiple cycles allow 
for confirmation of validity, which is all made possible by increased time. 
 
4.3.1.2 Methodological strength and collaboration 
The approach is accessible as it is based on best practices from a range of 
disciplines that offer structured and organized methods to conduct intellectual inquiry.  
The methodologies utilized are also fairly simple in concept, despite some of the labor-
intensive aspects.  Scientists may find the adaptation of concepts from nonlinear 
programming to make very good sense as an analogy to ethics analysis.   
The nonlinear approach helps researchers and policymakers make decisions about 
new technologies in two ways.  First, it highlights potential pitfalls, which can directly 
impact the ways technologies are introduced to the public.  Many genetic health 
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technologies will have similar characteristics when it comes to uncertainties, surrounding 
dual use, unintended, unanticipated, and unknown outcomes.  Starting and continuing the 
discourse will help assist policymakers in understanding public perception of the 
acceptability of risk.  Ideally it will also help society to arrive closer to some consensus 
about what is and what is absolutely not acceptable.  
The potential, and arguably necessity, for increased inclusion of different 
perspectives is a benefit of this model.  The nonlinear approach does not function 
properly without multidisciplinary collaboration, public participation, and stakeholder 
engagement.  In order to create an accurate concept map, there must be inclusion and 
engagement of the relevant parties and experts in discourse through interdisciplinary 
collaboration. 
 
 4.3.1.3 Wider ethical considerations 
In current HTA models, including those used by NICE and EUnetHTA, ethics 
assessment occurs at one point—if it happens at all—and then is often left untouched, 
unless substantial changes are made to the technology.  A strength of the nonlinear 
approach is that it is iterative; that is, it is applied repeatedly.  By moving ethical 
assessments into the research and design phases of technologies that are likely to be 
applied to human health, it becomes possible to conduct ethics assessment multiple times 
throughout the development of the technology, thereby allowing time for an iterative 
process to take place.  As multiple ethics assessments occur they build very much like a 
spiral, continually refining, aligning, with the ultimate aim, in case of HTA ethics 
assessment, of building consensus and developing direction and recommendations for 
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policy.  As a result of nonlinear thinking, this model can more easily address a wider 
range of ethical considerations and stakeholder perspectives, thereby adding depth and 
breadth.  
When addressing emerging genetic health technologies this becomes more 
important, as the implications of these technologies are still widely speculative.  A few 
examples of the wider ethical considerations surrounding emerging genetic health 
technologies include: what does it mean to be human? what is life? how does one 
understand autonomy in relation to future generations and future research?  It is not 
unreasonable for there to be an acknowledgment of these issues as emerging genetic 
health technologies become a realization.  For example, biobanking has become 
incredibly important.  A biobank is a location where blood samples or tissue samples are 
stored.  Depending upon the level of consents and the nature of the biobank, patient 
information may or may not be attached to the samples.72  This obviously presents issues 
of privacy and confidentiality.  But a more subtle ethical issue that has come to the fore is 
the question of future research and the role informed consent, as well as how the 
underlying principle of autonomy may play in this.73  Often when tissue samples or blood 
samples are collected it is done so with the knowledge that the samples will be used in 
future research.  Because the research is in the future, it is impossible to know what the 
research might actually entail.  If a patient gives consent, they are giving blanket consent 
to any research, whether they may find that research acceptable or not.74  These wider 
ethical issues will be examined in greater detail in Chapter Five. 
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 4.3.1.3.1 Ethical and socio-economic considerations 
Given the type of data collected and the method by which it is collected, the 
nonlinear approach can yield some very rich analysis surrounding socio-economic 
concerns and perspectives.  The nonlinear approach has the capacity to address 
socioeconomic issues in the sense that it can take seriously the concerns of individuals 
and subgroups representative of various economic classes.  That being said, this is 
possible only if the participant selection reflects this diversity.  The richness of the data, 
and breadth of the social issues depends greatly on the diversity of participants.  If there 
is representation of various socioeconomic classes, then the nonlinear approach has the 
capacity to not only reveal the difference in perspectives, but also take each group's 
perspective as seriously as the other.  This means that no additional weight will be given 
to preferred or special groups of individuals.  This dramatically widens the opportunity 
for many other ethics assessments.75  These wider considerations are necessary when 
addressing equity and socio-economic factors; they are critical to producing meaningful 
results.76  
 
4.3.1.4 Dissemination and transferability of findings  
The nonlinear approach can begin to address what some scholars have started 
calling the “moving target problem.”  This is problematic in HTA for a number of 
reasons.  The “moving target problem” arises when changes in the way a given 
technology is used, applied, or upgraded happen before the dissemination of information 
for the HTA process.  This dramatically affects the currency and relevance of the 
findings.77  The nonlinear approach directly addresses this problem.  This is an approach 
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that is built to be repeated continually until the technology is stabilized and there is 
general public consensus and education surrounding it.  Thus, as technologies hit major 
benchmarks or breakthroughs, methodology can be stopped at any point and started back 
at the beginning; after one cycle has completed, another cycle can begin as soon as there 
is a shift in research, a major break through, or an update in the application of 
technology.  This is not a one-and-done approach; this is not a checklist approach.  It is 
meant to be fluid; it is meant to function simultaneously with the ongoing development of 
the technology.  Even after the technology has gained market approval, this approach can 
be employed to monitor shifts in it as well as provide a wealth of data to inform the 
assessment of future emerging technologies. 
Another way the nonlinear approach can address the transferability and 
dissemination of information challenges that current HTA creates, is the manner in which 
the results are presented.  As a result of the nonlinear approach, a graphic will be 
produced.  Graphics, especially the pictorial concept map, allow for clarity in 
understanding because the conventions and crosscutting links are visually available.  
Since the links are available, different organizations and agencies can utilize the concept 
maps as a foundation and add their unique dimensions and considerations.  This is much 
easier to promote collaboration and build understanding around, as opposed to a highly 
technical, dense document. 
 
4.3.1.5 Creating consistency in ethics assessment 
 The aim of this approach is not to have every single organization apply the 
approach in the exact same way; in fact, it is the opposite.  Flexibility was built into this 
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approach with the recognition that agencies and organizations of different scope, size, 
and needs would be integrating it.  This may seem as though it introduces anarchy into a 
fairly stable system, however just the opposite occurs.  Flexibility allows the increased 
ability to take contextual features into account.  This embraces the plurality of society as 
well as reflects the interdisciplinary nature of HTA. 
 The built-in flexibilities also allow for broader discourse to take place as each 
new cycle is started.  For example, if a technology is so new that there is little to no 
literature on the subject, then it may make sense for the first cycle of the nonlinear 
approach to include on the research team a selection of highly-qualified experts.  As the 
technology develops and reaches certain benchmarks, the time comes for the cycle to re-
engage.  In the second iteration it may be appropriate to extend the participant pool in 
concept mapping phase to a wider range of stakeholders and other interested parties.  As 
the technology becomes more mainstream, insofar as the layperson might recognize its 
existence, it is likely appropriate to engage the wider public, including non-experts as 
well as other interested parties.  In another example, for a technology that is somewhat 
established, or perhaps based on an existing technology or process, it may be appropriate 
to engage the wider public from the onset.  In short, the level of technological 
development and stability of the technology directly contribute to the context and level to 
which the nonlinear approach is used. 
 It would be legitimate to ask how this builds consistency, especially if every 
organization is using the tool as they deem appropriate.  The consistency is in the 
methodology.  If a sound methodology exists, it should produce valid results regardless 
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of the context.  In addition, the validity of the raw data yielded in the concept-mapping 
phase can always be assessed by external experts.   
 
 4.3.2 Limitations  
 The limitations of the nonlinear approach include the status quo of ethics 
assessment, the sum of the parts problem, the way in which this approach was generated, 
and the required need of ethics expertise.  The final issue to address is that ethics 
assessment does not necessarily solve ethics issues, problems, or controversies. 
 The first limitation surrounds the current status quo of ethics assessments.  That 
is, the assessment is recognized and accepted, but no actions are taken.  The second issue, 
the sum of the parts problem, surrounds the seemingly cobbled together methodologies 
suggested in this approach.  Methodologies from the social sciences, bioethics, 
mathematics, and higher education assessments have been integrated to produce the 
nonlinear approach.  Simply because all the phases in the approach are methodologically 
sound, does not mean that the sum of the phases is methodologically sound.  Although, it 
is argued in this dissertation that it is methodologically sound; without hard data, it is 
difficult to present a concrete case.  This will be explored in Chapter Five.  The third 
limitation is similar in nature to the second. The nonlinear approach, to date, has been 
developed in something of a vacuum, albeit a very well informed vacuum.  This is 
important to recognize because it can call into question some of the conclusions that will 
be drawn in Chapter Five.  However, it is equally important to note that the aim of this 
dissertation was to provide a sound methodological foundation; an aspect which can be 
established.  The final limitation is that this process still relies, to some extent, on ethics 
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experts. It has been noted by a number of scholars that there is a practical limitation 
based simply on the number of qualified individuals.78 
It should also be noted that ethics assessment cannot fix all the issue encountered 
in HTA; furthermore, it is unlikely that any one approach will successfully surmount all 
the practical issues surrounding the integration of ethics in HTA.79  Ethics assessment in 
HTA will not solve all ethical problems.  Rather, it positions stakeholders and 
policymakers to better anticipate ethical and social issues that are likely to arise through a 
thorough process that can address the complexities of these issues.  It is important to keep 
in mind that ethics is but one component of HTA.  Yet, it is one component that should 
pervade all aspects of HTA.  For example, when engaging in economic evaluations one 
should be keeping an eye on justice and fairness.  When engaging in comparative 
effectiveness, considerations of individual and social benefits are essential. 
 
4.3.3 Addressing the deficiencies  
This section addresses each of the deficiencies and gaps identified in Chapter 
Three.  In doing so, a clear justification for the nonlinear approach to ethics in HTA 
emerges.  The first deficiency surrounds priority setting, as well as the initiation and 
completion of HTA studies.  Since institutions conducting HTA set HTA priorities, this 
would likely require vast institutional organization as well as global cooperation.  These 
considerations are beyond the scope of this dissertation.  However, it is important to note 
the efforts currently taking place to coordinate efforts, such as those by the EUnetHTA, 
as well as argue for continued efforts in this area.80  The nonlinear approach begins to 
address issues of priority setting in a very subtle way.  This particular approach is created 
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specifically for emerging genetic health technologies; the narrowness on this focus 
indicates a very specific priority set by the author of this dissertation, which is informed 
by current advances in health technologies, the bioeconomy, and current bioethics 
literature.  The application of this approach to emerging genetic technologies is the focus 
of Chapter Five.  Also, in Chapter Five additional arguments and justifications will be 
provided surrounding the specific selection of emerging genetic health technologies as a 
priority ethics in HTA. 
The second deficiency is narrowness, first of HTA in general and then of ethics in 
HTA.  Typically, HTA focuses on cost-effectiveness and efficiency.  Ethics in HTA is 
typically employed through one methodology.  There is a range of methodologies 
available.  This approach offers a coherent way to employ multiple methodologies 
simultaneously in an effort to maximize time, resources, and ethical considerations.  
Elements from the dominant methodologies are integrated in such a way to bring three 
key aspects to the fore.  Based on the plurality of perspectives that concept mapping can 
include in one visual, there is increased breadth. 
Ethics assessment in current HTA occurs late in the research and design process 
and it is too narrowly conducted in many circumstances.  Typically, formal HTA occurs 
when a medical device or intervention is ready for human application.  Portions of HTA 
can be completed, specifically ethical considerations, before research and development 
reaches this critical threshold.  By conducting ethical assessment sooner, key issues can 
be anticipated and given adequate time for expert and public discourse.  This is similar to 
what is done in TA.  Ethical, social, and the resulting policy considerations should be 
forethought not an afterthought.81  Ethical assessments should not be reactionary; they 
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should be anticipatory and proactive.  The crux of this approach lies in the timeliness of 
its application.  This methodology is not intended to be applied to help technologies that 
are getting ready to hit the market or seeking market approval.  Although the 
methodologies are sound, it is simply not the intent here.  The ability to conduct this 
approach multiple times requires significant time in which to do so.  
The third gap is the clear lack of standards, benchmarks, and regulations.  The 
nonlinear approach does not make significant contributions in this particular gap.  The 
benchmark and standards have yet to be established for this type of methodology.  The 
only reasonable expectations are appropriate application of the methodology, and honesty 
in the reporting of data. Yet there is one area where this approach could make a positive 
impact, and that surrounds the transferability of information and dissemination of 
information.  Since part of the final product will be a visual—a pictorial concept map—it 
will be easier to recognize and understand by both the researchers and laypeople alike; 
this is part of the strength of using a concept map, as noted in the description above.  It 
has the capacity to absorb wide sets of perspectives, ideas, and facts and show there into 
relatedness.  The following sections address some of the additional benefits mentioned 
above.  
 
4.3.4 Addressing the Obstacles 
There are a host of practical obstacles surrounding ethics in HTA, three of which 
were addressed in Chapter Three.  This section will address three: financial limitations, 
time, and the technological imperative.82  
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4.3.4.1 Financial limitations and time 
 This approach cannot adequately address this obstacle at this time.  There is very 
limited research addressing the fiscal impact of ethics assessment.  It is unknown if there 
were will be a tangible return on investment.  However, there is precedent for integrating 
ethics into the research and design phases of emerging technologies.  In one significant 
example, ethical, legal, and social issues (ELSI) were given significant attention in the 
Human Genome Project.   Five per cent of the annual budget was allocated to the study of 
ELSI. This amounted to approximately $18 million per year.83 
There is no denying that ethical assessment takes thought and time.  Time is an 
issue.  For example, NICE reports that it takes at least 54 weeks to complete a thorough 
HTA report in the UK.84  Canada has developed the Rapid Report system takes upwards 
for five to six months.  The time to conduct appropriate ethical assessments in HTA is 
largely unknown.  This is likely due the sporadic integration of ethics and lack of 
tracking.  Only in the last five years have systematic reports been generated about ethics 
methodologies; hopefully in the next five years systematic reviews of fiscal impact, both 
in cost to implement and run, as well as the cost savings gained by utilizing ethics 
assessment, will be determined.  While this could be persuasive evidence, it would be a 
mistake to reduce the value of ethics assessments to cost savings. 
 
4.3.4.2 The technological imperative  
In Chapter Three, it was argued that based on the value laden nature of 
technology and the social good produced by it, there is an obligation to consider the 
impact of these technologies on societal values and norms.  In essence, this not only 
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justifies ethics assessment but also makes it an obligation.  Following this argument to its 
logical end, technology is a social good, social good should be enhanced, thus an 
obligation exists to continue to produce technology toward socially good ends. In sum, it 
can be argued that a moral obligation exists to continue the advancement of technology 
for social good. 
This approach takes a well-founded stance on the issue of the technological 
imperative. Technological progress will not stall or discontinue.  Nor should it.  It does 
not make sense to reduce the progress of technological innovation when it is aimed at 
producing a social good even if there is the risk of dual use or negative outcomes.  
Society has the obligation to ensure that the technologies applied to human health are safe 
and can exist within current societal norms.  That is not to say that just because a certain 
technology, such as emerging genetic health technologies, pushes the bounds of societal 
values and norms that scientific and technological progress in those areas should cease.  
Many do not agree with this position.  Bio-conservatives such as Leon Kass and Francis 
Fukuyama would heartily disagree with this, especially surrounding emerging genetic 
health technologies that push the bounds of the enhancements and trans-humanist 
enterprises.85 
One of the primary reasons for focusing this approach on emerging genetic health 
technologies is that these technologies are currently challenging social values, norms, 
and, in some cases, our very ontology, and they will continue to push the bounds of 
normative positions and ethical paradigms.  For example, the conception of autonomy in 
the United States is that it should be upheld.  Most federal legislation seeks to enhance 
autonomy as opposed to limit it.  The concept of autonomy, as most often expressed in 
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healthcare, is embodied in the idea of informed consent.  Yet this notion of informed 
consent seems to crumble or at the very least appear inadequate in upholding the 
economy when it comes to holding and maintaining blood and tissue samples in 
biobanks.  One must wonder how an individual can consent to future research when they 
do not know what that future research will be.  This question alone gives pause, as it 
requires everyone to reconsider informed consent.  Every individual who donates tissue 
or blood to biobanks signs an informed consent document.  Many consent to future 
research without knowing what the research will be; can it be concluded that is that truly 
the full embodiment of autonomy or the complete abuse of it?  The individual is clearly 
not informed; but at the same time they are making an autonomous decision not to be 
informed. These issues will be dealt with fully in Chapter Five. 
In the United States, the FDA does a fairly good job at determining the safety of 
medical interventions; however, ethical and social considerations are greatly lacking.  In 
this case, oversight does not entail regulation.  Oversight and regulation considerations 
must be non-restrictive, with research supporting oversight with the intent of guiding 
investigators and scientists to take seriously ethical and social considerations while they 
are conducting research, not after the research is completed.86  
 
4.4 Using ethics effectively and efficiently  
Two additional considerations are addressed in this section, which are key aspects 
of the nonlinear approach, including using ethics assessment efficiently and effectively 
as, well as having reasonable expectations for ethical contributions.  Ethics assessment 
should provide basic direction for stakeholders, policy makers, and the public.87  
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The primary aim of this approach is to support scientific developments and 
innovation, not stymie progress.  Therefore, ethics should be employed effectively and 
efficiently.  The nonlinear approach can be efficient when the appropriate tools are used, 
including software, solicitation of expertise, outsourcing some work when possible.  The 
nonlinear approach is effective when it provides useful information that can inform 
researchers during the research and design process, and, in turn, assist decision-makers 
and policymakers.  This means that the language used in assessment must be accessible 
to ordinary people not just the experts.  One advantage to the nonlinear approach, which 
enhances its efficiency and effectiveness, is its ability to produce data that can be used by 
a wide range of individuals and organizations.  For example, the information can inform 
HTA processes if the emerging technology is enrolled in a formal HTA process, this 
advantage will be addressed specifically in the following section.  Licensure bodies and 
policy-makers can also use the information yielded in this approach.  The benefit of this 
approach is that by removing it from the formal HTA process, but keeping it consistent 
with current ethics methodologies in HTA, the nonlinear approach becomes far more 
flexible and adaptable. 
 
4.4.1 Formal HTA processes and the nonlinear approach 
Since many technologies are not subject to formal HTA processes, and there are 
not very many HTA processes that include ethics assessments, it can be concluded that 
very few technologies are actually receiving ethics assessments in the form of HTA 
projects.  If possible, the nonlinear approach should be directly linked to an existing HTA 
processes.  If an ethics component already exists in HTA processes, much groundwork 
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has already been laid.  If there is no ethics assessment mechanism in the HTA process, 
then the nonlinear approach does provide valid data for consideration.  Furthermore, for 
its full strength to be realized, the information generated by the non-linear approach 
should directly feed into and inform existing ethics methodologies. 
Logically, the nonlinear approach pairs best with participatory-based ethics 
assessments.  Also, given the deliberative nature of concept mapping it could easily be 
paired with a wide reflective equilibrium.  Although, that is not to say that it would be at 
odds with other established ethics methodologies in HTA.  In an ideal setting the 
nonlinear approach provides the foundation for integrated approaches such as that 
suggested by Reuzel.  A participatory-based reflective equilibrium is the mechanism by 
which ethical assessments will be continually refined in order to build consensus around 
conclusions and recommendations.  Reuzel et al argues that agreement can be justified if 
it is regarded as a wide reflective equilibrium.  The wide reflective equilibrium is based 
on John Rawls’s initial conception of the reflective equilibrium; however, to be 
applicable here it must meet three criteria.  It must be inter-subjective, achieved by all 
individuals involved and, finally, a new equilibrium must be produced as opposed to 
forcing individuals into an established ethical measure.  The participatory-based 
reflective equilibrium will closely reflect Reuzel’s work surrounding a wide-reflective 
equilibrium.88  
The integrated model utilizes John Rawls’s concept of the reflective equilibrium.  
In this model, the starting point is a particular individual’s considered judgments.  
Considered judgments are judgments that display one’s moral capacities or competence 
with the least distortion.89  The key to Rawls’s notion of the reflexive equilibrium is that 
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when some aspect of moral theory, held by an individual, conflicts with their considered 
judgments, they are required to adjust one or the other to restore the equilibrium.  For 
Rawls, “it is an equilibrium because at last our principles and judgments coincide; and it 
is reflective since we know to what principles our judgments conform and the premises of 
their derivation.”90  This means that the process of revising and reevaluating one’s moral 
beliefs, in order to adhere with the moral principles society holds, will allow the 
individual to continually develop a consistent network of moral beliefs.  This is precisely 
what Beauchamp and Childress call for in the field of biomedical ethics.  Of course it 
would be foolish to think that the achievement of a completely stable equilibrium is 
realistic.  However, by continually navigating a network of moral beliefs, in light of the 
goal of stability, there will be a move closer to that stable equilibrium.91  If accepted and 
properly applied, the reflexive equilibrium is a sufficient methodology for justification.  
This would provide an ethics assessment with depth and breadth.  The strengths 
include validity of results, inclusion, transparency, and comprehensible results.  This 
would be invaluable for policymakers and health decision-makers.  In sum, the nonlinear 
approach can stand on its own to present ethical conclusions and recommendations of 
action steps to inform HTA processes that lack an ethics element, or it can greatly inform 
any ethics assessment that is already integrated in an HTA process. 
 
4.5 Conclusion 
This chapter established the methodological foundations as well as the practical 
phases for the nonlinear approach.  Methodologically, this is grounded in well-
documented sociological and mathematical and ethics disciplines.  Concept mapping has 
  
 
209 
 
a long-established history as well as recognized validity.  Nonlinear programming has 
been applied to multiple disciplines; and the basic tenants, applied here, lend additional 
validity to the nonlinear approach.  The ethics methodologies employed are recognized as 
valuable and consistent with current ethics assessments in HTA.  SCOT methodologies 
and participatory approaches both utilize stakeholder and public participants in discerning 
public values and norms surrounding technologies.  The nonlinear approach also 
integrates best practices in assessment.  By drawing parallels between assessment 
methods in other disciplines, in this case student-learning assessment, additional strength 
is attributed to the model. 
There are five practical phases to this approach. They are: (1) identification and 
inquiry; (2) research and data synthesis; (3) concept mapping; (4) evaluation; and, (5) 
closing the loop.  The nonlinear approach was developed to be continual process, 
whereby assessments can continue as technologies continue to develop, stabilize, evolve 
and possibly repurposed.  In phase one there are two actions.  The first is to identify a 
technology and become involved with research team, if possible.  The second action is to 
identify a research question surrounding ethical and social concerns.  The second phase 
of the nonlinear approach, research and data analysis, requires the completion of a 
literature review and analysis of the results.  This information should be used to inform 
the initial research questions. Adjustments should be made if necessary.  The third phase, 
concept mapping, is the labor-intensive phase.  It requires six individual steps including 
(1) preparing for concept mapping; (2) generating ideas; (3) structuring statements; (4) 
concept mapping analysis; (5) interpreting the maps; and, (6) utilization.  After the data 
has been collected the results should be shared with the participant pool for any 
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additional feedback.  Phase four includes an evaluation of the entire process.  The 
primary activity is to reflect on the outcomes established in phase two.  The final phase of 
the approach, closing the loop, includes two primary actions.  The first is to develop 
action steps based on the data and interpretation of the data in previous phases.  The 
second is to reflect upon when it is appropriate to reengage the nonlinear approach.  
 
Figure 3: Visual of the nonlinear approach with key actions 
 There are several intended benefits, including increased time, sound 
methodologies, increased inter- and multi-disciplinary collaboration, the inclusions of 
wider ethical and social issues including socioeconomic issues, improved transferability 
of information, and finally creating consistency in ethics assessment while not stymieing 
Phase 1:  Identification and 
Inquiry
• Identify emeging technology
•Research question formulation
Phase 2:  Research and 
Data Analysis
• Literature review
• Establish outcomes
Phase 3:  Concept Mapping
• Six steps of concept mapping
Phase 4:  Evaluation
•Reflect on outcomes
•Reflect on process
Phase 5:  Closing the Loop
• Idenity action steps
•Reflect on next cycle
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scientific progress.  In addition to benefits there are limitations as well.  They include the 
status quo of ethics assessment, the sum of the parts problem, the manner in which this 
approach was generated, the required need of ethics expertise, and the fact that ethics 
assessment does not necessarily solve ethics issues, problems, or controversies. 
The nonlinear approach cannot address the fiscal concerns relating to HTA or 
biotechnology research in general.  If anything, this model will likely put an additional 
strain on fiscal considerations given the expected continuous duration of the approach.  
There is precedent for allocating significant portions of the budget for ethical 
considerations in emerging genetic health technologies; and it is hoped that scientists 
would continue to build on this precedent.  Perhaps in the future, after the approach is 
utilized, there may be some way to calculate return on investment. 
 The following chapter will apply the nonlinear approach to emerging genetic 
health technologies.  This application will be conducted theoretically as the primary aim 
of this dissertation is to provide the foundational methodology to support the use of the 
nonlinear approach.   
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Chapter Five: Applying the non-linear approach to emerging genetic health 
technologies  
 
5.1 Introduction to emerging genetic health technologies 
Chapter Five will apply the nonlinear approach to an emerging genetic health 
technologies; specifically it will address a technology that has significant implications for 
the cultivation of protocells, gene therapy, and other emerging genetic technologies.  The 
technology is the recent breakthrough in expanding the genomic code.  This qualification 
is deliberate for two important reasons.  First, emerging genetic health technologies have 
applications and implications across a range of other emerging genetic health 
technologies.  Second, emerging genetic health technologies raise some crucial ethical 
concerns that challenge existing ethical paradigms. 
To accomplish this, the chapter will begin with a brief introduction to genetics as 
the future of medicine.  This will include identifying some ethically problematic existing 
technologies, as well as some ethically problematic emerging technologies.  This will be 
followed by a review of TA and HTA in this area. Then the nonlinear approach will be 
applied to the expanded genome.  This chapter will conclude with discussion and analysis 
of the application. 
 
5.1.1 Examples of existing and emerging genetic health technologies  
Genetics is the future of medicine, and brings with it a new set of ethical 
questions and concerns.  This is evident given the number of clinical trials surrounding 
genetic interventions, research prioritization, research that is being funded, and the 
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emergency of personalized or precision medicine.  President Barack Obama brought 
precision medicine to the national stage in his recent Precision Medicine Initiative.1  This 
section will address the ramifications of some existing genetic technologies, specifically 
using whole genome sequencing as a diagnostic tool in clinical medicine and biobanking.  
It will also address the implications and potential ramifications of emerging genetic 
technologies, specifically protocells and gene therapy. 
There are already plenty of examples that show how the introduction of genetic 
technologies and data into clinical care has forced clinicians to ask new questions about 
values and ethics.2  Using whole genome sequencing as a diagnostic tool in medicine is 
quickly becoming a reality.  An in-depth look at some of the looming ethical issues 
induced by utilizing whole genome sequencing as a diagnostic tool in medicine and 
biobanking is revealing.  Before examining emerging ethical and social issues in genetic 
health technologies it is helpful to understand some of the current predicaments in which 
society finds itself.  When ethics assessments are not conducted, society is even less 
prepared to address the questions posed by these technologies.   
 
5.1.1.1 Whole genome sequencing as a diagnostic tool in clinical medicine 
Examining how specific genes are expressed in plant, animal, and human 
genomes has a number of vital applications in healthcare.  Genetic screenings can help 
classify some conditions that play an important role in diagnostics.  It also opens the 
whole new world of pharmacogenomics and precision medicine.  Pharmacogenomics is 
the process of tailoring pharmaceuticals to specific patients, usually based on genomic 
indicators.3  In short, the drugs are based on the needs identified in the individual’s DNA.  
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One of the best examples of this is revealed in chemotherapy choices.  Understanding the 
cancers or the tumors genetic makeup physicians can best determine which chemotherapy 
choices are most likely to be effective.4  Genetic information can also tell much about the 
prognosis and prevention of some genetic disorders.  For example, this information can 
indicate how aggressive a cancer might be, which impacts the prognosis.  In addition, 
genetic information can also help identify individuals with specific gene mutations that 
increase the likelihood developing cancer, heart disease, diabetes, or other health issues 
later in life.5  When considering the use of whole genome sequencing as a diagnostic tool 
in clinical medicine, the key ethical issues can fall into four broad categories:  limited 
therapies, uncertainties in risk prediction, third-party notification or unintended 
notification, and access to genetic information. 
The first issue is limited therapies.  There are currently no gene-transfer therapies 
to assist with many identifiable genetic disorders.  The patient will be provided with 
information about their genetic health, which can be very useful in helping them to 
determine what type of life to lead.  However, there are no medical therapies to address 
many genetic problems directly (e.g. Parkinson’s and Alzheimer’s); the most that can be 
offered is symptom management.  Currently, there are no gene-transfer therapies adopted 
in the Western hemisphere.  China has claimed success with Gendicine; but this therapy 
has not been adopted elsewhere.  Absent gene-transfer therapies, patients will be 
provided with potentially devastating information and have no medical alternative.  This 
can have profound psychological effects.  Therefore, when the option of genome 
sequencing is presented to the patient it is imperative that they truly understand the 
implication of the results.  Healthcare professionals already prescribe and carry out a 
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number of various genetic screenings on a regular basis, for example, newborn screening, 
carrier screening, gene therapy, and gene-based therapy.6 
Although, it should be noted that while many genetic diseases cannot be treated, 
whole genome sequencing is particularly helpful in cases such as identifying potential 
breast cancer candidates.  This information is also helpful in guiding individuals toward 
better lifestyle practices.  Currently, in the United States there are hundreds of clinical 
trials in various trial phases being conducted.7 
The second issue surrounds uncertainties in risk prediction and probabilities. 
Patients have difficulty understanding risk probabilities and they are often poorly 
communicated.8  One problem revolves around interpreting the information revealed by 
sequencing an individual’s genome.  Take for example an individual who has their 
genome sequenced and is told they have a ten per cent chance of developing Alzheimer’s 
disease after the age of seventy.  What does that figure actually mean?  Is it an absolute 
one in ten chance; or is it a one in ten chance if a series of other genetic factors are 
expressed?  The answer is unclear; even geneticists face challenges when describing the 
true value of genetic probabilities.  Conveying this uncertainty in risk probabilities to 
patients is extremely difficult.  From an ethical perspective, one must consider how such 
information would impact a patient’s life decisions.  If an individual is given this 
information at age forty, will they then wonder and worry for the next thirty years about 
their prospects?  As genome sequencing becomes widely available, the disclosure of 
relevant information must be considered as well as developing meaningful ways to 
present risk probabilities to patients without creating undue fear.9 
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The third issue is unintended notification or third party notification.  Third parties 
may be unintentionally affected by the patient’s genetic test results.  An ethical 
consideration that requires immediate attention pertains to the biological relatives of 
those individuals having their genome sequenced.  Families share genetic material and 
the results of one individual’s test will have implications for others in the family, 
particularly for biological siblings and children.  When genetic information is being 
discussed, the familial implications must be considered as well as the privacy of both the 
patient and family members.  A number of recommendations have emerged due to this 
ethical dilemma of healthcare professional’s moral obligation to third-party relatives.  It 
has been suggested that these issues be addressed in the initial informed consent 
process.10  Health care professionals should discuss implications for the patient’s family 
and encourage patients to include close biologically-related relatives in some discussions.  
There should be a family-centered approach to informed consent with genome 
sequencing because the information affects not just patient but their immediate 
relatives.11 
The final problem addressed here, although others do exist, is access to genetic 
information.  Direct to consumer genome sequencing allows individuals to purchase 
genetic tests without the ability to interpret the tests.  Direct to consumer (DTC) 
marketing whole genome sequencing from companies such as 23andMe and deCODE 
genetics have a number of ethical implications.12  In the United States, more than sixty 
companies currently offer DTC genetics tests via the Internet.  Many states do not have 
any legislation governing or regulating DTC genetic test; but a few require that stores 
may only carry those over-the-counter tests approved by the Food and Drug 
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Administration (FDA).  The FDA has successfully prevented the direct sale of kits in 
retail stores such as Wal-Mart.13  The FDA maintains that genetic tests should be sought 
through a doctor to avoid misinterpretations of the results.  Moreover, many consumers 
are not equipped to address the complexities associated with understanding genetic test 
results.  As a result, consumers take the test results to their primary care physician for 
interpretation.  Many primary care physicians are not equipped to interpret genetic tests 
or provide genetic counseling.  Issues surrounding the consumers understanding can 
result in frustration and confusion.  It also has the potential to overload an already 
strained healthcare system, by requiring the physician to spend additional time with 
patients and potentially order more tests based on the result of a DTC scan.  This, 
ethically speaking, is a double-edged sword; it is imperative to help people care about 
their health and take advantage of any information available.  However, this must be 
balanced with the needs of both the individual and society.14 
The primary piece of legislation that protects individuals from being 
discriminated against by insurance agencies is the Genetic Information 
Nondiscrimination Act of 2008 (GINA).  This allows individuals to take advantage of the 
useful information genetic tests can provide without fear of increased insurance 
premiums or cancelation of coverage.  This provision falls under HIPAA.  However, it 
still remains unclear what the ramifications will be for insurance companies when an 
increased number of the population begins to have genome sequencing tests as a part of 
their general healthcare.15 
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It is clear from this glimpse into this singular application of genetic technology 
that the implications go far beyond the scope of safety, economic evaluation, and 
comparative effectiveness. 
 
5.1.1.2 Biobanking 
The second existing issue that will be addressed is biobanking.  Biobanking has 
become a very interesting ethical conundrum.  Biobanks seek to catalog individuals’ 
genetic material or tissue samples in order to create database or be used for future 
research.  There is one central ethical issue which revolves around informed consent. 
Informed consent was developed to help protect the individual from paternalism or being 
coerced into a particular course of treatment.  Informed consent is the practical 
expression of the principle of respect for autonomy.  The goal is to ensure that individuals 
fully understand what it is they are agreeing to before they agree to do it.  Patients or 
research participants express their consent by signing a document that details all relevant 
information.  Informed consent should be voluntarily given; and coercion should always 
be avoided.  In the case of biobanking it is not always known for what purpose the 
genetic data or tissue samples will be used.  Therefore, the question becomes whether an 
individual can consent to research that will happen in the future with very limited or no 
knowledge of what that might include.16 
Many articles and books have been published on this emerging issue.  One of the 
most influential publications, edited by Jan Helge Solbakk, Søren Holm, and Bjørn 
Hofmann, is The Ethics of Research Biobanking.17  This book provides an excellent 
overview of the key ethical issues surrounding autonomy and consent. In addition, 
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Heather Widdows has advocated for rethinking our approach to informed consent as it 
relates to biobanking and genetic research.  In their recent article, The Ethics of 
Biobanking: Key Issues and Controversies, Widdows and Cordell address these very 
issues.18  This builds on Widdows’ previous article, Conceptualizing the Self in the 
Genetic Era.19  The authors suggest that rather than consenting to a specific intervention, 
treatment, or research use, the participants would consented broadly to various forms of 
undisclosed research.  This is called broad consent.  Rethinking the very nature of 
informed consent has generated conversation surrounding the nature of autonomy in this 
new genetic era.  Questions surrounding whether the current understanding of autonomy 
is appropriate are essential if a number of paradigmatic shifts occur in the current social 
and normative understanding of autonomy.  Perhaps, as the authors suggest, autonomy 
may need to be removed as the primary ethical pillar of informed consent surrounding 
genetic data or material in research.20  A new understanding of autonomy and informed 
consent—as they relate to biobanking and other genetic research—is needed because the 
present understanding is not consistent with the practices of biobanking. 
 
5.1.2 Emerging technologies 
 From the two examples addressed above, it is clear that ethicists, policy makers, 
and society as a whole do not have a firm grasp on how to address these technologies.  
This challenge is compounded when addressing emerging genetic health technologies.  
This section will address some of the highlights, including protocells and gene transfer 
therapy, as it is impossible to provide an exhaustive account of all emerging genetic 
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health technologies.  The focus of this section will be the products of synthetic biology, 
specifically protocells, as well as gene therapy. 
The products of synthetic biology have already started to yield health advances. 
One example of this is the anti-malarial drug artemisinin.21  Through a reengineering of a 
microorganism that produces artemisinin, scientists were able to create artemisinin 
artificially.  As opposed to waiting for artemisinin to be produced naturally, and derive it 
from the plant parts of the Artemisia annua, which is the plant that artemisinin comes 
from.  It can now be produced far more cheaply and efficiently.  Most importantly it can 
potentially save thousands of lives.  It is projected that approximately 700,000 to 
1,000,000 deaths occur as a result of malaria and malaria-related complications each 
year.  The marketing for the synthetic drug began in 2012.  The manufacturing plant was 
built and production began in 2013.22  By August of 2014, Sanofi, the company 
responsible for production, had announced the release of the first batch of semi-synthetic 
artemisinin.  
Techniques used in synthetic biology, specifically those surrounding DNA 
sequencing and computer modeling of the sequencing, may streamline vaccine 
development and delivery.  In order to create new vaccines, a virus strain must first be 
identified.  Each strain has its own unique genetic code; this code is used to generate the 
vaccine.  Now that sequencing is faster and cheaper, this process is becoming more 
streamlined.  Moreover, the ability to “bank” the genetic information of various diseases 
and viruses has reduced the time it takes to identify the virus.23  
Other products of synthetic biology include the development of renewable and 
clean bio-fuels.  A recent topic of intense discussion has been the creation of genetically 
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modified organisms also called genetically manipulated organisms (GMOs), including 
both plants and animals.  There are many examples of these products.  One of the most 
well established GMOs in agriculture is the Gold Rice Project.24  Another example which 
has drawn national attention in the United States, creating a crisis of sorts, surrounds the 
release of genetically modified mosquitoes in the Florida Keys.25  While these are all 
interesting and compelling examples, the focus in this chapter is the application to health. 
In order to have a better understanding of the potential contributions of genetics and 
synthetic biology to human health two emerging technologies will be reviewed:  
protocells and gene therapy. 
  
5.1.2.1 The creation and cultivation of protocells 
Protocells are living organisms that are self-organizing, can replicate or 
reproduce, and have the capacity to evolve and adapt to their environment.  They 
spontaneously assemble from both organic and inorganic material.  These organisms, 
more simple than bacteria cells, consume raw materials and generate energy from them 
and their environment.26  There are two primary scientific methodologies used in 
protocell research—the top-down and the bottom-up approach.  The top-down approach 
involves modifying existing organisms in an effort to create new ones.  The bottom-up 
approach aims at using nonliving materials to create living organisms.27  
Cultivating the first protocell is a scientific milestone.  It represents the capacity 
to synthetize life in a laboratory.  Furthermore, the creation of protocells is the first step 
toward the next major development of intelligent machines.  Scholars predict that 
protocells will help bridge the gap between the living and nonliving.28  This would allow 
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scientists to dramatically increase the capacities of living and inanimate systems.  If these 
technologies can be harnessed, there are an abundance of practical applications including 
environmental, pharmacological and medical diagnostic functions.  For example, 
protocells might serve as vehicles to deliver and activate drugs in a very specific way and 
target particular tissues or organs.  At present, only living organisms can self-repair or 
heal, and actively learn and adapt to unpredictable environmental changes.  
Technological instruments alone are brittle, non-adaptive, and costly.  If the gap between 
living and nonliving, organic and inorganic, can be bridged, the possibilities for 
technological advancement are dramatically increased.  Protocells and gene therapies will 
be utilized hand-in-hand as protocells can provide the vehicle for successful gene 
therapies.29 
There are many potential benefits and areas of application for protocell research. 
The production of biofuels could reduce the United States’ and the world’s dependence 
on fossil fuel.  This in turn would reduce dangerous emissions as well as the political 
unpredictability surrounding existing fossil fuel consumption.30  With this promise of 
renewable energy come several risks.  Contamination of the natural ecosystem or any 
biological system, either accidentally or intentionally, by the release of organisms is a 
risk.31  Uncontrolled release of new microorganisms is a serious concern because there is 
no way to predict how the new organism will impact the existing system.  Moreover, this 
is compounded if the microorganism was not intended for that particular system.32  
Another potential benefit is the advancement and improvement of human health. 
Improved drugs, vaccines, and their delivery method could be adapted to 
pharmacogenomics. This means that protocells could be used as vehicles for drugs 
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tailored to an individual’s genetic code to combat a specific disease or disorders such as 
immunodeficiency virus and cystic fibrosis.33  This type of scientific breakthrough would 
greatly assist research efforts in gene therapy.  The use of protocells in medicine carries 
risks.  The primary risk is to the humans into whom they are being inserted and the 
environment in which those individuals live.  Unanticipated adverse health risks and 
other side effects may accompany the use of cell therapies.  Moreover, the human germ 
line may be unintentionally, or intentionally, altered.  Although this is a risk, it may not 
have negative outcomes or harms.34  
A third potential benefit is the ability to genetically alter crops and livestock. 
Currently some technologies have already enhanced agriculture; but protocells would 
provide increased potential. For example, plants could be genetically altered to yield 
higher levels of consumable proteins.  Another promising agricultural application is the 
production of environmental biosensors for monitoring soil nutrients.  In addition, the 
development of biosurfactants can bring needed bacteria and other agents to ecosystems 
as well as be tailored to clean and manage specific types of pollution.35  There are three 
primary risks associated with this type of research:  uncontrolled release or escape that 
disrupts or destroys an ecosystem; the evolution of these organisms into dangerous strains 
that are difficult to control; and the potential for increased pesticide resistance.36  
Biosecurity is also a primary concern because there is the potential for protocell 
research to be used with pernicious intent for nefarious purposes.  The dual-use of 
products from research must be carefully considered.37  However, the issue of dual-use is 
inherent in most emerging technologies.  There are already examples of reengineering 
viruses such as the polio virus and the Spanish flu.38  Therefore, concerns pertaining to 
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biosecurity and the threat of bioterrorism should not cripple research efforts.  Yet with 
the increasing availability of second hand equipment, and as DNA sequencing becomes 
easier and more accessible, danger rises from biohackers or garage biology.  Tucker and 
Zilinskas maintain that government-level biological warfare programs currently pose the 
greatest threat for potential misuse.  They also indicate that it is unlikely that new 
organisms will be developed and released; rather, it is more likely that a modified version 
of a preexisting organism like the polio virus will be developed.39 Whether new lethal 
components are created or existing ones are modified, the problem of abuse and misuse 
certainly exists. These fears are amplified by the fact that protocells evolve and their 
properties could change in unforeseeable ways.  This in turn makes evaluating long-term 
consequences very difficult.40  
 The consequences of creating artificial cells are unclear.  Yet, policy makers will 
have to make difficult decisions regarding the acceptability of risk in research protocols, 
where to allow field trials, whether to allow commercial application, addressing liability 
issues of harms, and considerations regarding the accessibility to scientific information 
that can be misused or abused.41  One of the roles ethics plays is to help discern the 
acceptability of risk and how to mitigate certain harms.  
 
5.1.2.2 Gene therapy  
Gene transfer utilizes genetic material or genetically modified organisms to study 
and alter human genetics and biology.42  Gene transfer can be used for both therapeutic 
purposes and for human enhancement.  For example, it can be used to treat cancer and 
cystic fibrosis or it can be used to create a new human trait or enhance an existing feature 
  
 
231 
 
in a healthy individual.  There are also investigative gene transfer studies that aim at 
marking individual genes in healthy participants.  Gene transfer is a growing field and 
comprises two-thirds of all phase one and phase two trials in the world.43  Currently, 
there are no commercial products available in North America, Japan, or Europe.  China 
has approved a gene transfer treatment, called Gendicine, to treat head and neck cancer. 44  
With any new technology or research initiative, particularly those involving human 
participants, many ethical considerations must be taken into account.  Both protocells and 
gene transfer carry significant risks as well as an increased level of uncertainty relating to 
the magnitude and severity of risks. 
Risk assessment in gene transfer technologies raises many concerns that overlap 
with clinical research ethics.  Ethics should play a significant role in risk assessment 
because the ultimate questions are value-laden and require ethical consideration.  For 
example, determining the acceptable amount of risk to a research participant is a value 
judgment that hinges on a number of factors including the social value of the protocol 
and potential benefits.  The level of risk incurred by any participant must be justified.45  
Risks in gene transfer technologies can be divided into two categories.  First, there is the 
technology itself, determining whether the hardware works and what physical or 
psychology risks the intervention(s) present to the participant.  Second are the risks 
associated with the clinical research trial process.  These risks include the blind ambition 
of science, financial conflicts of interests, pressure to execute the study quickly, and the 
list goes on.46  Risks are compounded by the involvement of human participants; and 
questions of using stable or even healthy patients in gene transfer studies have drawn a 
lot of attention.47  A prime example is the Gelsinger case.  A teenage boy, Jesse 
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Gelsinger, was enrolled in a gene transfer experiment to treat ornithine transcarbamylase 
deficiency, at the University of Pennsylvania.  His death was the first cause directly by 
gene transfer and raised many concerns regarding following research protocol, informed 
consent, and conflict of interest.48  But the aim of this dissertation is not to produce a 
laundry list of the inadequacies of current research ethics guidelines.  Rather, the focus 
here will be on the technology itself and how to address the uncertainty of risk in gene 
transfer trials; in addition, a new comprehensive model for risk-benefit analysis in 
research trials will be highlighted. 
 The risks associated with gene transfer technologies present a challenge because, 
like protocells, they contain a high level of uncertainty.  Jonathan Kimmelman, a 
professor in the Biomedical Ethics Unit at McGill University, makes the point that gene 
transfer research is not necessarily riskier than other types of research protocols; rather, 
the uncertainty of risk, both in severity and magnitude, is not as identifiable and 
predictable as in other medical interventions.49  Kimmelman notes several important risk 
factors in gene transfer.  He divides them into two groups.  The first group he calls 
“conceptual features,” which include: the use of active agents rather than chemicals, 
genetic material directly affects the individual’s genes, the drug functions both as the 
delivery vehicle and the therapy, gene therapy may have risks with long latencies, and 
there may be a risk to public health if certain viral vectors are present.50  When 
participants receive gene therapy or transfer, they typically must continue long-term 
treatment which can elevate risks as time passes; furthermore, many toxicities in gene 
transfer are immunologically based.51  The second classification of factors Kimmelman 
identifies are methodological risks, these include: there is limited number of animal 
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models that predict vector safety, meaning that it is difficult to predict toxicity; some 
vectors can produce a plethora of different human responses; and, gene vectors carry with 
them the possibility of “non-linear dose-response.”52 
Like protocell research, gene transfer can also challenge the conception of life, 
albeit, in a slightly different way.  If or when gene transfer therapies are successful, 
humans will have the capacity not only to treat genetic disease but also to enhance 
themselves.  Therefore, if one approaches ethical concerns in risk assessment 
comprehensively they must address the ethical concerns surrounding enhancement.  That 
is, they must determine to what extent they are willing to alter their genetic make-up and 
what the implications for future generations might be.  The possible human 
enhancements resulting from gene therapy research potentially include improving human 
health and extending life span, the eradication of disease, as well as elimination of 
unnecessary suffering.  More dramatic enhancement measures include the augmentation 
and improvement of human intellectual, physical and emotional capacities.  However 
much has to be accomplished before these technologies even stand the chance at 
becoming a reality.53   
Ronald Cole-Turner, from the Pittsburgh Theological Seminary, makes an 
important distinction.  In the past, technology has been used to enhance humanity though 
the human changing the world around them.  Now technology is being turned inward.  
The individual does not remain unchanged; they are changed to better suit the 
environment and compete in it.54  This is precisely what gene transfer technologies seek 
to accomplish; although their efforts are not necessarily geared toward human 
enhancement.  Advancing biomedical enhancement for the sake of human enhancement 
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is the beginning element for the transhumanists’ position.  According to the 
transhumanist position, the next stage of human evolution is rational evolution.  In this 
concept, scientists attempt to give humanity the best opportunity to not only survive, but 
have the best possible lives in the present and foreseeable future.55  As gene transfer 
technologies advance these wider philosophical, ethical, and social considerations must 
be taken seriously.   
 
5.2 Existing ethics assessments: TA/HTA currently being conducted 
 The second portion of Chapter Five deals with TA and HTA processes that have 
been completed or are currently underway, including the President’s Commission and a 
variety of scholarly publications.  Bjørn Hofmann’s Socratic approach has been applied 
to a number of genetic technologies including neonatal and newborn screening, stem cell 
transplantation and a few others.56  However these reports are incredibly difficult to 
locate.  These ethics assessments have occurred within existing HTA process.57  The 
FDA has assessed the genetic technologies that have been accepted into mainstream 
healthcare.  This ensures a certain level of safety, comparative effectiveness evaluation, 
and economic evaluation.  However, this does not include ethical or social assessments.  
Two types of publications will be addressed here, including comprehensive treatment of a 
particular technology or subset of technologies, and individual or singular publications on 
a specific issue or argument. There are many individual publications but not many 
comprehensive assessments. 
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5.2.1 The President’s Commission 
In 2010, the President’s Commission for the Study of Bioethical Issues (PCSBI) 
published New Directions: The Ethics of Synthetic Biology and Emerging Technologies.  
This was largely in response to J. Craig Venter’s work surrounding the synthetic cell, 
which was announced earlier that year.  However, a vast array of products and potential 
products resulting from processes involving synthetic biology were addressed, including, 
bio-fuels, GMOs, as well as biosafety and biosecurity risks.  President Obama 
commissioned this report to be forward-looking and anticipate ethical, social, and 
environmental issues that may arise.  Risk encompasses social, ethical, economic, and 
scientific considerations.  Certainly one principle or even a set a principles cannot 
adequately address all of these areas.  Currently, there is no comprehensive systematic 
assessment tool available; although suggestions regarding important aspects, such as risk 
and ethics in HTA, are being discussed.   
The PCSBI could be one such agency for oversight of emerging technologies; but 
federal oversight is often limited to those entities that are owned or funded by the US 
government.  Despite this limitation in direct governance and regulation, the PCSBI 
makes several useful suggestions for ethical considerations in synthetic biology.  They 
rely on the principles of public beneficence, responsible stewardship, intellectual freedom 
and responsibility, and democratic deliberation, as well as justice and fairness.58  These 
ethical principles are relevant to considering the social implications.  These are excellent 
aims generally speaking; however, when attempting to systematically assess the 
technology it becomes difficult to see exactly how these principles ought to be used.  It 
appears that these principles are to be applied in a similar manner as Beauchamp and 
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Childress’ four principle approach.   Furthermore, there is no clear way to balance these 
principles or resolve conflicts and naturally existing controversies, as there is no 
decision-making mechanism proposed.59  
 
5.2.2 Existing publications 
A variety of scholarship has emerged in recent decades regarding the ethical 
assessment of the products of synthetic biology; many of these publications emphasize 
issues in uncertainty, risk, and threats to the existing ethics paradigms.60  This scholarship 
is published as standalone articles, books and collective anthologies.  However, there are 
few comprehensive approaches to the assessment of the products of synthetic biology.  
Furthermore, outside of conjecture, speculation, and a few proposed frameworks, little 
has been done in the way of suggesting how to actually go about regulating or providing 
meaningful oversight in this field.61  Regulation is called for by many scholars; however, 
the mechanism to appropriately accomplish this is in question.62  One of very few 
comprehensive reports, outside of the PCSBI’s report, was published in October of 2007, 
by the J. Craig Venter Institute.  The report was titled Synthetic Genomics: Options for 
Governance.63  This document addressed the risks and benefits of creating new 
organisms or altering those in existence.  Several governance, standardization, and 
regulation options were outlined including policies for commercial gene synthesis firms, 
policies for monitoring and controlling equipment and reagents, and policies for users 
and organization.  Ethical considerations were only made insofar as to note that there are 
ethical concerns regarding the production of new organisms; although, specific ethical 
considerations were not addressed.  The interesting aspect of this publication is that it 
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was a private institute who commissioned the report in an effort to get ahead of the curve. 
Rather than waiting for ethical or regulatory issues to emerge, likely during some crisis of 
public conscience, the Venter Institute was attempting to deal with these issues upfront. 
In light of Venter’s research, two themes have permeated the literature surrounding 
protocells and gene therapy, including how life is defined, and whether scientists are 
“playing God” when they experiment with plant, animal or human genomes.  These will 
be addressed in the following section. 
 
5.2.2.1 “What is life?” and “Playing God” 
Two important ethical considerations flood this literature: what is the nature of 
life or the organisms scientists qualify as living, and whether building life in a laboratory 
is ethically permissible or simply “playing god” or “playing with fate.”  An important 
ethical consideration is that the products of protocell research may transgress cultural and 
moral norms, and most notably the very conception of life.64  The very conception of life, 
its intrinsic value, is seemingly challenged.  For anything to be described as living there 
first needs to be an understanding of what it means to be alive.  The definition of life has 
been sought out by the greatest minds in history; and yet there is no definitive answer.  
Some philosophers offer no better suggestion than to stop trying.  Mark Bedau in his 
article What is Life?, suggests that life may not have a unified all-encompassing 
explanation.65  Furthermore, life may cease to be a basic category of natural occurrence.  
He asserts that there really is no single answer to the question or definition of life and the 
question is basically wide open. 
  
 
238 
 
Many critics suggest that pursing protocell research is meddling in ideas beyond 
our control, violates nature’s sanctity, or is man’s attempt to “play God.”  Mark Triant 
and Mark Bedau argue in Social and Ethical Implications of Creating Artificial Cells 
that, overall, these types of blanket arguments are vague, unsophisticated, and largely ill-
conceived, thus presenting no founded reason to arrest the pursuit of this research.66  
However, questions about the nature of life are appropriate.  Creating life from inorganic 
materials elicits challenging philosophical questions about what it means to be alive; the 
distinction is now blurred.  Even though these considerations can be successfully argued 
in many fashions, it is important to address them as they may impact public opinion.67  
 
5.2.3 Gaps of current genetic HTA projects 
5.2.3.1 Ethics assessment is irregular and scatter-shot 
As outlined in Chapters Three and Four, there are gaps in ethics assessment.  
These gaps exist in emerging genetic health technologies.  This section will address these 
gaps.  Formal ethics assessment among emerging health technologies that involve the use 
of protocells is irregular and virtually non-existent.  For the purposes of clarity, formal 
ethics assessment takes place as part of an initiated HTA project; and informal ethics 
assessment refers to the scholarship published outside of initiated HTA projects.  As a 
result of the literature review, it is evident that most scholarship explores the risks, 
benefits, and various ethical arguments; yet in very few instances is direction provided to 
scientists, policymakers, or the public.  This scholarship is very important, but it is not 
ethics assessment; it is critical discourse surrounding ethical issues in this area, which 
could provide the foundation for ethics assessment.  PCSBI’s report on synthetic biology 
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is an excellent starting point, but it remains only an overview of potential issues.  
Venter’s report on governance is quickly become outdated, as it is nearly a decade old at 
this point.  Many of the singular publications are very insightful, but standing alone lack 
impact. 
There are a number of private companies addressing the assessment of genetic 
health technologies. There are three prominent companies in the USA:  ECRI Institute; 
Hayes, Inc.; and Blue Cross and Blue Shield Technology Evaluation Center.68  Private 
companies offer a range of services from HTA reports, horizon scanning, genetic test 
evaluations, and so on.  Many also have specific areas of focus.  For example, Blue Cross 
and Blue Shield Technology Evaluation Center emphasizes comparative effectiveness 
reports.69  While these private companies provide a very important function, many do not 
engage emerging technologies.  Again, they are geared toward assessing those 
technologies that are seeking market approval or licensure.  The same gaps that exist in 
the application of ethics to HTA in other health care contexts, ethics as a priority, 
narrowness and lateness of assessment, and general oversight and guidelines are the same 
for those applied to genetic technologies.   
 
5.2.3.2 Ethics as a priority 
 Among emerging genetic health technologies there is abundance of 
acknowledgments that ethics is important; however there is no consensus on how to go 
about articulating that fact. Thus far in the chapter, a wide range of publications have 
been addressed. These publications are critical in developing and continuing the 
discourse; however many are not comprehensive in nature and hence they are just 
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standalone publications.  It is unclear whether there is any impact at all, outside of 
identifying a problem.  Given the justification for the integration of ethics in Chapter 
Three, and the relationship between society and technology provided in Chapter One, 
there is a strong case for the meaningful integration of ethics at the research and design 
phase of emerging genetic health technologies.  However, this is not happening in a 
meaningful way; but that does not mean that it cannot. 
 
5.2.3.3 Narrowness and lateness 
Current ethics assessment is too narrow in the sense that many of the ethical 
considerations are considered in isolation from other variables and factors.  For example, 
there are limited publications at the intersection of emerging genetic health technologies, 
ethics, and bioeconomy.70  As shown throughout this dissertation, most HTA assessments 
occur only when the technology is seeking market approval; and ethics is often neglected.  
Given the ethical and social impact of emerging genetic health technologies described 
above, staying the course does not appear to be a wise option.  Formal ethics assessment, 
when it does occur, happens too late; this chapter is aimed to serve as proof of this.  The 
fact that minimal HTA reports have been initiated around emerging genetic health 
technologies indicates that assessment is already behind.  In the coming years the use of 
protocells and gene-transfer technologies will be starting human trials.  Worldwide there 
are currently more than 500 clinical trials involving gene transfer in various stages of 
completion.71  
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5.2.3.4 Oversight and regulation 
 In the book Building Genetic Medicine, Shobita Parthansarathy, provides a 
comparative analysis of how politics played a critical role in shaping the treatments for 
breast cancer in the United States and the United Kingdom.  In this global era, national 
contexts and politics play an important role in the adoption of certain genetic 
technologies.  In the UK, genetic testing for the BRCA is generally seen as a form of 
preventative medicine; whereas in the United States this genetic testing is more or less 
offered on demand.  This difference in the offering of services, Parthasarathy notes, is 
likely due to differences in approaches to health care and commercialization of 
research.72   
Many other scholars have called for regulation and oversight in the field of 
emerging genetic technologies.  However, the only oversight that seems to be occurring 
is the oversight in determining which technologies are adopted and approved for use in 
the healthcare setting.  Outside of this regulation conducted by the FDA in the US, the 
NIH have guidelines pertaining to what research is eligible for funding, which provides 
some level of oversight as the researchers seeking funding are obliged to follow the 
ethical guidelines set by the NIH.73  Privately funded research, however, does not fall 
under the same regulatory guidelines. 
 
5.3 Applying a nonlinear model to emerging genetic health technologies: 
Conceptualizing nonlinear thinking in this context 
In the first sub-section the context and justification will be given for the selection 
of emerging genetic health technologies as a case study.  This area of research was 
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selected because of the aim in application to human health, the immense moral 
controversies that are elicited, as well as the current stages of research of these 
technologies (protocell cultivation and gene therapy).  As previously stated, the primary 
aim of this dissertation is to describe and justify the methodological foundations for the 
nonlinear approach.  The application articulated in this chapter is purely hypothetical.  It 
is outside the scope of this dissertation to engage a research project and fully carry out the 
nonlinear approach in practice. 
 
5.3.1 Phase one: identification and inquiry  
There are two overarching activities that need to be completed in this phase.  
First, the approach must be utilized by an emerging technology.  Practically, it would be 
helpful to have a designated facilitator and organizer for this process.  The size of the 
team necessary to carry out the approach is dependent upon the number of participants.  
The more participants the larger the team needs to be to accommodate the steady and 
efficient flow of the nonlinear approach. 
It is noted throughout the literature that there is a lack of oversight and 
regulations; this may or may not be beneficial.  Oversight can be understood in two ways:   
regulating research in this area, or initiating TA or HTA reports.  This section will not 
focus on regulation, but rather on lack of investigation into the ethical and social 
ramifications, both positive and negative, of emerging genetic health technologies.  There 
are a number of oversight challenges; for example, how does one properly do risk 
assessment; how does one deal with uncertainties and protections; and, in light of 
increased ease of access to genetic materials, how does one address biosecurity and 
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biosafety, working together to help creative safety nets surrounding synthetic biology and 
emerging genetic technologies.  
Regulatory programs from the US Department of Agriculture, FDA, 
Environmental Protection Agency, the Occupational Safety and Health Administration, 
Department of Transportation, and the Department of Commerce all play key roles in 
supporting the safety net to protect both the general public and those working in this 
field.74  For example, the FDA assesses particular foods, drugs and other goods that could 
be released in the general public. 75 The EPA addresses safety measures with new 
chemicals and manages emergency programs for the cleanup of environmental 
contamination and hazards.76  Most applicable, however, is the role of the National 
Institutes of Health and the Center for Disease Control and Prevention.  There are a 
number of oversight strategies employed by the US government, many of which address 
and oversee research dealing with recombinant DNA and synthetic biology.  They strive 
to ensure ethical conduct of researchers and promote the safety of the researchers and the 
general public and biological research; this is done through risk assessments strategies, 
safety and containment standards for laboratories.77 
The biggest challenge to oversight is the fact that it only occurs for those labs and 
projects owned or funded by the federal government.  This means that if a project is 
privately funded and is not taking place in any government related facilities they are not 
subject to the same NIH and CDC oversight standards.78  They do however have to 
comply with state and federal statutes and laws surrounding transportation, commerce, 
and distribution of the products and synthetic biology.  To demonstrate this point, 
consider the Dickey-Wicker amendment which banned stem cell research in the United 
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States; all laboratories had to comply with this law.  However, before the law was passed 
only labs that received federal funding had to follow the rules set by the NIH and the 
CDC surrounding the use of stem cells in research.79  
The reason for addressing oversight so specifically at the start of this phase, is to 
identify the hardships that can exist in identifying those emerging technologies that need 
to be assessed.  As stated in Chapter Four, the ideal way to execute this approach is to be 
on board at the start of a new research project, or to come on board shortly after one has 
been started. 
For this hypothetical analysis, the technology that will be assessed falls under the 
category of synthetic biology.  In the spring of 2014, scientists announced the first 
functioning semi-synthetic genome.  That, in and of itself, is not a breakthrough, as 
Venter had created a fully synthetic genome successfully in 2010.  The special aspect of 
this research was the addition of two nucleotides to the organism’s genetic code.  The 
following excerpt  from the abstract summarizes the work, published in Nature. 
 
Organisms are defined by the information encoded in their genomes, and 
since the origin of life this information has been encoded using a two-
base-pair genetic alphabet (A–T and G–C).  In vitro, the alphabet has been 
expanded to include several unnatural base pairs (UBPs).  We have 
developed a class of UBPs formed between nucleotides bearing 
hydrophobic nucleobases, exemplified by the pair formed between 
d5SICS and dNaM (d5SICS–dNaM),which is efficiently PCR-amplified 
and transcribed in vitro, and whose unique mechanism of replication has 
been characterized. 80 
 
What this scientific abstract reports is that two new “letters” (nucleotides or base-pairs) 
have been artificially added to the code of life—deoxyribonucleic acid (DNA).  These are 
artificial and have been given the designation X and Y. 
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 Every life form on earth, every single species from the fruit fly to humans, uses 
the same genetic code.  It is comprised of nucleotides or bases represented by the letters 
A, C, G, and T.  The sequence of nucleotides forms proteins, and proteins determine what 
types of cells to make.  In a way, the addition of X and Y nucleotides has created an alien 
life form.  This living organism is wholly different right down to the most basic, 
fundamental structure.  This builds on Venter’s work and takes it to the next level.  
Adding more letters to DNA allows for more creativity and variability in modifying 
existing genomes or creating new ones. 
 The researchers were able to insert an X-Y pair—man-made, chemically created 
nucleotides.  They were inserted into the common bacterium E. coli.  The bacteria 
responded to the modified genetic code.  The cell reproduced as bacteria do, and 
replicated the X-Y nucleotides along with the other naturally occurring nucleotides.  This 
E. coli bacterium now has six letters in its genetic code.  The researchers allowed the cell 
to reproduce 24 times (24 doublings) over the span of fifteen hours.81  The implications 
of this are astounding.  In a New York Times article, one of the lead researchers stated:  
“If you have a language that has a certain number of letters, you want to add letters so 
you can write more words and tell more stories.”82  With the addition of stable 
nucleotides comes the possibility for new types of proteins and new types of organisms of 
a wider variety.  This increases biological diversity, or at least has the potential to do so.  
The aim is to use the artificially constructed proteins and genomes to create 
antibiotics, vaccines, and other health related and non-health related products.  However, 
much more work needs to be done before this these products can come to fruition.  
Ambrx, a biotechnology company based in San Francisco, is already incorporating novel 
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amino acids into the development of new site-specific treatments.83  In similar research, a 
team in Florida, lead by Dr. Benner, is attempting to build base pairs that do not exist in 
nature.84  Thus, it can be concluded that the world is not too far from witnessing usable 
replicating unnatural genetic structures. 
 Now that the technology has been identified, the next activity is to develop the 
research question.  The research question proposed here is “How will expanding the 
genetic code, through chemically created nucleotides, impact our values and norms?” 
 In this hypothetical application of the nonlinear approach, the participants include 
eight scientists, two policy experts, six medical doctors, and four ethicists.  Due to the 
fact that this is the first cycle addressing an emerging technology the participant pool is 
kept intentionally small.  In subsequent cycles the participant pool will be expanded 
dramatically in order to provide a wider representation of diverse perspectives.  In this 
model it is helpful to begin with a baseline; and experts in the field are in a prime position 
to provide this. 
 
5.3.2 Phase two: research and data analysis  
The second phase includes research and initial data analysis.  That is, to determine  
what publications exist pertaining to any aspect of this technology and how does the 
aggregate of this information inform the current undertaking. 
Of the three recommended ways to conduct the literature review, the third option 
was selected for this application.  Given the author’s experience in bioethics research 
methods, this was used to conduct the literature review.  This research was not 
outsourced, nor did it follow the guidelines suggested by Droste et al.  Again, this 
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example reinforces the flexibility of the model in that it can to adapt to different research 
styles and strengths.  
A literature review was conducted.  The search engines used were Google scholar, 
Ebsco host, PubMed and investigation of specific bioethics and scientific journals (e.g. 
The Hastings Center Report, American Journal of Bioethics, Medicine, Healthcare and 
Philosophy, Journal of Medical Ethics, Nature, Science, Nature Review Microbiology, 
Nature Reviews Genetics, etc.). The search terms included “expanded genome,” 
“synthetic nucleotides,” “ethics and expanded genome,” and “ethical issues in synthetic 
nucleotides.”   
The research showed that others scientists were engaged in similar research 
simultaneously with Romesberg et al.  Two of these included Yang et al who published 
Amplification, mutation, and sequencing of a six-letter synthetic genetic system, in 
2011,85 and  Yamashign et al published Highly Specific Unnatural Base Pair Systems as 
a Third Base Pair for PCR Amplification in 2012.86  Several other scientific research 
articles included Romesberg et al’s work as a reference.  This work has been gaining 
some traction, which is evident from its recent article metric reports.  The article has had 
over 70,000 views online, and it is referenced in eighty-nine news articles, forty scientific 
blogs, and forty-nine Google+ posts.87  The original article has been cited by thirteen 
other publications.  Other relevant publications on this work include Thyer and Ellefson’s 
article Synthetic Biology: New Letters for life’s alphabet88  and two publications by Roy 
Sleator, The genetic code, and Genetics just got SEXY: Sequences encoding XY.89  Only 
one tangentially touched on ethical or social topics.  These included Woyke and Rubin’s 
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article Searching for the branches on the tree of life, which dealt with search for new 
forms of life.90  
Ethics publications on this specific topic were not found.  However, there are a 
wealth of publications on synthetic biology, as a technology and as a discipline, and 
ethical considerations contained therein.  These will be used to inform the questions 
surrounding the emerging technology of expanded genomes.  Specifically, the ethics 
articles already mentioned in this chapter will be used as the foundation. The general lack 
of social and ethical considerations surrounding this recent breakthrough indicates that it 
is an appropriate place to start. The intended outcome for this research is threefold.  First, 
to gain expert feedback, arguments, and opinions regarding the identified research 
question: “How will expanding the genetic code, through chemically created nucleotides, 
impact our values and norms?”  The second outcome of this research is to identify gaps in 
understanding of social and ethical considerations pertaining to expanding DNA.  The 
final outcome, for this cycle, is to identify additional stakeholders for future involvement 
in the concept mapping phase. 
 
5.3.3 Phase three: concept mapping 
Following the methodology articulated by Kane and Trochim, a concept map will 
be produced.  The steps include (1) preparing for concept mapping; (2) generating ideas; 
(3) structuring statements; (4) concept mapping analysis; (5) interpreting the maps; and, 
(6) utilization.91  The application will follow all of these steps; however, this is purely 
hypothetical.  No experts were actually consulted, and no participants were contacted.  
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This is strictly a thought experiment to demonstrate the basic processes and key 
considerations. 
 
5.3.3.1 Preparing for concept mapping  
 Based on the literature review, a number of knowledge sources were identified in 
relation to the research question.  These include molecular biology, genetics and 
genomics, synthetic biology, bioethics, public policy, law, social issues, and healthcare.  
This identification of knowledge sources indicates what groups or individuals should 
participate in the first round of concept mapping.  These groups or individuals would 
include scientists with expertise in molecular biology, genetics/genomics, and synthetic 
biology, medical professions who utilized genetic/genomic tools and/or engage in 
research relating to genetics, professional ethicists (e.g. ideally individuals who have 
published on the topic), and the research team.   
  
5.3.3.2 Generating ideas 
There are two actions that must be completed in this step.  First is the generation 
of statements. The second action is to distribute content and collect responses.  
Generating statements should be based upon the connection to the research question.  The 
statement should also be informed by a literature review conducted in the previous step.  
Based on the hypothetical research search question established in step one, as well 
as the literature review provided in step two, and for the purposes of this dissertation 
considering all points already discussed in this chapter, a number of hypothetical 
statements were developed.  In this case, the statements created are intentionally broad. 
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This was done to allow experts as much flexibility and open-endedness in their responses 
as possible.  Adjustments may have to be made depending upon the participant pool and 
the context of the project and research question. There is no magic number for the 
appropriate number of statements to give participants; for data management purposes, it 
appears that between six and ten statements are reasonable.92  Each participant will be 
asked to answer all of the following as fully as possible.  Possible statements for this 
hypothetical application include: 
 
1. Opinion: What does altering the ‘alphabet of life’, expanding the genetic code, 
mean for the future of medicine?  
2. Opinion: What does this work indicate about life on this planet and possibly 
elsewhere in the universe?  
3. Fill in the blank: Governments and regulatory agencies should,… ,in response 
to these developments. 
4. What ethical considerations apply to this technology? 
5. Open-ended question: This technology will impact… 
6. Open-ended question: This technology will be considered successful, if, as a 
result, it produces…  
7. Open-ended question: This technology will be considered a risk or 
unsuccessful, if… 
 
 After careful consideration and attention to wording and structure, the statements 
will be distributed to the fictitious participants.  Given the technical nature of the content 
and low number of participants in this first cycle, it is recommended to send an e-
document that can be completed by the participant in his or her own time. 
 In this hypothetical example, a month will be given for completion of the initial 
responses.  Three open forums will be held via Adobe Connect, which is an excellent 
audio and web conferencing tool.  The first is an optional information session describing 
the project, timeline, expectations, goals, and a question and answer period.  This 
information will also be provided in the packet sent to participants.  The two subsequent 
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meetings are discussion-based meetings, designed to focus on specific statements and 
participant answers.  This will give experts the opportunity to cross-pollinate and 
exchange or inform ideas, facts, and opinions.  This will also assist the participants in 
formulating their responses, as the discourse generated by the discussion group will 
encourage critical and in-depth thinking, as well as opinions and multiple perspectives. 
Meetings may or may not be required depending upon the preference and 
flexibility of the facilitator and the context of the project.  In this hypothetical case, the 
meetings are not required, but strongly encouraged.  Of these two opportunities 
participants will be asked to participate in one.  Ideally, each meeting will have a 
diversity of participants to the extent practicable.  If the participants cannot attend one of 
these web-based meetings, their written responses should be included in the following 
steps. 
After responses are collected the information must be synthesized.  For the sake 
of this hypothetical application, the assumption is made that all twenty participants fully 
responded to all statements.  This leaves the facilitator(s) with approximately 140 unique 
answers to the statements that must be reviewed and synthesized.  The synthesis of these 
answers should result in the elimination of any redundancies and answers, determining 
what answers fall outside the scope of the current research question, and determining 
which answers are simply not relevant to this research at all. 
To further this hypothetical application, statement 4 will be analyzed.  Statement 
4 asked participants to consider what relevant ethical considerations should be included.  
To begin the analysis, a list of all answers should be created.  Individual participants 
might provide multiple answers to a single question; this is encouraged and all answers 
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should be recorded.  One of the best ways to collect and sort information is through 
Microsoft excel.  As demonstrated in the table below, all hypothetical participants, their 
demographic information, and responses to the statements, in this case statement four, 
can all be compiled in the same spreadsheet.  The benefit of this approach is that it makes 
initial sorting and categorizing of respondents and relevant topics more simple.  The table 
below has sorted all respondents based on their professional discipline.  
 
 
Participant 
Demographic 
(Profession) Comment 1 Comment 2 
P4 MD 
Implications for clinical trials - 
informed consent   
P15 MD 
Risks to patient health - drug 
interaction 
Risk to patient health - 
implication for other gene's 
expression 
P7 MD 
 Do more social good by 
providing more options for 
treatment   
P5 MD 
 Biological diversity could 
improve the ecosystems and 
environment, thus improving 
human health   
P11 Scientist 
 There are none, technology is 
value-free   
P20 Scientist 
 Do not stymie scientific 
progress, as it is a social good   
P16 Scientist 
Science is a social good because 
it can improve human life   
P2 Scientist 
 Natural, non-natural, post-
natural: does it matter?   
P14 Scientist 
 Ethical consideration include 
uncertainties in risk assessment   
P6 Scientist 
 Someone using the technology 
for nefarious purposes   
P19 Scientist 
 The technologies will have a 
positive impact on the world, it 
is a moral obligation to purse it   
P13 Scientist 
 Ethics cannot be considered 
until the technology is developed   
P18 Ethicist 
How do we define natural vs. 
non-natural or post-natural if the 
organism is living? 
What does it mean for 
something to be alive? 
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P1 Ethicist 
Implications for the 
transhumanist agenda 
Considerations for the bio-
conservative agenda 
P10 Ethicist Ethically justifiable risks 
 Unanticipated and unknown 
risks may be unacceptable 
P17 Ethicist 
If applied to humans, what does 
it mean to be human? 
What are individuals with 
expanded DNA? 
P8 
Social 
Scientist Public attitudes: Yuck factor  
 Impact on religion, cultural 
influences 
P3 
Political 
Scientist 
Policy makers should be 
educated about this surge in 
research   
P12 Policy Expert 
 Oversight and regulation should 
be implemented 
Biosecurity measure should 
be taken by laboratories 
P9 Policy Expert 
All novel organisms, whether 
modified or complete synthetic, 
ought to be registered for safety 
 Public safety should be 
above scientific progress 
 
It should be noted that everything contained in this table is strictly hypothetical.  
Obviously, the comments are not nearly as detailed here as they would be in reality.  The 
table is meant to demonstrate organizational techniques as well as broad strokes of 
potential ethical and social issues that might arise, based on the research presented in this 
dissertation.  The ethical and social considerations, as well as the risks and scientific 
considerations, do stem specifically from the literature.  Yet, there is no way to know 
what is and what is not important for the participants listed above.  An additional 
limitation in creativity represented in the perspectives provided above is due to the 
author’s lack of a scientific and medical background.  
 
5.3.3.3 Structuring statements  
Based on the responses for step two, the participants will be asked to perform 
three relatively simple tasks.  Participants will be provided with the unique responses to 
all the questions; however the questions will no longer be important, only the resulting 
topics informed by the question.  First, participants will sort each item and place them in 
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groups with those most related to it in meaning.  Essentially, participants will be 
categorizing the items based on relationship.  Participants should be informed of any 
specific guidelines.  The basic guidelines include that there cannot be the same number of 
ideas as groups, this means that participants actually have to engage in the sorting 
process.  They cannot establish every idea as separate from another, thereby having the 
same number of groups as ideas.  All the statements cannot be put in the same group, 
because this provides no distinction.  There should be no miscellaneous group.  If the 
statement is wholly unique it should be separated out.  
After the participants have sorted all the items into groups, they must rank the 
statements based on a set of criteria provided by the facilitator(s).  In this hypothetical 
case, the participants are asked to rank the statements by perceived levels of importance.  
That means, does the issue or idea need to be addressed immediately or not.  A simple 
Likert scale will be used to rank the statements.  Participants will rank each item on a 
scale of 1 to 5, one being not important and five being very important.  Items should be 
ranked on their own merits; they should not be ranked in relation to one another.  For 
example, to items in the same group might have the same level of importance based on 
the criteria.  
The final task participants will complete is to provide some very basic 
demographic information.  This should include gender identification, age range, 
geographic region of residence, professional or employment status, type of employer (e.g. 
for profit, non-profit, government, university, etc.) level of education, ethnicity, religious 
affiliation, household composition (e.g. single, married, divorced, children, etc.), and 
household income.  This basic demographic information will allow for the easy sorting of 
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participants into subgroups for more detailed analysis.  For example, it would be very 
useful to know if a certain demographic, such as African-American females, widely 
accepted the potential use of emerging technology; whereas Caucasian males widely 
rejected the potential adoption of the same emerging technology.  This sort of 
information can further inform and justify the appropriateness of the agreed upon action 
steps developed in phase four of the nonlinear approach. 
Here is how this might hypothetically play out in this defined scenario.  A 
snapshot of the process will be presented as it is necessary to provide a full assessment of 
fictitious data.  After removing all redundancies and synthesizing responses into distinct 
opinions and ideas or conceptual domains, statements will be redistributed to the group of 
participants and they will sort them, and rank each statement.  In an example provided by 
Kane and Trochim involving the Delaware Department of Health and Social Services, 
participants submitted more than 500 responses. 93  This was synthesized into 
approximately 118 distinct conceptual domains.  This number will vary from case to 
case.  Regardless of the participant sample size Kane and Trochim recommend having no 
more than 100-120, as numbers beyond that can become unmanageable to both 
participants and facilitators.94  
In this hypothetical application, of the 140 responses to statements the assumption 
is that there are twenty-two unique conceptual domains or ideas.  It should be noted that 
this is a completely arbitrary number.  In this hypothetical example, the twenty-two 
distinct domains include: lives not saved if research is halted; bio security; dual use; 
unanticipated risks; unknown risks; unintended use; medical benefits; improve 
treatments; environmental applications; public attitudes; socioeconomic concerns; policy 
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issues (e.g. oversight and regulation); religion; cultural norms; health as a social good; 
reframes our understanding of microbiology; reframes our understanding of life and 
nature; playing God; impacted norms; autonomy; justice; and the obligation to minimize 
risks.  
The twenty-two unique conceptual domains are then returned to the participants 
for sorting and ranking of importance.  Several weeks should be allowed for the 
completion of this task.  The hypothetical results of this are that the topics are sorted into 
four major categories: ethical considerations, risks, social issues, and scientific 
advantages.  Connections identified by the participants are revealed, as not all 
participants placed each statement in the same grouping.  Rankings were averaged across 
the domains to determine which were considered more or less relevant based on level of 
importance to immediately address.  
 
5.3.3.4 Concept mapping analysis  
Based on the information collected, a very simple pictorial concept map can be 
constructed.  The pictorial concept map reflects the categorization and rankings of the 
statements by the participants.  Sample rankings of importance are indicated on the 
concept map in numeric form for the category of “risks.”  The sample rankings reflect the 
participant average in the Likert scores for each of the statements.  For example, if three 
participants ranked a certain statement as a five on the Likert scale, while the other 
seventeen marked it as a one, this can be represented as an average, which would be 1.6.  
In this example, the Likert average appears in parentheses behind the topic name.  
Depending upon the context of the project, most importantly what the facilitators are 
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trying to express through the numbers—whether it reflects the popularity, importance, or 
feasibility surrounding the statements—it may be appropriate to represent this figure in 
different ways. 
The crosscutting arrows represent potential crosscutting issues categorized by the 
different participants.  For example, in the “ethical considerations” category a participant 
might put the obligation to minimize risk as well as the risk of not having the capacity to 
save lives.  The green line in the concept map below linking those two ideas indicates this 
connection.  In the concept map below, it is evident how unknown or unconstrained 
problems can be represented.  They simply receive their own concept box.  There are a 
number of stand-alone boxes in the concept map below that indicate unknown or 
unanticipated items.   
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Figure 4: Concept map reflecting ethical and social considerations surrounding the expanded genome. 
The concept map above was created using MindMaple, a free iOS application. 
The information represented in this concept map is purely hypothetical.  This is still 
useful in demonstrating the visual strength of this method.  As participant numbers 
increase, utilizing the pictorial concept map becomes more and more challenging.  This is 
when the transition to scatter charts or plot charts becomes critical.  The software, 
suggested in Chapter Four, can handle robust statistical analyses and provide visual 
representation of their statistics.  The process would be conducted in the exact same way; 
and the data would be collected and organized in the exact same way.  However, the 
difference is the visualization of the data.  When using a scatter chart or plot chart, the 
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data gathered from participant responses to statements, as well as their rankings, is 
actually entered in to a matrix that can be statistically analyzed. That pure statistical 
analysis is represented; but there is room for human error in the pictorial concept map.  
The facilitators are responsible for providing an accurate representation of stakeholder 
perspectives in pictorial concept mapping.  The justification for using the pictorial map in 
the first cycle is to explicitly and visually call out those cross cutting themes.  While 
scatter charts and plot maps are more reliant on statistics there are times when 
crosscutting connections are not always as obvious; this is simply due to the nature of the 
visual. 
  
4.3.3.5 Interpreting the maps 
It is strongly recommended that the concept map, pictorial or otherwise, be shared 
with the participants for additional reflection and feedback. This adds to the validity of 
the findings.  It also promotes a culture of transparency and inclusion, which is helpful 
for emerging technology because it can alleviate some of the natural fears and 
speculation that can accompany new technologies. 
Drawing conclusions from nonexistent data and hypothetical thinking is rather 
pointless.  Yet, in this hypothetical exercise it is important to provide examples of how 
conclusions can be drawn based on the information presented.  In the concept map above, 
there seem to be a lot of scientific considerations linked to risks, yet there are not as many 
ethical considerations linked to risk.  This could indicate that among the hypothetical 
participants there is recognition of risks, but there is not the recognition of the underlying 
ethical implications that accompany risk.  Given the fact that the hypothetical participants 
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were largely comprised of scientists and medical doctors this conclusion might make 
sense.  Another conclusion that can be drawn from this basic hypothetical concept map is 
that there is a close relation between social issues and ethical considerations.  Although, 
this should not come as a major surprise as ethical and social considerations are often 
taken together in the same context. 
 
5.3.3.6 Utilization 
The final step of the concept mapping exercise is to use the observations, 
connections, and data to discern actions steps.  Based on this new information a series of 
steps can be taken to improve the scientific research process as well as the 
communicative aspects of emerging technologies.  From this completely hypothetical set 
of data, one might conclude that it would be beneficial to educate scientists about the link 
between ethics and risk.  Another possible action step would be to identify additional 
participants based on the results of this research.  For example, comments surrounding 
oversight and policy hypothetically arose; thus it might be appropriate to engage more 
policy experts as well as those who work and regulatory fields that might apply to this 
emerging technology. 
The most important aspect of this final step of the concept mapping process is to 
approach the data with honesty and transparency.  Share the findings.  Avoid any 
temptation to manipulate, skew or, positively or negatively, spin data.  This final concept 
mapping step overlaps with and transitions directly into phase four of the nonlinear 
approach. 
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5.3.4 Phase four: evaluation 
This phase calls for honest assessment of whether the intended outcomes, set in 
phase two, were met.  To review, there were three outcomes identified.  The first is to 
gain expert feedback, arguments, and opinions regards to the identified research question: 
“How will expanding the genetic code, through chemically created nucleotides, impact 
our values and norms?”  The second outcome of this research is to identify gaps in 
understanding of social and ethical considerations pertaining to expanding DNA.  The 
final outcome, for this cycle, is to identify additional stakeholders for future involvement.  
If the intended outcomes were not met, reflection on possible explanations for this should 
be completed.  Also, the action steps identified should include some recognition of this 
and suggest ways to address it. 
In this hypothetical application, the first and second outcomes were met. 
However, in this example the sample size was small.  The second cycle may wish to 
remain within disciplinary expertise, as this first cycle did, but broaden and increase the 
number of participants.  Arguably, the third outcome has been addressed as well, yet not 
completely answered.  There was an identification of the need for additional experts from 
the fields of policy and regulatory bodies.  As the cycles continue over time, this outcome 
will likely need be continually assessed as new stakeholders and other relevant parties are 
identified.  This outcome will provide a good starting point when the approach is 
reengaged for a second cycle. 
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5.3.5 Phase five: closing the loop 
Reflection should occur on two levels.  First, reflections surrounding the 
methodological aspects in the process should be conducted.  Take time to identify 
problem spots and pitfalls.  It is helpful to identify what did not run smoothly, or what 
was particularly difficult to address, and this information can shape future cycles.  It is 
also helpful to articulate what did work and what was helpful in the process.  As different 
organizations find certain aspects, techniques, or software that work well for them, 
documenting this and sharing it with other organizations will assist in furthering the 
discourse surrounding this approach, as well as overall development and improvement of 
this approach. 
The second level of reflection that needs to occur is when the approach needs to 
be reengaged.  This approach is not meant to run through a single cycle.  It is meant to 
have as many cycles as needed to shed light on the relevant issues, frame the question 
properly, and provide insights for decision-makers and policymakers.  It is unlikely this 
will be attainable in one cycle.  Since this approach is engaging emerging technologies 
very early in the research and development phases, they are likely to be substantial 
breakthroughs and benchmarks that are met throughout the research process.  As these 
benchmarks are met and major breakthroughs occur, the approach should be reengaged 
and the process should start over building on the work of prior cycles. 
As John Cupato, Professor of Chemistry and Biochemistry at Arizona State University 
suggests, there are some foreseeable next steps in which to apply this technology, 
including, “developing systems that carry more than one unnatural base pair and encode 
functional information; finding new ways to reduce the dependency of an organism on 
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nucleoside triphosphates supplied to the medium; and increasing the scale of the bacterial 
cultures so that large quantities of modified protein can be produced by recombinant 
protein expression.”95  These might serve as sound a benchmark points that spark the re-
engagement of this cycle.  Another determining factor will be the scope and goals of the 
current research team whom are applying this approach. 
 In this hypothetical assessment some recommended actions would include the 
following: (1) additional research into any number of the hypothetical crosscutting 
themes surrounding ethics and risk; (2) broadening to participant pool to more experts 
and relevant stakeholders; and, (3) monitoring the literature for relevant publications and 
monitor the technology for advances, benchmarks or breakthroughs.   
 
5.4 Discussion and analysis 
This section will address the results of the previous section by providing a 
summary overview and analyzing the benefits of limitations of a nonlinear approach in 
this hypothetical application. 
 
5.4.1 Benefits of the nonlinear approach 
The benefits of the nonlinear approach include increased time, sound 
methodologies, increased inter- and multi-disciplinary collaboration, the inclusions of 
wider ethical and social issues including socioeconomic issues, allowing for improved 
transferability of information, and finally it is a step closer toward creating consistency in 
ethics assessment while not stymieing scientific progress. 
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The benefit of increased time was evident in the fact that this technology is still at 
least five to ten years from human health or cosmetic application.  This allows ample 
time to conduct several cycles of the nonlinear approach, as well as engage in meaningful 
reflection and discourse.  This also allows for the integration of new literature as it is 
published, the inclusion of additional relevant parties as they become apparent, as well as 
the comparison of data between cycles. 
Through continued collaboration over cycles, the efficiency of the approach will 
be enhanced.  Each phase is grounded in a sound methodology, lending validity to the 
whole process.  The validity of the whole approach is demonstrated in the ability to effect 
positive action and if necessary positive change.  This can be accomplished through 
social programming as technologies near market readiness or ensuring that certain 
populations will have access to beneficial treatments.  An overarching benefit of the 
nonlinear approach is that ethics assessment occurs as the technology develops.  This is 
immensely important because it can reduce the risk of slowing the progression of 
scientific research.  It also addresses one of the largest obstacles in HTA, which is time. 
For example, the roots of stem cell research date back to the 1950’s and 1960’s with the 
discovery of stem cells; by 2001 stem cell research was well underway, but brought to an 
abrupt halt through a reduction in federal funding, under the Bush administration, when 
ethical, social, and legal considerations came to light.  It is possible that some of the 
ethical, social, and legal concerns could have been anticipated and addressed if ethics 
assessment had occurred earlier in the process.96  This approach embraces these 
opportunities.  This also ties directly to the benefit of enhancing consistency and validity 
of ethical assessments, while not stymieing the progress of science and development of 
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new technologies.  This is because this approach is not meant to be a watchdog or 
oversight tool.  It is intended to provide accurate data surrounding important ethical and 
social considerations related to an emerging technology and support actions to either 
better understand these issues (e.g. through additional research) or provide 
recommendations and actions to begin addressing these issues. 
A plethora of perspectives on multiple issues can be taken into consideration 
collectively in an effort to develop a map of the moral and social landscape through the 
nonlinear approach.  Elements such as: ethical concerns surrounding risks, benefits, 
human health and enhancement; social concerns such as socio-economic implications and 
public perception; economic considerations such the impact of bioeconomy; political 
considerations surrounding policymaking; and, global impact will be considered 
collectively, rather, than singularly as recent scholarship has done.  The example 
provided in the hypothetical application surrounding the significant variance in 
perspective of African American females and Caucasian males shows a small snapshot of 
the types of connections and data that can be gathered.  
It has been suggested by scholars, and has been asserted in this approach, that 
ethics can play an informative role in priority setting.97  This includes priority setting not 
only for the assessment of emerging technologies but also priority setting for 
philosophical ethics as well as bioethics.  For example, through continued cycles of this 
approach it may become evident that issues surrounding the definition of life are not as 
important as understanding how informed consents might be impacted by this new 
technology.  Characterizing or defining “life” it is very important for our ontological 
understanding of humanity and nature, and this topic should not be dismissed.  However, 
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it should be recognized that there may be more pressing issues than concluding this 
debate.  If policymakers, scientists, the public need ethical guidance pertaining to the 
issues of surrounding autonomy and informed consent the bioethics community should 
contribute to that discourse.  As the overarching aims continue to guide development, the 
nonlinear approach should continue to yield valid results in the form of action steps taken 
and completed. 
 An additional benefit of this methodology is that it can inform the HTA and ethics 
community as to what type of publications would be most beneficial.  This could be 
viewed as a type of priority setting for academics.  This adds to the relevancy of bioethics 
publications.  This can be linked to the benefit of providing transferable data. The 
dissemination of data will vary from team to team, and from organization to organization. 
Regardless of how the information is shared, it should be understandable since it can be 
represented in multiple ways, including pictorial concept maps, scatterplots, statistics and 
so on.  In the hypothetical example, the concept map clearly expresses crosscutting 
themes and ideas; it also represents the level of importance of each topic.  This visual 
representation is very intellectually accessible. 
 
5.4.2 Limitations of the nonlinear approach 
There are limitations in and of the nonlinear approach.  It is susceptible to some of 
the same obstacles as other ethics assessment in HTA.  The largest obstacle centers on 
fiscal challenges, specifically budget projections and resource allocation.  Since this 
approach runs in multiple cycles, and it cannot be completely predicted how many cycles 
this will involve, it is very difficult to anticipate the cost of implementation.  After the 
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approach has been in place for a few fiscal cycles, these issues will likely work 
themselves out.  However, this approach will still require annual funds.  From a purely 
speculative position, this approach will likely cost more than other ethics methodologies 
and tools. 
  Another limitation is that this approach may fall victim to the same treatment as 
other ethics methodologies and tools; that is they are acknowledged, accepted, but not 
acted upon.  There is the risk that the study will produce valid data, but that data will not 
be acted upon.  If the nonlinear approach is to be effective the final phase, closing the 
loop, must occur.  The data collected, conclusions drawn, and action steps drafted must 
be enacted.  Anything less than this renders the entire process rather pointless.  
Possibly the greatest limitation of this approach is the fact that it was produced 
largely in a vacuum, albeit a very well-informed vacuum. This was not produced in 
conjunction with an HTA process or with a research team.  Therefore, anticipating any 
pitfalls or challenges is very challenging when conducting a hypothetical application. 
That does not discredit the observations made here, and merely points the fact that there 
are going to be some challenges not addressed in this dissertation.  Yet, it is important to 
note that the primary aim of this dissertation was to demonstrate the methodological 
soundness and validity of this approach.  Dabbling in the practical application was 
necessary to demonstrate some of these points.  Concrete conclusions cannot be drawn at 
this point about certain practical implementation elements of the nonlinear approach.  
Even the hypothetical application did not shed much light on practical pitfalls and trouble 
spots.  These can only be identified as they come up in the course of implementation.  
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It may seem that the results can still be manipulated by some individual with a 
specific biases or agenda or interpret with a particular spin.  No research is tamper-proof; 
however, the built in checks and balance system for sharing the concept mapping results 
with the participants can alleviate some of this concern, and lends additional validity to 
the process.  The real advantage is the ability to take into consideration those problems 
for which scholars and society lack answers.  For example, in the concept map there was 
a box for unknown and unanticipated risks.  The fact that the existence of unknown and 
unanticipated risks can be taken into account is critical, especially as additional 
information and layers are added to the concept map.  By keeping them on the radar, 
these issues will not be neglected or avoided.  In addition, they will also not dominate the 
discourse, as the data will show what issues should be prioritized.  Despite some of these 
practical limitations, the benefits assessed in the previous section outweigh them.  The 
only potential non-starter for this approach is the budgetary allocation issue.  
  
5.5 Conclusion  
Chapter Five has provided an overview of existing and emerging issues in genetic 
health technologies.  Specifically, ethical issues surrounding the use of whole genome 
sequencing as a diagnostic tool in medicine as well as biobanking were explored. There 
are many ways that genetic technology impacts daily life; these two were selected as case 
studies because even though they are in use there are still many ethical questions that 
need to be addressed.  With regard to emerging technologies the emphasis was placed on 
the contributions of synthetic biology.  A review of some emerging products of synthetic 
biology was described including genetically modified organisms, genetically modified 
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foods, applications in medicine, specifically protocells and gene therapy.  An overview of 
some of the ethical questions and considerations that these technologies elicit was 
provided, specifically those surrounding protocells and gene therapy.  This was done to 
set the stage for the hypothetical assessments of a very specific emerging technology that 
could utilize both protocells and within the next decade or two could have dramatic 
implications for gene therapy.  
The emerging technology assessed by the nonlinear approach was the expansion 
of the “alphabet of life,” the expansion of the genomic code, moving from nucleotides 
from four base pairs to six.  All phases of the nonlinear approach were demonstrated 
through the hypothetical application.  Suggestions on practical implantation strategies 
were addressed and discussed.  
The final portion of this chapter examined the projected benefits and limitations 
of the nonlinear approach within the context of the hypothetical example.  The example 
yielded a number of hypothetical next actions, including additional research and inclusion 
of wider and more diverse perspectives.   
The final chapter will provide concluding remarks and further reflection on the 
nonlinear approach and its application to emerging genetic health technologies. 
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Chapter Six: Conclusion 
 
6.1 Summary 
This dissertation has presented the nonlinear approach as a way to conduct ethics 
assessments in HTA.  The overarching aims of the approach are: (1) begin ethics 
assessments earlier, (2) provide a flexible framework whereby ethics experts and non-
experts can coherently work together; (3) support, not stymie, scientific progress; (4) 
provide meaningful discourse and recommendations; and, (5) continually improve by 
assessing the ethics assessment mechanism itself. 
The nonlinear approach includes five overarching phases: identification and 
inquiry, research and data analysis, concept mapping, evaluation, and closing the loop.  
These five phases are grounded in established methodologies from various disciplines 
including bioethics, sociology, and mathematics.  The summary provided in this chapter 
reviews the foundational arguments and the model itself, and provides closing remarks on 
the future of genetic health technologies. 
 
6.2 Foundations 
Chapters One, Two and Three laid the foundation for this approach.  The 
argument is that technology has normative value; it is value-laden.  Technology is not 
value-neutral or value-free.  This is proven to the extent that it can be, through inductive 
logic, by the following argument.  Humans create and invent for a purpose; and our 
human activities have purpose and normative value and normative force. 
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 Heidegger was correct in cautioning against humanity’s quick embrace of 
technology and of the technological mindset centering on efficiency.  This potential, if 
gone undetected, could have profound effects on human ontology and dramatic 
implications for our ethical paradigms.  Society and technology are not sole drivers of 
one or the other.  Society is not completely determined by technology; and, similarly, 
technology is not wholly determined by society.  They are two sides of the same coin; 
they shape each other.  
 The understanding of the relationship between society and technology is directly 
impacted by one's perspective on the value-laden nature or value-neutrality of 
technology.  This dissertation argues that not only is technology value-laden, but also 
those technologies that impact human health carry special status.  
Given the current state of health care in the United States and globally, cost-
effectiveness has become a huge issue.  Every reimbursement agency must pick and 
choose pharmaceuticals, medical devices, and other health technologies that they will 
support. 
HTA is conducted differently by every agency and organization.  There are 
evidence-based practices available in economic evaluations and comparative 
effectiveness.  This is because safety and cost effectiveness are considered the most 
important aspects of a new technology that is going to be integrated into the health 
system.  Yet, there is a general consensus on the importance of ethical and social 
considerations of new technologies.  However, standards for assessing organizational 
impact—which includes social and ethical considerations—are few and far between.  
HTA procedures and methodologies are more developed in Western Europe and North 
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America than other parts of the world.  Multinational organizations, such as EUnetHTA, 
HTAi, and INAHTA, are making positive strides, and seek to assist those nations with 
underdeveloped HTA programs. 
Some very foundational questions arise.  What is the role and scope of HTA?  
What is the role and scope of ethics in HTA, if any?  Most countries understand HTA is 
important; but there are significant questions concerning the scope and how to most 
effectively integrate HTA.  Each country and organization performs HTA a little bit 
different, or very different in some cases; this makes the sharing or transferability of 
information incredibly difficult.  In a sense, each agency is on its own at this point in 
time.  Outside of the multinational organizations, which emphasize collaborative work, 
many HTA bodies are developing their own standards and processes.  The HTA 
landscape is constantly in flux, which makes contributing to the field all the more 
difficult.  Is HTA to simply be informative, or should the assessment cross into the 
appraisal category, with recommendations expected as a result.  If recommendations are 
expected to be provided, as they are with appraisals, then the inclusion of ethics is 
inescapable.  Yet if HTA processes remain completely neutral, taking a value-free or 
value-neutral position on technology, it can be difficult to make a case for ethics. 
Despite HTA's origins dating back to the 1970s, little progress has been made 
with regard to standardization.  Perhaps the lack of standards, agreed upon 
methodologies, and dissemination of information are reflective of the social and political 
contexts in which healthcare systems rest. 
Several arguments were provided in order to present a philosophical justification 
for the integration of ethics in HTA.  However, this is not just a philosophical argument. 
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When reviewing the evidence and analysis provided in Chapters One and Two, it is clear 
that all technologies have some special status as they must go through extensive testing, 
licensing procedures, and in many cases some form of HTA.  It is clear that federal 
governments and global organizations have elevated emerging technologies to a special 
status because they have the ability to do great good or great harm.  One of the 
overarching goals in medicine, the primary goal in fact, is to help people.  Health 
technologies produce a social good, because they increase the quality of human life.  
Therefore, these technologies must be regulated and checked for safety in order to stay 
true to this goal.  Nor should major corporations profit from promising to heal people but 
rather selling ineffective drugs.  The argument simply stated is that the promotion of 
health, the absence of pain, and improved health are considered a moral good.  
Technology is a means to that intended end.  Therefore, when assessing risks and 
benefits, and engaging in comparatives effectiveness evaluations and economic analysis, 
the underlying presupposition is that this is being done to achieve a moral good.  These 
normative implications provide justification for including ethics in HTA. 
Evidence was also presented that there is a general consensus among the HTA 
community of ethics relevance and integral position in the process.  Many concerns that 
arise under the categories of benefit, risk, and cost effectiveness are inextricably linked to 
moral concerns.  Health is valued by all.  Emerging health technologies directly impact 
health; so a variety of perspectives must be taken into account in technology assessment 
since health is relevant to almost everyone.  Furthermore, especially in health care, when 
new technologies are introduced they create new care or therapeutic options that will 
impact those already in existence. 
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Emerging genetic health technologies pose an even greater challenge.  This is due 
partially to the increased level of uncertainties and unanticipated outcomes of the 
adaptation of genetic technologies.  In addition, the ethical questions posed by emerging 
and genetic health technologies call one to question and reevaluate their existing ethical 
paradigms—for example, the way one understands autonomy, and the way one 
understands the very nature of humanity. 
 
6.3 The nonlinear approach 
The nonlinear approach was developed specifically for emerging genetic health 
technologies.  Emerging genetic technologies are of a unique variety, as the very nature 
of the technology calls into question some of society’s most foundational normative 
principles.  As such, at this point in time, a practical methodology is needed to address 
these specifically.  This is largely due to the level of uncertainty in risk prediction 
surrounding unanticipated and unknown risks.  This is tempered with the knowledge that 
emerging genetic technologies, as well as the products of synthetic biology, can yield a 
great public good, such as increasing the quality of life for humans, improving the 
environment, providing alternate fuel sources, and so on. 
The aim of the approach is to be flexible, accessible, and inclusive.  It is flexible 
based on the context of technology.  It can be adapted to meet the needs and scope of the 
project.  It is an accessible methodology in that it is easily understood.  However, experts 
are needed to undertake the data analysis and project design aspects.  This approach can 
be used by scientists, developers, and any person(s) involved in the development of a 
given technology.  
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This assessment tool would be employed while the technology is still in the 
research and design phase.  This means that it is employed long before formal HTA 
processes address the technology.  It can be engaged from the very start of a new project. 
This is a recurring approach.  As the project reaches certain benchmarks for major 
breakthroughs, the process will continually be re-engaged.  The ethics assessment will 
continue to grow with the emerging technology.  
In phase one, researchers identify a technology by engaging a specific research 
team, firm or study.  The first cycle of the approach begins with a research question.  
Depending upon the development of the technology, this research question may be more 
or less developed.  The aim is to select an emerging technology, not a technology that is 
ready to go to market or being evaluated for licensure.  While the basic methodology 
would work, the cyclical nature of the nonlinear approach requires more time for 
maximum effectiveness. 
Phase two consists of performing initial research, including a literature review and 
analysis of that research.  This can be done in one of three ways.  The research can be 
conducted internally, utilizing evidence-based practice research methods specifically for 
HTA.  Those methods were published by Droste et al, and reviewed in both Chapters 
Three and Four.  This initial research can be outsourced to a research firm, university, or 
other appropriate organization.  The third option is to conduct research internally based 
on disciplinary research methods.  This was the method utilized in the hypothetical 
application in this dissertation.  In any case, the research team must familiarize 
themselves with the material and conduct an initial analysis of existing publications.  This 
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will indicate whether or not they need to reassess the research question proposed in phase 
one.  
Phase three is the most labor-intensive phase in this approach.  A concept map 
should be developed by soliciting the perspectives and opinions of experts, stakeholders, 
and other relevant parties.  This is labor-intensive because it requires organization of 
participants, the execution of a fairly robust methodological process, and concept 
mapping.  Concept mapping also includes collecting, sorting, and mapping the data 
collected from the participants.  The depth and breadth of information that can be 
collected, integrated, and visually displayed in the concept map is robust; furthermore, 
the validity and outcomes of this methodology warrants its use.  Visual representation of 
statistics can lead to the identification of crosscutting themes and perspectives, social and 
ethical problems that may arise with adopting the new technology, and general attitudes 
of the public.  The concept mapping methodology utilized in this dissertation was that 
forwarded by Kane and Trochim, both of whom have extensive publications and 
experience in this area.  There are six general steps in concept mapping, they include (1) 
preparing for concept mapping; (2) generating ideas; (3) structuring statements; (4) 
concept mapping analysis; (5) interpreting the maps; and, (6) utilization.  The 
hypothetical application, surrounding the expanded genome of E. coli bacterium, 
presented this approach.  Throughout this process, commentary was provided about 
flexibility, potential pitfalls, as well as recommendations on evidence-based methods and 
best practices.  A hypothetical concept map was developed.   
Phase four evaluates all the information and data collected thus far in the process.  
This includes taking into account the initial research question, literature review, 
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participant responses and interactions, and concept map.  The primary activity is to 
reflect upon the outcomes set in phase two, as well as the results of the concept map.  
Phase five requires the researchers to close the loop.  This closure happens in two 
ways.  First, based on the evaluation in phase four, action should be taken.  The action 
can simply be pursuing further research or it could be as extreme as engaging in some 
sort of public education initiative.  The outcomes of the concept map will identify the 
gaps in understanding, as well as illuminate additional connections in social and ethical 
understanding and attitudes towards emerging technologies.  The second aspect of 
closing the loop is a reflective exercise.  This reflection occurs on two levels.  The first 
reflection occurs on the process as a whole, identifying what worked, what did not work, 
and what can be improved.  This reflection is noted so refinements can be made and the 
second cycle undertaken.  The second level of reflection that occurs is when to reengage 
the approach.  It is recommended that with any shift and technological development or 
major breakthrough that the approach be reengaged to adjust to these new findings. 
The prospective benefits include increased time, sound methodologies, increased 
inter- and multi-disciplinary collaboration, the inclusion of wider ethical and social issues 
including socioeconomic issues, improved transferability of information, and finally it is 
a step closer toward creating consistency in ethics assessment while not stymieing 
scientific progress.  This approach allows for the involvement of more individuals; and 
inclusion increases transparency. This approach is cyclical in nature, meaning that it is 
not a one and done process. It is ongoing and happens concurrently with technological 
development. That allows for increased checks and balances, accuracy and validity. The 
approach is accessible as it is based on best practices from a range of disciplines that 
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offer structured and organized methods to conduct intellectual inquiry.  This approach is 
accessible to scientists and non-ethics experts due to its interdisciplinary methodology.  
However, ethics expertise is still needed in the research and evaluation portions of the 
approach.  These benefits were demonstrated in a hypothetical thought experiment.  The 
limitations include the status quo of ethics assessment, the sum of the parts problem, the 
way in which this approach was generated, and the required need of ethics expertise.  The 
final issue to address is that ethics assessment does not necessarily solve ethics issues, 
problems, or controversies.  Overall, it was argued that the benefits outweigh the 
limitations. 
 
6.4 Ethics 
 The nonlinear approach embodies ethics at two levels.  The first is nonlinear 
approach’s consistency with philosophical foundations calling for the inclusion of ethics 
in HTA, and the second is the ethics assessment conducted within the nonlinear 
approach.  
The consistency of the nonlinear approach with strong philosophical traditions is 
of great benefit.  Based on the arguments from technology as value-laden, the 
relationship between society and technology, and the role health technologies there is a 
strong argument for a moral obligation to conduct ethics assessment in emerging 
technologies.  The nonlinear approach builds on this philosophical foundation and is 
consistent with it, thereby giving it additional soundness.  
The second level of ethics engagement is the ethical considerations within the 
nonlinear approach.  Through concept mapping a wide range of diverse perspectives are 
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taken into account through participant involvement.  This leads to enhanced issue 
identification and making the connections between various ideas and concerns, which has 
the potential to lead to heightened discourse surrounding these ethical issues.  Ethical 
approaches that included stakeholder participation early in the research and design phases 
of research, like the nonlinear approach, can assist in building transparency, public 
education, and identifying key action steps necessary for either integrating or not 
integrating a particular emerging technology.  This nonlinear approach allows ethics and 
emerging genetic health technologies to move from the theoretical arguments of 
philosophy and sociology into the practical world.  It does not matter how strong a 
theoretical argument is—if it remains difficult to hear, people will ignore it.  This is 
evident from the lack of ethics integration in HTA.  However, if tangible and valid 
evidence is produced, it cannot be ignored.  The nonlinear approach is grounded in valid 
methodological practices, and has a strong theoretical basis and justification as well. 
 The nonlinear approach will not solve ethical problems, although it has the 
potential to address some ethical problems.  The final phase of the nonlinear approach 
calls for the drafting of actions that can be taken based on the data and information 
gathered.  These action steps can include identifying areas for further research, social 
change initiatives (e.g. awareness campaigns, education, advocacy initiatives, and so on), 
or priority setting for research in bioethics (e.g. research and discourse needed to 
understand ethical dimensions of emerging trend in society or technology).  The action 
steps identified in phase five can dramatically impact multiple areas, as suggested above.  
A long-term goal for all ethics assessment should be to support objective 
assessment of science and technological development, and make informed ethical and 
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social decisions grounded evidence-based practice.  In a perfect world the goal would be 
to move away from political agendas.  It seems as though whichever party has controlled 
the White House determines what science is ethically acceptable and ethically 
unacceptable. In conclusion, one of the long-term goals of ethics assessment in emerging 
health technologies should be to elevate ethical assessment and discourse out of political 
agendas.  Ethics assessment should follow sound methodologies to arrive at well-
supported justifications and evidence based guidelines for both scientific and 
technological research and progress. 
 
6.5 Emerging genetic health technologies 
 The specific technology assessed using the nonlinear approach was a semi- 
synthetic organism that had an expanded genome.  All life on this planet as we know it 
consists of the genetic base pairs A (adenine), T (thymine), G (guanine) and C (cytosine). 
The research team led by Romesberg added two additional nucleotides to the E. coli 
bacterium.  These nucleotides were man-made and chemically created; they were given 
the designation X and Y and are called unnatural base pairs for short (UBPs).  Other 
researchers have pointed out that this is a significant breakthrough.  However, there is 
still much work to be done.  Looking ahead, this emerging technology has the potential to 
impact molecular, pharmaceuticals, medicine, biotechnology, and biochemistry.  If these 
organisms can stabilize with these new man-made base pairs, this could also dramatically 
increase biodiversity. 
There are a plethora of other emerging genetic technologies that will be applied to 
human health.  These range from genetically modified organisms (GMOs) geared toward 
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improving the environment or specific ecosystems, to those applied to medicine as gene 
therapy treatments or new cancer interventions.  One of the goals of ethics assessment is 
to address those social concerns and attitudes that typically arise from emerging 
technologies. The goal of ethics is to discern not only whether the emerging technology 
poses minimal physical risk, but also how it impacts social norms and values.  The recent 
debacle in the Florida Keys is a prime example of how all of this went awry.  In recent 
years in the Florida Keys there has been an uptick in two mosquito borne diseases, 
dengue and chikungunya, both of which are quite painful.  Researchers at Oxitec have 
developed a mosquito with an altered genetic code. As a result, it causes the offspring of 
any aegypti mosquito that mates with the GM mosquito to die.1  Oxitec’s application to 
the FDA is still under review.  However, attitudes in Key West City are hostile toward 
the release of genetically modified mosquitos.   
The trial is set to run near Key Haven, a location with over 400 homes within 
close vicinity of the release. It should be noted that more than 70 million mosquitoes have 
been released as a result of trials in other counties.  The results have been very positive; 
some reports note 60-70% reduction in the aegypti mosquito population.  Brazil is 
currently planning a commercial release of the modified mosquito.  
The benefits include the use of fewer pesticides, cost-savings (as ten per cent of 
the pesticide budget is going specifically toward aegypti mosquitos, which comprises one 
per cent of the mosquito population in the Keys), and human health and safety benefits. 
Yet, these GMOs are met with hostility, fear and, more specifically, a petition signed by 
more than 150,000 individual opposing the release.2   
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Emerging genetic health technologies, such as those similar to GM mosquito 
mentioned above or those applied directly in a hospital or care setting, are geared toward 
improving human life.  The goal to help a people, this is the goal of medicine, and it has 
moral implications.  Thus, close attention must be paid to these technologies, and they 
must be assessed. 
 
6.6 Closing remarks 
The HTA landscape is scattershot and constantly in flux.  Ethics methodologies 
and integration into HTA processes are even more uneven.  This is not the fault of any 
particular group or individual; there are a lot of excellent efforts underway to support this 
integration.  However, the current HTA landscape is not conducive for this.  It is 
immensely difficult to create a clear picture in one's mind of what is currently happening 
in HTA, even more so in ethics and HTA.  This challenge is compounded when the aim 
is to make recommendations, as it is hard to make recommendations about a moving 
target.  This dissertation has attempted to address this chaos by providing an approach 
that can be adapted both outside and inside of HTA processes.  It also benefits any size 
organization that wishes to employ this approach; whether it be a small research team or 
multinational organization this methodology can be executed at any level due to its 
flexibility. 
                                                 
ENDNOTES 
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2  M. de Meir, "Petitioning Commissioner of Agriculture and Consumer Services Adam H Putman and 33 
Others: Say no to Genetically Modified Mosquitoes Release in the Florida Keys," accessed March 29, 
2015, https://www.change.org/p/say-no-to-genetically-modified-mosquitoes-release-in-the-florida-keys  
 
  
 
289 
 
Bibliography 
23andMe. "Find Out what Your DNA Says about You and Your Family." Accessed March 14, 2015. 
https://www.23andme.com/  
Agency for Healthcare Research and Quality. "Evidency Based Practice Reports." Accessed November 4, 
2014. http://www.ahrq.gov/research/findings/evidence-based-reports/index.html 
———. "Mission and Budget." US Department of Health and Human Services. Accessed March 12, 2015. 
http://www.ahrq.gov/cpi/about/mission/index.html 
———. "Technology Assessment Program." AHRQ. Accessed February 2, 2015. 
http://www.ahrq.gov/research/findings/ta/#tacomplete 
Allen, M., S. S. Brar, and L. Farrell. "Medical Education Needs to Teach Health Technology Assessment." 
Medical Teacher 32, no. 1 (2010): 62-64.  
Alphey, Luke. "Genetic Control of Mosquitoes." Annual Review of Entomology 59, no. 1 (01/07; 2015/03, 
2014): 205-224.  
Alvarez, L. "A Mosquito Solution (More Mosquitoes) Raises Heat in Florida Keys." NY Times, 2015, sec. 
U.S.  
Ambrx. "Ambrx Technology." Accessed March 14, 2015. http://ambrx.com/technology/ 
Anbar, M. "Penetrating the Black Box: Physical Principles Behind Health Care Technology." In Machines 
at the Bedside, edited by S. J. Reiser and M. Anbar, 23-34. New York: Cambridge University Press, 
1984.  
Anderson, L. A., M. K. Gwaltney, D. L. Sundra, R. C. Brownson, M. Kane, and A. W. Cross. "Using 
Concept Mapping to Develop a Logic Model for the Prevention Research Centers Program." 
Preventing Chronic Disease: Public Health Research, Practice, and Policy 3, no. 1 (2006): 1-9.  
Andrianantoandro, Ernesto, Subhayu Basu, David K. Karig, and Ron Weiss. "Synthetic Biology: New 
Engineering Rules for an Emerging Discipline." Molecular Systems Biology 2, no. 1 (2006): n/a-n/a.  
Annas, George J. "Resurrection of a Stem-Cell Funding Barrier — Dickey–Wicker in Court." New England 
Journal of Medicine 363, no. 18 (10/28; 2015/04, 2010): 1687-1689.  
Arellano, L. E., J. M. Willett, and P. Borry. "International Survey on Attitudes Toward Ethics in Health 
Technology Assessment: An Exploratory Study." International Journal of Technology Assessment in 
Health Care 27, no. 1 (2011): 50-4.  
Arundel, A., D. Sawaya, and I. Valeanu. "Human Health Biotechnologies to 2015." OECD Journal: 
General Papers 11, no. 3 (2009): 113-207.  
Assasi, N., L. Schwartz, J. Tarride, K. Campbell, and R. Goeree. "Methodological Guidance Documents for 
Evaluation of Ethical Considerations in Health Technology Assessment: A Systematic Review." 
Expert Review of Pharmacoeconomics & Outcomes Research 14, no. 2 (2014): 203-220.  
  
 
290 
 
Avriel, M. Nonlinear Programming: Analysis and Methods. Dover Publishing, 2003.  
Baars, M. J., L. Henneman, and L. P. ten Kate. "Deficiency of Knowledge of Genetics and Genetic Tests 
among General Practitioners, Gynecologists, and Pediatricians: A Global Problem." Genetic Medicine 
7, (2005): 605-610.  
Baldwin, G., K. Richard I, T. Bayer, P. Freemont, T. Ellis, K. Polizzi, and S. Guy-Bary. Synthetic Biology: 
A Primer. Imperial College Press, 2012.  
Balmer, A. and P. Martin. Synthetic Biology: Social and Ethical Challenges. An Independent Review 
Commissioned by the Biotechnology and Biological Sciences Research Council. Institute for Science 
and Society, University of Nottingham, 2008.  
Banta, T. W. and C. Blaich. “Closing the Assessment Loop.” Change: The Magazine of Higher Learning, 
43: 1, 2009. 22-27.  
Banta, T. W., E. A. Jones, and K. E. Black. Designing Effective Assessment: Principles and Profiles of 
Good Practice. San Francisco, CA: Jossey-Bass, 2009.  
Banta, D. "Considerations in Defining Evidence for Public Health: The European Advisory Committee on 
Health Research, WHO Regional Office for Europe." International Journal of Technology 
Assessment in Health Care 19, (2003): 559-572.  
———. "The Development of Health Technology Assessment." Health Policy 63, (2003): 121-132.  
———. "Health Care Technology as a Policy Issue." In Health Technology Assessment, edited by R. 
Battista. Washington D.C.: Office of Technology Assessment, 1995.  
———. "What is Technology Assessment?" International Journal of Technology Assessment in Health 
Care 25, no. S1 (2009): 7-9.  
Banta, D., C. Behney, and J. Willems. Toward Rational Technology in Medicine. New York, NY: Springer, 
1981.  
Barlow-Stewart, Kristine. "Some Ethical Issues in Human Genetics." In The Australasian Genetics 
Resource Book, edited by Kristine Barlow-Stewart and Gayathri Parasivam. 8th ed. Vol. Fact Sheet 
23, 248-254. St. Leonards, N.S.W: Center for Genetics Education, 2007.  
Barlow-Stewart, Kristine and Mona Saleh. "Prenantal Testing- CVS and Amniocentesis Fact Sheet." In The 
Australasian Genetics Resource Book, 1-5. Australia: Centre for Genetics Education, 2007.  
Beauchamp, Tom L. and James F. Childress. Principles of Biomedical Ethics. 6th ed. New York: Oxford 
University Press, 2009.  
Bedau, M. "What is Life?" In A Companion to the Philosophy of Biology, edited by Sarkar and Plutynski, 
455-471. New York, NY: Blackwell, 2007.  
Bedau, M., J. McCaskill, N. Packard, E. Parke, and S. Rasmussen. "Introduction to Recent Developments 
in Living Technology." Artificial Life 19, no. 3-4 (2013): 291-298.  
  
 
291 
 
Bedau, M. and E. Parke. "Introduction to the Ethics of Protocells." In The Ethics of Protocells: Moral and 
Social Implications of Creating Life in the Laboratory, edited by M. Bedau and E. Parke, 1-17. 
Cambridge, MA: The MIT University Press, 2009.  
Bedau, M., E. Parke, U. Tangen, and B. Hantsche-Tangen. "Social and Ethical Checkpoints for Bottom-Up 
Synthetic Biology, Or Protocells." System Synthetic Biology 3, (2009): 65-75.  
Bedau, M. and M. Triant. "Social and Ethical Implications of Creating Artificial Cells." In The Ethics of 
Protocells: Moral and Social Implications of Creating Life in the Laboratory, edited by M. Bedau 
and E. Parke, 31-48. Cambridge, MA: The MIT University Press, 2009.  
Benner, Steven A. and A. M. Sismour. "Synthetic Biology." Nature Reviews. Genetics 6, no. 7 (print, 
2005): 533-543.  
Berg, Marc, Tom Van Der Grinten, and Niek Klazinga. "Technology Assessment, Priority Setting, and 
Appropriate Care in Dutch Health Care." International Journal of Technology Assessment in Health 
Care 20, no. 1 (Jan 2004, 2004): 35-43.  
Bijker, W. Of Bicycles, Bakelites and Bulbs: Toward a Theory of Sociotechnical Change. Cambridge, MA: 
MIT Press, 1995.  
———. The Social Construction of Technology. Eijsden, The Netherlands: 1990.  
Bijker, W. and J. Law. Shaping Technology / Building Society: Studies in Sociotechnical Change. 
Cambridge, MA: MIT Press, 1992.  
Bimber, B. "Karl Marx and the Three Faces of Technological Determinism." Social Studies of Science 20, 
no. 2 (1990): 333-351.  
———. "Three Faces of Technological Determinism." In Does Technology Drive History? The Dilemma 
of Technological Determinism, edited by M. Smith and L. Marx, 79-100. Cambridge, MA: MIT 
Press, 1998.  
Blue Cross Blue Shield. "Technology Evaluation Center." Accessed February 2, 2015. 
http://www.bcbs.com/blueresources/tec/ 
Boenink, M. "Molecular Medicine and Concepts of Disease: The Ethical Value of a Conceptual Analysis of 
Emerging Biomedical Technologies." Medicine, Health Care and Philosophy 13, (2010): 11-23.  
Bond, Kenneth, Mark Oremus, Katherine M. Duthie, and Glenn G. Griener. "Ethics Expertise for Health 
Technology Assessment: A Canadian National Survey." International Journal of Technology 
Assessment in Health Care 30, no. 2 (04, 2014): 131.  
Boniolo, G. "Methodological Considerations about the Ethical and Social Implications of Protocells." In 
The Ethics of Protocells: Moral and Social Implications of Creating Life in the Laboratory, edited by 
M. Bedau and E. Parke, 333-348. Cambridge, MA: The MIT University Press, 2009.  
Bostrom, N. "Human Genetic Enhancements: A Transhumanist Perspective." The Journal of Value Inquiry 
37, (2003): 493-506.  
Brannmark, J. and N. Sahlin. "Ethical Theory and the Philosophy of Risk: First Thoughts." Journal of Risk 
Research 13, no. 2 (2010): 149-161.  
  
 
292 
 
Braunack-Mayer, A. "Ethics and Health Technology Assessment: Handmaiden and/or Critic?" 
International Journal of Technology Assessment in Health Care 22, no. 3 (2006): 307-312.  
Brenner, M. and M. Hung. Cancer Gene Therapy by Viral and Non-Viral Vectors. In Translational 
Oncology, edited by R. Bast, M. Markman and E. Hawk. New Jersey: John Wiley and Sons, Inc., 
2014.  
Brown, P. and M. Calnan. "NICE Technology Appraisals: Working with Multiple Levels of Uncertainty 
and the Potential for Bias." Medicine, Health Care and Philosophy 16, (2013): 281-293.  
Buchanan, A. Beyond Humanity? The Ethics of Biomedical Enhancement. Oxford: Oxford University 
Press, 2011.  
Burke, W. and P. Bruce. "Personalized Medicine in the Ear of Genomics." Journal of the American 
Medical Association 298, no. 14 (2007): 1682-1684.  
Burke, Wylie. "Genetic Testing." In Geomic Medicine: Articles from the New England Journal of 
Medicine, edited by Alan E. Guttmacher, Francis S. Collins and Jeffery M. Drazen, 14-27. Baltimore: 
Johns Hopkins University Press, 2004.  
Burls, A., L. Caron, G. Cleret de Langavant, W. Dondorp, C. Harstall, E. Pathak-Sen, and B. Hofmann. 
"Tackling Ethical Issues in Health Technology Assessment: A Proposed Framework." International 
Journal of Technology Assessment in Health Care 27, no. 3 (2011): 230-7.  
Busse, Reinhard, Jacques Orvain, Marcial Velasco, Matthias Perleth, Michael Drummond, Felix Gïrtner, 
Torben Jørgensen, et al. "Best Practice in Undertaking and Reporting Health Technology 
Assessments." International Journal of Technology Assessment in Health Care 18, no. 2 (2002): 361-
422.  
Callahan, D. "Health Technology Assessment Implementation: The Politics of Ethics." Medical Decision 
Making 32, (2012): E14-E19.  
Callon, M. "Society in the Making: The Study of Technology as a Tool of Sociological Analysis." In The 
Social Construction of Technological Systems: New Directions in the Sociology and History of 
Technology, edited by W. Bijker, T. Hughes and T. Pinch, 83-106. Cambridge, MA: MIT Press, 1987.  
———. "Some Elements of a Sociology of Translation: Domestication of the Scallops and the Fishermen 
of Saint Brieuc Bay." In The Science Studies Reader, edited by M. Biagioli, 67-83. New York: 
Routledge, 1999.  
Calnan, M., D. Wainwright, P. Glasner, R. Newbury-Ecob, and E. Ferlie. "‘Medicine’s Next Goldmine?’ 
the Implications of New Genetic Health Technologies for the Health Service." Medicine, Health Care 
and Philosophy 9, (2006): 33-41.  
Canadian Agency for Drugs and Technologies in Health. "About Rapid Response Service." Canadian 
Agency for Drugs and Technologies in Health. Accessed March 1, 2015. 
http://www.cadth.ca/en/products/rapid-response/rapid-response-service  
Cañas, A. J. and Novak, J. D. "What is a Concept Map?" Accessed February 4, 2015.  
http://cmap.ihmc.us/docs/conceptmap.php  
  
 
293 
 
Carroll, J. D. and M. Wish. "Multidimensional Scaling: Models, Methods, and Relations to Delphi." In The 
Delphi Method: Techniques and Applications, edited by H. A. Linstone and M. Turoff, 402-431. 
Reading, MA: Addison-Wesley, 1975.  
Caulfield, T. "Direct-to-Consumer Genetics and Health Policy: A Worst-Case Scenario?" American 
Journal of Bioethics 9, no. 6-7 (2009): 48-50.  
Center for Evidence-based Policy. "Drug Effectiveness Review Program." OHSU. Accessed March 13, 
2015. http://www.ohsu.edu/xd/research/centers-institutes/evidence-based-policy-
center/derp/index.cfm  
———. "Medicaid Evidence-Based Decisions Project (MED)." OHSU. Accessed March 12, 2015. 
http://www.ohsu.edu/xd/research/centers-institutes/evidence-based-policy-center/med/index.cfm  
Chaput, John C. "Replicating an Expanded Genetic Alphabet in Cells." Chembiochem 15, no. 13 (2014): 
1869-1871.  
Clausen, C. and Y. Yoshinaka. "Social Shaping of Technology in TA and HTA." Poiesis Praxis 2, (2004): 
221-246.  
Cole-Turner, R. "Introduction: The Transhumanist Challenge.” In Transhumanism and Transcendence 
Christian Hope in an Age of Technological Enhancement, edited by R. Cole-Turner, 1-18. 
Washington DC: Georgetown University Press, 2011.  
———. "Transhumanism and Christianity." In Transhumanism and Transcendence Christian Hope in an 
Age of Technological Enhancement, edited by R. Cole-Turner, 193-204. Washington DC: 
Georgetown University Press, 2011.  
Cooper, M. Life as Surplus: Biotechnology and Capitalism in the Neoliberal Era Washington University 
Press, 2008.  
Coxon, A. P. M. Sorting Data: Collection and Analysis. Thousand Oaks, CA: SAGE, 1999.  
Cranor, C. "The Acceptability of the Risks of Protocells." In The Ethics of Protocells: Moral and Social 
Implications of Creating Life in the Laboratory, edited by M. Bedau and E. Parke, 49-68. Cambridge, 
MA: The MIT University Press, 2009.  
Culyer, A. and Y. Bombard. "An Equity Framework for Health Technology Assessments." Medical 
Decision Making 32, no. 3 (2011): 428-441.  
Culyer, Anthony J. and Yvonne Bombard. "An Equity Framework for Health Technology Assessments." 
Medical Decision Making 32, no. 3 (05/01, 2012): 428-441.  
Dancy, J. "Nonnaturalism." In The Oxford Handbook of Ethical Theory, edited by D. Copp, 122-145. New 
York: Oxford University Press, 2006.  
———. "Should We Pass the Buck?" In Philosophy, the Good, the True, and the Beautiful, edited by A. 
O'Hear, 159-174. Cambridge: Cambridge University Press, 2000.  
Daniels, N. Justice and Justification: Reflective Equilibrium in Theory and Practice. Cambridge: 
Cambridge University Press, 1996.  
  
 
294 
 
———. "Wide Reflective Equilibrium and Theory Acceptance in Ethics." Journal of Philosophy 76, no. 5 
(1979): 256-282.   
Davidson, M. L. Multidimensional Scaling. New York: John Wiley, 1983.  
de Meir, M. "Petitioning Commissioner of Agriculture and Consumer Services Adam H Putman and 33 
Others: Say No to Genetically Modified Mosquitoes Release in the Florida Keys." Change.org. 
Accessed March 29, 2015. https://www.change.org/p/say-no-to-genetically-modified-mosquitoes-
release-in-the-florida-keys  
de Vries, M., S. O. Hansson, and A. W. M. Meijers, eds. Norms in Technology. Philosophy of Engineering 
and Technology, edited by P. Vermaas. Vol. 9: Springer, 2013.  
Decker, M. "The Role of Ethics in Interdiscipline Technology Assessment." Poiesis Praxis 2, (2004): 139-
159-139-159.  
Decker, M. and T. Flescher. "When Should There Be Which Kind of Technology Assessment? A Plea for a 
Strictly Problem-Oriented Approach from the Very Outset." Poiesis Praxis 7, (2010): 117-133.  
Decker, M. and M. Ladikas. Bridges between Science, Society and Policy: Technology Assessment - 
Methods and Impacts. New York: Springer, 2004.  
deCODE genetics. "We Know Genetics." Accessed March 14, 2015. http://www.decode.com/  
Dengler, E., J. Liu, A. Kerwin, S. Torres, C. Olcott, B. Bowman, L. Armijo, et al. "Mesoporous Silica-
Supported Lipid Bilayers (Protocells) for DNA Cargo Delivery to the Spinal Cord." Journal of 
Controlled Release 168, no. 2 (2013): 209-224.  
DeParle, N. "Testimony on Health Technology Assessment by Nancy-Ann Min DeParle." Washington 
D.C., 1998.  
Deplazes, A. and M. Huppenbauer. "Synthetic Organisms and Living Machines: Positioning the Products 
of Synthetic Biology at the Borderline between Living and Non-Living Matter." System Synthetic 
Biology 3, (2009): 55-63.  
Derby, S. and R. Keeney. "Risk Analysis: Understanding ‘How Safe is Safe Enough?" Risk Analysis 1, no. 
3 (1981): 217-224.  
DeRidder, D., M. Depla, P. Severens, and M. Malsch. "Beliefs on Coping with Illness: A Consumer's 
Perspective." Social Science and Medicine 44, no. 4 (1997): 553-559.  
DeSanctis, G. and M. Poole. "Capturing the Complexity in Advanced Technology Use: Adaptive 
Structuration Theory." Organization Science 5, no. 2 (1994): 121-147.  
———. "Understanding the use of Group Decision Support Systems: The Theory of Adaptive 
Structuration." In Organizations and Communication Technology, edited by J. Fulk, 173-193. 
Newbury Park, CA: Sage, 1990.  
Doerflinger, R. M. "Old and New Ethics in Stem Cell Debate." Journal of Law, Medicine and Ethics 38, 
no. 2 (2010): 212-219.  
Doherty, R. "Getting Social with Recruitment." Strategic HR Review 19, no. 6 (2010): 11 - 15.  
  
 
295 
 
Doppelt, G. "The Value Ladenness of Scientific Knowledge." In Value-Free Science?: Ideals and Illusion, 
edited by H. Kincaid, J. Dupre and A. Wylie, 218-238: Oxford University Press, 2007.  
Douet, Lisa, Ruairidh Milne, Sydney Anstee, Fay Habens, Amanda Young, and David Wright. "The 
Completeness of Intervention Descriptions in Published National Institute of Health Research HTA-
Funded Trials: A Cross-Sectional Study." BMJ Open 4, no. 1 (11/29, 2013): e003713.  
Douglas, H. "Rejecting the Ideal of Value-Free Science." In Value-Free Science?: Ideals and Illusion, 
edited by H. Kincaid, J. Dupre and A. Wylie, 120-142: Oxford University Press, 2007.  
Douma, Kirsten F. L., Kim Karsenberg, Marjan J. M. Hummel, Jolien M. Bueno-de-mesquita, and Wim H. 
Van Harten. "Methodology of Constructive Technology Assessment in Health Care." International 
Journal of Technology Assessment in Health Care 23, no. 2 (Apr 2007, 2007): 162-8.  
Draborg, E., D. Gyrd-Hansen, P. B. Poulsen, and M. Horder. "International Comparison of the Definition 
and the Practical Application of Health Technology Assessment." International Journal of 
Technology Assessment in Health Care 21, no. 1 (2005): 89-95.  
Droste, Sigrid, Charalabos-Markos Dintsios, and Andreas Gerber. "Information on Ethical Issues in Health 
Technology Assessment: How and Where to Find Them." International Journal of Technology 
Assessment in Health Care 26, no. 4 (Oct 2010, 2010): 441-9.  
Drummond, M. What Arethe HTA Processes in the UK? What is...? Series, 2009. 1-8.  
Drummond, M., P. Neumann, B. Jonsson, B. Luce, J. S. Schwartz, U. Siebert, and S. D. Sullivan. "Can We 
Reliably Benchmark Health Technology Assessment Organizations?" International Journal of 
Technology Assessment in Health Care 28, no. 2 (Apr, 2012): 159-165.  
Drummond, M., B. O'Brien, G. Stoddard, and G. Torrance. Methods for Economic Evaluation of Health 
Care Programmes. Oxford: Oxford Medical Publications, 1997.  
Drummond, Michael F., J. Sanford Schwartz, Bengt Jönsson, Bryan R. Luce, Peter J. Neumann, Uwe 
Siebert, and Sean D. Sullivan. "Key Principles for the Improved Conduct of Health Technology 
Assessments for Resource Allocation Decisions." International Journal of Technology Assessment in 
Health Care 24, no. 3 (Jul 2008, 2008): 244-258.  
Dupre, J. "Fact and Value." In Value-Free Science?: Ideals and Illusion, edited by H. Kincaid, J. Dupre and 
A. Wylie, 27-41: Oxford University Press, 2007.  
Duthie, K. and K. Bond. "Improving Ethics Analysis in Health Technology Assessment." International 
Journal of Technology Assessment in Health Care 27, no. 1 (2011): 64-70.  
ECRI Institute. "About ECRI Institute." Accessed February 2, 2015. 
https://www.ecri.org/about/Pages/default.aspx  
Eden, M. "The Engineering-Industrial Accord: Inventing the Technology of Health Care." In Machines at 
the Bedside, edited by S. J. Reiser and M. Anbar, 49-64. New York: Cambridge University Press, 
1984.  
Eike-Henner, W. K. "Resources Allocation in Healthcare: Implications of Models of Medicine as a 
Profession." Medscape General Medicine 7, (2007): 57.  
  
 
296 
 
Eisenberg, J. M. and D. Zarin. "Health Technology Assessment in the United States Past, Present, and 
Future." International Journal of Technology Assessment in Health Care 18, no. 2 (2002): 192-198.  
Enns, R. H. It's a Nonlinear World Springer US, 2010.  
EUnetHTA. "HTA Core Model." Accessed December 4, 2013. http://www.eunethta.eu/news/renewed-
version-hta-core-model-available  
European Network for Health Technology Assessment. "Common Questions: What is Health Technology 
Assessment (HTA)." Accessed July 3, 2014. http://www.eunethta.eu/about-us/faq#t287n73  
Fattore1, G., N. Maniadakis, L. Mantovani, and G. Boriani. "Health Technology Assessment: What Is It? 
Current Status and Perspectives in the Field of Electrophysiology." Europace 13, no. Suppl 2 (2011): 
ii4-ii53.  
Feinberg, J. The Moral Limits of the Criminal Law, Volume 1: Harm to Others. New York, NY: Oxford 
University Press, 1984.  
Ferrario, C. "Developing Nurses’ Critical Thinking Skills with Concept Mapping." Journal for Nurses in 
Staff Development 20, no. 6 (2004): 261-267.  
Fischhoff, B., S. Watson, and C. Hope. "Defining Risk." Policy Sciences 17, no. 2 (1984): 123-139.  
Flanagan, M., D. Howe, and H. Nissenbaum. "Embodying Values in Technology: Theory and Practice." In 
Information Technology and Moral Philosophy, edited by J. van den Hoven and J. Weckert, 322-353. 
Cambridge: Cambridge University Press, 2008.  
Food and Drug Administration. "New Technologies for Safety Assessments." United States Government. 
Accessed December, 2013. www.fda.gov  
———. "Science and Research." Accessed March 14, 2015. www.fda.gov/ScienceResearch/  
Foster, M., C. Royal, and R. Sharp. "The Routinisation of Genomics and Genetics: Implications for Ethical 
Practices." Journal of Medical Ethics 32, (2006): 635-638.  
Franssen, M. "The Goodness and Kindhood of Artefacts." In Norms in Technology, edited by M. de Vries, 
S. O. Hansson and A. W. M. Meijers, 155-169: Springer, 2013.  
———. "The Normativity of Artefacts." Studies in History and Philosophy of Science 37, no. 1 (2006): 42-
57.  
Fukuyama, F. Our Posthuman Future: Consequences of the Biotechnology Revolution. New York, NY: 
Farrar, Strauss and Giroux, 2002.  
Funtowicz, S. and J. Raventz. "Science for the Post-Normal Age." Futures 25, (1993): 739-755.  
Gagnon, M. P. and et al. "Effects and Repercussions of Local/hospital-Based Health Technology 
Assessment (HTA): A Systematic Review." Systematic Reviews 3, (2014): 129.  
Gallo, P. "Integrating Ethical Enquiry and Health Technology Assessment: Limits and Opportunities for 
Efficency and Equity." Poiesis Praxis 2, (2004): 103-117.  
  
 
297 
 
Garfinkel, M. S., D. Endy, G. L. Epstein, and R. M. Friedman. Synthetic Genomics: Options for 
Governance. Rockville, Maryland: J. Craig Venter Institute, 2007.  
Garrido, M. V. and R. Busse. Health Technology Assessment: An Introduction to Objectives, Role of 
Evidence, and Structure in Europe: World Health Organization on Behalf of the European 
Observatory on Health Systems and Policies, 2005.  
Garrido, M. V., F. B. Kristensen, C. P. Nielsen, and R. Busse. Health Technology Assessment and Health 
Policy-Making in Europe: Current Status, Challenges and Potential World Health Organization, 
2009.  
Gerhardus, A., and C. Dintsios. The Impact of HTA Reports on Health Policy: A Systematic Review: GMS 
Health Technology Assessment, 2008.  
Gethmann, C. F. "Participatory Technology Assessment: Some Critical Questions." Poiesis Praxis 1, 
(2002): 151-159.  
Ghaly, Mohammad. "Religio-Ethical Discussions on Organ Donation Muslims in Europe: An Example of 
Transnational Islamic Bioethics." Medicine, Healthcare, and Philosophy 15, (2012): 207-220.  
Giacomini, M., S. Winsor, and J. Abelson. "Ethics in Health Technology Assessment: Understanding 
Health Technologies as Policies." Healthcare Management Forum 26, (2013): 72-76.  
Gibbons, M., C. Limoges, H. Nowotny, S. Schwartzman, P. Scott, and M. Trow. The New Production of 
Knowledge: Dynamics of Science and Research in Contemporary Societies. London: SAGE, 1994.  
Gibson, Daniel G. et al. "Creation of a Bacterial Cell Controlled by a Chemically Synthesized Genome." 
Science 329, (2010): 52-56.  
Giddens, A. The Constitution of Society: Outline of the Theory of Structuration. Berkeley, CA: University 
of California Press, 1984.  
———. Politics, Sociology, and Social Theory: Encounters with Classical and Contemporary Social 
Thought. Stanford University Press, 1995.  
Goetghebeur, M. M., M. Wagner, and H. Khoury. "Combining Multicriteria Decision Analysis, Ethics and 
Health Technology Assessment: Applying the EVIDEM Decision-Making Framework to Growth 
Hormone for Turner Syndrome Patients." Cost Effectiveness and Resource Allocation 8, (2010): 4.  
Goodman, C. "HTA 101: Introduction of Health Technology Assessment." National Institutes of Health. 
Accessed June, 2013. http://www.nlm.nih.gov/nichsr/hta101/ta10103.html  
———. "Toward International Good Practices in Health Technology Assessment." International Journal 
of Technology Assessment in Health Care 28, no. 2 (Apr, 2012): 169-170.  
Goodman, Timothy. "Is There A Right to Health?" Journal of Medicine and Philosophy 30, no. 6 (2005): 
643-662.  
Gottweis, S. "Gene Therapy and the Public: A Matter of Trust." Nature 9, no. 11 (2002): 667-669.  
Grady, C. "Ethics and Genetic Testing." Adv Intern Med 44, (1999): 389-409.  
  
 
298 
 
Green, W. and J. Hutton. "Health Technology Assessment in England: An Analysis of the NICE Medical 
Technologies Evalution Programme." European Journal of Health Economics 15, (2014): 449-452.  
Grin, J. "Health Technology Assessment between Out Health Care System and Our Health." Poiesis Praxis 
2, no. 157-174 (2004).  
Grunwald, A. "Against Over-Estimating the Role of Ethics in Technology Development." Science and 
Engineering Ethics 6, (2000): 181-196.  
———. "The Normative Basis of (Health) Technology Assessment and the Role of Ethical Expertise." 
Poiesis Praxis 2, (2004): 175-193.  
———. "Technology Assessment Or Ethics of Technology?" Ethical Perspectives 6, no. 2 (1999): 170-
182.  
Gulácsi, L. and et al. "Health Technology Assessment in Poland, the Czech Republic, Hungary, Romania 
and Bulgaria." European Journal of Health Economics 15, no. Supp 1 (2014): S13-S25.  
Guttman, A. "The Ethics of Synthetic Biology: Guiding Principles for Emerging Technologies." Hastings 
Center Report 41, no. 4 (2011): 17-22.  
Gwinn, M., W. D. Dotson, and M. J. Khoury. PLoS Currents: Evidence on Genomic at the Crossroads of 
Translation, Version 8. PLoS Currents: Evidence on Genomic Tests, 2010.  
Habermas, J. Towards a Rational Society: Student Protest, Science, and Politics. Trans J. Shapiro: Beacon 
Press, 1971. 
Hanks, C., ed. Technology and Values: Essential Readings: Wiley-Blackwell, 2009.  
Hansson, S. O. "Decision Making Under Great Uncertainty." Philosophy of the Social Sciences 26, (1996): 
369-386.  
———. "Defining Technical Function." Studies in History and Philosophy of Science 37, no. 1 (2006): 19-
22.  
———. "Dimensions of Risk." Risk Analysis 9, no. 1 (1989): 107-112.  
———. "Ethical Criteria of Risk Acceptance." Erkenntnis 59, no. 3 (2003): 291-309.  
———. "A Philosophical Perspective on Risk." Ambio 28, no. 6 (1999): 539-542.  
———. "Risk and Ethics: Three Approaches." In Risk: Philosophical Perspectives, edited by T. Lewens, 
1-35. New York: Routledge, 2007.  
———. "Seven Myths of Risk." Risk Management 7, no. 2 (2005): 7-17.  
———. "Valuation of Artifacts and the Normativity of Technology." In Norms in Technology, edited by de 
Vries, Marc, Sven Ove Hansson, A. W. M. Meijers, 103-117: Springer, 2013.  
———. "What is Philosophy of Risk?" Theoria 62, no. 1‐2 (1996): 169-186.  
  
 
299 
 
Hantsche-Tangen, B. "The Ambivalence of Protocells: Challenges for Self-Reflexive Ethics." In The Ethics 
of Protocells: Moral and Social Implications of Creating Life in the Laboratory, edited by M. Bedau 
and E. Parke, 199-220. Cambridge, MA: The MIT University Press, 2009.  
Harker, J. and J. Kleijnen. "What is a Rapid Review? A Methodological Exploration of Rapid Reviews in 
Health Technology Assessments." International Journal of Evidence Based Healthcare 10, (2012): 
397-410.  
Hauskeller, C. "Towards a Critical Evaluation of Protocell Research." In The Ethics of Protocells: Moral 
and Social Implications of Creating Life in the Laboratory, edited by M. Bedau and E. Parke, 307-
332. Cambridge, MA: The MIT University Press, 2009.  
Hayes, Inc. "Health Technology Assessment and Consulting Services." Hayes, Inc. Accessed February 2, 
2015. http://www.hayesinc.com/hayes/products_and_services/  
Health Technology Assessment International. "What is HTA?" Accessed July 3, 2014. 
http://www.htai.org/index.php?id=428  
Heidegger, M. "The Question Concerning Technology." In Technology and Values: Essential Readings, 
edited by C. Hanks, 97-113: Wiley-Blackwell, 2009.  
Heilbroner, R. "Do Machines Make History?" Technology and Culture 8, no. 3 (1967): 335-346.  
Heitman, E. "Ethical Issues in Technology Assessment: Conceptual Categories and Procedural 
Considerations." International Journal of Technology Assessment in Health Care 14, no. 3 (1998): 
544-566.  
Henshall, C. "Describe Decision-Making Systems, Assess Health Technology Assessment Reports." 
International Journal of Technology Assessment in Health Care 28, no. 2 (Apr, 2012): 168.  
Hilgartner, S. "Making the Bioeconomy Measurable: Politics of an Emerging Anticipatory Machinery." 
Biosocieties 2, no. 3 (2007): 382-386.  
Hoa, Y. and A. Thomas. "Health Technology Assessment and Comparative Effectiveness Ressearch: A 
Pharmaceutical Industry Perspective." Expert Reviews Pharmacoeconomics 13, no. 4 (2013): 447-
454.  
Hofmann, B. "Is There a Technological Imperative in Health Care?" International Journal of Technology 
Assessment in Health Care 18, no. 3 (2002): 675-689.  
———. "On the Value-Ladenness of Technology in Medicine." Medicine, Health Care and Philosophy 4, 
(2001): 335-346.  
———. "Toward a Procedure for Integrating Moral Issues in Health Technology Assessment." 
International Journal of Technology Assessment in Health Care 21, no. 3 (2005): 312-320.  
———. "When Means Become Ends: Technology Producing Values." International Journal of Media, 
Technology and Lifelong Learning 2, no. 2 (2006): 1-12.  
———. "Why Ethics Should Be Part of Health Technology Assessment." International Journal of 
Technology Assessment in Health Care 24, no. 4 (2008): 423-9.  
  
 
300 
 
———. "Is There a Technological Imperative in Health Care?" International Journal of Technology 
Assessment in Health Care 18, no. 3 (2002): 675-89.  
———. "Why Not Integrate Ethics in HTA: Identification and Assessment of the Reasons." GMS Health 
Technology Assessment 10, (11/26, 2014): Doc04.  
Hofmann, Bjørn, Sigrid Droste, Wija Oortwijn, Irina Cleemput, and Dario Sacchini. "Harmonization of 
Ethics in Health Technology Assessment: A Revision of the Socratic Approach." International 
Journal of Technology Assessment in Health Care 30, no. 1 (Jan, 2014): 3-9.  
Houkes, W. N. "Knowledge of Artefact Functions." Studies in History and Philosophy of Science 37, no. 1 
(2006): 102-113.  
———. "Rules, Plans, and the Normativity of Technological Knowledge." In Norms in Technology, edited 
by M. de Vries, S. O. Hansson and A. W. M. Meijers, 35-54: Springer, 2013.  
Hsu, L. "Developing Concept Maps from Problem-Based Learning Scenario Discussions." Journal of 
Advanced Nursing 48, no. 5 (2011): 510-518.  
Hudson, Kathy L., M. K. Holohan, and Francis S. Collins. "Keeping Pace with the Times — the Genetic 
Information Nondiscrimination Act of 2008." New England Journal of Medicine 358, no. 25 (06/19, 
2008): 2661-2663.  
Huesch, D. "One and Done? Equality of Opportunity and Repeated Access to Scarce, Indivisible, Medical 
Resources." BMC Medical Ethics 13, no. 11 (2012): 1-12.  
Hughes, D. B., B. W. Ullery, and P. A. Barie. "The Contemporary Approach to the Care of Jehovah's 
Witnesses." Journal of Trauma 65, no. 1 (2008): 237-247.  
Hughes, T. "The Evolution of Large Technological Systems." In The Social Construction of Technological 
Systems: New Directions in the Sociology and History of Technology, edited by W. Bijker, T. Hughes 
and T. Pinch, 51-82. Cambridge, MA: MIT Press, 1987.  
———. Human-Built World: How to Think about Technology and Culture. Chicago, IL: University of 
Chicago Press, 2004.  
Hughes, T. and R. Mayntz. The Development of Large Technical Systems. Boulder, CO: Westview Press, 
1988.  
Human Genome Research Institute. "ELSI Planning and Evaluation History." Accessed June 18, 2014. 
http://www.genome.gov/10001754  
International Network of Agencies for Health Technology Assessment (INAHTA). "Handling Ethical 
Issues in INAHTA Agencies." INAHTA Newsletter XI, no. 1 (2003): 8.  
J. Craig Venter Institute. "Press Release: Synthetic Genomics Inc. and J. Craig Venter Institute Form New 
Company, Synthetic Genomics Vaccines Inc. (SGVI), to Develop Next Generation Vaccines." 
Accessed October 27, 2011. www.syntheticgenomics.com/media/press/100710.html.  
Janssens, A. C., M. Gwinn, L. A. Bradley, B. A. Oostra, C. M. van Duijn, and M. J. Khoury. "A Critical 
Appraisal of the Scientific Basis of Commercial Genomic Profiles Used to Assess Health Risks and 
Personalize Health Interventions." American Journal of Human Genetics 82, (2008): 593-599.  
  
 
301 
 
Jegalian, K. Genetics: The Future of Medicine. National Human Genome Research Institute, NIH, 2011.  
Jennett, B. "Health Technology Assessment." BMJ: British Medical Journal 305, no. 6845 (1992): 67.  
———. "Technology Assessment - Extending the Scope of Evaluation Or Fudging the Issues?" Health 
Policy 11, (1989): 73-77.  
Johnson, A., N. Sikich, G. Evans, and et al. "Health Technology Assessment - A Comprehensive 
Framework for Evidence- Based Recommendations in Ontario." International Journal of Technology 
Assessment in Health Care 25, no. 2 (2009): 141-150.  
Jonas, H. "Technology and Responsibility: Reflections on the New Tasks of Ethics." Social Research 15, 
no. 1 (1973): 31-54.  
Jonsson, E. "The Development of Health Technology Assessment in Europe." International Journal of 
Technology Assessment in Health Care 18, (2002): 171-183.  
Jönsson, B. "Health Technology Assessment: Regulators Or Payers—Who Will Take the Lead?" Clinical 
Therapeutics 30, no. 5 (2008): 960-963.  
Kaebnick, G. and T. Murray. Synthetic Biology and Morality: Artificial Life and the Bounds of Nature. 
Basic Bioethics. Cambridge, MA: The MIT University Press, 2013.  
Kamat, N., J. Katz, and D. Hammer. "Engineering Polymersome Protocells." Journal of Physical 
Chemistry Letters 2, no. 13 (2011): 1612-1623.  
Kane, M. and P. Q. McMahon. "Using Concept Mapping to Improve Health Care Decision Making." 
Health Care Biller, (July) 2002.  
Kane, M. and W. Trochim. "Concept Mapping for Applied Social Research." In The Sage Handbook of 
Applied Social Research Methods, edited by L. Brickman and D. J. Rog. 2nd ed., 435-474: SAGE, 
2009.  
Kastenhofer, K. and D. Allhutter. "Technoscience and Technology Assessment." Poiesis Praxis 7, (2010): 
1-4.  
Khangura, S., P. Polisena, T. Clifford, K. Farrah, and C. Kamel. "Rapid Review: An Emerging Approach to 
Evidence Synthesis in Health Technology Assessment." International Journal of Technology 
Assessment in Health Care 30, no. 1 (2014): 20-27.  
Khoury, M. J., W. G. Feero, and M. Reyes. "The Genomic Applications in Practice and Prevention 
Network." Genetics in Medicine: Official Journal of the American College of Medical Genetics 11, 
(2009): 488-494.  
Khoury, M. J., M. Reyes, M. Gwinn, and W. G. Feero."A Genetic Test Registry: Bringing Credible and 
Actionable Data Together." Public Health Genomics 13, (2010): 360-361.  
Khoury, Muin, Linda L. McCabe, and Edward R. B. McCabe. "Population Screening in the Age of 
Genomic Medicine." New England Journal of Medicine 348, no. 1 (2003): 50-58.  
Kimmelman, J. Gene Transfer and the Ethics of First-in-Human Research: Lost in Translation. 
Cambridge: Cambridge University Press, 2010.  
  
 
302 
 
———. "Recent Developments in Gene Transfer: Risk and Ethics." British Medical Journal 330, no. 7482 
(2005): 79-82.  
King, N. and L. Churchill. "Assessing and Comparing Potential Benefits and Risks of Harm." In The 
Oxford Textbook of Clinical Research Ethics, edited by Emanuel et al., 514-526. New York, NY: 
Oxford University Press, 2008.  
Klein, H. and D. Kleinman. "The Social Construction of Technology: Structural Considerations." Science, 
Technology and Human Values 27, (2002): 28-52.  
Knoppers, Bartha, Sylvie Bordet, and Rosario Isasi. "Preimplantation Genetic Diagnosis: An Overview of 
Socio-Ethical and Legal Considerations." Annual Review of Genomics and Human Genetics 7, 
(2006): 201-21.  
Kolasa, K., S. Schubert, A. Manca, and T. Hermanowski. "A Review of Health Technology Assessment 
(HTA) Recommendations for Drug Therapies Issued between 2007 and 2009 and their Impact on 
Policymaking Processes in Poland." Health Policy 102, no. 2-3 (2011): 145-151.  
Krippendorf, K. Content Analysis: An Introduction to its Methodology. 2nd ed. Thousand Oaks, CA: 
SAGE, 2004.  
Kristensen, F. B., K. Lampe, D. L. Chase, S. H. Lee-Robin, C. Wild, M. Moharra, M. V. Garrido, et al. 
"Practical Tools and Methods for Health Technology Assessment in Europe: Structures, 
Methodologies, and Tools Developed by the European Network for Health Technology Assessment, 
EUnetHTA." International Journal of Technology Assessment in Health Care 25, no. S2 (2009): 1-8.  
Kriza, Christine, Philip Wahlster, Mayra Marin, Peter Kolominsky-Rabas, Jill Hanass-Hancock, Nicola 
Deghaye, Emmanuel Ankrah Odame, et al. "A Systematic Review of Health Technology Assessment 
Tools in Sub-Saharan Africa: Methodological Issues and Implications." Health Research Policy & 
Systems 12, no. 1 (12, 2014): 35-57.  
Kroes, P. Technical Artefacts: Creations of Mind and Matter: A Philosophy of Engineering Design. 
Philosophy of Engineering and Technology. Vol. 6 Springer, 2012.  
Krueger, Andrew T. and Eric T. Kool. "Redesigning the Architecture of the Base Pair: Toward 
Biochemical and Biological Function of New Genetic Sets." Chemistry & Biology 16, no. 3 (3/27, 
2009): 242-248.  
Kuehn, B. M. "NIH Launching Genetic Test Registry." The Journal of the American Medical Association 
303, (2010): 1685.  
Kuh, G. and Ikenberry, S. "More than You Think, Less than We Need: Learning Outcomes Assessment in 
American Higher Education." National Institute for Learning Outcomes Assessment. Accessed 
November 13, 2014. www.learningoutcomeassessment.org  
Kuzma, Jennifer and Todd Tanji. "Unpacking Synthetic Biology: Identification of Oversight Policy 
Problems and Options." Regulation & Governance 4, no. 1 (2010): 92-112.  
Lampe, K., N. Kovanen, L. Raustia, U. Saalasti-Koskinen, O. Saarekas, and M. Mäkelä.  
Upgrading and Extending the Possibilities of the HTA Core Model: European Commission, 2012.  
  
 
303 
 
Lampe, K., M. Mäkelä, M. V. Garrido, et al. "European Network for Health Technology Assessment 
(EUnetHTA). The HTA Core Model: A Novel Method for Producing and Reporting Health 
Technology Assessments." International Journal of Technology Assessment in Health Care 25, no. 
Supp 2 (2009): S9-S20.  
Lancy, H. Is Science Value Free?: Values and Scientific Understanding. Routledge, 2004.  
Latour, B. "Networks, Societies, Spheres: Reflections of an Actor-Network Theorist." International 
Journal of Communication 5, (2011): 796–810.  
———. Reassembling the Social – an Introduction to Actor-Network-Theory. Oxford University Press, 
2005.  
———. "Where are the Missing Masses? The Sociology of a Few Mundane Artifacts." In Shaping 
Technology / Building Society: Studies in Sociotechnical Change, edited by W. Bijker and J. Law, 
225-258. Massachusetts: MIT Press, 1992.  
Lavis, John N., Michael G. Wilson, Jeremy M. Grimshaw, R. Brian Haynes, Mathieu Ouimet, Parminder 
Raina, Russell L. Gruen, and Ian D. Graham. "Supporting the use of Health Technology Assessments 
in Policy Making about Health Systems." International Journal of Technology Assessment in Health 
Care 26, no. 4 (Oct, 2010): 405-14.  
Law, J. and M. Callon. "The Life and Death of an Aircraft: A Network Analysis of Technical Change." In 
Shaping Technology / Building Society: Studies in Sociotechnical Change, edited by W. Bijker and J. 
Law. Cambridge, MA: MIT Press, 1992.  
Lea, Dale Halsey, Janet Williams, and Patricia Donahue. "Ethical Issues in Genetic Testing." Journal of 
Midwifery and Women's Health 5, no. 3 (2005): 234-240.  
Lehoux, P. and S. Blume. "Technology Assessment and the Sociopolitics of Health Technologies." Journal 
of Health Politics, Policy, and Law 25, no. 6 (2000): 1083-1120.  
Lehoux, P., M. Hivon, B. William-Jones, F. A. Millers, and Urbach D.R. "How do Medical Device 
Manufacturer's Websites Frame the Value of Health Innovation? An Empirical Ethics Analysis of 
Five Canadian Innovations." Medicine, Healthcare, and Philosophy 15, no. 1 (2012): 61-77.  
Lehoux, P. and B. Williams-Jones. "Mapping the Integration of Social and Ethical Issues in Health 
Technology Assessment." International Journal of Technology Assessment in Health Care 23, no. 1 
(2007): 9-16.  
Lessard, C. "Complexity and Reflexivity: Two Important Issues for Economic Evaluation in Health Care." 
Social Science and Medicine 64, no. 8 (2007): 1754-65.  
Lettieri, E., C. Masella, and U. Nocco. "Budgeting and Health Technology Assessment: First Evidence 
Obtained from Proposal Forms used to Submit the Adoption of New Technology." International 
Journal of Technology Assessment in Health Care 24, no. 4 (2008): 502-510.  
Leys, M. "Health Care Policy: Qualitative Evidence and Health Technology Assessment." Health Policy 
65, (2003): 217-226.  
———. "Health Technology Assessment: The Contribution of Qualitative Research." International 
Journal of Technology Assessment in Health Care 19, no. 2 (2003): 317-329.  
  
 
304 
 
Lilienfeld, R. The Rise of Systems Theory: An Ideological Analysis. New York: Wiley, 1978.  
Lloyd-Puryear, M. and I. Forsman. "Newborn Screening and Genetic Testing." Journal of Obstetric, 
Gynecology, and Neonatal Nursing 31, (2002): 200-7.  
Lock, M. "On Dying Twice: Culture, Technology and the Determination of Death." In Living and Working 
with the New Medical Technologies, edited by M. Lock, A. Young and A. Cambrosio, 233-262. 
Cambridge: Cambridge University Press, 2000.  
Luce, B. and R. S. Cohen. "Health Technology Assessment in the United States." International Journal of 
Technology Assessment in Health Care 25, no. S1 (2009): 33-41.  
Luce, John and Ann Alpers. "End of Life Care: What do the American Courts Say?" Critical Care 
Medicine 29, no. 2 (2001): 40-45.  
Luenberger, D. and Y. Ye. Linear and Non-Linear Programming Springer, 2008.  
Luhmann, N. Introduction to Systems Theory. Translated by P. Gilgen. Polity, 2012.  
———. Theory of Society. Cultural Memory in the Present. Translated by R. Barrett. Vol. 1 Stanford 
University Press, 2012.  
Machery, E. "Why I Stopped Worrying about the Definition of Life… and Why You Should as Well." 
Synthesis no. 1 (2011): 1-41.  
MacKenzie, D. and J. Wajcman. The Social Shaping of Technology: How the Refrigerator Got its Hum 
Open University Press, 1985.  
Malone, B. "10 Years After the Human Genome Project." Clinical Laboratory News 37, (2011): 3-5.  
Malyshev, Denis A., Kirandeep Dhami, Thomas Lavergne, Tingjian Chen, Nan Dai, Jeremy M. Foster, 
Ivan R. Correa, and Floyd E. Romesberg. "A Semi-Synthetic Organism with an Expanded Genetic 
Alphabet." Nature 509, no. 7500 (05/15, 2014): 385-388.  
Manne, A. D. "ETA: A Model for Energy Technology Assessment." The Bell Journal of Economics 7, no. 
2 (1976): 379-406.  
Martelli, N., A. S. Lelong, P. Prognon, and J. Pineau. "Hospital-Based Health Technology Assessment for 
Innovative Medical Devices in University Hospitals and the Role of Hospital Pharmacists: Learning 
from International Experience." International Journal of Technology Assessment in Health Care 29, 
no. 2 (2013): 185-91.  
Martin, C., B. Williams-Jones, and M. G. Ortuzar. "Ethical Health Technology Assessment in Latin 
America: Lessons from Canada and Argentina." Acta Bioethica 17, no. 2 (2011): 225-236.  
Massa, T. "An Industry Perspective: Challenges in the Development and Regulation of Drug-Device 
Combination Products." In Innovation and Invention in Medical Devices, edited by K. Hanna, F. J. 
Manning, P. Bouxsein and A. Pope, 16. Washington, D.C.: National Academy Press, 2001.  
Mathes, T., E. Esther Jacobs, J. C. Morfeld, and D. Pieper. "Methods of International Health Technology 
Assessment Agencies for Economic Evaluations- a Comparative Analysis." BMC Health Services 
Research 13, no. September (2013): 371.  
  
 
305 
 
McEwen, Jean E., Joy T. Boyer, and Kathie Y. Sun. "Evolving Approaches to the Ethical Management of 
Genomic Data." Trends in Genetics 29, no. 6 (6, 2013): 375-382.  
McGowan, M. and J. Fishman. "Using Lessons Learned from BRCA Testing and Marketing: What Lies 
Ahead for Whole Genome Scanning Services." American Journal of Bioethics 8, no. 6 (2008): 18-20.  
McGuire, A. L., T. Caulfield, and M. K. Cho. "Research Ethics and the Challenge of Whole-Genome 
Sequencing." Nature Reviews Genetics 9, (2008): 153-154.  
McQueen, D. and L. Anderson. "What Counts as Evidence: Issues and Debates." In Evaluation in Health 
Promotion: Principles and Perspectives, edited by I. Rootman, M. Goodstadt, B. Hyndman, D. 
McQueen, L. Potvin, J. Springett and E. Ziglio. Copenhagen: WHO Regional Office for Europe, 
2001.  
Mebane, W. R. "Congressional Campaign Contributions, District Service and Electoral Outcomes in the 
United States: Statistical Tests of a Formal Game Model with Nonlinear Dynamics." In Political 
Complexity: Nonlinear Models of Politics, edited by D. Richards. Ann Arbor: University of Michigan 
Press, 2000.  
Meslin, Eric M. "Protecting Human Subjects from Harm through Improved Risk Judgment." IRB: Ethics 
and Human Research 12, no. 1 (1990): 7-10.  
Misa, T. "How Machines Make History, and How Historians (and Others) Help Them to Do So." Science, 
Technology and Human Values 132, no. 3-4 (1988): 308-311.  
Mitton, C. and C. Donaldson. "Health Care Priority Setting: Principles, Practice and Challenges." Cost 
Effectiveness and Resource Allocation 2, no. 3 (2004): 3.  
Moret-Hartman, M., G. Van Der Wilt, and J. Grin. "Health Technology Assessment and Ill-Structured 
Problems: A Case Study Concerning the Drug Mebeverine." International Journal of Technology 
Assessment in Health 23, no. 3 (2007): 316-323.  
"National Center for Ethics in Healthcare." United States Department of Veteran Affairs. Accessed Oct 17, 
2012. http://www.ethics.va.gov  
National Conference of Commissioners of Uniform State Laws. Uniform Determination of Death Act. 
Kauai, Hawaii: National Conference of Commissioners on Uniform State Laws, 1980.  
National Human Genome Research Institute. "Genetic Information Nondiscrimination Act of 2008." 
National Institutes of Health. Accessed March 14, 2015. http://www.genome.gov/10002328  
National Information Center on Health Services Research and Health Care Technology (NICHSR). "HTA 
101: II. Fundamental Concepts." National Institutes of Health. Accessed June, 2013. 
http://www.nlm.nih.gov/nichsr/hta101/ta10104.html  
———. "HTA 101: V. Economic Analysis Methods." Accessed June 17, 2014. 
http://www.nlm.nih.gov/nichsr/hta101/ta10107.html  
National Institute for Health and Care Excellence. "Developing NICE Technology Appraisals." Accessed 
December, 2013. 
http://www.nice.org.uk/aboutnice/howwework/devnicetech/developing_nice_technology_appraisals.j
sp  
  
 
306 
 
National Institutes of Health. "Assessing Medical Technologies." Accessed June, 12, 2013. 
http://www.nap.edu/openbook.php?record_id=607  
National Research Council, Committee on the Life Sciences and Social Policy. Assessing Biomedical 
Technologies: An Inquiry into the Nature of the Process. Washington, D.C.: National Academy of 
Sciences, 1975.  
Nature. "Article Metrics for: A Semi-Synthetic Organism with an Expanded Genome." Nature. Accessed 
March 21, 2015. 
http://www.nature.com.authenticate.library.duq.edu/nature/journal/v509/n7500/nature13314/metrics/  
NCSS Statistical Software. "NCSS10 Data Analysis: Data Analysis, Graphics." Accessed February 4, 2015. 
http://www.ncss.com/software/ncss/  
Needham, J. Integrative Levels: A Revaluation of the Idea of Progress. Oxford: Clarendon Press, 1937.  
Neelameghan, A. "Systems Thinking in the Study of the Attributes of the Universe of Subjects." In 
Information Science: Search for Identity, edited by A. Debons, 139-170. New York: Marcel Dekker, 
1974.  
Neumann, P. J. "What We Talk about When We Talk about Health Care Costs." The New England Journal 
of Medicine 366, no. 7 (2012): 585-6.  
Nielsen, C., T. Funch, and F. Kristensen. "Health Technology Assessment: Research Trends and Future 
Priorities in Europe." Journal of Health Services Research and Policy 16, no. Supp 2 (2011): 6-15.  
Nielsen, C., T. Funch, and F. Kristensen. "Health Technology Assessment: Research Trends and Future 
Priorities in Europe." J Health Serv Res Policy 16, no. Suppl 2 (2011): 6-15.  
Noorani, H., D. Husereau, R. Boudreau, and B. Skidmore. "Priority Setting for Health Technology 
Assessments: A Systematic Review of Current Practical Approaches." International Journal of 
Technology Assessment in Health Care 23, no. 3 (2007): 310-315.  
Novak, J. D. and D. B. Gowin. Learning How to Learn. New York: Cambridge University Press, 1984.  
O’Donnell, J., S. Pham, C. Pashos, D. Miller, and M. Smith. "Health Technology Assessment: Lessons 
Learned from Around the World—An Overview." Value in Health 12, no. Suppl 2 (2009): S1-S5.  
Office of General Counsel, Organized Medical Staff Section. Conflict of Interest Guidelines for Organized 
Medical Staffs: American Medical Association, 2007.  
"Office of the National Coordinator for Health Information Technology." U.S. Department of Health and 
Human Services. Accessed Oct 17, 2012. 
http://healthit.hhs.gov/portal/server.pt/community/healthit_hhs_gov__home/1204  
Office of Science and Technology Policy. "National Bioeconomy Blueprint Released." Accessed February 
1, 2015. https://www.whitehouse.gov/blog/2012/04/26/national-bioeconomy-blueprint-released  
Office of Technology Assessment. Assessing the Efficacy and Safety of Medical Technologies. Washington, 
D.C.: US Government Printing Office, 1978.  
  
 
307 
 
———. Development of Medical Technology: Opportunities for Assessment. Washington D.C.: Office of 
Technology Assessment, 1975.  
Office of the Press Secretary. "Fact Sheet: President Obama's Precision Medicie Initiative." The White 
House. Accessed March 14, 2015. https://www.whitehouse.gov/the-press-office/2015/01/30/fact-
sheet-president-obama-s-precision-medicine-initiative  
Organisation for Economic Co-operation and Development. The Bioeconomy to 2030: Designing a Policy 
Agenda. OECD Publishing, 2009.  
Organization for Economic Co-operation and Development (OECD). The Bioeconomy to 2030 Designing a 
Policy Agenda: Main Findings and Policy Conclusions: OECD, 2009.  
Orlikowski, W. J. "The Duality of Technology: Rethinking the Concept of Technology in Organizations." 
Organization Science 3, no. 3 (1992): 398-427.  
———. "Using Technology and Constituting Structures: A Practice Lens for Studying Technology in 
Organizations." Organization Science 3, no. 3 (2000): 404-428.  
Ornetzeder, M. and K. Kastenhofer. "Old Problems, New Directions and Upcoming Requirements in 
Participatory Technology Assessment." Poiesis Praxis 9, (2012): 1-5.  
Paddon, C. J. and J. D. Keasling. "Semi-Synthetic Artemisinin: A Model for the use of Synthetic Biology 
in Pharmaceutical Development." Nature Reviews Microbiology 12, (2014): 355-367.  
Padela, A. I., A. Arozullah, and E. Moosa. "Brain Death in Islamic Ethico-Legal Deliberation: Challenges 
for Applied Islamic Bioethics." Bioethics 27, no. 3 (2013): 132-139.  
Pagon, R. A., P. Tarczy-Hornoch, and P. K. Baskin. "Gene Tests - Gene Clinics: Genetic Testing 
Information for a Growing Audience." Human Mutation 19, (2002): 501-509.  
Park, K. "Protocells for DNA Cargo Delivery to the Spinal Cord." Journal of Controlled Release 168, no. 2 
(2013): 238.  
Parthasarathy, S. Building Genetic Medicine: Breast Cancer, Technology, and the Comparative Politics of 
Health Care. The MIT Press, 2012.  
Patenaude, J., G. A. Legault, J. Beauvias, L. Bernier, J. P. Beland, P. Boissy, V. Chenel, et al. "Framework 
for the Analysis of Nanotechnologies' Impacts and Ethical Acceptability: Basis of an Interdisciplinary 
Approach to Assessing Novel Technologies." Science and Engineering Ethics 21, (2015): 293-315.  
Pearson, S. D. and P. B. Bach. "How Medicare Could Use Comparative Effectiveness Research in 
Deciding on New Coverage and Reimbursement." Health Affairs 29, no. 10 (2010): 1796-80.  
Perrone, M. "FDA Halts Sales of 23andMe DNA Test Kits." News, USA Today, 2013.  
Perry, S. "Risk: Harm, Interests, and Rights." In Risk: Philosophical Perspectives, edited by T. Lewens, 
190-210. New York: Routledge, 2007.  
Perry, S. and M. Thamer. "Health Technology Assessment: Decentralized and Fragmented in the US 
Compared to Other Countries." Health Policy 40, (1997): 177-198.  
  
 
308 
 
Peterson-Iyer, K. "Pharmacogenomics, Ethics, and Public Policy." Kennedy Institute of Ethics Journal 18, 
no. 1 (2008): 35-56.  
Pickering, A. Science as Practice and Culture. Chicago, IL: University of Chicago Press, 1992.  
Pinch, T. and W. Bijker. "The Social Construction of Facts and Artifacts: Or "FDA Halts Sales of 23andMe 
DNA Test Kits." USA Today How the Sociology of Science and the Sociology of Technology Might 
Benefit Each Other." In The Social Construction of Technological Systems: New Directions in the 
Sociology and History of Technology, edited by W. Bijker, T. Hughes and T. Pinch, 17-50. 
Massachusetts: MIT Press, 1994.  
Porcar, M., A. Danchin, V. Lorenzo, dos Santos V., N. Krasnogor, S. Rasmussen, and A. Moya. "The Ten 
Grand Challenges of Synthetic Life." Systems and Synthetic Biology 5, no. 1-2 (2011): 1-9.  
Porter, A. L. "Technology Assessment." Impact Assessment 13, no. 2 (1995): 135-151.  
Potrykus, Ingo. "Lessons from the ‘Humanitarian Golden Rice’ Project: Regulation Prevents Development 
of Public Good Genetically Engineered Crop Products." New Biotechnology 27, no. 5 (11/30, 2010): 
466-472.  
Prakash, S. and M. L. Jones. "Artificial Cell Therapy: New Strategies for the Therapeutic Delivery of Live 
Bacteria." Journal of Biomedicine and Biotechnology 1, (2005): 44-56.  
Presidential Commission for the Study of Bioethical Issues. New Directions: The Ethics of Synthetic 
Biology and Emerging Technologies. Washington, D.C., 2010. Washington DC: Presidential 
Commission for the Study of Bioethical Issues, 2010.  
President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral 
Research. Defining Death: A Report on the Medical, Legal, and Ethical Issues in the Determination 
of Death. Washington, D.C.: President's Commission for the Study of Ethical Problems in Medicine 
and Biomedical and Behavioral Research, 1981.  
Raftery, J. and J. Powell. "Health Technology Assessment in the UK." The Lancet 382, no. 9900 (2013): 
1278-1285.  
Rajczi, Alex. "Making Risk-Benefit Assessments of Medical Research Protocols." Journal of Law, 
Medicine, and Ethics 32, (2004): 338-348.  
Rawls, J. A Theory of Justice. Cambridge: Harvard University Press, 1999.  
Rawls, John. Political Liberalism. 2nd ed. New York: Columbia University Press, 2005.  
———. A Theory of Justice. Cambridge: Belknap Press of Harvard University Press, 2005.  
Reiser, S. J. and M. Anbar. The Machine at the Bedside: Strategies for Using Technology in Patient Care. 
New York: Cambridge University Press, 1984.  
Rettig, R. A. Health Care in Transition: Technology Assessment in the Private Sector. Santa Monica, CA: 
RAND, 1997.  
Reuzel, R. P. B. "Health Technology Assessment and Interactive Evaluation: Different Perspectives." 
Dissertation, University of Nijmegen, 2001.  
  
 
309 
 
Reuzel, R. P. B., W. Oortwijn, M. Decker, C. Clausen, P. Gallo, J. Grin, A. Grunwald, L. Hennen, G. van 
der Wilt, and Y. Yoskinaka. "Ethics and HTA: Some Lessons and Challenges for the Future." Poiesis 
Praxis 2, (2004): 247-256.  
Reuzel, R. P. B., G. van der Wilt, H. A. M. J. ten Have, and P. F. de Vries Robbe. "Interactive Technology 
Assessment and Wide Reflective Equilibrium." Journal of Medicine and Philosophy 26, no. 3 (2001): 
245-261.  
———. "Reducing Normative Bias in Health Technology Assessment: Interactive Evaluation and 
Casuistry." Medicine, Health Care and Philosophy 2, (1999): 225-263.  
Rid, A. and D. Wendler. "A Framework for Risk-Benefit Evaluation in Biomedical Research." Kennedy 
Institute of Ethics Journal 21, no. 2 (2011): 141-179.  
Ritrovato, M., F. C. Faggiano, G. Tedesco, and P. Derrico. "Decision-Oriented Health Technology 
Assessment: One Step Forward in Supporting the Decision-Making Process in Hospitals." Value in 
Health. In Press, (2015).  
Robertson, J. "The $1000 Genome: Ethical and Legal Issues in Whole Genome Sequencing of Individuals." 
American Journal of Bioethics 3, no. 3 (2003): 35-42.  
Ruiz-Mirazo, K., C. Briones, and A. de la Escosura. "Prebiotic Systems Chemistry: New Perspectives for 
the Origins of Life." Chemical Reviews 114, no. 1 (2014): 285.  
Ruszczynski, A. Nonlinear Optimization. Princeton University Press, 2006.  
Ryan, M., D. Scott, C. Reeves, A. Bate, and E. van Teijlingen. "Eliciting Public Preferences for Healthcare: 
A Systematic Review of Techniques." Health Technology Assessment 5, no. 5 (03/27, 2001): 186.  
Saarni, S. I., A. Braunack-Mayer, B. Hofmann, and G. van der Wilt. "Different Methods for Ethical 
Analysis in Health Technology Assessment: An Empirical Study." International Journal of 
Technology Assessment in Health Care 27, no. 4 (2011): 305-317.  
Sacchini, D., A. Virdis, P. Refolo, M. Pennacchini, and I. C. de Paula. "Health Technology Assessment 
(HTA): Ethical Aspects." Medicine, Health Care and Philosophy 12, (2009): 453-457.  
Sackett, D. L. and et al. "Evidence Based Medicine: What It Is and What It Isn’t." British Medical Journal 
312, (1996): 71-72.  
Sandman, L. and E. Heintz. "Assessment Vs. Appraisal of Ethical Aspects of Health Technology 
Assessment: Can the Distinction be Upheld?" GMS Health Technology Assessment 26, no. 10 (2012): 
Doc05.  
Saretzki, T. "Legitimation Problems of Participatory Processes in Technology Assessment and Technology 
Policy." Poiesis Praxis 9, (2012): 7-26.  
Satellite Symposia. Regional Networks of HTA in the Americas, in Europe and in Asia: What Can They 
Learn from Each Other and What Are the Opportunities for Collaboration. Bilboa, Spain, 2012.  
Schlander, M. Health Technology Assessments by the National Institute for Health and Clinical Excellence: 
A Qualitative Study. New York, NY: Springer, 2007.  
  
 
310 
 
Schmidt, Markus. "Diffusion of Synthetic Biology: A Challenge to Biosafety." Systems and Synthetic 
Biology 2, no. 1-2 (06/01, 2008): 1-6.  
Schneiderman, L. J. and N. S. Jecker. Wrong Medicine. Baltimore: Johns Hopkins University, 1995.  
Schrodinger, E. What is Life?. Cambridge: Cambridge University Press, 1944.  
Shih, Jhih-Shyang, Armistead G. Russell, and Gregory J. McRae. "An Optimization Model for 
Photochemical Air Pollution Control." European Journal of Operational Research 106, no. 1 (4/1, 
1998): 1-14.  
Skorupinski, B. and K. Ott. "Technology Assessment and Ethics: Determining a Relationship in Theory 
and Practice." Poiesis Praxis 1, (2002): 95-122.  
Sleator, R. D. "The Genetic Code. Rewritten, Revised, Repurposed." Artificial DNA: PNA & XNA 5, no. 2 
(2014): e29408.  
———. "Genetics Just Got SEXY: Sequences Encoding XY." Bioengineered 5, no. 4 (2014): 214-215.  
Smith, M. "Health Technology Assessment and the NHS R&D Initiative." Journal of Medical Engineering 
and Technology 20, no. 6 (1996): 192-195.  
Smith, M. and L. Marx. Does Technology Drive History? The Dilemma of Technological Determinism. 
Cambridge, MA: MIT Press, 1994.  
Solbakk, J. H., S. Holm, and B. Hofmann, eds. The Ethics of Research Biobanking: Springer US, 2009.  
Solter, D. "From Teratocarcinomas to Embryonic Stem Cells and Beyond: A History of Embryonic Stem 
Cell Research." Nature Reviews Genetics 7, no. April (2006): 319-327.  
Sorenson, C., M. Drummond, and P. Kanavos. Ensuring Value for Money in Health Care: The Role of 
Health Technology Assessment in the European Union. Observatory Studies Series. Vol. Book 11 
World Health Organization, 2008.  
Southern, D. M., D. Young, D. Dunt, N. Appleby, and R. Batterham. "Integration of Primary Healthcare 
Services: Perceptions of Austrialian General Practitioners, Non-General Practitioner Health Service 
Providers and Consumers at the General Practice-Primary Care Interface." Evaluation and Program 
Planning 25, (2002): 47-59.  
Southern, D. M., Batterham RW FAU, Appleby NJ FAU, D. FAU Young, D. FAU Dunt, and R. Guibert. 
"The Concept Mapping Method. An Alternative to Focus Group Inquiry in General Practice." 
Australian Family Physician 28, no. Supp 1 (1999): S35-S40.  
Spence, H. First Principles of a New System of Philosophy. Classic Reprint Series ed. Forgotten Books, 
2010.  
Stahl, James E. "Modelling Methods for Pharmacoeconomics and Health Technology Assessment: An 
Overview and Guide." Pharmacoeconomics 26, no. 2 (01/15, 2008): 131-148.  
Steinbrook, R. "The Gelsinger Case." In The Oxford Textbook of Clinical Reserach Ethics, edited by E. 
Emanuel, C. Grady, R. Crouch, R. Lie, F. Miller and D. Wendler, 110-120. New York: Oxford 
University Press, 2008.  
  
 
311 
 
Sullivan, S., J. Watkins, B. Sweet, and S. Ramsey. "Health Technology Assessment in Health-Care 
Decisions in the United States." Value in Health 12, no. Suppl 2 (2009): S39-S44.  
Sundström, P. "Interpreting the Notion of Technology as Value-Neutral." Medicine, Health Care and 
Philosophy 1, no. 1 (1998): 41-45.  
Suskie, L. Assessing Student Learning: A Common Sense Guide. 2nd ed. San Fransisco, CA: Jossey-Bass, 
2009.  
Systat Software Inc. "SigmaPlot Overview." Accessed February 4, 2015. 
http://www.sigmaplot.com/products/sigmaplot/sigmaplot-details.php  
Szczepura, A. and J. Kankaanpää. Assessment of Health Care Technologies: Case Studies, Key Concepts 
and Strategic Issues Wiley, 1996.  
ten Have, H. A. M. J. "Ethical Perspectives on Health Technology Assessment." International Journal of 
Technology Assessment in Health Care 20, no. 1 (2004): 71-6.  
Teutsch, S. M., L. A. Bradley, and G. E. Palomaki. "The Evaluation of Genomic Applications in Practice 
and Prevention (EGAPP) Initiative: Methods of the EGAPP Working Group." Genetics in Medicine: 
Official Journal of the American College of Medical Genetics 11, (2009): 3-14.  
The Lewin Group. Outlook for Medical Technology Innovation, Report 4: The Impact of Regulation and 
Market Dynamics on Innovation. Washington D.C.: AdvaMed, 2001.  
The White House. National Bioeconomy Blueprint. Washington, D.C.: The White House, 2012.  
Thinkmap. "Thinkmap SDK." Accessed February 4, 2015. http://www.thinkmap.com/thinkmapsdk.jsp  
Thomas, J., M. Newman, and S. Oliver. "Rapid Evidence Assessments of Research to Inform Social Policy: 
Taking Stock and Moving Forward." Evidence & Policy 9, (2013): 5-27.  
Thyer, Ross and Jared Ellefson. "Synthetic Biology: New Letters for Life's Alphabet." Nature 509, no. 
7500 (05/15, 2014): 291-292.  
Timmermann, C. and J. Anderson, eds. Devices and Designs: Medical Technologies in Historical 
Perspective: Palgrave Macmillan, 2007.  
Trochim, William M., Derek A. Cabrera, Bobby Milstein, Richard S. Gallagher, and Scott J. Leischow. 
"Practical Challenges of Systems Thinking and Modeling in Public Health." American Journal of 
Public Health 96, no. 3 (09/19, 2005): 538-546.  
Trochim, William M. K. and Rhoda Linton. "Conceptualization for Planning and Evaluation." Evaluation 
and Program Planning 9, no. 4 (1986): 289-308.  
Tucker, J. and R. Zilinskas. "The Promise and Perils of Synthetic Biology." The New Atlantis A Journal of 
Technology and Society 12, (2006): 1-23.  
U.S. Energy Information Administration. "What is U.S. Electricity Generation by Energy Source?" 
Accessed February 5, 2015. http://www.eia.gov/tools/faqs/faq.cfm?id=427&t=3  
  
 
312 
 
U.S. National Institutes of Health. "Clinical Trials." U.S. National Institutes of Health. Accessed March 4, 
2013, www.clinicaltrials.gov  
———. "ClinicalTrials.Gov." Accessed March, 14, 2015, www.clinicaltrials.gov  
United States Environmental Protection Agency. "Science and Technology." EPA. Accessed March 14, 
2015. http://www2.epa.gov/science-and-technology  
US Department of Health and Human Services. "Pandemic Flu History." USDHHS. Accessed February 5, 
2015, http://www.flu.gov/pandemic/history/  
Vaesen, K. "Artefactual Norms." In Norms in Technology, edited by M. de Vries, S. O. Hansson and A. W. 
M. Meijers, 119-136: Springer, 2013.  
van den Besselaar, P. "Empirical Evidence of Self-Organization?" Journal of the American Society for 
Information Science and Technology 54, no. 1 (2003): 87-90.  
Van der Wildt, G., R. Reutzel, and H. Banta. "The Ethics of Assessing Health Technologies." Theoretical 
Medicine and Bioethics 21, (2000): 101-113.  
Van Inwagen, P. An Essay on Free Will. Oxford: Oxford University Press, 1983.  
Velasco-Garrido, M. and R. Busse. Policy Brief: Health Technology Assessment: An Introduction to 
Objectives, Role of Evidence, and Structure in Europe: World Health Organization on Behalf of the 
European Observatory on Health Systems and Policies, 2005.  
Verbeek, P. Moralizing Technology: Understanding and Designing the Morality of Things. Chicago: 
University of Chicago Press, 2011.  
Verheijde, Joseph L., Mohamed Y. Rady, and Joan McGregor. "Recovery of Tranplantable Organs after 
Cardiac or Circulatory Death: Transforming the Paradigm for the Ethics of Organ Donations." 
Philosophy, Ethics, and Humanities in Medicine 2, no. 8 (2007).  
von Wright, G. H. Norm and Action; A Logical Enquiry. New York: Humanities, 1963.  
Waelbers, K. Doing Good with Technologies: Taking Responsibility for the Social Role of Emerging 
Technologies. New York: Springer, 2011.  
Wajcman, J. "Addressing Technological Change: The Challenge to Social Theory." Current Sociology 50, 
no. 3 (2002): 347-363.   
Ware, R. and R. Hicks. "Doing More Harm than Good? Do Systematic Reviews of PET by Health 
Technology Assessment Agencies Provide an Appraisal of the Evidence That Is Closer to the Truth 
than the Primary Data Supporting Its Use?" The Journal of Nuclear Medicine 52, no. 12 (suppl) 
(2011): 64S-73S.  
Watt, A., A. Cameron , L. Sturm, and et al. "Rapid Versus Full Systematic Reviews: Validity in Clinical 
Practice?" ANZ Journal of Surgery 78, (2008): 1037-1040.  
Webster, A. Health, Technology and Society: A Sociological Critique. Palgrave Macmillan, 2007.  
  
 
313 
 
———. "Innovative Health Technologies and the Social: Redefining Health, Medicine, and the Body." 
Current Sociology 50, no. 3 (2002): 443-457.  
Wendler, David and Franklin Miller. "Risk-Benefit Analysis and the Net Risks Test." In The Oxford 
Textbook of Clinical Research Ethics, edited by Ezekial Emanuel. New York: Oxford University 
Press, 2008.  
Widdows, H. and S. Cordell. "Ethics of Biobanking: Key Issues and Controversies." Health Care Annals 
19, (2011): 207-219.  
Widdows, H. "Conceptualizing the Self in the Genetic Era." Health Care Annals 15, (2007): 5-12.  
Williams, M. "Concept Mapping: A Strategy for Assessment." Nursing Standard 19, no. 9 (2008): 33-38.  
Wills, P., D. Williams, D. Trussell, and L. Mann. "Harnessing Our Very Life." Artificial Life 19, no. 3-4 
(2013): 451-469.  
Winner, L. "Technology as Forms of Life." In Readings in the Philosophy of Technology, edited by D. 
Kaplan, 103-113. Oxford: Rowman & Littlefield, 2004.  
Workman, F., M. Workman, and W. Allen. "A Structuration Agency Approach to Security Policy 
Enforcement in Mobile Ad Hoc Networks." Information Security Journal 17, (2008): 267-277.  
World Health Organization. Health Technology Assessment of Medical Devices. WHO Medical Device 
Technical Series. World Health Organization, 2011.  
"World Health Organizations." World Health Organization. Accessed Oct 17, 2012. http://www.who.int  
"World Medical Association." World Medical Association, Inc. Accessed Oct 4, 2012. http://www.wma.net  
Woyke, T. and E. Rubin. "Searching for New Branches on the Tree of Life." Science 346, no. 6210 (2014): 
698-699.  
Yamashige, R., M. FAU Kimoto, Y. FAU Takezawa, A. FAU Sato, T. FAU Mitsui, S. FAU Yokoyama, 
and I. Hirao. "Highly Specific Unnatural Base Pair Systems as a Third Base Pair for PCR 
Amplification." Nucleic Acids Research 40, (2012): 2793-2806.  
Yang, Z. and et al. "Expanded Genetic Alphabets in the Polymerase Chain Reaction." Angewandte Chemie 
International Edition 49, no. 1 (2010): 177-180.  
Yang, Z., F. Chen, J.B. Alvarado, and S. A. Benner. "Amplification, Mutation, and Sequencing of a Six-
Letter Synthetic Genetic System." Journal of the American Chemical Society 133, no. 15 (2011): 105-
112.  
 
 
 
 
